0001144204-15-063716.txt : 20151110 0001144204-15-063716.hdr.sgml : 20151110 20151109160158 ACCESSION NUMBER: 0001144204-15-063716 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151109 DATE AS OF CHANGE: 20151109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 151215537 BUSINESS ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 10-Q 1 v422880_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 000-30929

TG THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

36-3898269

(I.R.S. Employer Identification No.)

3 Columbus Circle, 15^th Floor

New York, New York 10019

(Address including zip code of principal executive offices)

(212) 554-4484

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	x
Non-accelerated filer	¨ (Do not check if smaller reporting company)	Smaller reporting company	¨

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

There were 52,519,686 shares of the registrant’s common stock, $0.001 par value, outstanding as of November 6, 2015.

TG THERAPEUTICS, INC.

FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 30, 2015

TABLE OF CONTENTS

		Page

SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS		3

PART I	FINANCIAL INFORMATION	4

Item 1	Financial Statements:	4

	Condensed Consolidated Balance Sheets as of September 30, 2015 (unaudited) and December 31, 2014	4

	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014 (unaudited)	5

	Condensed Consolidated Statement of Equity for the nine months ended September 30, 2015 (unaudited)	6

	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014 (unaudited)	7

	Notes to Condensed Consolidated Financial Statements (unaudited)	8

Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3	Quantitative and Qualitative Disclosures About Market Risk	28

Item 4	Controls and Procedures	28

PART II	OTHER INFORMATION	28

Item 1	Legal Proceedings	28

Item 1A	Risk Factors	28

Item 6	Exhibits	47

SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

Certain matters discussed in this report, including matters discussed under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words "anticipate," "believe," "estimate," "may," "expect," “plan,” “intend” and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed under the captions “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this report, as well as other factors which may be identified from time to time in our other filings with the Securities and Exchange Commission, or the SEC, or in the documents where such forward-looking statements appear. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements. Such forward-looking statements include, but are not limited to, statements about our:

expectations for increases or decreases in expenses;

expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidates or any other products we may acquire or in-license;

use of clinical research centers and other contractors;

expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities;

expectations for generating revenue or becoming profitable on a sustained basis;

expectations or ability to enter into marketing and other partnership agreements;

expectations or ability to enter into product acquisition and in-licensing transactions;

expectations or ability to build our own commercial infrastructure to manufacture, market and sell our drug candidates;

expectations for the acceptance of our products by doctors, patients or payors;

ability to compete against other companies and research institutions;

ability to secure adequate protection for our intellectual property;

ability to attract and retain key personnel;

ability to obtain reimbursement for our products;

estimates of the sufficiency of our existing cash and cash equivalents and investments to finance our operating requirements, including expectations regarding the value and liquidity of our investments;

stock price volatility;

expected losses; and

expectations for future capital requirements.

The forward-looking statements contained in this report reflect our views and assumptions only as of the date this report is signed. Except as required by law, we assume no responsibility for updating any forward-looking statements.

We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

TG Therapeutics, Inc.

Condensed Consolidated Balance Sheets

	September 30, 2015			December 31, 2014
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	65,461,940		$	55,713,784
Short-term investment securities		28,701,209			23,062,034
Interest receivable		158,527			85,516
Prepaid research and development		9,950,893			6,179,743
Other current assets		457,918			173,952
Total current assets		104,730,487			85,215,029
Restricted cash		578,126			575,012
Long-term investment securities		21,088,192			—
Property, plant and equipment, net		69,225			20,357
Goodwill		799,391			799,391
Other assets		141,717			137,101
Total assets	$	127,407,138		$	86,746,890

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$	8,583,003		$	3,991,625
Accrued compensation		768,750			702,000
Current portion of deferred revenue		152,381			152,381
Notes payable		181,668			275,190
Total current liabilities		9,685,802			5,121,196
Deferred revenue, net of current portion		1,409,524			1,523,810
Total liabilities		11,095,326			6,645,006
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value per share (10,000,000 shares authorized, none issued and outstanding as of September 30, 2015 and December 31, 2014)		—			—
Common stock, $0.001 par value per share (150,000,000 shares authorized, 52,558,217 and 44,974,248 shares issued, 52,516,908 and 44,932,939 shares outstanding at September 30, 2015 and December 31, 2014, respectively)		52,558			44,974
Contingently issuable shares		6			6
Additional paid-in capital		257,015,699			175,476,521
Treasury stock, at cost		(234,337	)		(234,337	)
Accumulated deficit		(140,522,114	)		(95,185,280	)
Total stockholders’ equity		116,311,812			80,101,884
Total liabilities and stockholders’ equity	$	127,407,138		$	86,746,890

The accompanying notes are an integral part of the condensed consolidated financial statements.

TG Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	Three months ended September 30,						Nine months ended September 30,
	2015			2014			2015			2014

License revenue	$	38,096		$	38,096		$	114,286		$	114,286

Costs and expenses:
Research and development:
Noncash stock expense associated with in-licensing agreements		—			4,138,844			—			5,350,094
Noncash compensation		35,756			1,200,575			2,733,110			6,402,296
Other research and development		11,538,246			8,352,154			29,719,891			13,197,183
Total research and development		11,574,002			13,691,573			32,453,001			24,949,573

General and administrative:
Noncash compensation		1,204,278			2,895,997			10,106,938			9,664,560
Other general and administrative		1,085,400			889,872			3,094,362			2,500,121
Total general and administrative		2,289,678			3,785,869			13,201,300			12,164,681

Total costs and expenses		13,863,680			17,477,442			45,654,301			37,114,254

Operating loss		(13,825,584	)		(17,439,346	)		(45,540,015	)		(36,999,968	)

Other (income) expense:
Interest income		(55,977	)		(12,107	)		(109,660	)		(38,308	)
Other income		—			—			—			(95,427	)
Interest expense		246,527			234,787			730,710			695,914
Change in fair value of notes payable		(360,218	)		(210,857	)		(824,231	)		(577,299	)
Total other (income) expense		(169,668	)		11,823			(203,181	)		(15,120	)

Net loss	$	(13,655,916	)	$	(17,451,169	)	$	(45,336,834	)	$	(36,984,848	)

Basic and diluted net loss per common share	$	(0.28	)	$	(0.51	)	$	(1.01	)	$	(1.14	)

Weighted average shares used in computing basic and diluted net loss per common share		47,946,309			34,188,108			44,810,352			32,436,420

The accompanying notes are an integral part of the condensed consolidated financial statements.

TG Therapeutics, Inc.

Condensed Consolidated Statement of Equity

for the nine months ended September 30, 2015 (Unaudited)

	Preferred stock				Common stock						Contingently issuable		Additional paid-in			Treasury Stock					Accumulated
	Shares		Amount		Shares			Amount			shares		capital			Shares		Amount			Deficit			Total
Balance at January 1, 2015		—	$	—		44,974,248		$	44,974		$	6	$	175,476,521			41,309	$	(234,337	)	$	(95,185,280	)	$	80,101,884
Issuance of common stock in connection with exercise of warrants						2,922,275			2,922					1,007,063											1,009,985
Issuance of common stock in connection with cashless exercise of warrants						2,915			3					(3	)										—
Issuance of restricted stock						480,592			481					(481	)										—
Forfeiture of restricted stock						(31,166	)		(31	)				31											—
Issuance of common stock to related party for cash (See Note 8)						114,855			115					749,889											750,004
Issuance of common stock in At the Market offering (net of offering costs of $1,262,569)						4,094,498			4,094					66,942,631											66,946,725
Compensation in respect of restricted stock granted to employees, directors and consultants														12,840,048											12,840,048
Net loss																						(45,336,834	)		(45,336,834	)
Balance at September 30, 2015		—	$	—		52,558,217		$	52,558		$	6	$	257,015,699			41,309	$	(234,337	)	$	(140,522,114	)	$	116,311,812

The accompanying notes are an integral part of the condensed consolidated financial statements.

TG Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows
(Unaudited)

	Nine months ended September 30,
	2015			2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Consolidated net loss	$	(45,336,834	)	$	(36,984,848	)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:
Gain on settlement of notes payable		—			(95,427	)
Noncash stock compensation expense		12,840,048			16,066,856
Noncash stock expense associated with in-licensing agreements		—			5,350,094
Depreciation		10,326			2,454
Amortization of premium on investment securities		377,770			127,260
Change in fair value of notes payable		(93,522	)		118,615
Changes in assets and liabilities:
Increase in restricted cash		(3,114	)		—
Increase in other current assets		(4,055,116	)		(7,585,956	)
Increase in accrued interest receivable		(73,011	)		(26,652	)
Decrease in other assets		—			13,870
Increase in accounts payable and accrued expenses		4,658,128			3,269,629
Decrease in interest payable		—			(94,590	)
Decrease in deferred revenue		(114,286	)		(114,286	)
Net cash used in operating activities		(31,789,611	)		(19,952,981	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment		(59,194	)		(4,498	)
Investment in held-to-maturity securities		(40,955,137	)		(9,218,008	)
Proceeds from maturity of short-term securities		13,850,000			—
Net cash used in investing activities		(27,164,331	)		(9,222,506	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the exercise of warrants		1,009,985			2,890,305
Proceeds from the exercise of options		—			145,200
Payment of notes payable		—			(677,778	)
Proceeds from sale of common stock, net		67,760,517			39,558,093
Financing costs		(68,404	)		—
Net cash provided by financing activities		68,702,098			41,915,820

NET INCREASE IN CASH AND CASH EQUIVALENTS		9,748,156			12,740,333

Cash and cash equivalents at beginning of period		55,713,784			40,485,466

CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	65,461,940		$	53,225,799

NONCASH TRANSACTIONS
Reclassification of deferred financing costs to additional paid-in capital	$	(63,788	)	$	—

The accompanying notes are an integral part of the condensed consolidated financial statements.

TG Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

Unless the context requires otherwise, references in this report to “TG” “Company,” “we,” “us” and “our” refer to TG Therapeutics, Inc. (formerly known as Manhattan Pharmaceuticals, Inc., or Manhattan) and our subsidiaries.

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs seeking to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors and anti-PD-L1 and anti-GITR antibodies.

We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have not received approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales from our drug candidates.

The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X of the Exchange Act. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the condensed consolidated financial statements have been included. Nevertheless, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying condensed December 31, 2014 balance sheet has been derived from these statements. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Liquidity and Capital Resources

We have incurred operating losses since our inception and expect to continue to incur operating losses for the foreseeable future and, may never become profitable. As of September 30, 2015, we have an accumulated deficit of $140.5 million.

Our major sources of cash have been proceeds from the private placement and public offering of equity securities. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on many factors, including our ability to obtain regulatory approval for our drug candidates; successfully complete any post-approval regulatory obligations; and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.

As of September 30, 2015, we had approximately $115.4 million in cash, cash equivalents, investment securities, and interest receivable. We anticipate that our cash and cash equivalents and investments will be sufficient to fund our anticipated operating cash requirements for more than 24 months from September 30, 2015. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current strategic plan, including the commercialization of any of our drug candidates.

Our common stock is listed on the Nasdaq Capital Market and trades under the symbol “TGTX.”

Recently Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update to ASC 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 is effective for us beginning in fiscal 2018. We are currently evaluating the impact of this update on our consolidated financial statements.

In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements—Going Concern, which requires that management of an entity should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued. This update will become effective beginning January 1, 2017, with early adoption permitted. The provisions of this standard are not expected to significantly impact the Company.

Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the consolidated financial statements.

Cash and Cash Equivalents

We treat liquid investments with original maturities of three months or less when purchased as cash and cash equivalents.

Restricted Cash

We record cash pledged or held in trust as restricted cash. As of September 30, 2015, we have approximately $0.6 million of restricted cash pledged to secure a line of credit as a security deposit for a Desk Space Agreement (see Note 8).

Investment Securities

Investment securities at September 30, 2015 and December 31, 2014 consist of short-term and long-term government securities. We classify these securities as held-to-maturity. Held-to-maturity securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method.

A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in interest and other (income) expense, net. Dividend and interest income are recognized when earned.

Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and short-term investments. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.

Revenue Recognition

We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.

Research and Development Costs

Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued liability balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.

Prepaid research and development in our consolidated balance sheet includes, among other things, certain fees related to development and manufacturing services. These development and manufacturing agreements often require payments in advance of services performed or goods received. Accordingly, as of September 30, 2015, we recorded approximately $9.1 million in prepaid research and development related to such advance agreements. As of September 30, 2015, approximately $1.5 million of the prepaid research and development balance has not yet been paid.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than “more likely than not,” a valuation allowance is then created.

We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination. We recognize interest and penalties related to uncertain income tax positions in income tax expense.

Stock-Based Compensation

We recognize all share-based payments to employees and non-employee directors (as compensation for service) as noncash compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

For share-based payments to consultants and other third-parties (including related parties), noncash compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties (including related parties) are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.

Basic and Diluted Net Loss Per Common Share

Basic net loss per share of our common stock is calculated by dividing net loss applicable to the common stock by the weighted-average number of our common stock outstanding for the period. Diluted net loss per share of common stock is the same as basic net loss per share of common stock since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because we incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 5,634,005 and 9,100,404 at September 30, 2015 and 2014, respectively. During the three and nine months ended September 30, 2015 and 2014, we incurred a net loss; therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.

Long-Lived Assets and Goodwill

Long-lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management’s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.

Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.

NOTE 2 – CASH AND CASH EQUIVALENTS

The following tables summarize our cash and cash equivalents at September 30, 2015 and December 31, 2014:

	September 30, 2015		December 31, 2014

Money market funds	$	5,626,816	$	12,364,537
Checking and bank deposits		59,835,124		43,349,247
Total	$	65,461,940	$	55,713,784

NOTE 3 – INVESTMENT SECURITIES

We record our investments as held-to-maturity at amortized cost.

The following tables summarize our investment securities at September 30, 2015 and December 31, 2014:

	September 30, 2015
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Obligations of domestic governmental agencies (maturing between October 2015 and August 2016) (held-to-maturity)	$	28,701,209	$	8,061	$	80	$	28,709,190

Long-term investments:
Obligations of domestic governmental agencies (maturing between October 2016 and September 2017) (held-to-maturity)		21,088,192		37,010		—		21,125,202
Total short-term and long-term investment securities	$	49,789,401	$	45,071	$	80	$	49,834,392

	December 31, 2014
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Obligations of domestic governmental agencies (maturing between January 2015 and December 2015) (held-to-maturity)	$	23,062,034	$	922	$	5,806	$	23,057,150
Total short-term investment securities	$	23,062,034	$	922	$	5,806	$	23,057,150

NOTE 4 – FAIR VALUE MEASUREMENTS

We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The fair value hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:

Level 1 – quoted prices in active markets for identical assets and liabilities;

Level 2 – inputs other than Level 1 quoted prices that are directly or indirectly observable; and

Level 3 – unobservable inputs that are not corroborated by market data.

As of September 30, 2015 and December 31, 2014, the fair values of cash and cash equivalents, restricted cash, and notes and interest payable, current portion approximate their carrying value.

At the time of our merger (we were then known as Manhattan Pharmaceuticals, Inc. (“Manhattan”)) with Ariston Pharmaceuticals, Inc. (“Ariston”) in March 2010, Ariston issued $15.5 million of five-year 5% notes payable (the “5% Notes”) in satisfaction of several note payable issuances. The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share. Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915. We have no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.

The cumulative liability including accrued and unpaid interest of the 5% Notes was approximately $19.5 million at December 31, 2014 and $20.3 million at September 30, 2015. No payments have been made on the 5% Notes as of September 30, 2015.

In December 2011, we elected the fair value option for valuing the 5% Notes. The fair value option was elected in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.

As of December 31, 2013, as a result of expiring intellectual property rights and other factors, it was determined that net product cash flows from AST-726 were unlikely. As we have no other obligations under the 5% Notes aside from the net product cash flows and the conversion feature, the conversion feature was used to estimate the 5% Notes’ fair value as of September 30, 2015 and December 31, 2014. The assumptions, assessments and projections of future revenues are subject to uncertainties, difficult to predict, and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could result in significantly different estimates of fair value and the differences could be material to our consolidated financial statements.

The following tables provide the fair value measurements of applicable financial liabilities as of September 30, 2015 and December 31, 2014:

	Financial liabilities at fair value as of September 30, 2015
	Level 1		Level 2		Level 3		Total

5% Notes	$	—	$	—	$	181,668	$	181,668
Totals	$	—	$	—	$	181,668	$	181,668

	Financial liabilities at fair value as of December 31, 2014
	Level 1		Level 2		Level 3		Total

5% Notes	$	—	$	—	$	275,190	$	275,190
Totals	$	—	$	—	$	275,190	$	275,190

The Level 3 amounts above represent the fair value of the 5% Notes and related accrued interest.

The following table summarizes the changes in Level 3 instruments during the nine months ended September 30, 2015:

Fair value at December 31, 2014	$	275,190
Interest accrued on face value of 5% Notes		730,710
Change in fair value of Level 3 liabilities		(824,232	)
Fair value at September 30, 2015	$	181,668

The change in the fair value of the Level 3 liabilities is reported in other (income) expense in the accompanying condensed consolidated statements of operations.

NOTE 5 - STOCKHOLDERS' EQUITY

Preferred Stock

Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, issuable in one or more series. Upon issuance, we can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.

Common Stock

Our amended and restated certificate of incorporation authorizes the issuance of up to 150,000,000 shares of $0.001 par value common stock.

In December 2014, we filed a shelf registration statement on Form S-3 (the “2015 S-3”), which was declared effective in January 2015. Under the 2015 S-3, the Company may sell up to a total of $250 million of its securities. In connection with the 2015 S-3, we amended our 2013 At-the-Market Issuance Sales Agreement with MLV & Co. LLC (the “2015 ATM”) such that we may issue and sell additional shares of our common stock, having an aggregate offering price of up to $75.0 million, from time to time through MLV & Co. LLC (“MLV”), acting as the sales agent. Under the 2015 ATM we pay MLV a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock sold through MLV.

During the nine months ended September 30, 2015, we sold a total of 4,094,498 shares of common stock under the 2015 ATM for aggregate total gross proceeds of approximately $68.2 million at an average selling price of $16.66 per share, resulting in net proceeds of approximately $67.0 million after deducting commissions and other transaction costs.

We currently have two shelf registration statements on Form S-3 filed and declared effective by the SEC (File No. 333-189015 and File No. 333-201339). After deducting shares already sold, approximately $248 million of common stock remains available for sale under these shelf registration statements. We may offer the securities under our shelf registration statements from time to time in response to market conditions or other circumstances if we believe such a plan of financing is in the best interests of our stockholders. We believe that these shelf registration statements provide us with the flexibility to raise additional capital to finance our operations as needed.

Equity Incentive Plans

An amendment to the TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan (“2012 Incentive Plan”) was approved by stockholders in June 2015. Pursuant to this amendment, 6,000,000 shares were added to the 2012 Incentive Plan. Shares available for the issuance of stock options or other stock-based awards under our 2012 Incentive Plan were 5,676,574 shares at September 30, 2015.

Stock Options

The following table summarizes stock option activity for the nine months ended September 30, 2015:

	Number of shares			Weighted- average exercise price		Weighted- average Contractual Term		Aggregate Intrinsic Value
						(in years)
Outstanding at December 31, 2014		194		$	971.70		3.50	$	—
Granted		—			—
Exercised		—			—
Forfeited		(152	)		463.32
Expired		(42	)		2,811.53
Outstanding at September 30, 2015		—		$	—		—	$	—

Exercisable at September 30, 2015		—		$	—		—	$	—

As of September 30, 2015, there are no unvested option awards and no unrecognized compensation cost related to option awards.

Restricted Stock

Certain employees, directors and consultants have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the nine months ended September 30, 2015:

	Number of Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2014		6,400,001		$	5.86
Granted		480,592			16.00
Vested		(819,622	)		5.02
Forfeited		(31,166	)		16.76
Outstanding at September 30, 2015		6,029,805		$	6.72

Total expense associated with restricted stock grants was approximately $12.8 million during the nine months ended September 30, 2015. As of September 30, 2015, there was approximately $18.9 million of total unrecognized compensation cost related to unvested time-based restricted stock, which is expected to be recognized over a weighted-average period of 2.0 years. This amount does not include, as of September 30, 2015, 1,866,167 shares of restricted stock outstanding issued to non-employees, the expense for which is determined each reporting period at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date.

Warrants

The following table summarizes warrant activity for the nine months ended September 30, 2015:

	Warrants			Weighted- average exercise price		Aggregate Intrinsic Value
Outstanding at December 31, 2014		4,148,228		$	0.94	$	61,792,184
Issued		—			—
Exercised		(2,925,687	)		0.35
Expired		(11,364	)		2.25
Outstanding at September 30, 2015		1,211,177		$	2.37	$	9,334,897

Stock-Based Compensation

We did not grant any stock options during the nine months ended September 30, 2015 and 2014.

The following table summarizes stock-based compensation expense information about restricted stock for the three and nine months ended September 30, 2015:

	Three months ended September 30, 2015		Nine months ended September 30, 2015
Stock-based compensation expense associated with restricted stock	$	1,240,034	$	12,840,048
Stock-based compensation expense associated with option grants		—		—
	$	1,240,034	$	12,840,048

NOTE 6 – NOTES PAYABLE

The following is a summary of notes payable:

	September 30, 2015						December 31, 2014
	Current portion, net		Non- current portion, net		Total		Current portion, net		Non- current portion, net		Total
Convertible 5% Notes Payable	$	181,668	$	-	$	181,668	$	275,190	$	-	$	275,190
Total	$	181,668	$	-	$	181,668	$	275,190	$	-	$	275,190

Convertible 5% Notes Payable

On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among Manhattan, Ariston and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of Manhattan (the "Merger Sub"). Pursuant to the terms and conditions of the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger. As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan.

The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share. Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915. We have no obligation under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above. Interest accrues monthly, is added to principal on an annual basis, every March 8, and is payable at maturity, which was March 8, 2015.

The cumulative liability including accrued and unpaid interest of these notes was approximately $20.3 million at September 30, 2015 and $19.5 million at December 31, 2014. No payments have been made on the 5% Notes as of September 30, 2015.

NOTE 7 – LICENSE AGREEMENTS

Anti-PD-L1 and anti-GITR

On March 3, 2015, we entered into a Global Collaboration Agreement (the “Collaboration”) with Checkpoint Therapeutics, Inc. (“Checkpoint”), a subsidiary of Fortress Biotech, Inc. (“Fortress”), a related party, for the development and commercialization of Checkpoint’s anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. Checkpoint retains the rights to develop and commercialize these antibodies in solid tumors.

Under the terms of the Collaboration, we made an up-front payment of $0.5 million, will make development and sales-based milestone payments up to an aggregate of $164 million, and will pay a tiered single digit royalty on net sales. The royalty term will terminate on a country by country basis upon the later of (i) ten years after the first commercial sale of any applicable licensed product in such country, or (ii) the expiration of the last-to-expire patent held by the Dana Farber Cancer Institute containing a valid claim to any licensed product in such country.

Michael Weiss, our Executive Chairman, Interim CEO and President is also the Executive Vice Chairman of Fortress and the Executive Chairman of Checkpoint (See Note 8).

TG-1101

In November 2012, we entered into an exclusive (within the territory) sublicense agreement with Ildong relating to the development and commercialization of TG-1101 in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize TG-1101 in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.

An upfront payment of $2.0 million, which was received in December 2012, net of $0.3 million of income tax withholdings, is being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which we will have certain ongoing responsibilities under the sublicense agreement. We recorded license revenue of approximately $0.1 million for each of the nine months ended September 30, 2015 and 2014 and, at September 30, 2015 and December 31, 2014, have deferred revenue of approximately $1.6 million and $1.7 million, respectively, associated with this $2.0 million payment (approximately $0.2 million of which has been classified in current liabilities at September 30, 2015 and December 31, 2014).

We may receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will make royalty payments to us on net sales of TG-1101 in the sublicense territory.

NOTE 8 – RELATED PARTY TRANSACTIONS

LFB Biotechnologies

On January 30, 2012, we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the “LFB License Agreement”). In connection with the LFB License Agreement, LFB Group was issued 5,000,000 shares of common stock, and a warrant to purchase 2,500,000 shares of common stock at a purchase price of $0.001 per share. In addition, on November 9, 2012, we nominated Dr. Yann Echelard to our Board of Directors as LFB Group’s nominee. LFB Group maintains the right to nominate a board member until such time as LFB Group owns less than 10% of the outstanding common stock.

In connection with the LFB License Agreement, LFB maintained the right to purchase at least $750,000 in additional shares of common stock at a purchase price per share as defined in a November 2012 securities exchange agreement. Accordingly, in February 2015, LFB purchased 114,855 shares of our common stock at a price of $6.53 per share for net proceeds of $750,000. In May 2015, LFB exercised their warrant to purchase 2,500,000 shares of common stock at a purchase price of $0.001 per share.

Under the terms of the LFB License Agreement, we utilize LFB Group for certain development and manufacturing services. We incurred approximately $4.9 million and $1.8 million in expenses for such services during the nine months ended September 30, 2015 and 2014, respectively, which have been included in other research and development expenses in the accompanying consolidated statements of operations. As of September 30, 2015 and December 31, 2014, we had approximately $0.4 million and $0.1 million, respectively, recorded in accounts payable related to the LFB License Agreement. In conjunction with the development and manufacturing services discussed above, certain agreements between us and LFB Group require payments in advance of services performed or goods delivered. Accordingly, as of September 30, 2015 and December 31, 2014, we recorded approximately $4.4 million and $1.9 million, respectively, in prepaid research and development for such advance payments.

Other Parties

In March 2014, we entered into a shared services agreement with Opus Point Partners Management, LLC (“Opus”) in which the parties agreed to share the costs of a rented facility and certain other services. Our Executive Chairman and Interim Chief Executive Officer, is a Managing Member of Opus. During the nine months ended September 30, 2015, we incurred expenses of approximately $0.2 million, principally for rent, related to this agreement. As of September 30, 2015, we had approximately $0.1 million recorded in accounts payable related to this shared services agreement.

As discussed in Note 7 above, with regard to the Collaboration with Checkpoint, our Executive Chairman and Interim Chief Executive Officer is also the Executive Vice Chairman of Fortress and the Executive Chairman of Checkpoint. In addition, Mr. Weiss holds equity interests in TG, Fortress and Checkpoint.

On October 3, 2014, we entered into a Desk Space Agreement (the “Desk Agreement”) with Fortress, to occupy approximately 40% of the New York City office space recently leased by Fortress. This Desk Agreement requires us to pay our respective share of the average annual rent and other costs of the 15 year lease. We approximate an average annual rental obligation of $1.1 million under the Desk Agreement. Fortress does not expect to take possession of the space until late 2015 or early 2016.

In connection with the Desk Agreement, we paid approximately $0.1 million in advance rent, which is recorded in other current assets in the accompanying consolidated balance sheets as of September 30, 2015 and December 31, 2014. During the nine months ended September 30, 2015, we incurred expenses of approximately $0.1 million, principally for our share of project management services, related to this agreement, of which $0.1 million was recorded in accounts payable. Also in connection with this lease, in October 2014 we pledged $0.6 million to secure a line of credit as a security deposit for the Desk Agreement, which has been recorded as Restricted Cash in the accompanying consolidated balance sheets.

In July 2015, we entered into a Shared Services Agreement (the “Shared Services Agreement”) with Fortress to share the cost of certain services such as facilities use, shared personnel costs and other shared overhead and administrative costs. This Shared Services Agreement requires us to pay our respective share of services utilized. In connection with the Shared Services Agreement, we incurred expenses of approximately $40,000 for shared services as of September 30, 2015, which included only costs for shared personnel costs.

On September 1, 2015, we paid $25,000 to Checkpoint as an option fee for the exclusive right to enter into a collaboration for certain compounds licensed by Checkpoint. The option has not been exercised as of September 30, 2015.

For the nine months ended September 30, 2015, we incurred expenses of approximately $23,000 to AOI Communications, L.P. for manuscript services related to TG-1101. Our Executive Chairman and Interim Chief Executive Officer is the owner of AOI Communications, L.P.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis contains forward-looking statements about our plans and expectations of what may happen in the future. Forward-looking statements are based on a number of assumptions and estimates that are inherently subject to significant risks and uncertainties, and our results could differ materially from the results anticipated by our forward-looking statements as a result of many known or unknown factors, including, but not limited to, those factors discussed in “Risk Factors.” See also the “Special Cautionary Notice Regarding Forward-Looking Statements” set forth at the beginning of this report.

You should read the following discussion and analysis in conjunction with the unaudited condensed consolidated financial statements, and the related footnotes thereto, appearing elsewhere in this report, and in conjunction with management’s discussion and analysis and the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014.

OVERVIEW

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs seeking to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors and anti-PD-L1 and anti-GITR antibodies.

TG-1101 (ublituximab)

Overview

TG-1101 (ublituximab) is a chimeric, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells. We hold exclusive worldwide rights to develop and commercialize TG-1101 for all indications, except for the territories of France and Belgium which have been retained by LFB Biotechnologies, and South Korea and Southeast Asia which were licensed to Ildong in November 2012.

Generally, anti-CD20 antibodies are believed to exert their B-cell depleting effects through three primary mechanisms: antibody dependent cell-mediated cytotoxicity (“ADCC”), complement dependent cytotoxicity (“CDC”), and direct or programmed cell death (“DCD” or “PCD”). TG-1101 has been specifically glycoengineered to enhance ADCC activity, which should enhance its ability to deplete B-cells and may improve its anti-cancer effects when compared to Rituxan^®, the leading anti-CD20 monoclonal antibody, which had worldwide sales in 2013 of approximately $8 billion.

Clinical Trials Overview and Recent Developments

Two single-agent, dose-escalation, Phase I studies were undertaken with TG-1101 to establish an optimal dose in patients with Non-Hodgkin’s Lymphoma (“NHL”) and Chronic Lymphocytic Leukemia (“CLL”). In both studies, single agent therapy with TG-1101 was deemed well tolerated by treating investigators and displayed promising clinical activity in relapsed and refractory patients. In oncology settings, anti-CD20 therapy is generally used in combination with other anti-cancer agents where it demonstrates maximum activity as opposed to single agent usage. As a result, subsequent clinical development for TG-1101 has focused on combination therapy. Currently, our combination trials for TG-1101 are evaluating the following regimens:

TG-1101 in combination with ibrutinib (trade name IMBRUVICA^®), a Bruton’s Tyrosine Kinase (“BTK”) inhibitor, for patients with CLL & Mantle Cell Lymphoma (MCL);

TG-1101 in combination with TGR-1202, our development stage PI3Kδ inhibitor, for patients with CLL and NHL, with select cohorts evaluating the triple combination of TG-1101 + TGR-1202 + ibrutinib; and

TG-1101 + TGR-1202 + Pembrolizumab for patients with CLL.

In addition, we have announced our intent of evaluating TG-1101 for the treatment of certain autoimmune diseases. Currently, TG-1101 is being evaluated as single agent for the treatment of acute neuromyelitis optica (NMO) relapses, with additional autoimmune related indications planned to be studied. Further details on our priority ongoing combination trials for TG-1101 are as follows:

TG-1101 in Combination with TGR-1202 for Relapsed/Refractory NHL & CLL

In November 2013, we initiated a multi-center, Phase I study to evaluate the safety and efficacy of the combination of TG-1101 and TGR-1202, our novel, once per day, PI3Kδ inhibitor, for patients with relapsed and/or refractory CLL and NHL. This is the first clinical trial evaluating the combination of TG-1101 and TGR-1202. In this study, dosing of TGR-1202 was commenced at 800mg once per day (QD) with dose escalation proceeding in a 3+3 design. Dose-escalation up to 1200mg micronized formulation has been completed and expansion cohorts are now being evaluated at various doses. Additional cohorts were added to this study to explore the triple therapy combination of TG-1101, TGR-1202, and ibrutinib.

The MD Anderson Cancer Center is the lead center for the trial with Nathan Fowler, MD, Assistant Professor and Co-Director of Clinical Research in the Department of Lymphoma, as the Study Chair for the NHL patient group and Susan O’Brien, MD, formerly of MD Anderson and now Professor and Medical Director for Cancer Clinical Trials and Research at UC Irvine as the Study Chair for the CLL patient group. As of October 2015, enrollment into this study is ongoing in select expansion cohorts.

Preliminary data from this study was presented at the 51^st American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL in May/June 2015, and again in June 2015 at both the 20^th European Hematology Association (EHA) Meeting held in Vienna, Austria as well as at the 13^th International Congress on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

TG-1101 in Combination with Ibrutinib for Relapsed/Refractory MCL & CLL

In December 2013, we initiated a multi-center Phase 2 clinical trial to evaluate the safety and efficacy of the combination of TG-1101 and ibrutinib for patients with CLL and MCL. This is the first clinical trial evaluating the combination of TG-1101 and ibrutinib, an oral Bruton’s Tyrosine Kinase (BTK) inhibitor.

TG Therapeutics partnered with the US Oncology Network and other select centers throughout the United States on the study, with Jeff Sharman, MD, Medical Director for Hematology Research, US Oncology Network, as the Study Chair. This trial has completed enrollment.

Preliminary data from this study was presented at the 56^th Annual American Society of Hematology (ASH) meeting held in San Francisco, CA in December 2014, and most recently updated at the 13^th International Congress on Malignant Lymphoma (ICML), held in Lugano, Switzerland in June 2015.

TG-1101 + TGR-1202 + Pembrolizumab for Relapsed/Refractory CLL

In September 2015, we initiated a Phase 1/2 clinical trial that will investigate the use of TG-1101, and TGR-1202 in combination with pembrolizumab (KEYTRUDA^®) the anti-PD-1 immune checkpoint inhibitor, in patients with relapsed or refractory CLL. This will be the first clinical trial evaluating the safety, tolerability and effectiveness of the triple combination of a PI3K delta inhibitor with an anti-CD20 mAb and an anti-PD-1 checkpoint inhibitor.

TG Therapeutics partnered with the Abramson Cancer Center of the University of Pennsylvania in Philadelphia, PA, with Dr. Anthony Mato, an assistant professor in the Perelman School of Medicine at the University of Pennsylvania, Director of the Center for CLL at Penn's Abramson Cancer Center, acting as Study Chair of the Phase 1/2 study.

TG-1101 + Ibrutinib Phase 3 Study Program – The GENUINE Trial

We reached an agreement with the U.S. Food and Drug Administration (the “FDA”) regarding a Special Protocol Assessment (“SPA”) on the design, endpoints and statistical analysis approach of a Phase 3 clinical trial for TG-1101 plus ibrutinib for the treatment of previously treated CLL patients with high risk cytogenetics. The SPA provides agreement that the Phase 3 trial design adequately addresses objectives that would support the regulatory submission for drug approval.

The Phase 3 trial, named the GENUINE trial, is a randomized controlled clinical trial, with patients receiving either TG-1101 plus ibrutinib or ibrutinib alone. The trial will enroll approximately 330 patients, with the first 200 patients evaluated for overall response rate (“ORR”), and all patients followed for progression-free survival (“PFS”). As per the SPA, if the data is positive, we plan to use the ORR data from the trial as the basis for submission of a Biologics License Application (BLA) for accelerated approval for TG-1101, with the PFS assessment intended to support a filing for full approval.

TG-1101 in Combination with TGR-1202 Phase 3 Study Program – The UNITY-CLL Trial

In September 2015, we reached an agreement with the FDA regarding an SPA on the design, endpoints and statistical analysis approach of a Phase 3 clinical trial for the proprietary combination of TG-1101 plus TGR-1202, for the treatment of CLL. The SPA provides agreement that the Phase 3 trial design adequately addresses objectives that, if met, would support the regulatory submission for drug approval of both TG-1101 and TGR-1202 in combination.

The Phase 3 trial, called the UNITY-CLL trial, is a randomized controlled clinical trial that includes two key objectives: first, to demonstrate contribution of each agent in the TG-1101 + TGR-1202 regimen (the combination sometimes referred to as "1303"), and second, to demonstrate superiority in Progression Free Survival (PFS) over the standard of care to support the submission for full approval of the combination. The study will randomize patients into four treatment arms: TG-1101 + TGR-1202, TG-1101 alone, TGR-1202 alone, and an active control arm of obinutuzumab (GAZYVA^®) + chlorambucil. An early interim analysis will assess contribution of each single agent in the TG-1101 + TGR-1202 combination regimen, which, if successful, will allow early termination of both single agent arms. A second interim analysis will be conducted following full enrollment into the study, which, if positive, we plan to utilize for accelerated approval. Assuming early termination of the TG-1101 and TGR-1202 single agent arms, the study will enroll approximately 450 patients.

TGR-1202

Overview

The phosphoinositide-3-kinases (“PI3Ks”) are a family of enzymes involved in various cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking, and immunity. There are four isoforms of PI3K (alpha, beta, delta, and gamma), of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas.

TGR-1202 is an orally available PI3K delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms. TGR-1202 has demonstrated activity in several pre-clinical models and primary cells from patients with hematologic malignancies.

We hold exclusive worldwide rights to develop and commercialize TGR-1202 for all indications worldwide, except for India which has been retained by Rhizen Pharmaceuticals S A.

Clinical Trials Overview and Recent Developments

Initial clinical development of TGR-1202 was focused on establishing preliminary safety and efficacy in a wide variety of hematologic malignancies. Upon identification of safe and active doses of TGR-1202, a combination clinical trial program was opened, exploring TGR-1202 in combination with a variety of agents. In addition to the previously described study in combination with TG-1101 with or without the BTK inhibitor, ibrutinib, our current combination clinical trials for TGR-1202 are:

TGR-1202 in combination with the anti-CD20 antibody, obinutuzumab (GAZYVA^®) and chlorambucil in patients with CLL;

TGR-1202 in combination with the anti-CD30 antibody drug conjugate, brentuximab vedotin (ADCETRIS^®), in patients with relapsed or refractory Hodgkin’s lymphoma;

TGR-1202 in combination with the BTK inhibitor, ibrutinib, in patients with previously treated CLL and MCL; and

TGR-1202 in combination with the JAK inhibitor, ruxolitinib (JAKAFI^®), in patients with previously treated Myelofibrosis or Polycythemia Vera.

Single Agent TGR-1202 in Patients with Relapsed/Refractory Hematologic Malignancies

In January 2013, we initiated a Phase I, open label, multi-center, first-in-human clinical trial of TGR-1202 in patients with hematologic malignancies. The study entitled TGR-1202-101, "A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR-1202 in Patients with Relapsed or Refractory Hematologic Malignancies," is being run in collaboration with the Sarah Cannon Research Institute in Nashville, TN with Howard “Skip” Burris, MD, Executive Director, Drug Development as the acting Study Chair. Enrollment is open to patients with relapsed or refractory NHL, CLL, and other select hematologic malignancies. As of October 2015, TGR-1202-101 is ongoing and enrolling patients in select expansion cohorts.

TGR-1202 Combination Trials

TGR-1202 is being evaluated in combination with the anti-CD20 antibody, obinutuzumab and chlorambucil in patients with previously untreated CLL; in combination with the anti-CD30 antibody drug conjugate, brentuximab vedotin, in patients with relapsed or refractory Hodgkin’s lymphoma; in combination with the BTK inhibitor, ibrutinib, in patients with CLL and MCL; and in combination with the JAK inhibitor, ruxolitinib, in patients with Myelofibrosis or Polycythemia Vera. It is anticipated that preliminary results from these studies will be presented at future medical conferences.

TGR-1202 in Solid Tumors

In addition to the exploration of TGR-1202 in various hematologic malignancies, a study was opened in October 2015 to evaluate TGR-1202 as a single agent as well as in combination with various chemotherapies for the treatment of select solid tumors. The study, entitled TGR-1202-102, “A Phase I Study Evaluating the Safety and Efficacy of TGR-1202 Alone and in Combination with either nab-paclitaxel + Gemcitabine or with FOLFOX in Patients with Select Relapsed or Refractory Solid Tumors” is being run in collaboration with the Sarah Cannon Research Institute in Nashville, TN with Johanna Bendell, MD, Director of GI Oncology Research as the acting study chair.

IRAK4

Interleukin-1 Receptor Associated Kinase 4, referred to as IRAK4, is a key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with Waldenström's Macroglobulinemia, a rare B-cell cancer, as well as in a sub-set of patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Additionally, IRAK4 is a key component of signaling pathways which regulate immune and inflammatory processes suggesting that inhibition of IRAK4 may also be useful in the treatment of autoimmune related disorders. We hold global rights to develop and commercialize the IRAK4 program, which was licensed from Ligand Pharmaceuticals. Our IRAK4 program is currently in pre-clinical development. In April 2015, we presented pre-clinical data on the IRAK4 compounds at the 2015 American Association for Cancer Research (AACR) Annual Meeting held in Philadelphia, PA.

PD-L1 and GITR

In March 2015, we entered into a global collaboration agreement for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. Our anti-PD-L1 and anti-GITR programs are currently in pre-clinical development.

GENERAL CORPORATE

Our license revenues currently consist of license fees arising from our agreement with Ildong. We recognize upfront license fee revenues ratably over the estimated period in which we will have certain significant ongoing responsibilities under the sublicense agreement, with unamortized amounts recorded as deferred revenue.

We have not earned any revenues from the commercial sale of any of our drug candidates.

Our research and development expenses consist primarily of expenses related to in-licensing of new product candidates, fees paid to consultants and outside service providers for clinical and laboratory development, facilities-related and other expenses relating to the design, development, manufacture, testing and enhancement of our drug candidates and technologies. We expense our research and development costs as they are incurred.

Our general and administrative expenses consist primarily of salaries and related expenses for executive, finance and other administrative personnel, recruitment expenses, professional fees and other corporate expenses, including investor relations, legal activities and facilities-related expenses.

Our results of operations include non-cash compensation expenses as a result of the grants of stock options and restricted stock. Compensation expense for awards of options and restricted stock granted to employees and directors represents the fair value of the award recorded over the respective vesting periods of the individual awards. The expense is included in the respective categories of expense in the consolidated statements of operations. We expect to continue to incur significant non-cash compensation expenses.

For awards of options and restricted stock to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date. This results in a change to the amount previously recorded in respect of the equity award grant, and additional expense or a reversal of expense may be recorded in subsequent periods based on changes in the assumptions used to calculate fair value, such as changes in market price, until the measurement date is reached and the compensation expense is finalized.

In addition, certain restricted stock issued to employees vest upon the achievement of certain milestones; therefore, the total expense is uncertain until the milestone is probable.

Our clinical trials will be lengthy and expensive. Even if these trials show that our drug candidates are effective in treating certain indications, there is no guarantee that we will be able to record commercial sales of any of our drug candidates in the near future. In addition, we expect losses to continue as we continue to fund in-licensing and development of new drug candidates. As we continue our development efforts, we may enter into additional third-party collaborative agreements and may incur additional expenses, such as licensing fees and milestone payments. In addition, we may need to establish the commercial infrastructure required to manufacture, market and sell our drug candidates following approval, if any, by the FDA, which would result in us incurring additional expenses. As a result, our quarterly results may fluctuate and a quarter-by-quarter comparison of our operating results may not be a meaningful indication of our future performance.

RESULTS OF OPERATIONS

Three months ended September 30, 2015 and September 30, 2014

License Revenue. License revenue was $38,096 for each of the three months ended September 30, 2015 and 2014. License revenue is related to the amortization of an upfront payment of $2.0 million received in 2012 associated with our license agreement with Ildong. The upfront payment from Ildong will be recognized as license revenue on a straight-line basis through December 2025, which represents the estimated period over which the Company will have certain ongoing responsibilities under the sublicense agreement.

Noncash Stock Expense Associated with In-Licensing Agreement (Research and Development). Noncash stock expense associated with in-licensing agreement (research and development) amounted to $4,138,844 during the three months ended September 30, 2014. The expense during the three months ended September 30, 2014 was recorded in conjunction with the stock issued to Ligand Pharmaceuticals as an upfront payment for the license to the IRAK4 inhibitors program.

Noncash Compensation Expense (Research and Development). Noncash compensation expense (research and development) related to equity incentive grants totaled $35,756 for the three months ended September 30, 2015, as compared to $1,200,575 during the comparable period in 2014. The decrease in noncash compensation expense was primarily related to milestone-based vesting of restricted stock grants to personnel that occurred during the period ended September 30, 2014 and a decrease in the measurement date fair value of certain consultant restricted stock during the period ended September 30, 2015.

Other Research and Development Expenses. Other research and development expenses increased by $3,186,092 to $11,538,246 for the three months ended September 30, 2015, as compared to $8,352,154 for the three months ended September 30, 2014. The increase was mainly due to increases in manufacturing and clinical trial expenses related to TG-1101 and TGR-1202 of $4.2 million and $1.4 million, respectively, offset by a decrease of $4.0 million related to the upfront cash milestone payment to Rhizen to exercise the license option for TGR-1202 during the three months ended September 30, 2014. We expect our other research and development costs to increase modestly for the remainder of 2015 due primarily to the enrollment of additional patients in our clinical trials.

Noncash Compensation Expense (General and Administrative). Noncash compensation expense (general and administrative) related to equity incentive grants decreased by $1,691,719 to $1,204,278 for the three months ended September 30, 2015, as compared to $2,895,997 for the three months ended September 30, 2014. The decrease in noncash compensation expense was primarily related to the recording of the fair value of equity awards granted to general and administrative personnel and directors, which are expensed over the vesting periods of the individual awards.

Other General and Administrative Expenses. Other general and administrative expenses increased by $195,528 to $1,085,400 for the three months ended September 30, 2015, as compared to $889,872 for the three months ended September 30, 2014. We expect our other general and administrative expenses to remain at a comparable level for the remainder of 2015.

Other (Income) Expense. Other income increased by $181,491 to $169,668 of income for the three months ended September 30, 2015, as compared to $11,823 of expenses for the three months ended September 30, 2014.

Nine months ended September 30, 2015 and September 30, 2014

License Revenue. License revenue was $114,286 for the nine months ended September 30, 2015 and 2014. License revenue is related to the amortization of an upfront payment of $2.0 million received in 2012 associated with our license agreement with Ildong.

Noncash Stock Expense Associated with In-Licensing Agreement (Research and Development). Noncash stock expense associated with in-licensing agreement (research and development) amounted to $5,350,094 during the nine months ended September 30, 2014. The expense during the nine months ended September 30, 2014 was recorded in conjunction with the stock issued to Rhizen of approximately $4.1 million to exercise our option to license TGR-1202, and approximately $1.2 million associated with the common stock issued to Ligand Pharmaceuticals as an upfront payment for the license to the IRAK4 inhibitors program.

Noncash Compensation Expense (Research and Development). Noncash compensation expense (research and development) related to equity incentive grants totaled $2,733,110 for the nine months ended September 30, 2015, as compared to $6,402,296 during the comparable period in 2014. The decrease in noncash compensation expense was primarily related to milestone-based vesting of restricted stock grants to non-executive personnel during the period ended September 30, 2014 and a decrease in the measurement date fair value of certain consultant restricted stock during the period ended September 30, 2015.

Other Research and Development Expenses. Other research and development expenses increased by $16,522,708 to $29,719,891 for the nine months ended September 30, 2015, as compared to $13,197,183 for the nine months ended September 30, 2014. The increase in other research and development expenses was due primarily to increases of approximately $13.0 million and $2.8 million for manufacturing and clinical trial expenses related to TG-1101 and TGR-1202, respectively, offset by a decrease of $4.0 million related to the upfront cash milestone payment to Rhizen to exercise the license option for TGR-1202 during the nine months ended September 30, 2014. We expect our other research and development costs to increase modestly for the remainder of 2015 as enrollment of additional patients increases on our clinical trials.

Noncash Compensation Expense (General and Administrative). Noncash compensation expense (general and administrative) related to equity incentive grants increased by $442,378 to $10,106,938 for the nine months ended September 30, 2015, as compared to $9,664,560 for the nine months ended September 30, 2014. The increase in noncash compensation expense was primarily related to the recording of the fair value of equity awards granted to general and administrative personnel and directors, which are expensed over the vesting periods of the individual awards.

Other General and Administrative Expenses. Other general and administrative expenses increased by $594,241 to $3,094,362 for the nine months ended September 30, 2015, as compared to $2,500,121 for the nine months ended September 30, 2014. We expect our other general and administrative expenses to remain at a comparable level for the remainder of 2015.

Other (Income) Expense. Other income increased by $(188,061) to $(203,181) for the nine months ended September 30, 2015, as compared to $(15,120) for the nine months ended September 30, 2014.

LIQUIDITY AND CAPITAL RESOURCES

Our primary sources of cash have been from the sale of equity securities, warrant and option exercises, and the upfront payment from our Sublicense Agreement with Ildong. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on a number of factors, including our ability to obtain regulatory approval for our drug candidates, successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.

As of September 30, 2015, we had approximately $115.4 million in cash and cash equivalents, investment securities, and interest receivable.

We anticipate that our cash and cash equivalents as of September 30, 2015 are sufficient to fund our anticipated operating cash requirements for more than 24 months from September 30, 2015. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant financing to provide the cash necessary to execute our current operations, including the commercialization of any of our drug candidates.

Cash used in operating activities for the nine months ended September 30, 2015 was $31,789,611 as compared to $19,952,981 for the nine months ended September 30, 2014. The increase in cash used in operating activities was due primarily to increased expenditures associated with our clinical development programs for TG-1101 and TGR-1202.

For the nine months ended September 30, 2015, net cash used in investing activities was $27,164,331 as compared to $9,222,506 for the nine months ended September 30, 2014. The increase in net cash used in investing activities was primarily due to purchases of investment in held-to-maturity treasury securities.

For the nine months ended September 30, 2015, net cash provided by financing activities of $68,702,098 related to our ATM program, as well as proceeds from the exercise of warrants. For the nine months ended September 30, 2014, net cash provided by financing activities of $41,915,820 related to net proceeds from the issuance of Common Stock as part of our underwritten public offering in March 2014, as well as proceeds from the exercise of warrants, net of payment of notes payable of $677,778.

OFF-BALANCE SHEET ARRANGEMENTS

We have not entered into any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

CRITICAL ACCOUNTING POLICIES

The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions.

We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following:

Revenue Recognition. We recognize license revenue in accordance with the revenue recognition guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.

Stock-Based Compensation. We have granted stock options and restricted stock to employees, directors and consultants, as well as warrants to other third parties. For employee and director grants, the value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model takes into account volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. We base our estimates of our stock price volatility on the historical volatility of our common stock and our assessment of future volatility; however, these estimates are neither predictive nor indicative of the future performance of our stock. For purposes of the calculation, we assumed that no dividends would be paid during the life of the options and warrants. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. In addition, we are required to estimate the expected forfeiture rate and only recognize expense for those equity awards expected to vest. As a result, if other assumptions had been used, our recorded stock-based compensation expense could have been materially different from that reported. In addition, because some of the options and warrants issued to employees, consultants and other third-parties vest upon the achievement of certain milestones, the total expense is uncertain.

Total compensation expense for options and restricted stock issued to consultants is determined at the “measurement date.” The expense is recognized over the vesting period for the options and restricted stock. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record stock-based compensation expense based on the fair value of the equity awards at the reporting date. These equity awards are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date. This results in a change to the amount previously recorded in respect of the equity award grant, and additional expense or a reversal of expense may be recorded in subsequent periods based on changes in the assumptions used to calculate fair value, such as changes in market price, until the measurement date is reached and the compensation expense is finalized.

Accruals for Clinical Research Organization and Clinical Site Costs. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.

Accounting Related to Goodwill. As of September 30, 2015 and December 31, 2014, there was $799,391 of goodwill on our consolidated balance sheets. Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value.

We are required to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. For all of our acquisitions, various analyses, assumptions and estimates were made at the time of each acquisition that were used to determine the valuation of goodwill and intangibles. In future years, the possibility exists that changes in forecasts and estimates from those used at the acquisition date could result in impairment indicators.

Accounting For Income Taxes. In preparing our consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process involves management estimation of our actual current tax exposure and assessment of temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities. We must then assess the likelihood that our deferred tax assets will be recovered from future taxable income and, to the extent we believe that recovery is not likely, we must establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we must include an expense within the tax provision in the consolidated statement of operations. Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We have fully offset our deferred tax assets with a valuation allowance. Our lack of earnings history and the uncertainty surrounding our ability to generate taxable income prior to the reversal or expiration of such deferred tax assets were the primary factors considered by management in maintaining the valuation allowance.

Fair Value of 5% Notes Payable. We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of three categories.

We elected the fair value option for valuing the 5% Notes. We elected the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.

RECENTLY ISSUED ACCOUNTING STANDARDS

In May 2014, the FASB issued an Accounting Standards Update to ASC 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 is effective for us beginning in fiscal 2018. We are currently evaluating the impact of this update on our consolidated financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The primary objective of our investment activities is to preserve principal while maximizing our income from investments and minimizing our market risk. We invest in government and investment-grade corporate debt in accordance with our investment policy. Some of the securities in which we invest have market risk. This means that a change in prevailing interest rates, and/or credit risk, may cause the fair value of the investment to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the prevailing interest rate later rises, the fair value of our investment will probably decline. As of September 30, 2015, our portfolio of financial instruments consists of cash equivalents, including bank deposits, and investments. Due to the short-term nature of our investments, we believe there is no material exposure to interest rate risk, and/or credit risk, arising from our investments.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of September 30, 2015, management carried out, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our disclosure controls and procedures are designed to provide reasonable assurance that information we are required to disclose in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in applicable rules and forms. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2015, our disclosure controls and procedures were effective.

Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We, and our subsidiaries, are not a party to, and our property is not the subject of, any material pending legal proceedings.

ITEM 1A. RISK FACTORS

You should carefully consider the following risks and uncertainties. If any of the following occurs, our business, financial condition or operating results could be materially harmed. These factors could cause the trading price of our common stock to decline, and you could lose all or part of your investment.

Risks Related to Our Business and Industry

Because we have in-licensed our product candidates from third parties, any dispute with or non-performance by our licensors will adversely affect our ability to develop and commercialize the applicable product candidates.

Our product candidates have been in-licensed from third parties. Under the terms of our license agreements, the licensors generally will have the right to terminate such agreement in the event of a material breach by us. The licensors will also have the right to terminate the agreement in the event we fail to use diligent and reasonable efforts to develop and commercialize the product candidate worldwide.

If there is any conflict, dispute, disagreement or issue of non-performance between us and our licensing partners regarding our rights or obligations under the license agreements, including any such conflict, dispute or disagreement arising from our failure to satisfy payment obligations under such agreement, our ability to develop and commercialize the affected product candidate and our ability to enter into collaboration or marketing agreements for the affected product candidate may be adversely affected. Any loss of our rights under these license agreements would delay or completely terminate its product development efforts for the affected product candidate.

We do not have full internal development capabilities, and are thus reliant upon our partners and third parties to generate clinical, preclinical and quality data necessary to support the regulatory applications needed to conduct clinical trials and file for marketing approval.

In order to submit and maintain an IND, BLA, or New Drug Application (“NDA”) to the FDA, it is necessary to submit all information on the clinical, non-clinical, chemistry, manufacturing, controls and quality aspects of the product candidate. We rely on our third party contractors and our licensing partners to provide a significant portion of this data. If we are unable to obtain this data, or the data is not sufficient to meet the regulatory requirements, we may experience significant delays in our development programs. Additionally, an IND must be active in each division in which we intend to conduct clinical trials. Currently we do not have an active IND for any of the IRAK4 inhibitors nor for our anti-PD-L1 and anti-GITR antibodies. Additionally, there can be no assurance given that any of the molecules under development in our IRAK4 inhibitor program or in our anti-PD-L1 and anti-GITR antibody research program will demonstrate sufficient pharmacologic properties during pre-clinical evaluation to advance to IND enabling studies, or that such IND enabling studies, if any are conducted, will provide data sufficient to support the filing of an IND, or that such IND, if filed, would be accepted by any FDA division under which we would seek to develop any product candidate. While we maintain an active IND for TG-1101 and TGR-1202 enabling the conduct of studies in the FDA’s Division of Hematology and Oncology, there can be no assurance that we will be successful in obtaining an active IND for TG-1101 or TGR-1202 in any other division under whose supervision we may seek to develop our product candidates, or that the FDA will allow us to continue the development of our product candidates in those divisions where we maintain an active IND.

We are highly dependent on the success of our product candidates and cannot give any assurance that these or any future product candidates will be successfully commercialized.

We are a development-stage biopharmaceutical company, and do not currently have any commercial products that generate revenues or any other sources of revenue. We may never be able to successfully develop marketable products. Our pharmaceutical development methods are unproven and may not lead to commercially viable products for any of several reasons.

If we are unable to develop, or receive regulatory approval for or successfully commercialize any of our product candidates, we will not be able to generate product revenues.

Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, any product candidate we advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.

Pharmaceutical development has inherent risk. We will be required to demonstrate through adequate and well-controlled clinical trials that our product candidates are effective with a favorable benefit-risk profile for use in diverse populations for their target indications before we can seek regulatory approvals for their commercial sale. Success in early clinical trials does not mean that later clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through initial clinical testing. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition, there is typically an extremely high rate of failure of pharmaceutical candidates proceeding through clinical trials.

We plan on conducting additional Phase I, II and III clinical trials for TG-1101 and TGR-1202. Early clinical results seen with TG-1101 and TGR-1202 in a small number of patients may not be reproduced in expanded or larger clinical trials. Additionally, individually reported outcomes of patients treated in clinical trials may not be representative of the entire population of treated patients in such studies. If the results from expansion cohorts or later trials are different from those found in the earlier studies of TG-1101 and TGR-1202, we may need to terminate or revise our clinical development plan, which could extend the time for conducting our development program and could have a material adverse effect on our business. Our IRAK4, anti-PD-L1 and anti-GITR programs are all in pre-clinical development and no assurance can be given that they will advance into clinical development. To date, none of these programs have been through formal toxicology testing required to enable clinical testing, and no assurance can be given that they will be safe enough to be advanced into clinical testing. Many drugs fail in the early stages of clinical development for safety and tolerability issues, accordingly if our pre-clinical assets advance into clinical development, no assurance can be made that a safe and efficacious dose can be found.

If we are unable to successfully complete our clinical trial programs, or if such clinical trials take longer to complete than we project, our ability to execute our current business strategy will be adversely affected.

Whether or not and how quickly we complete clinical trials is dependent in part upon the rate at which we are able to engage clinical trial sites and, thereafter, the rate of enrollment of patients, and the rate we collect, clean, lock and analyze the clinical trial database. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the study, the existence of competitive clinical trials, and whether existing or new drugs are approved for the indication we are studying. We are aware that other companies are currently conducting or planning clinical trials that seek to enroll patients with the same diseases that we are studying. Certain clinical trials are designed to continue until a pre-determined number of events have occurred in the patients enrolled. Trials such as this are subject to delays stemming from patient withdrawal and from lower than expected event rates. They may also incur additional costs if enrollment is increased in order to achieve the desired number of events. If we experience delays in identifying and contracting with sites and/or in patient enrollment in our clinical trial programs, we may incur additional costs and delays in our development programs, and may not be able to complete our clinical trials in a cost-effective or timely manner. In addition, conducting multi-national studies adds another level of complexity and risk. We are subject to events affecting countries outside the U.S. Negative or inconclusive results from the clinical trials we conduct or unanticipated adverse medical events could cause us to have to repeat or terminate the clinical trials.

In September 2014, we announced a Phase 3 clinical trial for TG-1101 in previously treated patients with high-risk CLL , and in September 2015 we announced a Phase 3 clinical trial for the combination of TG-1101 + TGR-1202 for patients with CLL, each of which are being conducted pursuant to SPAs with the FDA. Many companies which have been granted SPAs and/or the right to utilize the FDA’s Fast Track or accelerated approval process have ultimately failed to obtain final approval to market their drugs. Since we are seeking approvals under SPAs for some of our product registration strategies, based on protocol designs negotiated with the FDA, we may be subject to enhanced scrutiny. Further, any changes or amendments to a protocol that is being conducted under SPA will have to be reviewed and approved by the FDA to verify that the SPA agreement is still valid. Additionally, even if the primary endpoint in a Phase 3 clinical trial is achieved, a SPA does not guarantee approval. The FDA may raise issues of safety, study conduct, bias, deviation from the protocol, statistical power, patient completion rates, changes in scientific or medical parameters or internal inconsistencies in the data prior to making its final decision. The FDA may also seek the guidance of an outside advisory committee prior to making its final decision. Even with “fast track” or “priority review” status which we intend to seek for our product candidates, such designations do not necessarily mean a faster development process or regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures.

Any product candidates we may advance into clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.

The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates or any future product candidates are subject to extensive regulation by the FDA in the United States and by comparable health authorities worldwide or in foreign markets. In the United States, we are not permitted to market our product candidates until we receive approval of a BLA or NDA from the FDA. The process of obtaining BLA and NDA approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. Approval policies or regulations may change and the FDA has substantial discretion in the pharmaceutical approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. In addition, the FDA may require post-approval clinical trials or studies which also may be costly. The FDA approval for a limited indication or approval with required warning language, such as a boxed warning, could significantly impact our ability to successfully market our product candidates. Finally, the FDA may require adoption of a Risk Evaluation and Mitigation Strategy (REMS) requiring prescriber training, post-market registries, or otherwise restricting the marketing and dissemination of these products. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. Assuming successful clinical development, we intend to seek product approvals in countries outside the United States. As a result, we would be subject to regulation by the European Medicines Agency (“EMA”), as well as the other regulatory agencies in many of these countries, and other regulatory agencies around the world.

Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others. As in the United States, the regulatory approval process in Europe and in other countries is a lengthy and challenging process. The FDA, and any other regulatory body around the world can delay, limit or deny approval of a product candidate for many reasons, including:

the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;

we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for any indication;

the FDA may not accept clinical data from trials which are conducted by individual investigators or in countries where the standard of care is potentially different from the United States;

the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;

we may be unable to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks;

the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA, NDA or other submission or to obtain regulatory approval in the United States or elsewhere;

the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; or

the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

In addition, recent events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and other regulatory authorities in reviewing new pharmaceuticals based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Regulatory approvals for our product candidates may not be obtained without lengthy delays, if at all. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us from commercializing our product candidates.

Any product candidate we advance into clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent their regulatory approval or commercialization or limit their commercial potential.

Unacceptable adverse events caused by any of our product candidates that we take into clinical trials could cause either us or regulatory authorities to interrupt, delay, modify or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications. This, in turn, could prevent us from commercializing the affected product candidate and generating revenues from its sale.

We have not completed testing of any of our product candidates for the treatment of the indications for which we intend to seek product approval in humans, and we currently do not know the extent that adverse events, if any, will be observed in patients who receive any of our product candidates. To date, clinical trials using TG-1101 and TGR-1202 have demonstrated a toxicity profile that was deemed acceptable by the investigators performing such studies. Such interpretation may not be shared by future investigators or by the FDA and in the case of TG-1101 and TGR-1202, even if deemed acceptable for oncology applications, it may not be acceptable for diseases outside the oncology setting, and likewise for any other product candidates we may develop. Additionally, the severity, duration and incidence of adverse events may increase in larger study populations. With respect to both TG-1101 and TGR-1202, the toxicity when manufactured under different conditions and in different formulations is not known, and it is possible that additional and/or different adverse events may appear upon the human use of those formulations and those adverse events may arise with greater frequency, intensity and duration than in the current formulation. Further, with respect to TGR-1202, although more than 75 patients have been dosed in the ongoing first-in-human dose-escalation Phase I single agent study, the full adverse effect profile of TGR-1202 is not known. It is unknown as the additional patients are exposed for longer durations to TGR-1202, whether greater frequency and/or severity of adverse events are likely to occur. Common toxicities of other drugs in the same class as TGR-1202 include high levels of liver toxicity and colitis, the latter of which notably has presented with later onset, with incidence increasing with duration of exposure. To date, the incidence of these events has been limited for TGR-1202, however no assurance can be given that this safety and tolerability profile will continue to be demonstrated in the future as higher doses, longer durations of exposure, and multiple drug combinations are explored. If any of our product candidates cause unacceptable adverse events in clinical trials, we may not be able to obtain marketing approval and generate revenues from its sale, or even if approved for sale may lack differentiation from competitive products, which could have a material adverse impact on our business and operations.

Additionally, in combination clinical development, there is an inherent risk of drug-drug interactions between combination agents which may affect each component’s individual pharmacologic properties and the overall efficacy and safety of the combination regimen. Both TG-1101 and TGR-1202 are being evaluated in combination together, as well as with a variety of other active anti-cancer agents, which may cause unforeseen toxicity, or impact the severity, duration, and incidence of adverse events observed compared to those seen in the single agent studies of these agents. Further, with multi-drug combinations, it is often difficult to interpret or properly assign attribution of an adverse event to any one particular agent, introducing the risk that toxicity caused by a component of a combination regimen could have a material adverse impact on the development of our product candidates. There can be no assurances given that the combination regimens being studied will display tolerability or efficacy suitable to warrant further testing or produce data that is sufficient to obtain marketing approval.

If any of our product candidates receives marketing approval and we, or others, later identify unacceptable adverse events caused by the product, a number of significant negative consequences could result, including:

regulatory authorities may withdraw their approval of the affected product;

regulatory authorities may require a more significant clinical benefit for approval to offset the risk;

regulatory authorities may require the addition of labeling statements that could diminish the usage of the product or otherwise limit the commercial success of the affected product;

we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;

we may choose to discontinue sale of the product;

we could be sued and held liable for harm caused to patients;

we may not be able to enter into collaboration agreements on acceptable terms and execute on our business model; and

our reputation may suffer.

Any one or a combination of these events could prevent us from obtaining or maintaining regulatory approval and achieving or maintaining market acceptance of the affected product or could substantially increase the costs and expenses of commercializing the affected product, which in turn could delay or prevent us from generating any revenues from the sale of the affected product.

We may experience delays in the commencement of our clinical trials or in the receipt of data from preclinical and clinical trials conducted by third parties, which could result in increased costs and delay our ability to pursue regulatory approval.

Delays in the commencement of clinical trials and delays in the receipt of data from preclinical or clinical trials conducted by third parties could significantly impact our product development costs. Before we can initiate clinical trials in the United States for our product candidates, we need to submit the results of preclinical testing, usually in animals, to the FDA as part of an IND, along with other information including information about product chemistry, manufacturing and controls and its proposed clinical trial protocol for our product candidates.

We plan to rely on preclinical and clinical trial data from third parties, if any, for the IND submissions for our product candidates. If receipt of that data is delayed for any reason, including reasons outside of our control, it will delay our plans for IND filings, and clinical trial plans. This, in turn, will delay our ability to make subsequent regulatory filings and ultimately, to commercialize our products if regulatory approval is obtained. If those third parties do not make this data available to us, we will likely, on our own, have to develop all the necessary preclinical and clinical data which will lead to additional delays and increase the costs of our development of our product candidates.

Before we can test any product candidate in human clinical trials the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as in-vitro and animal studies to assess the potential safety and activity of the pharmaceutical product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including good laboratory practices (“GLP”).

We must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the IND on a clinical hold within that 30-day time period. In such a case, we must work with the FDA to resolve any outstanding concerns before the clinical trials can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trial.

The FDA may require that we conduct additional preclinical testing for any product candidate before it allows us to initiate the clinical testing under any IND, which may lead to additional delays and increase the costs of our preclinical development.

Even assuming an active IND for a product candidate, we do not know whether our planned clinical trials for any such product candidate will begin on time, or at all. The commencement of clinical trials can be delayed for a variety of reasons, including delays in:

obtaining regulatory clearance to commence a clinical trial;

identifying, recruiting and training suitable clinical investigators;

reaching agreement on acceptable terms with prospective contract research organizations (“CROs”) and trial sites, the terms of which can be subject to extensive negotiation, may be subject to modification from time to time and may vary significantly among different CROs and trial sites;

obtaining sufficient quantities of a product candidate for use in clinical trials;

obtaining institutional review board (“IRB”) or ethics committee approval to conduct a clinical trial at a prospective site;

identifying, recruiting and enrolling patients to participate in a clinical trial;

retaining patients who have initiated a clinical trial but may withdraw due to adverse events from the therapy, insufficient efficacy, fatigue with the clinical trial process or personal issues; and

unexpected safety findings.

Any delays in the commencement of our clinical trials will delay our ability to pursue regulatory approval for our product candidates. In addition, many of the factors that cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate.

Delays in the completion of clinical testing could result in increased costs and delay our ability to generate product revenues.

Once a clinical trial has begun, patient recruitment and enrollment may be slower than we anticipate. Clinical trials may also be delayed as a result of ambiguous or negative interim results. Further, a clinical trial may be suspended or terminated by us, an IRB, an ethics committee or a Data Safety and Monitoring Committee overseeing the clinical trial, any of our clinical trial sites with respect to that site or the FDA or other regulatory authorities due to a number of factors, including:

failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;

inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;

unforeseen safety issues or any determination that the clinical trial presents unacceptable health risks; and

lack of adequate funding to continue the clinical trial.

Changes in regulatory requirements and guidance also may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for re-examination, which may impact the costs, timing and successful completion of a clinical trial. If we experience delays in the completion of, or if we must terminate, any clinical trial of any product candidate that we advance into clinical trials, our ability to obtain regulatory approval for that product candidate will be delayed and the commercial prospects, if any, for the product candidate may be harmed. In addition, many of these factors may also ultimately lead to the denial of regulatory approval of a product candidate. Even if we ultimately commercialize any of our product candidates, other therapies for the same indications may have been introduced to the market during the period we have been delayed and such therapies may have established a competitive advantage over our product candidates.

We intend to rely on third parties to help conduct our planned clinical trials. If these third parties do not meet their deadlines or otherwise conduct the trials as required, we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.

We intend to use CROs to assist in the conduct of our planned clinical trials and will rely upon medical institutions, clinical investigators and contract laboratories to conduct our trials in accordance with our clinical protocols. Our future CROs, investigators and other third parties may play a significant role in the conduct of these trials and the subsequent collection and analysis of data from the clinical trials.

There is no guarantee that any CROs, investigators and other third parties will devote adequate time and resources to our clinical trials or perform as contractually required. If any third parties upon whom we rely for administration and conduct of our clinical trials fail to meet expected deadlines, fail to adhere to its clinical protocols or otherwise perform in a substandard manner, our clinical trials may be extended, delayed or terminated, and we may not be able to commercialize our product candidates.

If any of our clinical trial sites terminate for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be jeopardized.

As all of our product candidates are still under development, manufacturing and process improvements implemented in the production of those product candidates may affect their ultimate activity or function.

Our product candidates are in the initial stages of development and are currently manufactured in small batches for use in pre-clinical and clinical studies. Process improvements implemented to date have changed, and process improvements in the future may change, the activity profile of the product candidates, which may affect the safety and efficacy of the products. No assurance can be given that the material manufactured from any of the optimized processes will perform comparably to the product candidates as manufactured to date and used in currently available pre-clinical data and or in early clinical trials reported in this or any previous filing. Additionally, future clinical trial results will be subject to the same level of uncertainty if, following such trials, additional process improvements are made. In addition, we are currently in the process of engaging a secondary manufacturer for TG-1101 to meet our current clinical and future commercial needs and anticipate engaging additional manufacturing sources for TGR-1202 to meet expanded clinical trial and commercial needs. No assurance can be given that the secondary manufacturing will be successful or that material manufactured by the secondary manufacturer will perform comparably to TG-1101 or TGR-1202 as manufactured to date and used in currently available pre-clinical data and or in early clinical trials reported in this or any previous filing. If the secondary manufacturer is not successful in replicating the product or experiences delays, or if regulatory authorities impose unforeseen requirements with respect to product comparability from multiple manufacturing sources, we may experience delays in clinical development.

If we fail to adequately understand and comply with the local laws and customs as we expand into new international markets, these operations may incur losses or otherwise adversely affect our business and results of operations.

We expect to operate a portion of our business in certain countries through subsidiaries or through supply and marketing arrangements. In those countries, where we have limited experience in operating subsidiaries and in reviewing equity investees, we will be subject to additional risks related to complying with a wide variety of national and local laws, including restrictions on the import and export of certain intermediates, drugs, technologies and multiple and possibly overlapping tax structures. In addition, we may face competition in certain countries from companies that may have more experience with operations in such countries or with international operations generally. We may also face difficulties integrating new facilities in different countries into our existing operations, as well as integrating employees hired in different countries into our existing corporate culture. If we do not effectively manage our operations in these subsidiaries and review equity investees effectively, or if we fail to manage our alliances, we may lose money in these countries and it may adversely affect our business and results of our operations.

If our competitors develop treatments for the target indications for which any of our product candidates may be approved, and they are approved more quickly, marketed more effectively or demonstrated to be more effective than our product candidates, our commercial opportunity will be reduced or eliminated.

We operate in a highly competitive segment of the biotechnology and biopharmaceutical market. We face competition from numerous sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. Many of our competitors have significantly greater financial, product development, manufacturing and marketing resources. Large pharmaceutical companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. Additionally, many universities and private and public research institutes are active in cancer research, some in direct competition with us. We may also compete with these organizations to recruit scientists and clinical development personnel. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

The cancer indications for which we are developing our products have a number of established therapies with which we will compete. Most major pharmaceutical companies and many biotechnology companies are aggressively pursuing new cancer development programs for the treatment of NHL, CLL, and other B-cell proliferative malignancies, including both therapies with traditional, as well as novel, mechanisms of action.

If approved, we expect TG-1101 to compete directly with Roche Group’s Rituxan^® (rituximab) and Gazyva^® (obinutuzumab or GA-101), Spectrum Pharmaceuticals’ Zevalin^® (Y⁹⁰-Ibritumomab Tiuxetan), and Genmab and GlaxoSmithKline’s Arzerra^® (ofatumumab) among others, each of which is currently approved for the treatment of various diseases including NHL and CLL. In addition, a number of pharmaceutical companies are developing antibodies targeting CD20, CD19, and other B-cell associated targets, chimeric antigen receptor T-cell (CAR-T) immunotherapy, and other B-cell ablative therapy which, if approved, would potentially compete with TG-1101. New developments, including the development of other pharmaceutical technologies and methods of treating disease, occur in the pharmaceutical and life sciences industries at a rapid pace.

With respect to TGR-1202, there are several PI3K delta targeted compounds both approved, such as Gilead’s Zydelig™ (idelalisib), and in development, including, but not limited to, Infinity Pharmaceuticals’ duvelisib (IPI-145), which if approved we would expect to compete directly with TGR-1202. In addition, there are numerous other novel therapies targeting similar pathways to TGR-1202 both approved and in development, which could also compete with TGR-1202 in similar indications, such as the BTK inhibitor, ibrutinib (FDA approved for MCL, CLL, and WM and marketed by Pharmacyclics and Janssen), or the bcl-2 inhibitor ABT-199 (under clinical development by AbbVie and Roche).

These developments may render our product candidates obsolete or noncompetitive. Compared to us, many of our potential competitors have substantially greater:

research and development resources, including personnel and technology;

regulatory experience;

pharmaceutical development, clinical trial and pharmaceutical commercialization experience;

experience and expertise in exploitation of intellectual property rights; and

capital resources.

As a result of these factors, our competitors may obtain regulatory approval of their products more rapidly than us or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop products for the treatment of lymphoma or CLL that are more effective, better tolerated, more useful and less costly than ours and may also be more successful in manufacturing and marketing their products. Our competitors may succeed in obtaining approvals from the FDA and foreign regulatory authorities for their product candidates sooner than we do for our products.

We will also face competition from these third parties in recruiting and retaining qualified personnel, establishing clinical trial sites and enrolling patients for clinical trials and in identifying and in-licensing new product candidates.

We rely completely on third parties to manufacture our preclinical and clinical pharmaceutical supplies and we intend to rely on third parties to produce commercial supplies of any approved product candidate, and our commercialization of any of our product candidates could be stopped, delayed or made less profitable if those third parties fail to obtain approval of the FDA, fail to provide us with sufficient quantities of pharmaceutical product or fail to do so at acceptable quality levels or prices.

The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted only after we submit a BLA or NDA to the FDA, if at all. We do not control the manufacturing process of our product candidates and are completely dependent on our contract manufacturing partners for compliance with the FDA’s requirements for manufacture of finished pharmaceutical products (good manufacturing practices, GMP). If our contract manufacturers cannot successfully manufacture material that conforms to our target product specifications, patent specifications, and/or the FDA’s strict regulatory requirements of safety, purity and potency, we will not be able to secure and/or maintain FDA approval for our product candidates. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If our contract manufacturers cannot meet FDA standards, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates. No assurance can be given that a long-term, scalable manufacturer can be identified or that they can make clinical and commercial supplies of our product candidates that meet the product specifications of previously manufactured batches, or is of a sufficient quality, or at an appropriate scale and cost to make it commercially feasible. If they are unable to do so, it could have a material adverse impact on our business.

In addition, we do not have the capability to package finished products for distribution to hospitals and other customers. Prior to commercial launch, we intend to enter into agreements with one or more alternate fill/finish pharmaceutical product suppliers so that we can ensure proper supply chain management once we are authorized to make commercial sales of our product candidates. If we receive marketing approval from the FDA, we intend to sell pharmaceutical product finished and packaged by such suppliers. We have not entered into long-term agreements with our current contract manufacturers or with any fill/finish suppliers, and though we intend to do so prior to commercial launch of our product candidates in order to ensure that we maintain adequate supplies of finished product, we may be unable to enter into such an agreement or do so on commercially reasonable terms, which could have a material adverse impact upon our business.

In most cases, our manufacturing partners are single source suppliers. It is expected that our manufacturing partners will be sole source suppliers from single site locations for the foreseeable future. Given this, any disruption of supply from these partners could have a material, long-term impact on our ability to supply products for clinical trials or commercial sale. If our suppliers do not deliver sufficient quantities of our product candidates on a timely basis, or at all, and in accordance with applicable specifications, there could be a significant interruption of our supply, which would adversely affect clinical development and commercialization of our products. In addition, if our current or future supply of any or our product candidates should fail to meet specifications during its stability program there could be a significant interruption of our supply of drug, which would adversely affect the clinical development and commercialization of the product.

We currently have no marketing and sales organization and no experience in marketing pharmaceutical products. If we are unable to establish sales and marketing capabilities or fail to enter into agreements with third parties to market and sell any products we may develop, we may not be able to effectively market and sell our products and generate product revenue.

We do not currently have the infrastructure for the sales, marketing and distribution of our biotechnology products, and we must build this infrastructure or make arrangements with third parties to perform these functions in order to commercialize our products. We plan to either develop internally or enter into collaborations or other commercial arrangements to develop further, promote and sell all or a portion of our product candidates.

The establishment and development of a sales force, either by us or jointly with a development partner, or the establishment of a contract sales force to market any products we may develop will be expensive and time-consuming and could delay any product launch, and we cannot be certain that we or our development partners would be able to successfully develop this capability. If we or our development partners are unable to establish sales and marketing capability or any other non-technical capabilities necessary to commercialize any products we may develop, we will need to contract with third parties to market and sell such products. We currently possess limited resources and may not be successful in establishing our own internal sales force or in establishing arrangements with third parties on acceptable terms, if at all.

If any product candidate that we successfully develop does not achieve broad market acceptance among physicians, patients, healthcare payors, and the medical community, the revenues that we generate from its sales will be limited.

Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors, and the medical community. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is also necessary for commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including:

the efficacy and safety as demonstrated in clinical trials;

the clinical indications for which the product is approved;

acceptance by physicians, major operators of cancer clinics and patients of the product as a safe and effective treatment;

the potential and perceived advantages of product candidates over alternative treatments;

the safety of product candidates seen in a broader patient group, including its use outside the approved indications;

the cost of treatment in relation to alternative treatments;

the availability of adequate reimbursement and pricing by third parties and government authorities;

relative convenience and ease of administration;

the prevalence and severity of adverse events; and

the effectiveness of our sales and marketing efforts.

If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate sufficient revenue from these products and we may not become or remain profitable.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.

We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials, and will face an even greater risk if we sell our product candidates commercially. Although we are not aware of any historical or anticipated product liability claims against us, if we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to cease clinical trials of our drug candidates or limit commercialization of any approved products. An individual may bring a liability claim against us if one of our product candidates causes, or merely appears to have caused, an injury. If we cannot successfully defend our self against product liability claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

decreased demand for our product candidates;

impairment to our business reputation;

withdrawal of clinical trial participants;

costs of related litigation;

distraction of management’s attention from our primary business;

substantial monetary awards to patients or other claimants;

the inability to commercialize our product candidates; and

loss of revenues.

We believe that we have obtained sufficient product liability insurance coverage for our clinical trials. We intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for any of our product candidates. However, we may be unable to obtain this product liability insurance on commercially reasonable terms and with insurance coverage that will be adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in class action or individual lawsuits relating to marketed pharmaceuticals. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.

Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.

We intend to seek approval to market our future products in both the United States and in countries and territories outside the United States. If we obtain approval in one or more foreign countries, we will be subject to rules and regulations in those countries relating to our product. In some foreign countries, particularly in the European Union, the pricing of prescription pharmaceuticals and biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for any of our product candidates and may be affected by existing and future healthcare reform measures.

Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which pharmaceuticals they will pay for and establish reimbursement levels. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor’s determination that use of a product is:

a covered benefit under its health plan;

safe, effective and medically necessary;

appropriate for the specific patient;

cost-effective; and

neither experimental nor investigational.

Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require that we provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Additionally, while we may seek approval of our products in combination with each other, there can be no guarantee that we will obtain coverage and reimbursement for any of our products together, or that such reimbursement will incentivize the use of our products in combination with each other as opposed to in combination with other agents which may be priced more favorably to the medical community.

In both the United States and certain foreign countries, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably. In particular, the Medicare Modernization Act of 2003 revised the payment methodology for many products reimbursed by Medicare, resulting in lower rates of reimbursement for many types of drugs, and added a prescription drug benefit to the Medicare program that involves commercial plans negotiating drug prices for their members. Since 2003, there have been a number of other legislative and regulatory changes to the coverage and reimbursement landscape for pharmaceuticals. Most recently, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the “Affordable Care Act,” was enacted. The Affordable Care Act contains a number of provisions, including those governing enrollment in federal healthcare programs, the increased use of comparative effectiveness research on healthcare products, reimbursement and fraud and abuse changes, and a new regulatory pathway for the approval of biosimilar biological products, all of which will impact existing government healthcare programs and will result in the development of new programs. An expansion in the government’s role in the U.S. healthcare industry may further lower rates of reimbursement for pharmaceutical and biotechnology products.

There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare products and services. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:

the demand for any products for which we may obtain regulatory approval;

our ability to set a price that we believe is fair for our products;

our ability to generate revenues and achieve or maintain profitability;

the level of taxes that we are required to pay; and

the availability of capital.

In addition, governments may impose price controls, which may adversely affect our future profitability.

We will need to increase the size of our organization and the scope of our outside vendor relationships, and we may experience difficulties in managing this growth.

As of September 30, 2015, we had approximately thirty full and part time employees. Over time, we will need to expand our managerial, operational, financial and other resources in order to manage and fund our operations and clinical trials, continue research and development activities, and commercialize our product candidates. Our management and scientific personnel, systems and facilities currently in place may not be adequate to support our future growth. Our need to effectively manage our operations, growth, and various projects requires that we:

manage our clinical trials effectively;

manage our internal development efforts effectively while carrying out our contractual obligations to licensors, contractors and other third parties;

continue to improve our operational, financial and management controls and reporting systems and procedures; and

attract and retain sufficient numbers of talented employees.

We may utilize the services of outside vendors or consultants to perform tasks including clinical trial management, statistics and analysis, regulatory affairs, formulation development, chemistry, manufacturing, controls, and other pharmaceutical development functions. Our growth strategy may also entail expanding our group of contractors or consultants to implement these tasks going forward. Because we rely on a substantial number of consultants, effectively outsourcing many key functions of our business, we will need to be able to effectively manage these consultants to ensure that they successfully carry out their contractual obligations and meet expected deadlines. However, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for our product candidates or otherwise advance its business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may be unable to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.

If we fail to attract and keep key management and clinical development personnel, we may be unable to successfully develop or commercialize our product candidates.

We will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts for our product candidates and future product candidates. We are highly dependent on the development, regulatory, commercial and financial expertise of the members of our senior management. The loss of the services of any of our senior management could delay or prevent the further development and potential commercialization of our product candidates and, if we are not successful in finding suitable replacements, could harm our business. We do not maintain “key man” insurance policies on the lives of these individuals. We will need to hire additional personnel as we continue to expand our manufacturing, research and development activities.

Our success depends on our continued ability to attract, retain and motivate highly qualified management and scientific personnel and we may not be able to do so in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that will impede significantly the achievement of our development objectives, our ability to raise additional capital, and our ability to implement our business strategy.

If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.

In addition to FDA restrictions on the marketing of pharmaceutical and biotechnology products, several other types of state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical and medical device industries in recent years, as well as consulting or other service agreements with physicians or other potential referral sources. These laws include anti-kickback statutes and false claims statutes that prohibit, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or, in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally-financed healthcare programs, and knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and any practices we adopt may not, in all cases, meet all of the criteria for safe harbor protection from anti-kickback liability. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer’s products from reimbursement under government programs, criminal fines and imprisonment. Any challenge to its business practices under these laws could have a material adverse effect on our business, financial condition, and results of operations.

We use biological and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.

We use hazardous materials, including chemicals and biological agents and compounds, which could be dangerous to human health and safety or the environment. Our operations also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our pharmaceutical development efforts.

In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. If one of our employees was accidentally injured from the use, storage, handling or disposal of these materials or wastes, the medical costs related to his or her treatment would be covered by our workers’ compensation insurance policy. However, we do not carry specific biological or hazardous waste insurance coverage and our property and casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, or operations otherwise affected.

All product candidate development timelines and projections in this report are based on the assumption of further financing.

The timelines and projections in this report are predicated upon the assumption that we will raise additional financing in the future to continue the development of our product candidates. In the event we do not successfully raise subsequent financing, our product development activities will necessarily be curtailed commensurate with the magnitude of the shortfall. If our product development activities are slowed or stopped, we would be unable to meet the timelines and projections outlined in this filing. Failure to progress our product candidates as anticipated will have a negative effect on our business, future prospects, and ability to obtain further financing on acceptable terms (if at all), and the value of the enterprise.

Risks Relating to Acquisitions

Acquisitions, investments and strategic alliances that we may make in the future may use significant resources, result in disruptions to our business or distractions of our management, may not proceed as planned, and could expose us to unforeseen liabilities.

We may seek to expand our business through the acquisition of, investments in and strategic alliances with companies, technologies, products, and services. Acquisitions, investments and strategic alliances involve a number of special problems and risks, including, but not limited to:

difficulty integrating acquired technologies, products, services, operations and personnel with the existing businesses;

diversion of management’s attention in connection with both negotiating the acquisitions and integrating the businesses;

strain on managerial and operational resources as management tries to oversee larger operations;

difficulty implementing and maintaining effective internal control over financial reporting at businesses that we acquire, particularly if they are not located near our existing operations;

exposure to unforeseen liabilities of acquired companies;

potential costly and time-consuming litigation, including stockholder lawsuits;

potential issuance of securities to equity holders of the company being acquired with rights that are superior to the rights of holders of our common stock or which may have a dilutive effect on our stockholders;

risk of loss of invested capital;

the need to incur additional debt or use cash; and

the requirement to record potentially significant additional future operating costs for the amortization of intangible assets.

As a result of these or other problems and risks, businesses we acquire may not produce the revenues, earnings, or business synergies that we anticipated, and acquired products, services, or technologies might not perform as we expected. As a result, we may incur higher costs and realize lower revenues than we had anticipated. We may not be able to successfully address these problems and we cannot assure you that the acquisitions will be successfully identified and completed or that, if acquisitions are completed, the acquired businesses, products, services, or technologies will generate sufficient revenue to offset the associated costs or other negative effects on our business.

Any of these risks can be greater if an acquisition is large relative to our size. Failure to effectively manage our growth through acquisitions could adversely affect our growth prospects, business, results of operations, financial condition and cash flows.

Risks Relating to Our Intellectual Property

Our success depends upon our ability to protect our intellectual property and proprietary technologies, and the intellectual property protection for our product candidates depends significantly on third parties.

Our commercial success depends on obtaining and maintaining patent protection and trade secret protection for our product candidates and their formulations and uses, as well as successfully defending these patents against third-party challenges. If any of our licensors or partners fails to appropriately prosecute and maintain patent protection for these product candidates, our ability to develop and commercialize these product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. This failure to properly protect the intellectual property rights relating to these product candidates could have a material adverse effect on our financial condition and results of operations.

Currently, the composition of matter patent and several method of use patents for TG-1101 in various indications and settings have been applied for but have not yet been issued, or have not yet been issued in all jurisdictions in which such applications have been filed. While a composition of matter patent has been granted in the US for TGR-1202, composition of matter patents and/or method of use patents for our IRAK4 inhibitor program and anti-PD-L1 and anti-GITR programs have also been applied for but have not yet been issued to date. There can be no guarantee that any of these patents for which an application has already been filed, nor any patents filed in the future for our product candidates will be granted in any or all jurisdictions in which there were filed, or that all claims initially included in such patent applications will be allowed in the final patent that is issued. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our partners will be successful in protecting our product candidates by obtaining and defending patents.

These risks and uncertainties include the following:

the patent applications that we or our partners file may not result in any patents being issued;

patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked or circumvented, or otherwise may not provide any competitive advantage;

as of March 16, 2013, the U.S. converted from a “first to invent” to a “first to file” system. If we do not win the filing race, we will not be entitled to inventive priority;

our competitors, many of which have substantially greater resources than we do, and many of which have made significant investments in competing technologies, may seek, or may already have obtained, patents that will limit, interfere with, or eliminate its ability to make, use, and sell our potential products either in the United States or in international markets;

there may be significant pressure on the U.S. government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful as a matter of public policy regarding worldwide health concerns; and

countries other than the United States may have less restrictive patent laws than those upheld by United States courts, allowing foreign competitors the ability to exploit these laws to create, develop, and market competing products.

If patents are not issued that protect our product candidates, it could have a material adverse effect on our financial condition and results of operations.

In addition to patents, we and our partners also rely on trade secrets and proprietary know-how. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, third parties may still obtain this information or we may be unable to protect its rights. If any of these events occurs, or we otherwise lose protection for our trade secrets or proprietary know-how, the value of this information may be greatly reduced.

Patent protection and other intellectual property protection are crucial to the success of our business and prospects, and there is a substantial risk that such protections will prove inadequate.

If we or our partners are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.

Our commercial success also depends upon our ability and the ability of any of our future collaborators to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products, some of which may be directed at claims that overlap with the subject matter of our intellectual property. For example, Roche has the Cabilly patents in the U.S. that block the commercialization of antibody products derived from a single cell line, like TG-1101. Also, Roche, Biogen Idec, and Genentech hold patents for the use of anti-CD20 antibodies utilized in the treatment of CLL in the U.S. While these patents have been challenged, to the best of our knowledge, those matters were settled in a way that permitted additional anti-CD20 antibodies to be marketed for CLL. If those patents are still enforced at the time we are intending to launch TG-1101, then we will need to either prevail in a litigation to challenge those patents or negotiate a settlement agreement with the patent holders. If we are unable to do so we may be forced to delay the launch of TG-1101 or launch at the risk of litigation for patent infringement, which may have a material adverse effect on our business and results of operations.

In addition, because patent applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that our product candidates or proprietary technologies may infringe. Similarly, there may be issued patents relevant to our product candidates of which we are not aware.

There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we or any collaborators of ours infringe their intellectual property rights, we may have to:

obtain licenses, which may not be available on commercially reasonable terms, if at all;

abandon an infringing product candidate or redesign its products or processes to avoid infringement;

pay substantial damages, including treble damages and attorneys’ fees, which we may have to pay if a court decides that the product or proprietary technology at issue infringes on or violates the third party’s rights;

pay substantial royalties, fees and/or grant cross licenses to our technology; and/or

defend litigation or administrative proceedings which may be costly whether we win or lose, and which could result in a substantial diversion of our financial and management resources.

No assurance can be given that patents issued to third parties do not exist, have not been filed, or could not be filed or issued, which contain claims covering its products, technology or methods that may encompass all or a portion of our products and methods. Given the number of patents issued and patent applications filed in our technical areas or fields, we believe there is a risk that third parties may allege they have patent rights encompassing our products or methods.

Other product candidates that we may in-license or acquire could be subject to similar risks and uncertainties.

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which typically are very expensive, time-consuming and disruptive of day-to-day business operations. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly. The adverse result could also put related patent applications at risk of not issuing.

Interference proceedings provoked by third parties or brought by the U.S. Patent and Trademark Office (“PTO”) may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our collaborators or licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.

We may be subject to claims that our consultants or independent contractors have wrongfully used or disclosed alleged trade secrets of their other clients or former employers to it.

As is common in the biotechnology and pharmaceutical industry, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants were previously employed at, may have previously been, or are currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or their former or current customers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and day-to-day business operations.

Risks Relating to Our Finances and Capital Requirements

We will need to raise additional capital to continue to operate our business.

As of September 30, 2015, we had net cash, cash equivalents, investment securities and interest receivable of approximately $115.4 million. We believe that our cash and cash equivalents and investments, inclusive of the amounts raised subsequent to the end of the quarter, will sustain our operations for more than 24 months from September 30, 2015. As a result, we will need additional capital to continue our operations beyond that time. Required additional sources of financing to continue our operations in the future might not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we might be unable to complete planned preclinical and clinical trials or obtain approval of any of our product candidates from the FDA or any foreign regulatory authorities. In addition, we could be forced to discontinue product development, reduce or forego sales and marketing efforts and forego attractive business opportunities. Any additional sources of financing will likely involve the issuance of our equity securities, which would have a dilutive effect to stockholders.

Currently, none of our product candidates have been approved by the FDA or any foreign regulatory authority for sale. Therefore, for the foreseeable future, we will have to fund all of our operations and capital expenditures from cash on hand and amounts raised in future offerings or financings.

We have a history of operating losses, expect to continue to incur losses, and are unable to predict the extent of future losses or when we will become profitable, if ever.

We have not yet demonstrated an ability to obtain regulatory approval for or commercialize a product candidate. Our short operating history makes it difficult to evaluate our business prospects and consequently, any predictions about our future performance may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical or biotechnology products. Our prospects must be considered in light of the uncertainties, risks, expenses and difficulties frequently encountered by companies in the early stages of operations and the competitive environment in which we operate.

We have never been profitable and, as of September 30, 2015, we had an accumulated deficit of $140.5 million. We have generated operating losses in all periods since we were incorporated. We expect to make substantial expenditures resulting in increasing operating costs in the future and our accumulated deficit will increase significantly as we expand development and clinical trial efforts for our product candidates. Our losses have had, and are expected to continue to have, an adverse impact on our working capital, total assets and stockholders’ equity. Because of the risks and uncertainties associated with product development, we are unable to predict the extent of any future losses or when we will become profitable, if ever. Even if we achieve profitability, we may not be able to sustain or increase profitability on an ongoing basis.

We have not generated any revenue from our product candidates and may never become profitable.

Our ability to become profitable depends upon our ability to generate significant continuing revenues. To obtain significant continuing revenues, we must succeed, either alone or with others, in developing, obtaining regulatory approval for and manufacturing and marketing our product candidates (or utilize early access programs to generate such revenue). To date, our product candidates have not generated any revenues, and we do not know when, or if, we will generate any revenue. Our ability to generate revenue depends on a number of factors, including, but not limited to:

successful completion of preclinical studies of our product candidates;

successful commencement and completion of clinical trials of our product candidates and any future product candidates we advance into clinical trials;

achievement of regulatory approval for our product candidates and any future product candidates we advance into clinical trials (unless we successfully utilize early access programs which allow for revenue generation prior to approval);

manufacturing commercial quantities of our products at acceptable cost levels if regulatory approvals are obtained;

successful sales, distribution and marketing of our future products, if any; and

our entry into collaborative arrangements or co-promotion agreements to market and sell our products.

If we are unable to generate significant continuing revenues, we will not become profitable and we may be unable to continue our operations without continued funding.

We will need substantial additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our development programs or commercialization efforts.

We expect to spend substantial amounts on development, including significant amounts on conducting clinical trials for our product candidates, manufacturing clinical supplies and expanding our pharmaceutical development programs. We expect that our monthly cash used by operations will continue to increase for the next several years. We anticipate that we will continue to incur operating losses for the foreseeable future.

We will require substantial additional funds to support our continued research and development activities, as well as the anticipated costs of preclinical studies and clinical trials, regulatory approvals, and eventual commercialization. We anticipate that we will incur operating losses for the foreseeable future. We have based these estimates, however, on assumptions that may prove to be wrong, and we could expend our available financial resources much faster than we currently expect. Further, we will need to raise additional capital to fund our operations and continue to conduct clinical trials to support potential regulatory approval of marketing applications. Future capital requirements will also depend on the extent to which we acquire or in-license additional product candidates. We currently have no commitments or agreements relating to any of these types of transactions.

The amount and timing of our future funding requirements will depend on many factors, including, but not limited to, the following:

the progress of our clinical trials, including expenses to support the trials and milestone payments that may become payable under our license agreements;

the costs and timing of regulatory approvals;

the costs and timing of clinical and commercial manufacturing supply arrangements for each product candidate;

the costs of establishing sales or distribution capabilities;

the success of the commercialization of our products;

our ability to establish and maintain strategic collaborations, including licensing and other arrangements;

the costs involved in enforcing or defending patent claims or other intellectual property rights; and

the extent to which we in-license or invest in other indications or product candidates.

Until we can generate a sufficient amount of product revenue and achieve profitability, we expect to finance future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances. If we were to be unable to raise additional capital, we would have to significantly delay, scale back or discontinue one or more of our pharmaceutical development programs. We also may be required to relinquish, license or otherwise dispose of rights to product candidates or products that it would otherwise seek to develop or commercialize itself on terms that are less favorable than might otherwise be available.

Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.

We may raise additional funds through public or private equity offerings, debt financings or licensing arrangements. To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt financing we enter into may involve covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, redeem our stock, make certain investments and engage in certain merger, consolidation or asset sale transactions, among other restrictions.

In addition, if we raise additional funds through licensing arrangements, it may be necessary to relinquish potentially valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. If adequate funds are not available, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and we may be required to delay, significantly curtail or eliminate the development of one or more of our product candidates.

Risks Related to Our Common Stock

We are controlled by current officers, directors and principal stockholders.

Our directors, executive officers, their affiliates, and our principal stockholders beneficially own approximately 40% of our outstanding voting stock, including shares underlying outstanding options and warrants. Our directors, officers and principal stockholders, taken as a whole, have the ability to exert substantial influence over the election of our Board of Directors and the outcome of issues submitted to our stockholders.

Our stock price is, and we expect it to remain, volatile, which could limit investors’ ability to sell stock at a profit.

The trading price of our common stock is likely to be highly volatile and subject to wide fluctuations in price in response to various factors, many of which are beyond our control. These factors include:

publicity regarding actual or potential clinical results relating to products under development by our competitors or us;

delay or failure in initiating, completing or analyzing nonclinical or clinical trials or the unsatisfactory design or results of these trials;

achievement or rejection of regulatory approvals by our competitors or us;

announcements of technological innovations or new commercial products by our competitors or us;

developments concerning proprietary rights, including patents;

developments concerning our collaborations;

regulatory developments in the United States and foreign countries;

economic or other crises and other external factors;

period-to-period fluctuations in our revenues and other results of operations;

changes in financial estimates by securities analysts; and

sales of our common stock.

We will not be able to control many of these factors, and we believe that period-to-period comparisons of our financial results will not necessarily be indicative of our future performance.

In addition, the stock market in general, and the market for biotechnology companies in particular, has experienced extreme price and volume fluctuations that may have been unrelated or disproportionate to the operating performance of individual companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance.

We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of your stock.

We have never paid dividends on our common stock and do not anticipate paying any dividends for the foreseeable future. You should not rely on an investment in our stock if you require dividend income. Further, you will only realize income on an investment in our stock in the event you sell or otherwise dispose of your shares at a price higher than the price you paid for your shares. Such a gain would result only from an increase in the market price of our common stock, which is uncertain and unpredictable.

Certain anti-takeover provisions in our charter documents and Delaware law could make a third-party acquisition of us difficult. This could limit the price investors might be willing to pay in the future for our common stock.

Provisions in our amended and restated certificate of incorporation and restated bylaws could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, or control us. These factors could limit the price that certain investors might be willing to pay in the future for shares of our common stock. Our amended and restated certificate of incorporation allows us to issue preferred stock without the approval of our stockholders. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock or could adversely affect the rights and powers, including voting rights, of such holders. In certain circumstances, such issuance could have the effect of decreasing the market price of our common stock. Our restated bylaws eliminate the right of stockholders to call a special meeting of stockholders, which could make it more difficult for stockholders to effect certain corporate actions. Any of these provisions could also have the effect of delaying or preventing a change in control.

On July 18, 2014, the Board of Directors declared a distribution of one right for each outstanding share of common stock. The rights may have certain anti-takeover effects. The rights will cause substantial dilution to a person or group that attempts to acquire us on terms not approved by the Board of Directors unless the offer is conditioned on a substantial number of rights being acquired. However, the rights should not interfere with any merger, statutory share exchange or other business combination approved by the Board of Directors since the rights may be terminated by us upon resolution of the Board of Directors. Thus, the rights are intended to encourage persons who may seek to acquire control of the Company to initiate such an acquisition through negotiations with the Board of Directors. However, the effect of the rights may be to discourage a third party from making a partial tender offer or otherwise attempting to obtain a substantial equity position in the equity securities of, or seeking to obtain control of, the Company. To the extent any potential acquirers are deterred by the rights, the rights may have the effect of preserving incumbent management in office.

ITEM 6. EXHIBITS

The exhibits listed on the Exhibit Index are included with this report.

	31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated November 9, 2015.

	31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated November 9, 2015.

	32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated November 9, 2015.

	32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated November 9, 2015.

	101	The following financial information from the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2015, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statement of Equity, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Condensed Consolidated Financial Statements (filed herewith).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TG THERAPEUTICS, INC.

Date: November 9, 2015	By:	/s/ Sean A. Power
		Sean A. Power
		Chief Financial Officer
		Principal Financial and Accounting Officer

EXHIBIT INDEX

The following exhibits are included as part of this Quarterly Report on Form 10-Q:

	31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated November 9, 2015.

	31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated November 9, 2015.

	32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated November 9, 2015.

	32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated November 9, 2015.

	101	The following financial information from the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2015, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statement of Equity, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Condensed Consolidated Financial Statements (filed herewith).

EX-31.1 2 v422880_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael S. Weiss, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of TG Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2015	/s/ Michael S. Weiss
	Michael S. Weiss
	Executive Chairman, Interim Chief Executive Officer and President
	Principal Executive Officer

EX-31.2 3 v422880_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Sean A. Power, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of TG Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2015	/s/ Sean A. Power
	Sean A. Power
	Chief Financial Officer
	Principal Financial and Accounting Officer

EX-32.1 4 v422880_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

STATEMENT OF CHIEF EXECUTIVE OFFICER OF
TG THERAPEUTICS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of TG Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2015 as filed with the Securities and Exchange Commission (the “Report”), I, Michael S. Weiss, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2015	/s/ Michael S. Weiss
	Michael S. Weiss
	Executive Chairman, Interim Chief Executive Officer and
	President
	Principal Executive Officer

EX-32.2 5 v422880_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

STATEMENT OF CHIEF FINANCIAL OFFICER OF
TG THERAPEUTICS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of TG Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2015 as filed with the Securities and Exchange Commission (the “Report”), I, Sean A. Power, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2015	/s/ Sean A. Power
	Sean A. Power
	Chief Financial Officer
	Principal Financial and Accounting Officer

EX-101.INS 6 tgtx-20150930.xml XBRL INSTANCE DOCUMENT 0001001316 2014-01-01 2014-09-30 0001001316 2014-01-01 2014-12-31 0001001316 2015-01-01 2015-09-30 0001001316 2014-07-01 2014-09-30 0001001316 2015-07-01 2015-09-30 0001001316 2015-09-30 0001001316 2015-11-06 0001001316 2014-12-31 0001001316 2013-12-31 0001001316 2014-09-30 0001001316 us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001001316 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-09-30 0001001316 us-gaap:RetainedEarningsMember 2015-01-01 2015-09-30 0001001316 us-gaap:PreferredStockMember 2014-12-31 0001001316 us-gaap:CommonStockMember 2014-12-31 0001001316 tgtx:ContingentlyIssuableShareMember 2014-12-31 0001001316 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001001316 us-gaap:RetainedEarningsMember 2014-12-31 0001001316 us-gaap:TreasuryStockMember 2014-12-31 0001001316 us-gaap:PreferredStockMember 2015-09-30 0001001316 us-gaap:CommonStockMember 2015-09-30 0001001316 tgtx:ContingentlyIssuableShareMember 2015-09-30 0001001316 us-gaap:AdditionalPaidInCapitalMember 2015-09-30 0001001316 us-gaap:TreasuryStockMember 2015-09-30 0001001316 us-gaap:RetainedEarningsMember 2015-09-30 0001001316 us-gaap:MinimumMember 2015-01-01 2015-09-30 0001001316 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-09-30 0001001316 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:OtherLongTermInvestmentsMember 2015-09-30 0001001316 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2015-01-01 2015-09-30 0001001316 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:OtherLongTermInvestmentsMember 2015-01-01 2015-09-30 0001001316 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2014-12-31 0001001316 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2014-01-01 2014-12-31 0001001316 tgtx:ManhattanAndAristonPharmaceuticalsMergerMember us-gaap:ConvertibleNotesPayableMember 2010-03-01 2010-03-31 0001001316 tgtx:ManhattanAndAristonPharmaceuticalsMergerMember us-gaap:ConvertibleNotesPayableMember 2010-03-31 0001001316 us-gaap:ConvertibleNotesPayableMember 2015-09-30 0001001316 us-gaap:ConvertibleNotesPayableMember 2014-12-31 0001001316 us-gaap:ConvertibleNotesPayableMember 2015-01-01 2015-09-30 0001001316 us-gaap:ConvertibleNotesPayableMember 2014-01-01 2014-12-31 0001001316 us-gaap:FairValueInputsLevel1Member 2015-09-30 0001001316 us-gaap:FairValueInputsLevel2Member 2015-09-30 0001001316 us-gaap:FairValueInputsLevel3Member 2015-09-30 0001001316 us-gaap:FairValueInputsLevel1Member 2014-12-31 0001001316 us-gaap:FairValueInputsLevel2Member 2014-12-31 0001001316 us-gaap:FairValueInputsLevel3Member 2014-12-31 0001001316 tgtx:AtmMember 2015-01-01 2015-09-30 0001001316 tgtx:EquityIncentivePlansMember 2015-09-30 0001001316 tgtx:IncentivePlanMember 2015-09-30 0001001316 us-gaap:EmployeeStockOptionMember 2014-12-31 0001001316 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001001316 us-gaap:EmployeeStockOptionMember 2015-09-30 0001001316 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0001001316 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001001316 us-gaap:RestrictedStockMember 2015-09-30 0001001316 us-gaap:RestrictedStockMember 2014-12-31 0001001316 tgtx:CorporateMilestoneMember 2015-09-30 0001001316 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001001316 tgtx:ConvertibleNotesMember 2015-09-30 0001001316 tgtx:ConvertibleNotesMember 2014-12-31 0001001316 tgtx:AristonMember us-gaap:ConvertibleNotesPayableMember 2015-01-01 2015-09-30 0001001316 us-gaap:LicensingAgreementsMember 2012-01-01 2012-12-31 0001001316 tgtx:TgOneOneZeroOneMember 2014-12-31 0001001316 tgtx:CollaborationAgreementMember 2015-01-01 2015-09-30 0001001316 tgtx:LfbGroupMember 2012-01-01 2012-01-30 0001001316 tgtx:LfbGroupMember 2012-01-30 0001001316 tgtx:LfbGroupMember us-gaap:MaximumMember 2012-11-09 0001001316 tgtx:LfbLicenseAgreementMember 2015-02-01 2015-02-28 0001001316 tgtx:LfbLicenseAgreementMember 2015-02-28 0001001316 tgtx:LfbLicenseAgreementMember 2015-01-01 2015-09-30 0001001316 tgtx:LfbGroupMember 2015-05-01 2015-05-30 0001001316 tgtx:LfbGroupMember 2015-05-30 0001001316 tgtx:LfbGroupMember 2014-01-01 2014-09-30 0001001316 tgtx:LfbGroupMember 2015-01-01 2015-09-30 0001001316 tgtx:LfbGroupMember 2015-09-30 0001001316 tgtx:LfbGroupMember 2014-12-31 0001001316 tgtx:DeskAgreementMember 2014-10-03 0001001316 tgtx:DeskAgreementMember 2015-01-01 2015-09-30 0001001316 tgtx:DeskAgreementMember 2014-10-31 0001001316 tgtx:OpusMember 2015-01-01 2015-09-30 0001001316 tgtx:OpusMember 2015-09-30 0001001316 tgtx:SharedServicesAgreementMember 2015-07-15 2015-09-30 0001001316 tgtx:CollaborationAgreementMember 2015-08-31 2015-09-01 0001001316 tgtx:AtmMember 2015-09-30 0001001316 tgtx:TgOneOneZeroOneMember 2015-09-30 0001001316 tgtx:DeskAgreementMember 2014-10-01 2014-10-03 0001001316 us-gaap:LicensingAgreementsMember 2015-01-01 2015-09-30 0001001316 tgtx:DeskAgreementMember 2015-09-30 0001001316 tgtx:AoiCommunicationsLpMember 2015-01-01 2015-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

65461940

55713784

28701209

23062034

158527

85516

9950893 6179743

457918

173952

104730487

85215029

69225

20357

799391

141717

137101

127407138

86746890

8583003

3991625

768750

702000

152381

1409524

1523810

11095326

6645006

52558

44974

6 6

257015699

175476521

234337

-140522114

-95185280

116311812

80101884

127407138

86746890

578126

575012

21088192

181668

275190

9685802

5121196

114286

0 5350094 4138844 0 2733110 6402296

29719891

13197183

38096

35756 1200575

11538246

8352154

11574002

13691573

32453001

24949573

1204278 2895997 10106938 9664560

1085400

889872

3094362

2500121

2289678

3785869

13201300

12164681

13863680

17477442

45654301

37114254

-13825584

-17439346

-45540015

-36999968

55977

12107

109660

38308

95427

246527

234787

730710

695914

360218 210857 824231 577299

169668

-11823

203181

15120

-13655916

-17451169

-45336834

-36984848

-0.28

-0.51

-1.01

-1.14

47946309

34188108

44810352

32436420

1009985 2922 1007063 2922275

481

-481

480592

750004

115

749889

114855

12840048

0 3 -3 2915 66946725 4094 66942631 4094498

-45336834

-31

31166

44974

175476521

-95185280

44974248

41309

-234337

52558

257015699

-234337

-140522114

52558217

41309

95427

16066856

12840048

2454

10326

127260

377770

-118615 93522

7585956

4055116

26652

73011

3269629

4658128

-94590

-114286

-19952981

-31789611

4498

59194

-9222506

-27164331

2890305

1009985

677778

39558093 67760517

41915820

68702098

12740333

9748156

40485466

53225799

3114

68404

-13870

13850000 0 0 5350094 40955137 9218008 -63788 0 P24M

115400000

9100404

5634005

600000

5626816

12364537

59835124

43349247

49789401

28701209

21088192

45071

8061

49834392

28709190

21125202

37010

23062034

922

5806

23057150

23062034

922

5806

23057150

15500000

1125

0.5

0.05

20300000

19500000

0.05

181668

275190

730710

-824232

181668

10000000

0.001

150000000

0.001

75000000

250000000

16.66

248000000

5676574

6000000

194

152

971.7

463.32

2811.53

P3Y6M

P0Y

480592

819622

31166

6029805

5.02

16.76

6.72

6400001

5.86

P2Y

18900000

1866167

12800000

0 2925687 11364

1211177

0 0.35 2.25 2.37 9334897 61792184 0.94

4148228

1240034

12840048

181668

275190

181668

275190

0.5

1125

0.05

1600000

1700000

300000

5000000

200000

164000000

500000

5000000

2500000 0.001

0.1

114855

6.53

750000

750000 2500000 0.001

1800000

4900000

400000

100000

4400000 1900000 1100000 0.4

100000

600000

200000

100000

10-Q false 2015-09-30 2015 Q3 TG THERAPEUTICS, INC. 0001001316 --12-31 Accelerated Filer TGTX 52519686

0.001

10000000

0.001

150000000

52558217

44974248

52516908

44932939

1262569

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 1  ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Description of Business</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs seeking to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors and anti-PD-L1 and anti-GITR antibodies.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have not received approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales from our drug candidates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X of the Exchange Act. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the condensed consolidated financial statements have been included. Nevertheless, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying condensed December 31, 2014 balance sheet has been derived from these statements. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Liquidity and Capital Resources</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">We have incurred operating losses since our inception and expect to continue to incur operating losses for the foreseeable future and, may never become profitable. As of September 30, 2015, we have an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">140.5</font> million.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our major sources of cash have been proceeds from the private placement and public offering of equity securities. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on many factors, including our ability to obtain regulatory approval for our drug candidates; successfully complete any post-approval regulatory obligations; and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of September 30, 2015, we had approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">115.4</font> million in cash, cash equivalents, investment securities, and interest receivable. We anticipate that our cash and cash equivalents and investments will be sufficient to fund our anticipated operating cash requirements for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24</font> months from September 30, 2015. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current strategic plan, including the commercialization of any of our drug candidates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our common stock is listed on the Nasdaq Capital Market and trades under the symbol “TGTX.”<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Recently Issued Accounting Standards</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In May 2014, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update to ASC 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 is effective for us beginning in fiscal 2018. We are currently evaluating the impact of this update on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial StatementsGoing Concern, which requires that management of an entity should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued. This update will become effective beginning January 1, 2017, with early adoption permitted. The provisions of this standard are not expected to significantly impact the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Use of Estimates</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Cash and Cash Equivalents</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We treat liquid investments with original maturities of three months or less when purchased as cash and cash equivalents.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Restricted Cash</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We record cash pledged or held in trust as restricted cash. As of September 30, 2015, we have approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.6</font> million of restricted cash pledged to secure a line of credit as a security deposit for a Desk Space Agreement (see Note 8)<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Investment Securities</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Investment securities at September 30, 2015 and December 31, 2014 consist of short-term and long-term government securities. We classify these securities as held-to-maturity. Held-to-maturity securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in interest and other (income) expense, net. Dividend and interest income are recognized when earned.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Credit Risk</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and short-term investments. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Revenue Recognition</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Research and Development Costs</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued liability balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Prepaid research and development in our consolidated balance sheet includes, among other things, certain fees related to development and manufacturing services. These development and manufacturing agreements often require payments in advance of services performed or goods received. Accordingly, as of September 30, 2015, we recorded approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.1</font> million in prepaid research and development related to such advance agreements. As of September 30, 2015, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million of the prepaid research and development balance has not yet been paid.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Income Taxes</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than “more likely than not,” a valuation allowance is then created.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination. We recognize interest and penalties related to uncertain income tax positions in income tax expense.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Stock-Based Compensation</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We recognize all share-based payments to employees and non-employee directors (as compensation for service) as noncash compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">For share-based payments to consultants and other third-parties (including related parties), noncash compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties (including related parties) are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Basic and Diluted Net Loss Per Common Share</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Basic net loss per share of our common stock is calculated by dividing net loss applicable to the common stock by the weighted-average number of our common stock outstanding for the period. Diluted net loss per share of common stock is the same as basic net loss per share of common stock since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because we incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,634,005</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9,100,404</font> at September 30, 2015 and 2014, respectively. During the three and nine months ended September 30, 2015 and 2014, we incurred a net loss; therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Long-Lived Assets and Goodwill</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Long-lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management’s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">  <i></i></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following tables summarize our investment securities at September 30, 2015 and December 31, 2014:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>September 30, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Amortized cost,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>unrealized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>unrealized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Estimated fair</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>as adjusted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>holding gains</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>holding losses</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Short-term investments:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Obligations of domestic governmental agencies (maturing between October 2015 and August 2016) (held-to-maturity)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>28,701,209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,061</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>28,709,190</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Long-term investments:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Obligations of domestic governmental agencies (maturing between October 2016 and September 2017) (held-to-maturity)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,088,192</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,010</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,125,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total short-term and long-term investment securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>49,789,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>45,071</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>49,834,392</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>December 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Amortized cost,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>unrealized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>unrealized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Estimated fair</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>as adjusted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>holding gains</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>holding losses</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Short-term investments:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Obligations of domestic governmental agencies (maturing between January 2015 and December 2015) (held-to-maturity)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>23,062,034</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>922</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,806</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>23,057,150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total short-term investment securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>23,062,034</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>922</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,806</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>23,057,150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 3  INVESTMENT SECURITIES</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We record our investments as held-to-maturity at amortized cost.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following tables summarize our investment securities at September 30, 2015 and December 31, 2014:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>September 30, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Amortized cost,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>unrealized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>unrealized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Estimated fair</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>as adjusted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>holding gains</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>holding losses</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Short-term investments:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Obligations of domestic governmental agencies (maturing between October 2015 and August 2016) (held-to-maturity)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>28,701,209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,061</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>28,709,190</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Long-term investments:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Obligations of domestic governmental agencies (maturing between October 2016 and September 2017) (held-to-maturity)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,088,192</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,010</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21,125,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total short-term and long-term investment securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>49,789,401</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>45,071</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>49,834,392</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>December 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Gross</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Amortized cost,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>unrealized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>unrealized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Estimated fair</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>as adjusted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>holding gains</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>holding losses</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Short-term investments:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Obligations of domestic governmental agencies (maturing between January 2015 and December 2015) (held-to-maturity)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>23,062,034</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>922</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,806</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>23,057,150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total short-term investment securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>23,062,034</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>922</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,806</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>23,057,150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

12840048

1240034

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 5 - STOCKHOLDERS' EQUITY</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Preferred Stock</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our amended and restated certificate of incorporation authorizes the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000,000</font> shares of preferred stock, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> par value, with rights senior to those of our common stock, issuable in one or more series. Upon issuance, we can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Common Stock</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our amended and restated certificate of incorporation authorizes the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,000,000</font> shares of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> par value common stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In December 2014, we filed a shelf registration statement on Form S-3 (the “2015 S-3”), which was declared effective in January 2015. Under the 2015 S-3, the Company may sell up to a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250</font> million of its securities. In connection with the 2015 S-3, we amended our 2013 At-the-Market Issuance Sales Agreement with MLV & Co. LLC (the “2015 ATM”) such that we may issue and sell additional shares of our common stock, having an aggregate offering price of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75.0</font> million, from time to time through MLV & Co. LLC (“MLV”), acting as the sales agent. Under the 2015 ATM we pay MLV a commission rate of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.0</font>% of the gross proceeds from the sale of any shares of common stock sold through MLV.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">During the nine months ended September 30, 2015, we sold a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,094,498</font> shares of common stock under the 2015 ATM for aggregate total gross proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">68.2</font> million at an average selling price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16.66</font> per share, resulting in net proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">67.0</font> million after deducting commissions and other transaction costs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We currently have two shelf registration statements on Form S-3 filed and declared effective by the SEC (File No. 333-189015 and File No. 333-201339). After deducting shares already sold, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">248</font> million of common stock remains available for sale under these shelf registration statements. We may offer the securities under our shelf registration statements from time to time in response to market conditions or other circumstances if we believe such a plan of financing is in the best interests of our stockholders. We believe that these shelf registration statements provide us with the flexibility to raise additional capital to finance our operations as needed.</font></div> <strong><i><font style="FONT-SIZE: 10pt"> </font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Equity Incentive Plans</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">An amendment to the TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan (“2012 Incentive Plan”) was approved by stockholders in June 2015. Pursuant to this amendment, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,000,000</font> shares were added to the 2012 Incentive Plan. Shares available for the issuance of stock options or other stock-based awards under our 2012 Incentive Plan were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,676,574</font> shares at September 30, 2015.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Stock Options</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes stock option activity for the nine months ended September 30, 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number<br/> of shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-<br/> average<br/> exercise price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-<br/> average<br/> Contractual<br/> Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate<br/> Intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="41%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="3"> <div>(in years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Outstanding at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>194</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>971.70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(152)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>463.32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(42)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,811.53</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Outstanding at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Exercisable at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of September 30, 2015, there are no unvested option awards and no unrecognized compensation cost related to option awards.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Restricted Stock</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Certain employees, directors and consultants have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the nine months ended September 30, 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number of Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average<br/> Grant Date<br/> Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Outstanding at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,400,001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5.86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>480,592</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(819,622)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(31,166)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16.76</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Outstanding at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,029,805</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.72</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -1pt; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Total expense associated with restricted stock grants was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12.8</font> million during the nine months ended September 30, 2015. As of September 30, 2015, there was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18.9</font> million of total unrecognized compensation cost related to unvested time-based restricted stock, which is expected to be recognized over a weighted-average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.0</font> years. This amount does not include, as of September 30, 2015, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,866,167</font> shares of restricted stock outstanding issued to non-employees, the expense for which is determined each reporting period at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Warrants</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table summarizes warrant activity for the nine months ended September 30, 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-<br/> average<br/> exercise price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate<br/> Intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Outstanding at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,148,228</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>61,792,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,925,687)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(11,364)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Outstanding at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,211,177</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,334,897</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">  </font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Stock-Based Compensation</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We did not grant any stock options during the nine months ended September 30, 2015 and 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes stock-based compensation expense information about restricted stock for the three and nine months ended September 30, 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Three months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Nine months ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September 30, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Stock-based compensation expense associated with restricted stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,240,034</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>12,840,048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Stock-based compensation expense associated with option grants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,240,034</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>12,840,048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

40000

25000

145200

275190

P5Y

20300000

19500000

0.030

68200000

67000000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table summarizes warrant activity for the nine months ended September 30, 2015:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-<br/> average<br/> exercise price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate<br/> Intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Outstanding at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,148,228</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>61,792,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,925,687)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(11,364)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Outstanding at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,211,177</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,334,897</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

200000

This Desk Agreement requires us to pay our respective share of the average annual rent and other costs of the 15 year lease.

license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated

2000000 9100000 1500000

100000

23000

EX-101.SCH 7 tgtx-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Consolidated Statement of Equity link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Condensed Consolidated Statement of Equity [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 107 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - CASH AND CASH EQUIVALENTS link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - INVESTMENT SECURITIES link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - NOTES PAYABLE link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - LICENSE AGREEMENTS link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - CASH AND CASH EQUIVALENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - INVESTMENT SECURITIES (Tables) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - CASH AND CASH EQUIVALENTS (Details) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - INVESTMENT SECURITIES (Details) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - FAIR VALUE MEASUREMENTS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - STOCKHOLDERS' EQUITY (Details 2) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - STOCKHOLDERS' EQUITY (Details 3) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - STOCKHOLDERS' EQUITY (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - NOTES PAYABLE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - LICENSE AGREEMENTS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - RELATED PARTY TRANSACTIONS (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 tgtx-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 tgtx-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 tgtx-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Legal Entity [Axis] Investments, Debt and Equity Securities [Abstract] Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Stockholders' Equity Note [Abstract] Shareholders Equity and Share-based Payments [Text Block] Debt Disclosure [Abstract] License Agreement [Abstract] License Agreement [Abstract] License Agreement Disclosure [Text Block] License Agreement Disclosure [Text Block] The entire disclosure for research, development, and License Agreement activities, including contracts and arrangements to be performed for others and with federal government. Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Disclosure [Text Block] Accounting Policies [Abstract] Business Description [Policy Text Block] Business Description [Policy Text Block] Reflects the description of business of the entity. Liquidity Disclosure1 [Policy Text Block] Liquidity Disclosure [Policy Text Block] Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations. New Accounting Pronouncements, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Marketable Securities, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Cash and Cash Equivalents [Abstract] Schedule of Cash and Cash Equivalents [Table Text Block] Held-to-maturity Securities [Table Text Block] Statement Of Financial Position [Abstract] Statement [Table] Scenario [Axis] Scenario, Unspecified [Domain] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Totals Cash and cash equivalents at beginning of period CASH AND CASH EQUIVALENTS AT END OF PERIOD Short-term Investments, Total Short-term investment securities Interest Receivable, Current Interest receivable Prepaid Research And Development Prepaid research and development Sum of the amounts paid in advance for capitalized costs that will be expensed with Research and development. Other Assets, Current Other current assets Assets, Current, Total Total current assets Restricted Cash and Cash Equivalents, Noncurrent Restricted cash Long-term Investments, Total Long-term investment securities Property, Plant and Equipment, Net, Total Property, plant and equipment, net Goodwill Goodwill Other Assets, Noncurrent Other assets Liabilities and Equity [Abstract] Liabilities and stockholders’ equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued expenses Deferred Compensation Liability, Current, Total Accrued compensation Deferred Revenue, Current Current portion of deferred revenue Notes Payable, Current, Total Notes payable Notes payable, Current portion, net Liabilities, Current, Total Total current liabilities Deferred Revenue, Noncurrent Deferred revenue, net of current portion Liabilities, Total Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders Equity Attributable To Parent [Abstract] Stockholders’ equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value per share (10,000,000 shares authorized, none issued and outstanding as of September 30, 2015 and December 31, 2014) Common Stock, Value, Issued Common stock, $0.001 par value per share (150,000,000 shares authorized, 52,558,217 and 44,974,248 shares issued, 52,516,908 and 44,932,939 shares outstanding at September 30, 2015 and December 31, 2014, respectively) Contingently Issuable Shares Contingently issuable shares The shares issuable for merger of companies Additional Paid in Capital, Total Additional paid-in capital Treasury Stock, Value Treasury stock, at cost Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders Equity, Including Portion Attributable to Noncontrolling Interest, Total Total stockholders’ equity Balance Balance Liabilities and Equity, Total Total liabilities and stockholders’ equity Fair Value, Liabilities Measured On Recurring and Nonrecurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] Fair Value, Liabilities Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Change In Level Three Fair Value During Period [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule Of Warrants Activity [Table Text Block] Tabular disclosure for warrants activity. Schedule Of Share Based Compensation Expense [Table Text Block] Tabular disclosure of Share based compensation expense during the period. Schedule Of Debt [Table Text Block] Schedule of Debt [Table Text Block] Significant Accounting Policies [Table] Schedule reflecting the organisation and summary of significant accounting policies. Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Equity Components [Axis] Equity Component [Domain] Class of Stock [Axis] Class of Stock [Domain] Title of Individual [Axis] Relationship to Entity [Domain] Related Party [Axis] Related Party [Domain] Vesting Period [Axis] Represents vesting Period Vesting Period [Domain] Represents vesting Period. Market Capitalization Target [Axis] Represents Market capitalization target. Market Capitalization Target [Domain] Represents Market capitalization target Immaterial Error [Axis] Represents immaterial error. Immaterial Error [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Range [Axis] Range [Domain] Minimum [Member] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Period Anticipated Sufficient To Fund Operating Cash Flow Disclosure about period anticipated sufficient to fund operating cash flow. Cash, Cash Equivalents, and Short-term Investments, Total Schedule of Cash and Cash Equivalents [Table] Entity [Domain] Cash and Cash Equivalents [Line Items] Money Market Funds, at Carrying Value Money market funds Cash Checking and bank deposits Schedule of Held-to-maturity Securities [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] US Government Agencies Debt Securities [Member] Obligations of domestic governmental agencies [Member] Schedule of Fair Value of Separate Accounts by Major Category of Investment [Axis] Schedule of Fair Value of Separate Accounts by Major Category of Investment, Category [Domain] Short-term Investments [Member] Other Long-term Investments [Member] Schedule of Held-to-maturity Securities [Line Items] Held-to-maturity Securities Amortized cost, as adjusted Held-to-maturity Securities, Unrecognized Holding Gain Gross unrealized holding gains Held-to-maturity Securities, Unrecognized Holding Loss Gross unrealized holding losses Held-to-maturity Securities, Fair Value Estimated fair value Fair Value, by Balance Sheet Grouping [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Financial and Nonfinancial Liabilities, Fair Value Disclosure, Total 5% Notes Notes Payable, Fair Value Disclosure Totals Fair Value, Measurement Changes In Level 3 Instruments [Table] Fair value disclosures related to financial assets (as defined) and financial liabilities (as defined) contained in the entity's balance sheet. Disclosures contained in this table include the changes in level 3 instruments. Fair Value, Measurement Changes In Level 3 Instruments [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance Fair value at December 31, 2014 Fair value at June 30, 2015 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings Interest accrued on face value of 5% Notes Amount of interest recognized during the period, arising from liabilities measured at fair value on a recurring basis using unobservable inputs (level 3). Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Change in fair value of Level 3 liabilities Fair Value Measurement [Table] Type Of Transaction [Axis] Type Of Transaction [Domain] Manhattan and Ariston Pharmaceuticals Merger [Member] Other Operating Cost And Expense [Axis] Other Operating Cost And Expense [Domain] Notes Issued Notes Issued Debt Instrument, Convertible, Conversion Price Debt Instrument, Convertible, Conversion Price Percentage Of Cash Proceeds From Operation To Repay Convertible Debt Percentage Of Cash Proceeds From Operation To Repay Convertible Debt Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt. Long-term Debt, Gross Long-term Debt, Gross Debt Instrument, Term Statement Of Stockholders Equity [Abstract] Equity Incentive Plans Stock Option Activity [Table] Option Indexed to Issuer's Equity [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Number of shares, Outstanding Beginning Balance Number of shares, Outstanding Ending Balance Restricted Stock, Outstanding, Number, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Number of shares, Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period Number of shares, Exercised Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Number of shares, Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Expirations In Period Number of shares, Expired Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Number of shares, Exercisable at September 30, 2015 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Weighted - average exercise price, Outstanding Beginning Balance Weighted - average exercise price, Outstanding Ending Balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted - average exercise price, Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted - average exercise price, Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted - average exercise price, Forfeited Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted - average exercise price, Expired Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted - average exercise price, Exercisable at September 30, 2015 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted - average Contractual Term (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted - average Contractual Term, Exercisable at September 30, 2015 (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding Beginning Balance Aggregate Intrinsic Value, Outstanding Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable at September 30, 2015 Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares Authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Equity Incentive Plans Restricted Stock Activity [Table] Award Type [Axis] Equity Award [Domain] Restricted Stock [Member] Equity Incentive Plans Restricted Stock Activity [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Number Number of Shares, Outstanding at Begining Balance Number of Shares, Outstanding at Ending Balance Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period Number of Shares, Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period Number of Shares, Vested Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Forfeited In Period Number of Shares, Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance Weighted Average Grant Date Fair Value, Outstanding at Begining Balance Weighted Average Grant Date Fair Value, Outstanding at Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Forfeited Equity Incentive Plans Warrant Activity [Table] Equity Incentive Plans Warrant Activity [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Class of Warrant or Right, Outstanding Warrants, Outstanding at Beginning Balance Warrants, Outstanding at Ending Balance Warrant Or Right Issued Warrants, Issued Reflects the number of warrants issued during the period. Warrant Or Right Exercised Warrants, Exercised Reflects the number of warrants exercised during the period. Warrant Or Right Expired Warrants, Expired Reflects the number of warrants expired during the period. Warrant Or Right Outstanding Weighted Average Exercise Price Weighted - average exercise price of Warrants, Outstanding at Beginning Balance Weighted - average exercise price of Warrants, Outstanding at Ending Balance Reflects the weighted average exercise price of warrants outstanding. Warrant Or Right Issued Weighted Average Exercise Price Weighted - average exercise price of Warrants, Issued Reflects the weighted average exercise price of warrants issued. EX-101.PRE 11 tgtx-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`)"`:4?G?S$WN0$``)T7```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V8RT[#,!!%?Z7*%C6N'=ZBW5"V@`0_8))I8S6.+=M]_3UV"@BJ@EJ@ MTMWDT3N>>Y-QSJ(WSVM+OK?23>N'61V"O6;,ES5IZ7-CJ8W*Q#@M0[QU4V9E M.9-38F(P.&>E:0.UH1]2CVQT\[`@YU1%O=N-D'H/,VEMHTH9E&G9HJVVNO;- M9*)*JDPYUW%)'J(UG40]ZSU*%^ZECBW8JF&=L#GR/.GL?PR]=20K7Q,%W>0^ MK!ORN_PWRKOSF"9RWH2#C-_>7>ZHZ6I\K>R;U=TJ=O'QMV$65;^7P_;"GY(I MG89FV^F7%>G^E\^R]1(7NAD[N51;!HNCC2F=::W?]W=`[T;/N=$1(')1#@.0H0'*<@N0X`\EQ#I+C`B3')4B.*Y`QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C M-Z."N[_8_`)02P,$%`````@`D(!I1PQUTFF.`0``J18``!H```!X;"]?&?/ODKC;671NJN@^S]^;:ANWP M?Y]5,?9;8T)1N<:&AZYW[;!Z[GQCX_#I2]/;XF)+9SC/E\9/YV2'W<_9L^-I MG_GCB;+9B_6EB_OLK?.74#D7@QE?]#!L,"S?>O>?[;OSN2[<8U>\-JZ-?U28 MKPTRDP[B=!!#@B0=))"@>3IH#@E:I(,6D*!E.F@)"5JE@U:0H'4Z:`T)VJ2# M-I`@RA49C-&;%;T9HSC-&;U;T9HS> MK.C-&+U9T9LQ>K.B-V/T%D5OP>@MBMZ"T5L4O05T5Z)=EF#T%D5OP>@MBMZ" MT5L4O06CMTST#I7U[O0NBDH?QPOG\?7>^[XS-1*C!>%'(G!6:,P4>=YE08^.\ M<+9:YV/75Q1,Y&R M]'-^#.IXDS(+S/.,)U1S*;PY3PJIY$8#])BP;.*^!%0,$QFSY*'@^LD;U)BF MJ\+@A&;,-[F\#W'LVXN%?+G,@IU:S):D_4T;>T8*E) MVHI^=%:8FR=39U9R_2T5=RQM8E]/'K18L4*5E9X-OPS,@ MO%#>9*_'>Y9H63RW::]/[5(JD[+I:D7,^I0#;JEBI7GA[&G!J=`.4/R/&0Z= M.FWMK>PL5[KP?LGB7FT9TVKB'IV5V<0V;?[5.Q]5"&.UD>ZQ,N]9ME;=I8=P MG3$5;1:TT/])BJJF@Q#G(Z=1_2$$@"(%2&BS'4$@ZE2F>4U)CI8OS7&JV60HN:49%PL`)G/,^'*S-RZSY!,ZW$SBC$SC?K9PHOH9A\!N2(`H! M#*<`+^=S&*]!=`5P<&W/`_%-A:T,]',9K.`,A01;T4&X0IC,S3S`R%_&`0F0 M'7D%@QB84$L$Y@CB98SF;T;%)/)_W$2S*8KQAVH-9&T%AA%!&"S@&E[.D!4Q M"WP48@3@=8PZ,L9H!@F:FE`Q60,2PQ!#OY3-#N\4]NR-!KXE+/A(Z&WV?GEK M/%.?^NA\(+U;[^XL+>&[H9U:#8=]M9HR3?MH5>)YUE>LFM6?,[3WOIMC_WCM M3>DLIY,"SD[@V-O3S;&?K=T<\IY=UEF['0N(^:MZH)F=\_IP:!%[GA05]]65 MWKR;7]S$;OL/TOL+4$L#!!0````(`)"`:4?F3V^0/P$``&D#```1````9&]C M4')O<',O8V]R92YX;6S-DTU/PS`,AO\*ZKU+L\&D15T/@#@Q"8DA$+>0>%M8 M\Z'$4]=_3Y9U+0,NNW&K:[^/7\=)*1P3UL.3MPX\*@A7>UV;P(2;9QM$QP@) M8@.:AU&L,#&YLEYSC*%?$\?%EJ^!C(MB2C0@EQPY.0!SUQ.SJI2""0\_P M4O1XM_-U@DE!H`8-!@.A(TJRZL5LC6U,209]54;'-0^XL%*M%,C;=BC[G8J= M$;P.1SG(OGWZ^Z>'E"%95[D/JJ]JFF;43%)=')B2M\7C."WN24YL5L2:>LN&;CV?MALC-_@V'=#?%O'9\,INVB MPAHNW&W2R+3<])E`$H+PRJ&RYB)?/N M+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\,`*I4Q>M5II`,,X?+&A`T%116F]?(+3E'S/X M%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53" MQ,!J9S]6:\?1TDB`@LE]E`6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@ MX_%X.+;+THMP'`3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMH MG`J-6T_3:W?=TXZ)QJW0>`V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2 M%;7E0-,@`%AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9R MG9`%#@`WQ-%,4'RO0;:*X,*2TER0UL\IM5`:")K(@?5'@B'%W*_]]9>[R:0S M>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+`GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,B MUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0'`*D"3&6H8;XM,:L$>`3?;>^",C? MC8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[`?_1 MVC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO`JQ`GH9%LE M"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ MZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J= MW#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B M(>ZAAIC/PT.'>7M?F&>5QE`T%&ULK"0L1K=@N-?Q+!3@9&`MH`>#KU$"\E)5 M8#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6Q MP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>; MG*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4< M!A87,N10[I*0!A,!S93)1/`"@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E M$A2*L`P%(1=RX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TSU#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+? M.7#;.MX#7N83+$.D?L%]BHJ`$:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4 MJUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5 MBZPYC0IO0=5`Y3_;U`UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%0 M2P,$%`````@`D(!I1[Z2!,=:`@``;@L```T```!X;"]S='EL97,N>&ULS59= M:]LP%/TK0AVCA1';Z9JVJVT8A17"N5/G-\ZITCAFJ1J+$7*_D0C*D M]%067E5*C++*!#'JC7U_XC%$.(Q#7K,I4Q5(1S,__YXFZ(G]N%"P@"Q`6Q1M'Z,<"%M;I=AF&?D]YEDD430;W]O3Y?T['8P MVR.4;FY/`W%8(J6PY%,]`:T]6Y9ZA43+8'RU%F`'G3<1,L.R MRQS`%12'%.=*!TA2S,VH1&FD"Z4$TT9&4"$XHH9R%=$:FC;%E#Z93_!WOL'= MY,#YF#OV(3`J5J8^B-;LR\`>JK?.YKC7:<<'\8(F[Q+H:%26=/F=DH(S[,0Z M:"K:V2[Z8`M]'*(5*Y@+25ZTORF$5`-80K#`4I%T'?DK43G#C6HKV&OR;0H/ MW?)[:CK^J?5J=`E^]/$[[XR^W7"@^,8I-$4UO>2G(Z MZ1N1\)I9!!Z!-^E^?4&*FZLU=I,G`1*'"_<,NI_T]$DUWQZ5^H:>:R'UM)D% M.V/VT\%`ESM64_V[VC-IWVU54U-CN\W7@=IN>L?W.GBAZ;?0]+YAM-([QDPM.EA-N0P^?]+3+1?LGC7:@A'=[U-:LUGP+`(D MJ#:DXH95LV!DN^J)]0::P_[ZP(7KC(?C8.!@QZU^:5"I*M;!BAW7?[V\"%#% MMO0@3&&#/:X["T(\PGC2,=QG]YP]:0AT`XB6AG]G!7V-.NRY_&I9`=KR1IO<;;?]LN:2U_R'B]OV]$X]W:F&_U#24)&7C1*BG>5> MM)/L"OJ_$1NCX67O0T,?,Y>)63`96N!WKODC%]S\,PO:MF!N)X.?MM(>_VL+ MR?9PCBE&L:P0D<924"*[Y-FC<3'8CY.J7;B9"(@"*`"AZ,R@W]F&W#$`C`!J]%S0&H#$`C=\+ MF@#0!(`F[P5=`=`5`%V=@M;9;9PF?\=%LDY1G"Y0OEFMXNP!K6]0GMP"T`<` M^N")*,[O6D#;(']NDOMX2=(B!XB/`/'Q%)&D]R0O5G82RLE\DR5%0N#T<`@- M')X";N(D0W;9#4$K$N>;C*Q^BB#L2>RQ."_6\S_NULL%R?)?VFT4#W`^=#?T MR)NN"Y*C+_%#?+TD<")T-?3(NDSF),T)BF\SS%K&$-4[^;U7;WG ML[9@AD(4]!E[?#Z3-8?AHK]!*#?VR'TV;1T,HJ#AV&/X112&AF-H./88?AD% MKV`,#<<>P_TR^8X*&HX]AE\DH1"BH.'XS88?45"K"#H>>1R_C.K]T:'LT1OO MYU=4`5%0]NC_KFKO<4>]`L,CN1^!"O9L#E3T4%#RR"/YZ?W?XT$4E#SR2'[^ M9]`B(0I*'DU>JL;70M'6RERRRI71NEW&UJ&EJZWMH_L=CL;NJG3]E:VW9X$K MBFW]>Q!B;L?6&PO=V]R:W-H965T&ULC979CILP%(9?!?$`8VR6 M+")(DXRJ]J+2:"[::R=Q`AK`C.V$Z=O7"V&,:Q5N\,+_G\_+L9WWE+WSDA`1 M?#9URW=A*42W!8"?2M)@_D0[TLH_%\H:+&2370'O&,%G;6IJ@*(H`PVNVK#( M==\K*W)Z$W75DE<6\%O38/9G3VK:[T(8/CK>JFLI5`!@\QO08$"C`:'_&N+!$(\&LW3`C$S/ZP4+ M7.2,]@'OL-IMN)5RIH+(R(&<#-=-O5RF]UY$.;BK,!/%WBB05L!1`61L+P!- M`7MDV9$/<+`5\3P@=F80:WNL[8(IO.0M0-9VQ!OINR-)#.2 M!:FR<1`;&Y%X$1/)@EG`R#U0D1TA\R[6H$F'#8E@#!'!R=Z:X6Y3\8%[UK8>OY"=FUZKEP9$*>=7K M6_Y"J2!R*-&3O!E*^02/C9I;^SXT!=_`5!+`P04```` M"`"0@&E'_B^_W5`$``"7$P``&````'AL+W=OM-=*3,?&2I974N+MVYA-M>Z^=X>O>]6/ZORW#ZNCUUW>OW!]].+\>N?Y!M-]E'W/Y4^7-[JL^KQA\>U[_!0RYX+QD4?Y_\ MM47WJ][\4UU_[PM_[A_7K/?@2__<]544X?+F-]A_*EJ?U^4_IWUW#&[9>K7WA^*U[+[5US_\]`ZJK_"Y+MOA=_7\VG9U M]1ZR7E7%S_%Z.@_7Z_B/95,8'<"G`/X1`/)F@)@"1!*0C'T_7B3Q8HB78[R)+9['EQ@E9I!H)34XR2AACH5*&1#&RON. M9.)(8D>6=#1*U"0Q##ASI*-(*)CF3"QPI!)'"CLB&]HIU!`HJ^BNS+',*@4+ M!DPG9C0R(\AQV&G4BG.*62=(-UBGP3@CQ7T_)O%CL!\@_1C4CE3&`3FJ.9:! M$4[Q^VYLXL9B-YQT8W$S3!K!I*5'RT:CQ4$Q-/JSEEQBR6%+Y$#L'&I(&0MH M(6,_L4R%:7_?#;"46@S[D:2?23.M&V#6@B,[,X^4;(&=7R`*V(ZB[0">J(YS M4I9'LK#2E5G@)^4I<.R''(?=I!D;,LX)1\[[_)9NWE%*:,"(%C2B)\TTJ248 MH&=TK!,&V!)'*:$!(UK0B`:,7N!&LK`?T.L^DEIMI+9NR51*,0T*[85BP4J% ME*V`X4IOLK]#RE?`@)4T8`&CTV@;V$!;BG0LI*5+ M^CEE+&#(2AJR$%%6<6%GEL@-W;RC%+&`&2MIQ@*F)UC0>F8V8ATW"I;,19Y2 MEF/*2IJR'+/3Z3"7&`W92*B``[@%B0-/42P4=I1Q]X(BD8 M)8T.B>L"7RE2.4:JF@$81N4G+J2@TY/\IG#^J)I"56"H*AI@`K/R4R"8XH&7 M-,-BK5,0DGR[8'*+E*P"DU71%!,1,$$+")L0S?M(:EE(TNR2@[1(X2HP7-7, MX3Z"Z\T\+9+.Y&D9^H1R*5[\7T7SZZ^IJ^!!SJ.O.A_K8Y\"4HR_V M'X72'[K^UH3[9OQN-!:Z^O+^&>SC6]SV/U!+`P04````"`"0@&E'6DE:A"," M``!.!P``&````'AL+W=O/B.34=[ MT;`^X/2T";]$ZUVA%4;PJZ&C<.:!9M\S]J:#'\=-"#4";>E!Z@Q$#5>ZHVVK M$ZG"?VXY_Y?41G=^S_[-=*OH]T30'6M_-T=9*U@8!D=Z(I=6OK+Q.[VU@'7" M`VN%>0:'BY"LNUO"H"/O=FQZ,X[V39K=;'X#NAG0PQ`E3PWQS1#/#,"2F;Z^ M$DFJDK,Q$`/1'SM:*SG7253F0#4C3&C^+KMZK7!>@JO.,Y%LK009"?(I=A,% M?DB`JN^%0#,(9/R)A2BF)7H+826YD<`5A)%/M5M6+;+$,Y;884FAE\5*L)%$ MT/Z\.$^%BT3)C"AQB;Q];Q.GD!_%KUADP#,&[#(@+P/^D,&O6&1(9PRIRQ![ M&=)/[9)EU2)+-F/)7);$RY*Y'Q\_VR;/E8M,^8PI=YFPEREW*F&$<8ZBS(OD M"I.DR!*4Y!\3%3.BPB5*O43%E"A*"YA[B8HI48R*N)@1`>?H&\B9_B3\W/0B MV#.I3E%S@)X8DU2E@RNU&6MUN3V"EIZDGF9JSNUY;P/)AOOM];A"JW]02P,$ M%`````@`D(!I1]E?OR;'!```$14``!@```!X;"]W;W)KK#2:BYUK)S@!#<:L[839M]_V M`=+=4QX)#^+XZE^FNV;YKR8S^N7?5YD]6-Y MSD_NF]>R*K+&/59O\_IY^3=O#/9?FC??AK]S1C[1CR8_[2M"XR]_:1K_/CL?7D>OYWWNNF+*XFLZ3(?O;OAU/W?NF_,6PPHPUP,,";P:T?VH`/!OS30/S60`P& M8FH/^C.#Y,STB.P00\I]H?-TAN4-`"?=!P MB2#IA?,YM!JLL4`J#'KFX%##[TLTD43C2R2G/#6A1"T8(W?O.@"YLHXEM\3& M!SD*R1FC-?H@"BNL[W%4HXTT6O_@3M@&P.+XS^YO\X&Y[6"!VI"S%(!HK+16 MD[,4>F3`E.6DRVU`6J6$5&R"S%_2'/@RR4&E`W,=E)%N-]`R?=`8:^B0MPDX M[H(05R2X#4!T\0IP0A`&C$6B+Y*G%24TI`!>!VA6G#+Z9B^"5$AV\,`9!#= MAJ@+CN[/JQ/'U<95!$@OFDW:&7'.!C]I&[H0`3]_/DAIZ7"P#CFW7=E(+`LY M5\VID>T?@-QP-F62XL0-?N8V(P';3Z`CN_XNLKF/;`/DP4J7&29(BA,U^)F: MWKHIA/E221Q9M8#C0IN15?,YS9D>*;8"3KF,!E/.<9RFP?H*Z5ID8&['B"&, M1.8`Q#93C6@,0%>^(1\)5P$HM48[X><1QK4$^K4$_6LE11:<%N5."ZTR``$, MTO56Z`\9!T-KC#J6KHZ9(#&N(]"O(^BME0Z,O@9DY6(,T)5SA&HA`4;2;(BZ MPM(E-$Z>E6V(NH!LA'M-4!L7%.@7%(8N*`;&]IVQ1QQ9S@B3Y"IM0@P>1_)K MC$TYE!B7$>B7$88N(S!(^=H*Y>HX6F"0\@48`XRXJ\>NMNVNKDI7P_-7TNO;7>;O.^8'M?%+6GL%@#T;Z!Q;:_J_MT MOUJ>L[?\[ZQZ.YSJY+ELFK+H+JA>R[+)W=#=`L^2?9[M;@_'_+5I/^IV-?H; MN_ZA*<_7"\C;+>CJ?U!+`P04````"`"0@&E'&(F![,D#``!R$```&````'AL M+W=O_O;K>DWW*FI[+Z5>^-::+?17ZH M7R;[ICD^QW']OC=%6G\KC^9@?]F559$V]K+ZB.MC9=)M)RKRF!(BXR+-#I/9 MM+OWO9I-R\\FSP[F>Q75GT615O_.35Z>7B8P.=_XD7WLF_9&/)O&%]TV*\RA MSLI#5)G=R^0/>-Y`TB(=\3,SI]HYC]KBW\KR5WOQY_9E0MH:3&[>FS9$:@]? M9F'RO(UD,_\S!+WF;(7N^3GZJGM<6_Y;6IM%F?^=;9N]K99,HJW9I9]Y\Z,\ M;O^LF[(X2R91D?[NC]FA.Y[Z7S099+B`#@)Z$0`?%;!! MP"X"*D8%?!#PJX"."L0@$!K_T4 MA[YI/:(Z1!,@H#7'P(4+$HQ8N@3GB4+CO+J4Q(B52X`27$E!`2/7+OE$&6=, M8=S&XQ(!6E!-[K>3!>UD;CL3M$L](D:ZY!)=ERA'1V;M@:R[L#*IW&,+0K;HRG!QJB@CJ55R>:8ZF\AL`#W=!!%NUE01?O7-_M MAG9-0*.#MW*C/+G0S5J3H-;$JQ6?L(F[?C01CM_?S`,D?.T0+Q-J6/,!&FO+ M@`P6Q/"^>''8`VV!_[TEP2L7=%8- MZ`MA#MI;4G82@,8[N_#0&_[E(H(*@7;^U.K:_\T'@ M1%!J5^T#K0U?+."]60#?"D-RW^]=I.L7!;3VM4=B^[S8^5`ZIA_FK[3ZR`YU M]%8V]INK^]S:E65C;##RS:['O4FWEXO<[)KV5-GSJO\D[B^:\GC^PK_\FV'V M'U!+`P04````"`"0@&E'6F5WD9\!``!V`P``&````'AL+W=OTIM,X#B]@Y'T/Y/ MAT9QYU/34SL:X&TD*4E9GF^IXD)G=15KSZ:N<')2:'@VQ$Y*3XBO(?G9'K(\ M6``)C0L*W"]G>`0I@Y!O_+9H?K0,Q.OXHOX][M:[/W$+CRC_B-8-WFR>D18Z M/DGW@O,/6+90!L$&I8U?TDS6H;I0,J+X>UJ%CNN<_I3W"^UK`EL(;"6P9#PU MBC:?N.-U97`F=N1A=L7>PTT0\[,QC;M/U7-=%&5%ST'H!G-,&)8P*X)Z M]2];L-L61W9-+[;_%]A\\KB)`M\6@=VM1YV:),PN8=B6E=O[3XWHU<$H,'V< MOR4-3MJE$UBKZQ5[8/%@/^!U-?(>?G'3"VW)"9T?3YQ,A^C`&\GORHP,_A&L MB83.A7#G8Y/N14HG+^61LS.N/HB\VZ[8Y+[I3,!,%,"0K8+.:-'K4L'GGH>+.:079;2=9Y"0C3I!UD@7]2+!* M"&590T1HA#%6F]N6;&3)!I8R?FSLS;$)%1JU$$[==N(B)XX,#KNDMB[,62`8 MUDZH`J43O$@1\T`0-YIU,XNFCC#S/_SP$)V$#(Q(L/0+HF1@R5YQ),DJ1>,SPK#K%!*GC=$EC+",?XDY1^[[;:S M:#:CA-92\LN0*C-MM4O9H3(&H-3$EN-M:=(9"BEY4T0'QFA(L!0C51*F(O^F MD+>A2B02;98R;3%5)<$JLGEO98A+9;2],K\Y$7K".`,);U(9#\6,!<)8OHC8@J![/[/. M7%G:5"J=T^!L2J$6DQ9DR#5,0"/$:`0@N;'CN)U%LV'MI./!1G5*N80J"F+2 M`B$M\J0%I'!SGFZ\-*=2!](*D>(KABX0Z"(/75"4$[[$$/Q^(%#";5`2B50:1,H0Q:`$`DK%@Q+<;3<$D6:H#1,V!\:( M1()(Q2,20^[YKHS0DM^S1(E^@2Y@QC MUB)AK>)9BR%#C2\T0#B^`"!*)9W4%E)L_?)MG`!7\<#%D*(N4U9J_IU+A+Y0 M5@(Q9>IBW"+!+?_5N9E+.5")H8L$NCIE&<3010)=S4-W%LUG)<8/]Y6U&>IB-ZO@ MR*LNVY?Q*+!;/#6OQWXZ5KH\O1PW?H;AR"QZOI7W^71H^!%FLSX5+^5?1?MR M.':+QZ;OFWH\BWMNFK[TWL0G/^;[LMA=;JKRN1\N,W_=3D>'TTW?G-Y/0B_' ML9O_`5!+`P04````"`"0@&E'V=*`8J$!``"Q`P``&````'AL+W=O;`?@R+M6O=W1SKEARYBM.M#"WN$` MO?_3H-'"^=2TS`X&1!U)6C&>9?=,"]G3LHBU%U,6.#HE>W@QQ(Y:"_.Q!X73 MCJ[HJ?`JV\Z%`BL+MO!JJ:&W$GMBH-G1I]5VGP=$!/R5,-FSF`3O!\2WD/RN M=S0+%D!!Y8*"\,L1GD&I(.0;_Y\UOUH&XGE\4O\9I_7N#\+",ZI_LG:=-YM1 M4D,C1N5>K@)(EZ9>&\VIG'Z5#V6JPTOV#$(76#V"<,3 M9D$PKWZS!;]LL>=G=/X]?7WE%D,HH4_PK2RM^2`SI]L/-0&T8$WD=UM M*.G\^UD2!8T+X8./3;I2*7$XG![(\DK+3U!+`P04````"`"0@&E'>O(8'Z(! M``"Q`P``&````'AL+W=O+.IZ9EMC?`ZTA2DN59=LL4%YJ6 M1:R]F++`P4FAX<40.RC%S?\=2!RW=$&/A5?1=BX46%FPF5<+!=H*U,1`LZ6/ MB\UN%1`1\"9@M"BXCNG/.IMHUPGY1,AGPGTDL-0HVGSFCI>%P9'8GH>S6VP\W`01KTR\ M-QO3.'VJ'LK%^K9@AR!TAMDE3)XP,X)Y]:LM\O,6N_R$GO],7UXX7$;Z&ULC5/+;MLP$/P5@A\0RK23%H8L($Y0M(<"00[MF996$A&2 MJY"4E?Y]^9`5VS#07L3=U?&AEW([VW@];QES=@Q;N#@

+'$C5H+^V8_&AV MM(@60$'MHX((RQ&>0*DH%!J_SYJ?+2/Q/#ZI?TO3!O<'X>`)U6_9^#Z8+2AI MH!6C\J\X?8=YA/LH6*-RZ4OJT7G4)PHE6GSD59JT3OG/UV*FW2;PF<"O""PW M2C:?A1=5:7$B;A#Q[%;;`+=1)"B3X,VE-$V?J\=J]5"4[!B%+C#[C.$9LR!8 M4+_9@E^VV/,S.O\W?7WE<)WHZ]GA?_3?7`ELDL!F%N`W1[S$K*^:L+,]U6"[ M='44EUNYR-/9_()K\I!=/!3V$X:1P[HP\FF0VT1/003Q=T])7UX M/TNBH/4Q_!)BFZ]43CP.IP>RO-+J+U!+`P04````"`"0@&E'K[O/"Z(!``"Q M`P``&0```'AL+W=O MP)$/);7=T]ZY8<>8K7M0W#[@`-K_:=$H[GQJ.F8'`[R))"59GF5;IKC0M"IC M[=54)8Y."@VOAMA1*6[^'4#BM*BZ\B:YWH<"JDBV\1BC05J`F!MH]?5KM M#D5`1,!O`9.]B$GP?D1\#\G/9D^S8`$DU"XH<+^[,9)0VT?)3N#:WVGFX"2)>F7AO M-J9Q^E0]5:MM4;)3$+K"'!(F3Y@%P;SZW1;Y=8M#?D'/OZ:O;QRN(WT].]Q\ M+5#<"!11H)@%MG='O,8\WC1A%WNJP'3QZEA2XZA=VKRENMS.ISR>R2>\*@?> MP2]N.J$M.:+S)QL/M45TX$UD#QM*>O]^ED1"ZT+XZ&.3KE1*'`[G![*\TNH_ M4$L#!!0````(`)"`:4<8S?57HP$``+$#```9````>&PO=V]R:W-H965T6C&-&\VP[`D4\EM=W1SKE^RYBM.E#9?=,<:%I6<3:JRD+')P4&EX-L8-2W/S;@\1Q1Q?T M5'@3;>="@94%FWFU4*"M0$T,-#OZN-CN5P$1`7\$C/8L)L'[`?$])+_J'DAVMJ<* M3!NOCB45#MJES9NK\^U\S..9?,'+HN07B*H@$` M`+$#```9````>&PO=V]R:W-H965TLMB#J1M&(\R[XQ+:2A M99%J+[8L!Z?U)_3M,']03AX1/57UKX+9C-*:FC$H/PKCC]A'F$3!2M4+GU)-3B/^D2A M1(N/:94FK>/TA_^8:;<)?";PA?`]2\:G1LGFD_"B+"R.Q/4BGMUJ&^`VB@1E M$KRYE*;II^JQ7-WS@AVCT`5F/V'XA%D0+*C?;,$O6^SY&9U_35]?.5PG^GIV MN/Y:(+\2R)-`/@OD-T>\Q&RNFK"S/=5@VW1U'*EP,'[:O*6ZW,X'GL[D$UX6 MO6CAM["M-(X338?:('H()K*[#25=>#]+HJ#Q,;P/L9VNU)1X[$\/9'FE MY7]02P,$%`````@`D(!I1WNF+&ZB`0``L0,``!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RK(2IX8L($Y0M(<"00[MF996$A&2 MJY*4E?Y]^9`5VS"0B[B[FIF=Y:.N6'+F*U[4-S>X0#: M_VG1*.Y\:CIF!P.\B20E69YE#TQQH6E5QMJKJ4H!-=[T*!525;>(U0H*U`30RT._JTVNZ+@(B`WP(F>Q:3X/V`^!Z2G\V. M9L$"2*A=4.!^.<(S2!F$?.._L^9GRT`\CT_JW^.TWOV!6WA&^4X3X(UBAM_))ZM`[5B4*)XA]I%3JN4_I3Y#/M-B&?"?E">,RB M\=0HVGSACE>EP8G8@8>S6VT]W`01KTR\-QO3.'VJ'JO5YJ%DQR!T@=DG3)XP M"X)Y]9LM\LL6^_R,GG]-7U\Y7$?Z>G:X^5J@N!(HHD`Q"SS>'/$2\^VJ"3O; M4P6FBU?'DAI'[=+F+=7E=C[%0V2?\*H<>`>_N.F$MN2`SI]L/-06T8$WD=W= M4]+[][,D$EH7PHV/3;I2*7$XG![(\DJK_U!+`P04````"`"0@&E'`-^X:*(! M``"Q`P``&0```'AL+W=OQ-W5S.PL'^6$ MYL/V`(Y\*JGM+NN=&[:4VKH'Q>T=#J#]GQ:-XLZGIJ-V,,";2%*2LCR_IXH+ MG55EK+V8JL312:'AQ1`[*L7-GSU(G'99D9T*KZ+K72C0JJ0+KQ$*M!6HB8%V MEST6V_TZ("+@3F\VST@#+1^E>\7I)\PC;()@C=+&+ZE'ZU"= M*!E1_#.M0L=U2G\VQ4R[36`S@2V$ASP:3XVBS>_<\:HT.!$[\'!VQ=;#31#Q MRL1[LS&-TZ?JL2H>\I(>@]`%9I\P+&$6!/7J-UNPRQ9[=D9G_Z:OKARN(GTU M._R/_NLK@7446,\"[.:(EYC551-ZMJ<*3!>OCB4UCMJES5NJR^U\9/%,ON!5 M.?`.?G'3"6W)`9T_V7BH+:(#;R*_VV2D]^]G222T+H3??&S2E4J)P^'T0)97 M6OT%4$L#!!0````(`)"`:4?"CF5)40(``.L(```9````>&PO=V]R:W-H965T M^Y>)B>H!!0^$OO@&;4GGPYJ010^*L/ M0/H"GJ$3N3H1H/`;P`'-<`!QSS6)`87?`PYHA@F(>_Q)`BC\-G!`^`"`R!P?N/<`R0#%`Q]`D.L#?->,&B9.MN=*M.?G M5@U=9UP=^_IS9)O9)[S(.WIBOZ@X5:U$.ZYT2[3=\,BY8CJ+\$G_JZ7^\A@G M-3LJ,\ST6`R]>)@HWMT^+<;OF^(_4$L#!!0````(`)"`:4=(A.\5HP$``+$# M```9````>&PO=V]R:W-H965T&+"!.$:2'`D$.[9F65A(1/E22LM*_+Q^R8AL&OWD/QL]S@+%D!`XX("\\L)GD"((.0;_UTT/UL&XF5\ M5G^.TWKW1V;A28L_O'6#-YMAU$+')N'>]/P"RPAE$&RTL/&+FLDZ+<\4C"3[ M2"M7<9W3GW*[T.X3Z$*@*^%[%HVG1M'F#^9871D](SNR<';YSL--$/'*R'NS M,8W3I^JIIOFF(J<@=(4Y)`R-F'Q%$*]^MP6];G&@%W3Z-7USXW`3Z9O4O=Q^ M+5#<"!11H%A&+.Z.>(TI;YJ0BSV58/IX=2QJ]*15R/K MX11/908#?[]K(F`SH5PZV.3KE1*G![/#V1]I?5_ M4$L#!!0````(`)"`:4>I)@OQI`$``+$#```9````>&PO=V]R:W-H965TZ:EE42$Y*HD M9:5_7SYDQ38,M!=Q=S4S.\M'.:%YMSV`(Q]*:KO/>N>&':6V[D%Q^X`#:/^G M1:.X\ZGIJ!T,\":2E*0LS[=4<:&SJHRU5U.5.#HI-+P:8D>EN/ES`(G3/BNR M<^%-=+T+!5J5=.$U0H&V`C4QT.ZSYV)W6`=$!/P4,-F+F`3O1\3WD'QO]ED> M+("$V@4%[I<3O("40<@W_CUK?K8,Q,OXK/XU3NO='[F%%Y2_1.-Z;S;/2`,M M'Z5[P^D;S"-L@F"-TL8OJ4?K4)TI&5'\(ZU"QW5*?S;%3+M/8#.!+82G/!I/ MC:+-+]SQJC0X$3OP<';%SL--$/'*Q'NS,8W3I^JI8L6VI*<@=(4Y)`R+F&)! M4*]^MP6[;G%@%W3V;_KJQN$JTE>I^_8_^J]O!-918#V/^'AWQ&O,TTT3>K&G M"DP7KXXE-8[:I]2*+-+6FO[+:6F;$%RE1BVY=:5NJ.DU\"J0I*`L36^IY)U* MBCSTGG61XV!%I^!9$S-(R?7''@2.NR1+SHV7KFFM;]`BIQ.OZB0HTZ$B&NI= MJEV2^@@@H+1>@;OE"/<@A!=RQF\GS2]+ M3[S0FX7)9B;`KIK,,:N%";TX.`FZ"??3D!('9>,) M3=WI"=RQ0-_N&XZ9<@!K;L^X>;4B!9&ULA53-;J,P$'X5BP>HP4F@C0A2TU75 M/:Q4];![=F``JS9F;1.Z;[^V(30@)"[8,WP_,^!QVDOUJ6L`@[X$;_0IJ(UI MCQCKO`9!]8-LH;%O2JD$-394%=:M`EIXDN"8A&&,!65-D*4^]ZZR5':&LP;> M%=*=$%3].P.7_2F(@EOB@U6U<0F@',G9(W_CIK?EHYXO[^IO_IN;?47 MJN%%\C^L,+4M-@Q0`27MN/F0_1N,+1R<8"ZY]D^4=]I(<:,$2-"O866-7_OA MS6,XTM8)9"20!0$/1K[,']30+%6R1[JE[M]%1PM73L0J(UN;]J'O?LA>,T+V M*;XZH1GF/&"(QT03`EOU50LRMSB3.SK9IN\6%>X\?3>XQT_;`ON%P-X+[,<6 M#ZLMSC'QMLEA87*8"22K)G/,X[9)O#")9P)/JR8SS"[<-DD6)LE,(%HUF6.6 M/Q7?'4$!JO*3IE$NN\8,9VW*3L/\3/P1_H9G:4LK^$55Q1J-+M+80?`S4$II MP!81/MCO6=OK9@HXE,9M$[M7PP0.@9'M[3Z9+K7L/U!+`P04````"`"0@&E' MF9*.E:,!``"Q`P``&0```'AL+W=OY#,WN@!E/_3:B.9\ZGIB!T,L":2I"`T MRVZ)9%SAJHRU-U.5>G2"*W@SR(Y2,O-_!T)/6[S"Q\([[WH7"J0JR<)KN`1E MN5;(0+O%#ZO-K@B("/C+8;(G,0K>]UI_A.2UV>(L6``!M0L*S"\'>`0A@I!O M_#EK_K0,Q-/XJ/X.-Z;S;#J(&6C<*]Z^D%YA'60;#6PL8O MJD?KM#Q2,)+L*ZU&D6;3\RQJC1Z0G9@X>Q6 M&P\W0<0K(^_-QC1.GZJ'BN9Y20Y!Z`RS2Q@:,:L%0;SZU1;TO,6.GM#I[_3\ MPF$>Z7GJ?I?_+E!<"!11H)A'+*Z.>(Y97S0A)WLJP73QZEA4ZU&YM'E+=;F= M#S2>R0^\*@?6P1]F.JXLVFOG3S8>:JNU`V\BNUECU/OWLR0"6A?".Q^;=*52 MXO1P?"#+*ZV^`5!+`P04````"`"0@&E'\Y`O=%D"``#$!P``&0```'AL+W=O M>%0J0!5+6+2J-9 MM&L#!J))8FH;,OW[^A&"DUJ%LB"V)+RO(@B ML3O1EH@7=J:=>G-@O"523?DQ$F=.R=Z0VB9"`*112^HNK$JS]L:KDEUD4W?T MC0?BTK:$_U[1AO7+$(:WA??Z>))Z(:K*:.3MZY9VHF9=P.EA&;["Q08B#3&( M'S7MA3,.=/@M8Q]Z\FV_#('.0!NZDUJ"J,>5KFG3:"7E_&L0O7MJHCN^J7\Q MY:KX6R+HFC4_Z[T\J;0@#/;T0"Z-?&?]5SK4D&C!'6N$^0]V%R%9>Z.$04L^ M[;/NS+.W;W(PT/P$-!#02!A]_(1X(,1W`OXG`0\$/"-$MA2S$1LB255RU@?B M3/3G`1<*SK6(4@Y4]<),S?[:U6N%XK2,KEIH@EE9##(8."(BI>ZU0%.+%7+H MR&>P=A%IX8-L)B+)XQ#QK,[8\..ASNRQ`)X)8".`C4"23#-VME`+R>P^89`@ M!"'V(3!"F^@U-TDF*A`ZO?8*IM99:X5!EZKS*DI?=(GG_GD$Q_H]YG`Y\T@F!^Y,'$*GY"XJ];`_[O<8)H+H$F*;#_YIF"YN<^G5]*79^@HNUK:]W&6J\DR.]#OAQ[H3P99)=1.; M2_C`F*0J'7A1A^:D6NHX:>A!ZF&FQMPV&3N1['SKF6/CKOX`4$L#!!0````( M`)"`:4>NS8_%!P(``-D%```9````>&PO=V]R:W-H965T+LX$6M`##+*&A9TZ55Z>=>557*LQ%-QU]5HL]MR]2?%R[DL$KS]#KQUIQJ MXR9`58*;[M"TO-.-[!+%CZOT2_Z\)8[PP,^&#WK23USVG93O;O#]L$HS%X$+ MOC?.@=GFPM=<"&=D%_X]>GXNZ833_M7]JZ_6IM\QS==2_&H.IK9ALS0Y\",[ M"_,FAV]\+,$GW$NA_3/9G[61[562)BW["&W3^78(;S`=97$!'`7P)LCQ/P5H M%*!'!7@4X$<%9!20F0"$VOW.;9AA5:GDD.B>N=\I?[:XZD@IB6X.*,[YB4P,#`Q8GU'D!BRF2)T&4.V=RZXN#'`UA$M!LZ*@=X`C0:+ M_QN@F0'R!G@TF*7LPFX$IO`,H9`N1\F@D,BF>$DSS)8YF7T]!0HH<%8MH]LT= MB"`DQ3+Z?;93$&=X85>GLR+!Y(ST[,1_,'5J.IWLI+''S9^THY2&6[OLR?K5 M]IZ]#00_&M)\D8G-@'15W_,AZ]<^.#QV5:COL$W$<&-WJH*Y- M$`!YTM&FC^M*GST-=<5/LFUZ]C1$XM1U=/CSR%I^7L4POAP\-_N#'`^2NDJ6 MN&W3L5XTO(\&MEO%#_!^#K&(P:6,LVLTY!IKK"_M77:Z2_T(%6_/V5[.5!Z46Q-&6[>BIE<_\ M_(W--60CX8:W0O]&FY.0O+N$Q%%'WZ=GT^OG>?JG!'.8/P#-`6@)6/+X`_`< M@*\!N:YT4J;K^D(EK:N!GR-QI./;AO<*/HPDBCE2Q0B]U=!-82&RVQFP4RC6\7B.3V\3I`Y! MJ@G2F2"S1?93&1.FT)B4%"5)`?0!UR8089`C@`,D98ZDS)*4>R5-F&R2E('" MK\=$$81N2\D=*;DEI?!*R8TD)?#J,"%9"?+;0@I'2&$)*;U""O-.2(E33)!7 MC@E4KRDK8`9N2RH=2:4EB=PF(`X!^:QW(7`_0N%V+9A]VLYNMX%YB)W-9H(@*$M(0FSA=A18A)C4 M;!58?3HA-^,V"EB&&+`T,H5D<;L))"'.(J9?(%2S`7`O+S%&C8X->SV"B6C# M3[V<9HKE=!GS'I`>5:[PNCK2/?M!AWW3B^B%2S7PZ%EGQ[ED2@JX4WXYJ$%T MV;1L)\=EH=;#-)I-&\F/ETES&7?KOU!+`P04````"`"0@&E'5';^?#\"```3 M"0``&0```'AL+W=O5%KM17MMP)!HG3AK&[)]^_H0:.(-8&Z(;?[Y\XU'8Z?H*7OG M%<;"^VQ(RU=^)42W!(!O*]P@_D0[W,I_]I0U2,@I.P#>,8QV.J@A(`R"%#2H M;OVRT&NOK"SH49"ZQ:_,X\>F0>SO,R:T7_G0/R^\U8=*J`50%N`2MZL;W/*: MMA[#^Y7_#2[7,%42K?A=XYZ/QIZ"WU#ZKB8_=RL_4`R8X*U0%D@^3GB-"5%. M\LT?@^G_=ZK`\?CL_J+3E?@;Q/&:DC_U3E22-O"]'=ZC(Q%OM/^!AQP29;BE MA.M?;WOD@C;G$-]KT*=YUJU^]N:?+!_"Y@/"(2"\!,#X9D`T!$16`#!D.J_O M2*"R8+3W>(=4M>%2RIDRD3(;KJ=XNLWHJPQ06X*2,)IIGHPF-9DZQGBB2 MBP1(@%F*T*((=7PT4(3W#2++(-(&\6`032%;DX;19%H#SECFBI-8.,ED=^+[!JEED#Y:G\PRR!SJDXTR#6;W M8EYQ%2*W('*'JN1W(>855R$6%L1BLA,.O0(#NV6#1ZL!OW0]=*C'(+JU%UA0TT&T4V0>Q@_7Q6Y4F+C4)7$[.28ZUZ,# MVJT/4Y<*I6YGZT0WBP1&UU>'#O@78H>ZY=Z&"GD3ZDMP3ZG`TBUXD@E6\@OE M,B%X+]0PDV-F[FPS$;0[?X)M,U M@$'O@K=Z%]7&=%N,=5F#8/I!=M#:E9-4@AD;J@KK3@$[^B+!,8GC#`O6M%&1 M^]R+*G+9&]ZT\**0[H5@ZN\>N!QV41)=$J]-51N7P$6.I[IC(Z#5C6R1@M,N M>DJV>^H0'O"K@4'/YLAY/TCYYH(?QUT4.PO`H32.@=GA#,_`N2.RPG]&S@]) M5SB?7]B_^=U:]P>FX5GRW\W1U-9L'*$CG%C/S:LRY(1G-\=D0+S#Y@B,Y!VKX"=35=-J=)#&]H5OB9.4!JR/^,&>;&U? MGRG@<#)N2NU=I^K5B%#*=-6F?WWVPNB96ID7NR%<\YW^O7RF764O?,2 M8P$^2=WPM5<*T:Y\G^]+3!"?T18W\LN1,H*$'+*3SUN&T4&32.V'03#W":H: M+\_TW"O+,WH6==7@5P;XF1#$_A6XIMW:@]YUXJTZE4)-^'GF#[Q#17##*]H` MAH]K[P6NMC!2$(WX4^&.W_6!,K^C]%T-?AW67J`\X!KOA9)`LKG@#:YKI20C M?_2BMYB*>-^_JO_0RY7V=XCC#:W_5@=12K>!!P[XB,ZU>*/=3]RO(5&">UIS M_0OV9RXHN5(\0-"G::M&MYWYL@AZFIL0]H1P(`QQW(2H)T13"7%/B&^$N4Z- M68I.Q!8)E&>,=H"W2!T/N))PID2D,I"KYWJH\VMF+WF81IE_44(6IC"8L,?$ M+LSF'@-=B*VEDMPB^=*ETVIH6RU"RT;BM&%AG#8L1/+<131*6*3Y4>]B_EP@ M'@G$6B#N!5+;9&.683"IR2:<8C,914FL*`MG%(.!@0$%L\B%VEHHN)Q-,#,? MF9E;9I;.G;,PB\"Y=X\P#XVD(R.I)0"?"RQ&`HOO[OYR)+"T'(2NC!=+*^/) ME(QKL'6O@^?'K.A!WSEG\,L#`JT5/7A!;%`\(4XXCA-:$L[K7XQ`$_8'CN\W MC)X?UL(&?3F)_MT;3#`[Z6+&P9Z>&V$>VV%V*)@OH7[#;_`\:]$)_T;L5#4< M[*B0E4`7@2.E`DL7P4Q>S5*6]&%0XZ-0W53VF2ER9B!H>ZW9PQ^'_#]02P,$ M%`````@`D(!I1QLSFN?;`@``]@L``!D```!X;"]W;W)K&ULE99=;]L@%(;_BN7[Q8"_(\=2DVG:+B95O=BN:4(2J[;)@#3=OQ]@ MXAI*%^^)$0$;QU;<]7X5&(TS**^/9(.LP7]$1Z^<^> ML@X+.62'B)\8P3L=U+41`B"+.MST85WIN4=65_0LVJ8GCRS@YZ[#[.^:M/2R M"F%XG7AJ#D>A)J*ZBL:X7=.1GC>T#QC9K\('N-P@I"1:\:LA%SZY#U3QSY2^ MJ,&/W2H$J@;2DJU0*;"\O)(-:5N529+_F*3O3!4XO;]F_Z:7*\M_QIQL:/N[ MV8FCK!:$P8[L\;D53_3RG9@UI"KAEK9<_P;;,Q>TNX:$08??AFO3Z^ME^*<` M)LP?@$P`&@-&CC\@-@'Q>T"N5SI4IM?U%0M<5XQ>`G["ZFW#I90SE41F#N1B MN![JQS7,OM:HR*OH526R-.M!@[0&^A2;J0*E\:B)9`7>,I!=QAI-$W@1EB*] M38B=A<8Z/C8++6XG2)P$B4Z0F`2E760_+&/0I,.3*I/;D-2!I%-(";R0=`(! MMQ&9@\@L!/0BLOL0N8/(+03R(O()X@M,T6U*X5`*BQ)[*<64DLR`E`ZDM"") M%U)ZG]9$L2GOW1<0N.<46(6DWD*,:/9[@Q_<`%J4S$\QG@&TJLSA(I^!0BX* M6:CNGT1;E/A$&TTH%D36`A3S(1]F$CX.6[(6Z MS>4]&]K282#HZ=IECZU^_0]02P,$%`````@`D(!I1TIZP)E'`@``90<``!D` M``!X;"]W;W)K&ULC97+CILP%(9?!;%OL,T](DB3 M&8W:1:71+-JUDS@!#<;4=L+T[>L+8G!FG6*HIOP2BXP2?3!!M`@1`$E!B$HBV",.]64M*)FK><_ MP>T>AEIB%+]JTHO)V-/)'QC[T),?IYT/=`ZD(4>I+;!ZW,@S:1KMI,A_!M,O MI@Z&1-<)\>\>K MD(S>0WR/XD_[K%OS[.V;#`QARP%H"$!C0&@"`@LR:;Y@BH!6@U`&E,U"R"$JG(+7!2?*8DSF<;,9)%SG9=(<` MRM5O]QB4.Z!\!LH605:3&TV\R5:4`X%[K,",DR]R!I&M"*[!_'=ZX12#P#)F M..-P*`BL^!]`Y)+0C`2726A*@LDF75.4>]QA.$.A950XV20%UWX^IXHSPATT:_Y&71X0OYB?FE;H5W8%(U8].'SXQ)HM(`&W6: M*W7GC9.&G*4>IFK,[2U@)Y)U]TMMO%G+?U!+`P04````"`"0@&E'\9=JS'$" M``!&"```&0```'AL+W=O*JWVT)Z=Q$G0`DYM9[/]]S4V8;%K*>00;//.^XP#GDEU M8_Q-G"F5P4?7]F(3GJ6\K*-([,^T(V+%+K17=XZ,=T2J*3]%XL(I.>B@KHU0 M'&=11YH^K"N]]L+KBEUEV_3TA0?BVG6$_]W2EMTV(83WA=?F=);#0E17T11W M:#K:BX;U`:?'3?@$ZRVD@T0K?C7T)F;C8$A^Q]C;,/EQV(3QD`-MZ5X.%D1= MWNDS;=O!29'_C*:?S"%P/KZ[?]/;5>GOB*#/K/W='.1991N'P8$>R;65K^SV MG8Y[T!GN62OT=["_"LFZ>T@8=.3#7)M>7V_F3A&/8?X`-`:@*0#G.G$#TFE^ M)9+4%6>W0%S(\/!@K>1\,%'.@O5E]KS'"5?0^&%F:K=$@K8%)$2EW M+P+9B"V:A6.4/#;`3HY8&^#1('ULD#@&B39(1H/,WF1OLC2:5&L22`J$BL>@ MU`&E%BCW@M(9*'Z,R!Q$9B$*+R*;(;Z@$J59D3\FY0XIMTBEEY3/20`X6_!X M"X=3S#DX]G**&0<0`.0+-E0ZH-("@1=D-*5Y.JL2E];G,1-B]X#%%A5YJ:-H M\4L!_QUCL"C83QD/.XR[PPN.$B"7A"Q2XB>A.0FMEAQ:<(\]8(N4^DEX]L#0 M"B]X+<`M#V#5!^RO#Z,HUZ(,\A)!L>!E![=$@%4CL+]&C"(#*]6O7)3NQJ)9 MG>\H/^EV)H(]N_;2%/1I=6J93TCWB4]Y75W(B?XD_-3T(M@QJ;J-;C1'QB15 MF<0KEI_4$L#!!0````(`)"`:4>& M(_P\[`$``&L%```9````>&PO=V]R:W-H965T5JC[L/CMD$E!MS-HF=/]^?2$4(E?I"_8,YYPY M8_#D`Q?OL@90Z(/15NZ"6JENB[&L:F!$/O`.6OWFQ`4C2H?BC&4G@!PMB5$< MAV&&&6G:H,AM[E44.>\5;5IX%4CVC!'Q;P^4#[L@"JZ)M^9<*Y/`18XGWK%A MT,J&MTC`:1<\1=LR,P@+^-W`(&=[9+P?.'\WP<_C+@B-!:!0*:-`]'*!$B@U M0KKPWU'SLZ0ASO=7]6?;K79_(!)*3O\T1U5KLV&`CG`B/55O?'B!L865$:PX ME?:)JEXJSJZ4`#'RX=:FM>O@WJP?1YJ?$(^$>"),=?R$9"0D-P3LG-F^?A!% MBESP`NMC',WKL+>!'?%D@N6DSL?1D;//QOD!Z(Y!:@=0)I.'28^NZ<)BU M.X0X#<,D]>'*)6ZC@>GFOJ/5C:/5PE'D=>0P*XOQ>B[]B"]-9#/!<]^;@;B;"^]1!7O6^7^XBD[S96GV%Z.3WB1=^0,OX@X-ZU$!Z[T M%;.WZ\2Y`NTD?-"G4NO)-P443LILUWHOW#!P@>+==;1-\[7X#U!+`P04```` M"`"0@&E'L_3!'YL#``"!$0``&0```'AL+W=O("UNZ_7TBB3=*@ ML0_EPW/O/;G>ZC[MBR8BN"ZBI"`-"H+LHF7,[%O9=V.>>GOBH;]M(&W:FNB_;?BE7\ MO`AA>+GQJ]P?^O%&M)Q'U[AM6;.F*WD3M&RW")_ATQJ3$2(0OTMV[K3S8"3_ MROG;>/%CNPC!R(%5;-./*8KA\,YR5E5CIJ'R7Y7TL^88J)]?LG\3RQWHOQ8= MRWGUI]SVAX$M"(,MVQ6GJO_%S]^96D,\)MSPJA/_@\VIZWE]"0F#NOB0Q[(1 MQ[/\)`4JS!V`5`"Z!ESKN`.P"L"^`40%D,\`T>M(+D4T8EWTQ7+>\G/0'8MQ M/.#3`&_')$/F8%A])RY%?^7=]R4F>!Z]CXD,S$IBD,#0U`7)=0B\(J*!@),% M,EFLD!:.G`7N(M8&(K[/`5N=P"(>JTZ0^PF(E8"(!$2V"9@<&[E."8EEFX#\ MFQ1CS7J<>:D+B&I@(`9`-#)VPNUGD9-,J868ZHW&SL94R_& M7JCU-&J2<6(Q3C3&F,3.*3Y(52&DFOB5#?^CZ#G1Z#5\<&>IKB">J0;UC M#U1#=C5D5'-._TJ!U"0@`@`F[GZ9P'1`:M_X-"O;BR$V6"&/%+8;0_*HGT/; M%6%LL'"Z3*Y`Q74C2C#'AEL(X+I MP^VWC0,:SA%3=_MUZZ`I\FP_LIT#&M@>LI6+DH=;8TL7I?=_$G*4FD[O M.WFVR)$AYJ'-S78UAHF!@NGXZVPO@V):4+CQ/V`B"#3\U MO=RI7N]>WS8\([$!_H0OY\=BSWX6[;YLNN"5]\,V6NR@=YSW;&`"9H-D#ZS8 M7B\JMNO'TV0X;^4;`GG1\^/EA=>E,QWF*I0GX"HN<$EX;44N!!&($6 M-YV;9V;MA><9.TO:=.2%.^+%U^942[T`\@S<>&73DDXT MK',XJ?;N(]H5"&J(0?QHR"!F;/S#VIH-OY=Z%V@.AY"BU!%;#A12$4JVD M=OXUB?[=4Q/G\ZOZ%Y.NLG_`@A2,_FQ*62NWT'5*4N$SE:]L^$JF'$(M>&14 MF*=S/`O)VBO%=5K\/HY-9\9A?!/`B;9.\":"=R.@X%."/Q%\BP!&9R:O9RQQ MGG$V.*+'^FNCG8)S+:*4'96,,*$IU[AZR?THSL!%"RTP3R/&,QAO#5$L$.$- M`I2!51>>Y<(S?']RD6P+^):`;P2"22!=FNS&-$9,;#`H0=%LGQFLF,.\.$0I MW+836':"N9T8KMH9,:'!K"**=<2')D++1#@SD:)5#^%LAT]*,H?=6Y+(2.'DGN*TCR'P5)+3OI'3V2;O;(.N)#$PC:_S_<[I() ML_GG+'"K90&SPZG')_(=\U/3">?`I#KGS!%7,2:)4H,/JNMJ=?_<`DHJJ:>Q MFO/Q1!X#R?KK!7.[Y?(_4$L#!!0````(`)"`:4>S)0UV'`(``)`&```9```` M>&PO=V]R:W-H965T0F MJ)1JUV$HRPH8D3/>0J/?'+E@1.FE.(6R%4`.EL1H&&.\"!FIFZ#([=ZK*')^ M5K1NX%4@>6:,B#];H+S;!%%PVWBK3Y4R&V&1ASWO4#-H9,T;)."X"5ZB]2[" M!F(1/VOHY&".C/D]Y^]F\?VP";#Q`!1*922('BZP`TJ-DH[\^RIZCVF(P_E- M_:M-5]O?$PD[3G_5!U5IMSA`!SB2,U5OO/L&UQQ2(UAR*NT3E6>I.+M1`L3( MAQOKQHZ=>[/$5]HT(;X2XI[0QYDF)%="UH MK>'"B&AEI).1=FG+Y78O19+%>7@Q0AYFZS"QQ413B-T0$:=)CPFU@TD;L6]C M&P\%)D-XB/1QA&24:&+YB4MTL7PL,!\)S*W`W!G(,M]DX])PF,Q5*GK&9CJ* MD@ZB)%DR&<5A(NRLX-DD:N>AHM7L"3.+D9F%E_)J\N/P,$L\>7:?83XUDHV, M9%Y5YH\%EB.!Y?^>_FHDL/()&WY`0_B#C5C41[KG0;LAWHR+D"[0+/]/=5 MZ=]#OZ!P5&::Z;EP#=,M%&]O_;__"15_`5!+`P04````"`"0@&E'25*M*_0" M``![#```&0```'AL+W=O/34-ZO[.<4W.4Q_XEXF?U?[`Q$0P*X.! MMZT:W-**M%Z'=U/_&4S6H!`0B?A5X3/5[CUA_HV0=S'XOIWZH?"`:[QA0@+Q MRP=>X+H62CSRGU[T&E,0]?N+^DJFR^V_(8H7I/Y=;=F!NPU];XMWZ%2SG^3\ M#?3VK)S#J:6Y"U!.B@3#$<1/BGA!? M"D)V)61W";`G0"M"H%97[LT2,30K.W+VZ!&) M-Q9,.+P3(ES9XQM"Y5!NN9K]F,4P*X,/(61@Y@H324R6NR!+'0)FS5BBH(5#'RL,A8,1*W+&`7GUC0T5VJ,@(E;I;N`D:49C`;EH@-B3@"`F[;8'D MRYMH]P=@-(@\=[[70*_H=.S"VA4-S))V]J(ER(PFDXQ^8^RR!D9=%V,D[!H# M^9>7UZXR4(SH+CU(KQ'WVHS#K>_AE/5`._41[_`-U^ZJEWAMA_+0F#VH[0ACFQL,G_IX= M^)?`,*CQCHE;R.\[=396`T:.EZ/^\+TQ^P=02P,$%`````@`D(!I1T'Q5LF# M!```"AD``!D```!X;"]W;W)K&ULG5G;:FH?=9Q++,35@O$#BV;]?+K)7W='8S;S8@$]WJ]5] MCH0\WU?UCV:C=>O]+(MM;MXTNL^:BVNEM]\NZJLNL[6[K=[_9 MU3I;#49EX?,@"/TRR[>SQ7QX]JU>S*N/MLBW^EOM-1]EF=7_7NNBVE_-V.SP MX'O^OFG[!_YB[A_M5GFIMTU>;;U:KZ]F?[#+%ZEZR(#X*]?[QKKV^L&_5M6/ M_N9A=34+^C'H0K^UO8NL^_K42UT4O:T/[^N#];DBW&_YKUNAE M5?R=K]I--]I@YJWT.OLHVN_5_EZ;'(81OE5%,WQZ;Q]-6Y4'DYE79C_'[WP[ M?._'7^+`F+D-N#'@1P,F3QH(8R"H$:0QD-0(RA@HJD%H#$*J060,(JI!;`QB MJD%B#!*J05_SL7(!V>18;$8V.92;D>O-#@5G@FQR*#G#-??']AV:_R9KL\6\ MKO9>L\MZ26"7/;[N_73.O:[EF^%V(-7X]',A$C;W/WM/`',]8KC!0).G"D_PY0C M%^8%8N(CQN_ZP-T,'#4#'SP(XR$A>!#(@Q@\R,%#A"J\'2LS0J(!PI@2,9>A M"_A@`V.A.%-.AZF-XTG$DACW\0A\!)$%ZZ"Q(.0H48[2RE$&@3/)$:,&3)*H M(,:4&''WTAK2"5Q*]/=D^PM9E$22DJ%"&2J0(2-X")&'<'(G1 M1M:L,"9CI0B!8A0HM@()%3D#C9ADG-8+19G3!(5)0#[.ZMTF5O4B%016<_TZ M$`NPI`<@E)LT!J0FQOJR?#`0BS+_#*L.FRX[#.L.$V`<3D&Y-R!U8"XM94Q_ M9O-?Q!'%!R884]-3QA1C(4C9V;C7!F3$41%3QEQDD(R4I85AFK%X>LJ80PR2 M*'%*KP$950A`F4$WT'#I*=R)I16SD@?G.S3E-BLY.19F)0>L9"0?7_8"TUG) M,2LY8"5SKLHIMUG)!3%ES$H.5F7&*3XP*_ET5G+,2@Y8R9PZ?V=`8\J#]M*2 MQKSD-B_=VZV4VXND3'[9YX\&:+9',7E0F.@\)I#4@"PI=I.4B$N)N">`HY,9 M"Q$'0L2<,W_';>'@BAI,8.400#F8<@8SH'@`!14JQN`D.IM0IQC<&-+E^7]Z)H`HZ%^H;`YI8/ZR"`JH@ M9:$66`7%=!446`4%5$'G:^\+!''2W&(%%&!GPDF3A@5+3-^9""P(`NY,W*N[ M^*V=A,1Z(($><.>KT=*`#J_9Y&!8$210!.X\V%DBD*0$PI24@)+X&&3,ZMF` MS/LM.2G,2`D8R9TG2$L$HNSSY9>C`LA']P9(RM]J"\Q;"=[:>>S4;@.*SFV. MB;CT%&X_YMO%>J[:MRN%@Z\!1>=MXW.5L>;0J_; M_C+JKNOQJ'Z\::O=X9^'X]\?B_\`4$L#!!0````(`)"`:4>1+*]JUC8``(@5 M`0`4````>&PO9NOI"*4-=-5!#)2$NG^%C-[MC^SWV19+HHX_',A3Y,BSG_[U6AX\I7XM(CB M[+=?S?-\^(4QBL2>RN9_*[#=O M\M_]Y@V^P^^=B,LDSN<9O#.3L^JW4[GLB?V^)X;]P4'URZODJ2?ZA\U?FO6X MB_CA?1A+,+,`O\2/Q)^JFX@`]KT*T^J>9M?/:/^]5/ M%!IOY6.8Y:D/PUSYB]IB[]Z)N]^?WXYOSC_<34ZGGIA<1!(^!Z^G?&3 MM5VE_BR,'\5TM;A/HOJ>[_ZE;8O)8@&D-LV3X*,GID3TXKK(L]R/<<3:CA.` M19S!.N"W+(G"&2WJK1_Y<2!A`#AQ&1R?#],SL?/U;@W#,@!2&=`A&+5!T\\R M&.2;VM=^-A>P*A'@+_+/1?CD1_!\C32F\R3-]W*9+D08/\DL)YK*9%"D81[6 M#_4DAF?A,9'*0,*@]U$->3>I7/KA#)[(`,PZC&D7Q_KKVU?R=1G$4^O=A1(NLX1F('5E^)I;^"G%!R_2#("T` M"O+3$LFO-O!8?1\D"WR`&&C;Y$L@#^2OR0.@\$'"AXC8)QD7-;Q?);DT"^E& MH+.E.M679R%0X_1!>47-$W0,C*4^0$4()A`P M(`3O84`M7.E!8";J4\50:NQ&<;=-EGC0N<:#H7=P<.P-!T2?_8/+@_A'\G^L'2[O*-M^8AZUG*(`^!YZP:-JH0GTT1IN2LD;;64CU!9+-W-Q-//]SX>.SF,@]!;/\KB*NOQ9L6:-4(W9+/ M#D!NED21GV:6E&JHJ0U0(Z]-WV`:V_3II$N(N\?BI1LJO[UV-XV/-V^E\='. M?31B>YK##V:*P#RNEZ@X`;UWJ"7[&ZOU-:7E?1C@$MH$R&V+PE!CJ%=)3'H- M;5Z+.92B21#2KI[#?`YB?B^B"8E]/*:2]]DV6)2$O?1[9%O.1-@5"D0F`-4JR^K>T2C@?`%&Y MJP>I;<9HDOQ@\RC-WYE7U=@U6I_[P-_A9?'@A_K``GG'ZS64I''Q-9H!E:1I MZV_]+`P8X6%4("7&ZDGB$8$ZLRQ&-V(@W\OP<8X#^4\`\T($HV?3L'(4BWLV;2JL0/ER34 M:\:\:X1U/.2(^(D6\[EN$+_C(5^Z[-:_(+^ MT&D`ZN<<5*Y]AR"!+Z$Z[<@/)J0X1I4)/B/N*3_)-`@S>O;93]%'4#<&OW"\ M+CI\R=C(OR,)A/[:B^X<>-/5I]8NI8E>\FS7'!=)^B##O$@WFJ7[Z<_"1)[` M.$S5H!:.LB[- M!RS]X).O!][P$"R4PY._V3S=?-FJ)SB/,G$:D?F(]`E_`43E8ADE*RDS#\1" M"B\DJ3%_LR+*FTZ(PX(ZO;0M+*CSG1>(EXKET>E`;I$T-_[*Z+;,H@WJ3A'^ MGZ4DDV_M(DJ>.Y3DT_'T]^+B_?7W4W%Q>WTIKF_.;\=WDZMW8GQZ-_ENY;> M^?@D(%;F>610TZE!E=5R5Y]NTZ/.Y!(V$#;JW.,%.GI^\K7["9YN^?"]:Y4D.:5:38: M_N4N07.9'-6':Z&._"&/@WD9^MH(4".`I M1)/D'M0(\TX[6*_.[S"X=7L^GI[#+X+`/+XZXU_.__AA\MWX_?G5W73C0`M* MPGOY&,8QSHPT20&Z1GPV323&=^(V?<+W3 MR;NKR<7D='QU!U1Y>OWAB@[OS?7[R2F09TL,`Q=R`P(,W?'BA_$].BF"O"[V MP\>8]H,!Z:8W[^2G7+R-@(*J[[9X]:^N[\[%0/SU?XLOV)3X'A@MZ-:^N`^3 M)2A#"YBF(,V%)*$?HSX;T%$'/.!I\@.@EHS@[;D.(J6>+19XV/S($8%Q`@^) M'+BO4@!00WZ[%\@H`O83`61\BF8PRR_R)%PLBEB"YI>(Q602)C.`]2(O'!,4^"B"@-,!G>)[,5S`EGAJ?#-U&_ M14S3;CB_04@@1F#M&H2G9\,^O0^F/@"CB`FXQ(DE`"9:+9;S)%CEN$:-H"A+ MW,W>O;O=&PS[0P_&$4GJ1]%*^$]^&)'LO)GL?PM/@YX,W'D>WL/L*6P7IE8? M9@GF("!RZ%'8,M!M$L-V4=8"D6D_#>"(1!,#<9F$J-;"A.$CRFQ8.+QZ+Z,0 M5D:*^SW(UP7&NGR62[A=X&I1^*!P-2A98`XSW'F0O?H+8QVK4H4!0.B-^[.=M[/[!_OIO< MW6J*"C7:<6V^"@<)B>Y`&)B.)6NV?KK"IRS2;ATO//='XXAMZVB@7R1+1"82<,_0`%+`,3SQ+`-R31'FI5$%T M]RU1A`$(<4K$O1:1"&P4OT4J9FD!O!O=_3@0:[KP[8)-3_B<#GDJ80B8QLS! M_F#R*<9FWS2^DL8-8S.R4;4D=",JB]@O0%I0'%E;324;1,D7BF49^^D9UH,T M`G#C@X%CIC,RR8CVRQJ,8($'(F59K<>8E&-!!"+@#9`%TWHW'-YY" M#=!2N'!F#IT4(40E38'@#&,XIT7`L0Z@RC\6@$@@1,R)030A'[G`DXWY0?3J M&*R1`'`PZ"/\;^4C.O1PW.G>O^`G..KYIX!=S^,@[Y%X2C$6H]@MHF9%*(#U M1\4,*3/2KU97^I`D.6M0*6H5*>LRN%?VBQ#Q`A4W01FFAH%]UU)$UNHC&2A6 M@LQ/296%'_N/DM,:D,!@A;`0#&"@38,`CYFATB&#GS$0:9;AH<&5^.QD)X$* M1TG+*ISD)81!Y'DO9:R!,^N)*V`5*0R$+CB"8/:R,4$-+Z(9LE+,<%,.OA^+ MV/'PD2"V=+QF0,P9`+M8F3)P3,9Q7,`C=9KYUAS<%28ZL7^\%JEN.%9V?[6G MQ;URN%"N'G%;`M@,B!YYAM;3`4HN+>`4@)PB8O=%8F-\>HGY/)6,WABSZ*H^ M_5K0/65&HND@Q#@Z<(J`@DH:^7I*(CTD_'M)YB?9U'IF6"&0-@";LGQAY#<"J/D]SCT0>R)L:?`/B&A?X:@!'@$7DH M4)09EDUB%TRN/3.`,V@"R'KD\_EKI>*5QW!AU82-2$$0UNHH)X1@!%J=^K/B M'I,&B:B,,NM`77E9S/_SR9(=VGT'C"1_!D&28&#*>V)'XCETYQ70*/P5*>9O`#[$#0UR,IV]AA%V;B-7\QHBD/,9[YEB#'`,$J)-JY2M$]!6@,MI\2R8;-%]77MU4#CZ`$X[1X`8\EL M@#V],XDN)V3ASW/);&^>/<(0#170SV\T\H7>](0I,ZIO0IS;H?BY`ULE!K M#D;/5R+5C&,&+Y:(E=2/,V`SR@>W"%&./28)'C0@-#"X0^1ER(3U9EEK%?X" MX<>S@<8:R8!$AR,R4#K#YI7QPQ:249=#=#$KW8N9=P)2L#9S*V2)59&=P&*+ M!HSG"`2,IV=@JB)C`\C?)T5NPJ3( M4+>=S92!B*PAE7,T*M!&\=@@7-#HU;%!:N2(K#VIW/+DOGNTTKYQ@_"A!`%` M1A`-4V2.>PHS)5@$PW$X-K9RH+T%VF@B$VY.EJG/L:?,U?_^-=@J/`40MD&@/7F8?!7*O4 M1CG1"C`;6*25Y(;6C<$(AXJ4$C*J&$"@K(6,90`I$@4:D)I2F2Y)PWQ\!!9/ MUAY3N(]>5)?QSI+B/E?4I16C?/7S7_XST0,Z5>;/!P"X!ACWJ7\;_H1P1]$V9MNC$*.EK*N2I+``_)<)G[S&J=8LPSS4W(GK/&)R*M#*%?J-T&GX`2\NL+Q!54"9*QZ\% MN@`A#,:-@9X"M5FUT?N5I3L4X!Q?X=R\G%59Q^C,#!T^IDFQY.THG=#N7\E@ M_"RD\7#)(.)``2-X)OR)LW!2+38[-0PB-)T-S31;&BA9#<:JG<( M'F9?^!]AN5E.,IC5N1^+V:-K.-+^E%:/E@X*O05'F?#$-(;76!#/I<,^V<6O M4W-:W\LMU2J!U$RS:ORF)1G-Q$UC$[,BU1S,P0F_3XX%966`]5YP!A]9,`&Q M@5F("K16ME&\&)CUQ+0`KL)/R!A%7*`M3WP@Q97GB;:)U^$9N"_Y>`$J@+"9 MXT-2F@)[#?U(QYQ"J0X,FG'*>@-*H\P5T@26*C@V0\81M(4L:&:4[*GZ#J3, M[)%9`H;%B)NER+7]K!H@WV7XNLIA8AE)=A. M9(3GEPY6#T4N?\QIANIS]JN;^`;9[VT*M*Q)OL>/`0O"L M0B3!(M,GV#)=$[!>@'RF\PN:,/J@I9:_RB5J$D$IYE&C/'111*`O,\"(\U%@ M!,ZE=LDG2@&`U0%U`M\`$><91H&J+/PQ8[^BGCP`!8U<.UK'39RT5.;J*+K" ME$/0<$#G&`.A*1UG#7G?1"QY?93N:1T59@>HYV5H"(?9',4J"<`]7/">6;`[ M'<^E%`#E>"LE`=`MD\:D6`K0]L19B#9)/#/4["3U&JIDFX.9$>@`,2[MPO'2 MHC/6$3C+!`]%2!Y@T))^E&6YKE2A@*X0 MOU8O$KT:,T.=4]*,&E7QTV1F8LKD@W<_8/,!Q-,*EB-]V(VT"42HZC1DY9>M M5R6@TP30Y_@9W,4R6O"%3"]7[]P.BM#3KO:E3@6#F8J,HZGQ'IB:!>P)U8!B MN0>RG2ZG\3@/E#6W"$&,YJA5FQ'"!QV;1`Y'U`EL2+%!]C;-/!T`2I.5'[&$ MCLO!E@KB4M[Z<0+E,JG`K@%)I**XKHFY08ZF18M$ M\SYB"4V)![$SV&7141T:858F'4_L#'>M-?=$L@GC`01=0HP*=>'T6GZ9@>'U M_5TMDHLXU_1L9R;'C9\E,1$J.2$CXP91LA#G(\8\8X01_I$55J_%5(!060KB M96=4W7I(*AD-AR1RCZ%E="Z2%C4Q04D;H5%&L3;:0#"3&DBY)RU@Q9DM1L/< MQ:"A?JURSYQSX-).$Z6\T\%$K_5.CK[SDDHMW$A3UE&&GKA*8H=5^+,GFLT0 M&P*EP(,Q]7E)_*9S MEEW68!:+3RE((O6ZJ^OR9`V7DC6U40P@=K.>K'%.QJT!^@(M,[(X9QS,TWF%6K": M%5;'-X%%QUK6V01NW-T&X=")"9JH72TBR1K:)5P1[,'`+68K^\2]KS*AGI/T MHR4\Q06`!1/3+E$4VU;JI%KS7;%`X+V/.H<0PRQ6!N'$%(RG3>,Z[6EWR!RW MQ+XG./FDA#'16((BK5,/WD-?OGX!78%6:7<@Z)Q*8PF2[/4#K>L^HL!(T1^H M=J(7HKUK'^/D&94J9-XZZQ^74C\+7L59XJI'KF)4VWLL'Y,\M,D'3Q3<1T5$ MD[SV/C)+-7GUAM]FEN-F.MI;8(@T]A170]&$"%>1-J7G9DV".9`IQ=JT0Y7P M:\)@>";3(LSUTSI=R5-\WT6_*A9@=,0*42*W!B4Z\E-':K%J:?0ZK;4N,<.0 M#"SRF>6!5J15D@?%535YJ_2`1K^50K//3B9'L7(X#0OTS$ATU)T;O+U["KHS%,\ M)*0\2$,_:TJ$:/B5G&7E[`>EUZ-@6"0(?669HY;I&0I"'=X%4#7-$K2&`@F2 M'8-NF`@INOMIYS@E#V"O:O^J8RC$1E5`=5-CVG([HS9HY%>2AMI*.I`R9;T] M%;_:26\@!KT#,6$;//<_&>.$>+E2/JRN9$6/%0G:EV+J<<`PK1[;,HF9[`G6 M;O!%1"1`AWVC?@[T<%_DAGT;QX3K0;V7^3.F.;3X?ZMNE8S/7Z@2Z#M=TF'J M5(B@]>&I0&6C&OZF%W#];,73G+"]9[2"-X?-@FZ)2NV]DC'K$/A62M+-#6J@ M:",/!WRM]'U"HSIE&-O)7&&"0K$9@EJ=U2-SP#1Q;#J\VJ-B+^Q.0\8PVV!7 M)%D#<\W:[J048W8N?"`/+LM#]J^I4ZQB7@`7PBT>>#(LV*[_"-KK/&%M'PRA M*/Q)JS)-:T7/MR%C3!I@@Q?4V)__\E^45T(CKO@S,$\\3`?PA5+C4`1&4?)L M`^!`A'CCA<)4WRL;*5&)$^$L]-,0:>$B@?KMKRFN\8!\.J'`@\&=A M8`0N/`0R%^/"3.%.0@Z.19<'2[19)D6A\_ML;;(HG6I8R[)(EPDEDT\IU7Z%4VVFFSE#A19*VTH5S*==QO(-2D\[VE+^%W/#*AG6O2\-7 MN]X:DLBLC]4``'DBBR?+>9$?WLVE^Z*#6>-NT+?5K"N&E`E$6$]\H-@5N7HJ MPRMW5C"7G*`.&ZDL M?-;O]-O,Q==LBZ0]9A]IGW`2RY5Q5NGX%VM?"@U*!':L0ATDJZ"O6X7\I$*0 M)J=94R%E[.,:#[S#_9'7[Q^($V_0[WNC_DA0;<>(K6>EL*;:2:54%P"T$_8D M\)'W+@C3H%@@V05DMU,:NY,N99.6G+UHN*.':>\6HA_.3P)2=%*7ZN/?_L?,5@-`9& M2&#BDS;!*@F88;$5W+2X9^5`UCH7@*]8+(VJ5?5?.IMGTC*F0C74SNE\;-YR M&)4#MU8-4#8J"I<_IKDFJ M3*ZZ6+12`V^JV8`Q_O6KK'(<7(>Z7A0L=2[CEK/3,$.(&75H7:F\"E>JZ8GI M4)A=*^N!-Z]"K3H+(J'RA[!-[0W76?>D)BK2;0BV-8&444^*("433N+J+)ZF MQPC]8.N`6=Y%F&E4.-?2&@BX$0:M%%^%9O/ZO`[T6#`K"#ZGF**)Q*7:# M!Z@^)%$HO>?>,%!\Q84J4G'F'`XN6F63NNB:'E`071Q1)P8OO-ER'F66G17` M3;*\BV,;'M#"?C>^E-]Z^Y]^.7<20-HOL+>_\>`0;V@,O?W#D7>P?R1.YS*@>[VXGWL__HA^ M?K22,W%PXAWO'WB#X4B,]KW]T8DW'!T)+K+WM3@\\$:'`^]DU,?!#[RCP;YW M=#RJ5=CETA^7L'HQ/3_]<$OU+=H+>`#W/I/W;,>I*D)3JURTX\09`0G,C,%7 M2DA6UH?;(20JD:6+BH])\N^^`B[W$9>-^W<,'[[G9A??D+183P;L-1'"NQ15 M(O[_N)([6,1&[W-^/;="%+D`YNSI'$-,92290":;_DOY5/E8-A8>S[X1U_;^ M$U6K``TSPYOR-H43;455MEGL\"ZQ_*%R%U\'>8(;,QFC]J+!X:[8J4)G%^AO M>.P=]0?>L'\"?QQ[_<,!_NSK;T#-/.F+IO+AK[O<0UJN10VFS3>N>#CP^L?' ML*JAV#_R^H.^^.M_X(>#X8&']_M5`>&V9-C&ZDFP63BB1\8.#?ATC;3C8;+A:59SQY%8`D_]P+B[/Q],/M^>73=+J`H']'<'PS+G2U,X6 MVU[X/(8V0H;6LE3*(5'*F8G=&6]E^T4!5^7BY%M]9YWS8\/6^)%6C.T`\Q#4 M@328@Y4+DHSU8YVVJ=(23%@!Z"N,ET7."2J.O>*9K`L.3[#E8N]KV.EX2'4C M8^U>4:D)V6OGC,%!'5WC1\6.U7T+%7Z)[26*!,,:;$1AE#?@!AI8"4W\_+_^ M7;S':"<7POESD7!J2ABHNA(<*F.M0-7!F*$E'[0N^=?.H*27,,#<%&H]8WDZ M$\M@5WBTXMNL]J][)"L4RGQ!UDY#(K.([0-Z3C,D*G\@.-/D/DFUC:I4G9F? M^^VW&)HO'WA-3O..-./*I0E/N?_UM9MJY36OVO3`#?6J0&99V^WI^I/:KXT* MPD*"&9.*';R2+;4KDK)*D/5>^C%`!Y1I<5,J6P3+G<1!CVZ\FF?PVNLNFRMC ML&+SI.LM]01?E<7;MACI![`!2/7+ZBH6*)4'O0-Q($B(">28E$Y*-^21\)R` MGC$X=1H3EP>B?`(#0$7R!_\LN"O%LY_5;QJ?P)3#?F]?8*B\Q.T'Z)*0D0HO M5.SDI0G&X`?:*7&@2*=*(_L>7]93]THY221,^=8EK`0G*;A4#I6L$RGZ2UT_ ML[V:GM,^'!\^T36ZXG1BL?5CL`=M/+W;.QH>,MZ+F`.?1.6VZHR:QKEX[J0& M&`CZ>*71NN5:)M66.'L_*8OI0?H;VPC1]E8/0&DY.I;Y"5HZHF_I"'7%3UX2$,$+-H[6*60)![+F\O MI6GKU#U>5<&5]'3(/J\L$_,`R'MOOM>O\]W]N527<]7JF$&#J:XKO%J+6>U) M<3HG03=0M[GUG>?RC4H[R>D7="W$H`6)UKF:*'` MVI>AY*]175;_&QP/O,/#8^GC=0YLOLZXN?\8JAT<'9(/8WQI6V?`0($:/ MKGWP_GWR)"MI^W6_E3WUK/?XJ@)3J6XI8,O9;=ZP5;L44[%?#\*)@$XHV$QY M!/@\`INFK8B_WI$+^9WCX<@;[@]W*TMJ(!('TW/IIK`T`J)I,G+YJBNGIBYK M]7*4N?G=7-NG=!2R4GEAFS!3\TM-[ZY/O_W]]?NS\]OIK\BS<_>GKIY$O])> M"ZJ=W5%3$<-AZAW]"MFB3IC:I'Q^IO:/_0":UB^JA?^I?,N"[S$P^64<3D"^ MRY>,).O?H,AAUA,K1KJG"NOMH5.ANU@B`W+Z*G%KHU(C@5]JTH/JK!5%8T3! M#TP=PL!>!A8F9C@]J@X=%)DTA;%5<:GIWK[849%[HFCX`%4L7=N`502P"1"D M[B7)DH&+`7HMX_4HY9J0Z"O-,/S#6_%5K)J*%`U!0SLZZ/7%/OP[L_&_3T,Q..P='HK#(QC]>[<,!2=$/2>=D,I*H%*P MI?S2&E!4A&IZ?BIVL%<@')2>V-_?WQL$[J]B&NXB7P0Q..8Z4^+=UP6ME^D,IRD6VO- M>NR0Z:TF4UC7L#(FJ>`-GY,Z;O3A)[:!W(Y11"I8-I3IY*9(D:S5JO`FD%ZG M)PX-=1]XAT>'WL'12!\H%;Z[XFB_;F.RY_PVUD4QJ(`\9:3MNNT4FV7*X(1< M(T>#WA&2WT&?Y=\[5?(>?H7_SE6A8OVW2@."OW<&!R`E1H?[O?TA/+:DPGH[ M(_ALZ!T/!KV#_>H2&F2(%KKZIYJ.[P9M]$;[9?G<%!>)4=E$-Q&*2U7(C%-2 MU.4Y]*B9K)Q2#@G=$';2V4JO]X33*9&Q=65R,E2/%--V9BT^#KT1D0#Z"@]Z MQX<&$Z/COG=P0F<9Z.,[WL?.\>#$.QP"N(%[#%V\P("#P\-=?/SH<`,<`.D- M3[SC/DIT>$5[/=N:037W2&@Q#(>]8]`2>B=B"`QHX!T?'L+:CL3W.K_CKNQ- MX?YQQ0)O&O]$QF;*V61\>VMEC8&PZ/J<`"'9;# M@7=T,O0&QR-J?]!P2G:&WLD0CO#QT2Z\M']@3\9@@,$>.!V]X<$&6!EX0WAC M<'2$W*ZWCS].O/W]D7=\W*J?8N$DFF]4H MC&?&_G.J8O#S5YN,T/31NOS'M53W-4)HU%<.W@'P'/P#Q,*+AU9'6I&Q9BTM MH]=KA]^=3\7-^$_CM^_/Z_7][_-2_*I5;ZP]^7FJX2&Z[4I+VBQ2>97$>_P_ M[2;3/RO=2[WZ!^87=&3@/V8?+1^?.LE\K!9KUZDDPO,MOH+N?87(_',T*:`O#]2^4CQ`/VE?K#//G5+NH( MZM(IG$(SN'7D4:1-_:Y>/P5-N8?92&<@B)ZY7):C.U.8/\%Z!LDS^K),-CUY MU^WZ2TN:%O=?[59U$ET'0*7=F8I<;,)5-^.A>EB!EO,VXV:2>6C M;A*6Y$`E5^HK^%`57==",^IYG%^/B)9W2A9,H@L&=M^Z*[L!A:K\1@XQ2M0- MPB6QTH*-]_*MWDQ6*G?HCF@@8SF?MAE.W6;/CWD]/SJ^FY&+^[ M/6\.T^DNF?:@MG/@^K-?SHZ/D!W7EPDF2DNY=<-]]AT+K\QVQ+LHN2=&&D7^ MO3X-=M7:H"U]SY8*E<;$/)-E`F,U641HZ-@GV!;V*T<$-,V<+O&^#1,L\.Z\ MJK_2+Y::D'E&>=NH0X.[#"S=MZ9"_@#2E\DW($LL=)0]N_7V_W.:AY$E ME5R7AM+..(3@%-NO+E@JHK:5\LG[BRXID1>+!(N06@=!J*;0I65!6D7I>&:'H2S1)]64"U1MB8S/0:8;YI4L!@WR:I M]-EGAW]+'YCW.`O]5BPVK#23S#DBVAC^I.Y*_HM[LYUJ[$ M(MTWG8P\SGACH@WKEU M9-NE0,=+7RX.CE$$+TH02A.N M]A&E4$+3&YY=!FDW*AY^8/QJ0^^@Y#\>]#]C?%VU3"EBYFSJLI!HS$?$,[X6 M1^RR%H,!&.T'!^(076+ZP^IJ6IA+RU*>S8U/9]?4S$)E_&QZ._][]SI,11\= M]4[@N![#`D=T?$?P;TLP/HBZ7&C MBJP[=S@$$'2+?`YG?]@JW_H.V,T*%>RG:L[8K8O*"HB?%??#VRY2`TJCCI9 MD%PWBE-ZQ4C4>2@?G(>N,7*-I@;U::+5(YBY+S&N`!??^RSWOL&.*8B!&ZJ5 M_QP2AL89I2P5NE422>(CCE1ZVH_RB)?UU/$L*Y$5!;%-L]@$%+^8BD%,00L) MD%9IC]4@2G#,=#L&;7:1+G;WSBO/XXYV;1-'][U6&CZ3V4H&G3ER7. MQ9#4P/?DG2&JA_6&%6_*&(5JV6 MR91/^E2?]#JH6I^H0ZU^EMUZ-H:;Z-HWZF@C+RBPH*;B.DM@)PC:2)=P,;E` MZ@',:)UC2QNR*F9X-XKC8$^F*A;5ZF[?F\D\+&C-H/W0N7'*8I@[DF;5^KI^ MJXAKG6YSS(U8O`"!6_P/'/03+6$`DAZ[>(%C??,U8*9MOZ;#?4ESP!W=GK#6 M*/@MWMM"PH%S$Z0A^SE^N.'[?R]6V-Q!8&-F\&USPFUSPFUSPFUSPFUSPFUS MPFUSPFUSPFUSPE^@.6$]-H/=.]"PN?/$*\B-ZTE].8FU MEZKZ?]:B\@6[=VZY_((PJL[R-V^A686(4[/*%JOZ\GTZC3J=&EC;]IW;]IW; M]IW_B.T[:XS8[<P8IIG.*4$Q&T+ MU6T+U6T+U6T+U6T+U6T+U6T+U6T+U7^4%JKU/@'$3N[\3Z_A4-5CD1]UVZIU MVZIUVZIUVZIUVZKU;]&JM;$"JBJ_Y98F\U0A0W5[M%RS\4LE0%<]M&T?V6T? MV6T?V6T?V?__^LA66>>Y]I/?8/6T.=WC^5+.R*UJR1>IVKY>@61YC_+DABK+ M<>EFNJ&\;6N[;6O[]]G6MF9]VKC_]0,8CD[OV8GM/4L=Z%!745S$M"K]_*M' MF(CSGAPK8VMCF'&WS7>WS7>;$F62;?/=;?/=;?/=;?/=5VJ^*W;N\(5Z#94I MF@`%WXCJZ,A+;[]<^M$)+A=[SVRU=];V6I.Y7I`)^\W?2WO>5CS5\E_=WKR_ M''::>VU^*6;^7KJ>;OOE;OOE;OOE7G8*&-L'UQ/OG=#*I0X68<:S*4B"H*!D M)_W!6\KU?E4.IRX75]5(QT6F*YMI7\9#<\NZ%S53_&;;G^\U^_/5-!\.TDUT M8USN7.(V8>8#>,/NB%1 M92HUS?+PAB%W#OJ%<.SZ^3ZW3=&VLU?C&UWXOTIT/Z]:!ZX/,6KE7XSW4YWV MI0.#GA,(5/Y;$X*P!7,H1"%GM7Y%ICY3N8N1#MBHJS+$2&UV-#D$PH4F=/5P M;QU-NK/,.07F2^@R^>_A=$?52!3]5%J5RJC^OX-HWVP9KZQJL;:0;4"^UUZ$.*FW+Q+'B6V.H+BVY M5]B&;J9_J-YJKUKJ^8P[/Q$2"S_:A9D^3,_$SM=U]#LW$MP"6ZI6M/CA/1ZC M"2`KJ[7\&+O15<>/=EZ*-"(+*FS1G:90_9AY=N>G&M,D(8AXMB(7[@%@.2*_G=-GZ:_7*U#)JR>X^,TAI+>I&S3E.X^+>6T]IZ!CY[ M'B[>9+V^FTS6ZH=;3QZN2^ZMNM4PI5L-U%:&RE\WU!C#DHBJFU('86@QU#7I M)`;."EQ/NXM:]]CZSO`SWMG_;%B*02<,+YWDNE/E_9E8[\_$\?YT06Z-HZ=^ MGV)3;T^+KVP3IT_W&JG3N5:$7@Q41\B[>DQ9B3&GQ%`SZ!YO=,MXV`(9_QY\ M"+]?AE&$!%KCAYWL\!*[F2DHUSI7.!Y$%\U=>"1MU"+=G_Z`+=C<@W&O, MRG(!',?C6,?:*0PQW**%6/)UU@XHF.'_7(>!;AG+%=&Y?^I-J=U%IMN\MATC MQAS;EPWZ`2:`8[;?M8HTW^A*PQ>H;EWK"Q2H+-Q*;*KB4@7NN+:3?M-6:K"Y M`V#67F7/VF;>28>CGNL4<=?IV$"D-3'%I9&K6?"E4:Q/HH.XK(>&CX!7LLC? MFJJ$BJ^O?UVY:=8_:%P%ZQ\U[IQ-1B4OP\NV>:YVN^D>UWHBJT,8M]>>T#FJ M4FT?:]L$\H5@WV"\%CQL\&8K8C9XMQ53&\W;B+H7PJX;EYMO_XN0JPL4XR4" M9!>.[[WZ=K^9<^RKNT:'+=;+!I-NL)6.=5G_(,@"8/^8X*STDQ>1ZH;C=*.M M8Y`7HZN3)X-F!A"M103:)!3,UC,363V"_[\ASZY-]D*^/6U@:``(0LQ&7&VZ M*>?6#[+/??US&[#MEL5O>(C'BO)IY>(,Z(VA;`#D-4;KQ$[G#-V';5AWP[D'2ND^GWFN5,QCL^.D`R3-1-,IBLV;S8JJ M_;Y=KCJ/-(O`MM5]H;##$[CYSC=5".6;WBD)]_EEJ% MX,O1^#I#U]?^LN._W^6/;TG/`%O2%.W'>Q7N46PHH1AI%^"LO%#!R7*V,229NBA MH68^M^9>B:?SJC`.ZM2JK#GWFY7G+UKE9NMK#+"H)`?;!8`"/].YC*@/G.H+ MB[<_M\ZT0JC]J",BI%P' M*3G`=(B\-M_=9:LN["Y=,8];#HHR&B_X@A%R_B9AA:^'&?NQC&^G9A4U.6C* M?A\]/KF%G"75<*7:)"I0D^_,QN):YW@HS9&4Y_#P:FSS858"KYPUJ/"K6@+= M<`>L:]4!JPZ@%(N5`(^^-.D];;BHXK7$NCV5EN.M41\VMH+*FA>J;L-79^=> M/9>H_5BT:(2M5MPOL3C+`[#S)++YFA54SDM8'V>I>+*[K$,WRZ`A*R"NDVGE M%4PW"#9XK>YI;_7F-F[W;^BU-S[MEKBU]E)WA*1?['(VGYU?3 M$=O8(")=.W[O54UBVW.\.^"@KI*K:M$U0,VXM!PV_.++=K=4[XM0 M=8V.9UO^#B!U`UQ_:JJK&>;5$(0H3VOHMGDWR+G&MF99&]8^J%+(%U*J9<(, MA*YI<2\48!HXFBD!5OW.-/(>.TU\;U3'#`?"BL<[;<"K(U5K;6,Z&':%]M&@ MV*.B^UR:OK'TO^\T=*?J0U23($V*1[Y!*=%V*759C?S,E*?&2A;4+2'%R?!> MX4#%,)S^1WQ9UG;SL[V%32EJ*J$28'$2H`.LJ>)4B+:5M+&4OI]&(8Y+-YC] M!J_0:1(!QTS4FAU278-9PXH;LV=NJ8#VJDVCT7VO6R7I^?OQW?D9\*U;T*SO M;L=7T_$IYB*]++L(W1K]0;-#\AI+"/;WFZ.RE_ZJUQX2E?<]O.?5^.4?_-B\ M66,(-&=;)/@J>8(%G32_>:L*H=SX*4#USO9KZV0IZW*):D?\XJUH8%IM`KRL MR]6$L5*^@%:=]:X9Y+34-<]PCJ1S#)W59&QGM0"0!V^E81+U!)HY77Z>ZHJ* MZW?,I:`QMJKHFGKL.)BI(9SM3>2"-X"(^M=%.PM5^7!9J^"\GI`:7,2JA#^F M2/1N.K33%A+RS&Y8SW:^4C4D.O>(1$,9)^V$TJJ+>\85C2TVZ8D:YU=T53$L M-(ZU)WA"DCZ6?"BHS&V=DM^J%IMN$GFG064$S!I#Y777>/XI4)ZL3=?9^,;& MJZ]C4/P;F$>?.E,%E;9_294WG5PG,'J>55_9#I-RT!+TSSYN<`RUW]QT]Z:4 M+%U.N'[(=+;B>\F%,R?Q3"YBT_K"T6>\+L6!V@E6EF@ZQA54W@J53[QP[13L M-!6)2#:KE7/Y`9'JFK!Y M`0``G1<``!,``````````````(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q0 M2P$"%`,4````"`"0@&E'2'4%[L4````K`@``"P``````````````@`'J`0`` M7W)E;',O+G)E;'-02P$"%`,4````"`"0@&E'#'72:8X!``"I%@``&@`````` M````````@`'8`@``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4 M````"`"0@&E'%LW-E:("``!2"@``$```````````````@`&>!```9&]C4')O M<',O87!P+GAM;%!+`0(4`Q0````(`)"`:4?F3V^0/P$``&D#```1```````` M``````"``6X'``!D;V-09 M7)PC$`8``)PG```3``````````````"``=P(``!X;"]T:&5M92]T:&5M93$N M>&UL4$L!`A0#%`````@`D(!I1[Z2!,=:`@``;@L```T``````````````(`! M'0\``'AL+W-T>6QEHL#``"6#``` M#P``````````````@`&B$0``>&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@` MD(!I1^D=H%U0`@``]`<``!@``````````````(`!6A4``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`D(!I1]E?OR;'!```$14` M`!@``````````````(`!OQX``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`D(!I1P4+<#ZF!```FA4``!@``````````````(`! MD"D``'AL+W=OO(8'Z(!``"Q`P``&``````````` M````@`%#,```>&PO=V]R:W-H965T&UL4$L!`A0#%`````@` MD(!I1V:L#1R?`0``L0,``!D``````````````(`!&S(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`D(!I1QY!>(JB`0`` ML0,``!D``````````````(`!I#<``'AL+W=OZ8L;J(!``"Q`P``&0``````````````@`%] M.0``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`D(!I1\*.94E1`@``ZP@``!D````````` M`````(`!+ST``'AL+W=O&PO=V]R:W-H M965TI)@OQI`$``+$#```9 M``````````````"``9%!``!X;"]W;W)K&UL4$L! M`A0#%`````@`D(!I1^P1"'ZM`0``%@0``!D``````````````(`!;$,``'AL M+W=O&PO=V]R:W-H965T9DHZ5HP$``+$#```9``````````````"` M`5!'``!X;"]W;W)K&UL4$L!`A0#%`````@`D(!I M1_.0+W19`@``Q`<``!D``````````````(`!*DD``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`D(!I1U1V_GP_`@``$PD` M`!D``````````````(`!\E```'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`D(!I1QLSFN?;`@``]@L``!D````````````` M`(`!#5@``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`D(!I1X8C_#SL`0``:P4``!D``````````````(`!16```'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@`D(!I1[,E M#78<`@``D`8``!D``````````````(`!>6@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`D(!I1Y$LKVK6-@``B!4!`!0` M`````````````(`!L7(``'AL+W-H87)E9%-T&UL4$L%!@`````M -`"T`+0P``+FI```````` ` end XML 13 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814

NOTES PAYABLE (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Notes Payable [Line Items]

Notes payable, Current portion, net $ 181,668 $ 275,190

Notes payable, Non-current portion, net 0 0

Total 181,668 275,190

Convertible Notes [Member]

Notes Payable [Line Items]

Notes payable, Current portion, net 181,668 275,190

Notes payable, Non-current portion, net 0 0

Total $ 181,668 $ 275,190

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: tgtx_NotesPayableLineItems

Namespace Prefix: tgtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_CashAndCashEquivalentsAxis=tgtx_ConvertibleNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

FAIR VALUE MEASUREMENTS (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

5% Notes $ 181,668 $ 275,190

Totals 181,668 275,190

Fair Value, Inputs, Level 1 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

5% Notes 0 0

Totals 0 0

Fair Value, Inputs, Level 2 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

5% Notes 0 0

Totals 0 0

Fair Value, Inputs, Level 3 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

5% Notes 181,668 275,190

Totals $ 181,668 $ 275,190

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of financial and nonfinancial obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_LiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value portion of notes payable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 16 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

CASH AND CASH EQUIVALENTS
9 Months Ended

Sep. 30, 2015

Cash and Cash Equivalents [Abstract]

Cash and Cash Equivalents Disclosure [Text Block]

NOTE 2 – CASH AND CASH EQUIVALENTS

The following tables summarize our cash and cash equivalents at September 30, 2015 and December 31, 2014:

September 30, 2015

December 31, 2014

Money market funds

$

5,626,816

$

12,364,537

Checking and bank deposits

59,835,124

43,349,247

Total

$

65,461,940

$

55,713,784

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 6.H.3)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13728-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section H

-Subsection 3

+ Details

Name: us-gaap_CashAndCashEquivalentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 17 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCKHOLDERS' EQUITY (Details 1) - Restricted Stock [Member]
9 Months Ended

Sep. 30, 2015

$ / shares

shares

Equity Incentive Plans Restricted Stock Activity [Line Items]

Number of Shares, Outstanding at Begining Balance 6,400,001

Number of Shares, Granted 480,592

Number of Shares, Vested (819,622)

Number of Shares, Forfeited (31,166)

Number of Shares, Outstanding at Ending Balance 6,029,805

Weighted Average Grant Date Fair Value, Outstanding at Begining Balance | $ / shares $ 5.86

Weighted Average Grant Date Fair Value, Granted | $ / shares 16

Weighted Average Grant Date Fair Value, Vested | $ / shares 5.02

Weighted Average Grant Date Fair Value, Forfeited | $ / shares 16.76

Weighted Average Grant Date Fair Value, Outstanding at Ending Balance | $ / shares $ 6.72

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: tgtx_EquityIncentivePlansRestrictedStockActivityLineItems

Namespace Prefix: tgtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCKHOLDERS' EQUITY (Details) - Employee Stock Option [Member] - USD ($)
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Equity Incentive Plans Stock Option Activity [Line Items]

Number of shares, Outstanding Beginning Balance 194

Number of shares, Granted 0

Number of shares, Exercised 0

Number of shares, Forfeited (152)

Number of shares, Expired (42)

Number of shares, Outstanding Ending Balance 0 194

Number of shares, Exercisable at September 30, 2015 0

Weighted - average exercise price, Outstanding Beginning Balance $ 971.7

Weighted - average exercise price, Granted 0

Weighted - average exercise price, Exercised 0

Weighted - average exercise price, Forfeited 463.32

Weighted - average exercise price, Expired 2,811.53

Weighted - average exercise price, Outstanding Ending Balance 0 $ 971.7

Weighted - average exercise price, Exercisable at September 30, 2015 $ 0

Weighted - average Contractual Term (in years) 0 years 3 years 6 months

Weighted - average Contractual Term, Exercisable at September 30, 2015 (in years) 0 years

Aggregate Intrinsic Value, Outstanding Beginning Balance $ 0

Aggregate Intrinsic Value, Outstanding Ending Balance 0 $ 0

Aggregate Intrinsic Value, Exercisable at September 30, 2015 $ 0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: tgtx_EquityIncentivePlansStockOptionActivityLineItems

Namespace Prefix: tgtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCKHOLDERS' EQUITY (Details 2)
9 Months Ended

Sep. 30, 2015

USD ($)

$ / shares

shares

Equity Incentive Plans Warrant Activity [Line Items]

Warrants, Outstanding at Beginning Balance 4,148,228

Warrants, Issued 0

Warrants, Exercised (2,925,687)

Warrants, Expired (11,364)

Warrants, Outstanding at Ending Balance 1,211,177

Weighted - average exercise price of Warrants, Outstanding at Beginning Balance | $ / shares $ 0.94

Weighted - average exercise price of Warrants, Issued | $ / shares 0

Weighted - average exercise price of Warrants, Exercised | $ / shares 0.35

Weighted - average exercise price of Warrants, Expired | $ / shares 2.25

Weighted - average exercise price of Warrants, Outstanding at Ending Balance | $ / shares $ 2.37

Aggregate Intrinsic Value of Warrants, Outstanding at Beginning Balance | $ $ 61,792,184

Aggregate Intrinsic Value of Warrants, Outstanding at Ending Balance | $ $ 9,334,897

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: tgtx_EquityIncentivePlansWarrantActivityLineItems

Namespace Prefix: tgtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the aggregate intrinsic value of warrants outstanding.
+ References
No definition available.
+ Details

Name: tgtx_WarrantOrRightAggregateIntrinsicValue

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Reflects the number of warrants exercised during the period.
+ References
No definition available.
+ Details

Name: tgtx_WarrantOrRightExercised

Namespace Prefix: tgtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the weighted average exercise price of warrants Exercised.
+ References
No definition available.
+ Details

Name: tgtx_WarrantOrRightExercisedWeightedAverageExercisePrice

Namespace Prefix: tgtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the number of warrants expired during the period.
+ References
No definition available.
+ Details

Name: tgtx_WarrantOrRightExpired

Namespace Prefix: tgtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the weighted average exercise price of warrants Expired.
+ References
No definition available.
+ Details

Name: tgtx_WarrantOrRightExpiredWeightedAverageExercisePrice

Namespace Prefix: tgtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the number of warrants issued during the period.
+ References
No definition available.
+ Details

Name: tgtx_WarrantOrRightIssued

Namespace Prefix: tgtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the weighted average exercise price of warrants issued.
+ References
No definition available.
+ Details

Name: tgtx_WarrantOrRightIssuedWeightedAverageExercisePrice

Namespace Prefix: tgtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects the weighted average exercise price of warrants outstanding.
+ References
No definition available.
+ Details

Name: tgtx_WarrantOrRightOutstandingWeightedAverageExercisePrice

Namespace Prefix: tgtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 20 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCKHOLDERS' EQUITY (Details 3) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense associated with restricted stock $ 1,240,034 $ 12,840,048

Stock-based compensation expense associated with option grants 0 0

Stock compensation expense $ 1,240,034 $ 12,840,048

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_RestrictedStockExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 21 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs seeking to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors and anti-PD-L1 and anti-GITR antibodies.

We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have not received approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales from our drug candidates.

The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X of the Exchange Act. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the condensed consolidated financial statements have been included. Nevertheless, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying condensed December 31, 2014 balance sheet has been derived from these statements. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Liquidity and Capital Resources

We have incurred operating losses since our inception and expect to continue to incur operating losses for the foreseeable future and, may never become profitable. As of September 30, 2015, we have an accumulated deficit of $140.5 million.

Our major sources of cash have been proceeds from the private placement and public offering of equity securities. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on many factors, including our ability to obtain regulatory approval for our drug candidates; successfully complete any post-approval regulatory obligations; and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.

As of September 30, 2015, we had approximately $115.4 million in cash, cash equivalents, investment securities, and interest receivable. We anticipate that our cash and cash equivalents and investments will be sufficient to fund our anticipated operating cash requirements for more than 24 months from September 30, 2015. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current strategic plan, including the commercialization of any of our drug candidates.

Our common stock is listed on the Nasdaq Capital Market and trades under the symbol “TGTX.”

Recently Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update to ASC 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 is effective for us beginning in fiscal 2018. We are currently evaluating the impact of this update on our consolidated financial statements.

In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements—Going Concern, which requires that management of an entity should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued. This update will become effective beginning January 1, 2017, with early adoption permitted. The provisions of this standard are not expected to significantly impact the Company.

Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the consolidated financial statements.

Cash and Cash Equivalents

We treat liquid investments with original maturities of three months or less when purchased as cash and cash equivalents.

Restricted Cash

We record cash pledged or held in trust as restricted cash. As of September 30, 2015, we have approximately $0.6 million of restricted cash pledged to secure a line of credit as a security deposit for a Desk Space Agreement (see Note 8).

Investment Securities

Investment securities at September 30, 2015 and December 31, 2014 consist of short-term and long-term government securities. We classify these securities as held-to-maturity. Held-to-maturity securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method.

A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in interest and other (income) expense, net. Dividend and interest income are recognized when earned.

Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and short-term investments. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.

Revenue Recognition

We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.

Research and Development Costs

Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued liability balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.

Prepaid research and development in our consolidated balance sheet includes, among other things, certain fees related to development and manufacturing services. These development and manufacturing agreements often require payments in advance of services performed or goods received. Accordingly, as of September 30, 2015, we recorded approximately $9.1 million in prepaid research and development related to such advance agreements. As of September 30, 2015, approximately $1.5 million of the prepaid research and development balance has not yet been paid.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than “more likely than not,” a valuation allowance is then created.

We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination. We recognize interest and penalties related to uncertain income tax positions in income tax expense.

Stock-Based Compensation

We recognize all share-based payments to employees and non-employee directors (as compensation for service) as noncash compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

For share-based payments to consultants and other third-parties (including related parties), noncash compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties (including related parties) are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.

Basic and Diluted Net Loss Per Common Share

Basic net loss per share of our common stock is calculated by dividing net loss applicable to the common stock by the weighted-average number of our common stock outstanding for the period. Diluted net loss per share of common stock is the same as basic net loss per share of common stock since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because we incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 5,634,005 and 9,100,404 at September 30, 2015 and 2014, respectively. During the three and nine months ended September 30, 2015 and 2014, we incurred a net loss; therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.

Long-Lived Assets and Goodwill

Long-lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management’s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.

Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6003-108592

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCKHOLDERS' EQUITY (Details Textual) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2015

Dec. 31, 2014

Stockholders Equity [Line Items]

Preferred stock, shares authorized 10,000,000 10,000,000 10,000,000

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001

Common stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition 2 years

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total $ 18,900,000 $ 18,900,000

Shares available from Shelf Registration Statement $ 248,000,000

Common Stock, Shares Authorized 150,000,000 150,000,000 150,000,000

Available-for-sale Securities, Equity Securities $ 250,000,000

Restricted Stock Or Unit Expense $ 1,240,034 $ 12,840,048

ATM [Member]

Stockholders Equity [Line Items]

Common Stock Value Reserved for Future Issuance $ 75,000,000

Commission Percentage 3.00% 3.00%

Common Stock [Member]

Stockholders Equity [Line Items]

Proceeds From Issuance Of Common Stock $ 68,200,000

Sale of Stock, Price Per Share $ 16.66 $ 16.66

Proceeds from Issuance of Common Stock, Net $ 67,000,000

Stock Issued During Period Shares Market Public Offering 4,094,498

Corporate Milestone [Member]

Stockholders Equity [Line Items]

Restricted Stock, Outstanding, Number, Ending Balance 1,866,167 1,866,167

Restricted Stock [Member]

Stockholders Equity [Line Items]

Restricted Stock Or Unit Expense $ 12,800,000

Incentive Plan 2012

Stockholders Equity [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 6,000,000 6,000,000

Equity Incentive Plans [Member]

Stockholders Equity [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 5,676,574 5,676,574

X

- Definition
Represents Commission percentage.
+ References
No definition available.
+ Details

Name: tgtx_CommissionPercentage

Namespace Prefix: tgtx_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the value of common stock reserved for future issuance.
+ References
No definition available.
+ Details

Name: tgtx_CommonStockValueReservedForFutureIssuance

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow from the additional capital contribution to the entity.
+ References
No definition available.
+ Details

Name: tgtx_ProceedsFromIssuanceOfCommonStockNet

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
No definition available.
+ Details

Name: tgtx_StockIssuedDuringPeriodSharesMarketPublicOffering

Namespace Prefix: tgtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents shares issued during the period under shelf registration statement.
+ References
No definition available.
+ Details

Name: tgtx_StockIssuedDuringPeriodSharesNewIssuesShelfRegistrationStatement

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: tgtx_StockholdersEquityLineItems

Namespace Prefix: tgtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of equity securities categorized neither as held-to-maturity nor as trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

+ Details

Name: us-gaap_AvailableForSaleSecuritiesEquitySecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_RestrictedStockExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: tgtx_AgreementAxis=tgtx_AtmMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: tgtx_CorporateMilestoneAxis=tgtx_CorporateMilestoneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=tgtx_IncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=tgtx_EquityIncentivePlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Balance Sheets - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Current assets:

Cash and cash equivalents $ 65,461,940 $ 55,713,784

Short-term investment securities 28,701,209 23,062,034

Interest receivable 158,527 85,516

Prepaid research and development 9,950,893 6,179,743

Other current assets 457,918 173,952

Total current assets 104,730,487 85,215,029

Restricted cash 578,126 575,012

Long-term investment securities 21,088,192 0

Property, plant and equipment, net 69,225 20,357

Goodwill 799,391 799,391

Other assets 141,717 137,101

Total assets 127,407,138 86,746,890

Current liabilities:

Accounts payable and accrued expenses 8,583,003 3,991,625

Accrued compensation 768,750 702,000

Current portion of deferred revenue 152,381 152,381

Notes payable 181,668 275,190

Total current liabilities 9,685,802 5,121,196

Deferred revenue, net of current portion 1,409,524 1,523,810

Total liabilities $ 11,095,326 $ 6,645,006

Commitments and contingencies

Stockholders’ equity:

Preferred stock, $0.001 par value per share (10,000,000 shares authorized, none issued and outstanding as of September 30, 2015 and December 31, 2014) $ 0 $ 0

Common stock, $0.001 par value per share (150,000,000 shares authorized, 52,558,217 and 44,974,248 shares issued, 52,516,908 and 44,932,939 shares outstanding at September 30, 2015 and December 31, 2014, respectively) 52,558 44,974

Contingently issuable shares 6 6

Additional paid-in capital 257,015,699 175,476,521

Treasury stock, at cost (234,337) (234,337)

Accumulated deficit (140,522,114) (95,185,280)

Total stockholders’ equity 116,311,812 80,101,884

Total liabilities and stockholders’ equity $ 127,407,138 $ 86,746,890

X

- Definition
The shares issuable for merger of companies
+ References
No definition available.
+ Details

Name: tgtx_ContingentlyIssuableShares

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the amounts paid in advance for capitalized costs that will be expensed with Research and development.
+ References
No definition available.
+ Details

Name: tgtx_PrepaidResearchAndDevelopment

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 710

-SubTopic 10

-Section 30

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 710

-SubTopic 10

-Section 25

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361

+ Details

Name: us-gaap_DeferredCompensationLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InterestReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568447-111683

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 24 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Statement of Equity [Parenthetical]
9 Months Ended

Sep. 30, 2015

USD ($)

Payments of Stock Issuance Costs $ 1,262,569

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 25 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814

LICENSE AGREEMENTS (Details Textual) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2012

Dec. 31, 2014

License Agreement [Line Items]

License revenue $ 38,096 $ 38,096 $ 114,286 $ 114,286

Deferred Revenue 1,600,000 1,600,000 $ 1,700,000

Additional Amount Receivable On Achievement Of Pre Specified Milestones 5,000,000

Deferred Revenue, Current 152,381 $ 152,381 152,381

Licensing Agreements [Member]

License Agreement [Line Items]

Upfront Fee Received From Sub License $ 2,000,000

Income taxes $ 300,000

Business Acquisition Purchase Agreement Period Description license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated

Collaboration Agreement [Member]

License Agreement [Line Items]

Upfront Payment Amount $ 500,000

Royalty Expense 164,000,000

TG-1101 [Member]

License Agreement [Line Items]

Deferred Revenue, Current $ 200,000 $ 200,000 $ 200,000

X

- Definition
Reflects potential milestone payments to be received upon achievement of pre-specified milestone.
+ References
No definition available.
+ Details

Name: tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: tgtx_LicenseAgreementLineItems

Namespace Prefix: tgtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents amount received for sub license.
+ References
No definition available.
+ Details

Name: tgtx_UpfrontFeeReceivedFromSubLicense

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents this element upfront payment amount.
+ References
No definition available.
+ Details

Name: tgtx_UpfrontPaymentAmount

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
In the year of acquisition, if the assets of the acquired institution exceed 10 percent of the consolidated assets at the end of the most recent period, describes the amounts of discounts and premiums for fair market value adjustments, methods of amortization (accretion), and estimated remaining lives.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionsPurchasePriceAllocationYearOfAcquisitionDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicensesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=tgtx_CollaborationAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=tgtx_TgOneOneZeroOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Significant Accounting Policies [Line Items]

Accumulated deficit $ 140,522,114 $ 95,185,280

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 5,634,005 9,100,404

Cash, Cash Equivalents, and Short-term Investments, Total $ 115,400,000

Restricted Cash and Investments 600,000

Prepaid Research And Development Payable 1,500,000

Prepaid Manufacturing $ 9,100,000

Minimum [Member]

Significant Accounting Policies [Line Items]

Period Anticipated Sufficient To Fund Operating Cash Flow 24 months

X

- Definition
Disclosure about period anticipated sufficient to fund operating cash flow.
+ References
No definition available.
+ Details

Name: tgtx_PeriodAnticipatedSufficientToFundOperatingCashFlow

Namespace Prefix: tgtx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the amount of prepaid manufacturing.
+ References
No definition available.
+ Details

Name: tgtx_PrepaidManufacturing

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the amount of prepaid research and development payable.
+ References
No definition available.
+ Details

Name: tgtx_PrepaidResearchAndDevelopmentPayable

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: tgtx_SignificantAccountingPoliciesLineItems

Namespace Prefix: tgtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.
+ References
No definition available.
+ Details

Name: us-gaap_RestrictedCashAndInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Sep. 01, 2015

Oct. 03, 2014

May. 30, 2015

Feb. 28, 2015

Jan. 30, 2012

Sep. 30, 2015

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Oct. 31, 2014

Nov. 09, 2012

Related Party Transaction [Line Items]

Other research and development $ 11,538,246 $ 8,352,154 $ 29,719,891 $ 13,197,183

Prepaid Research And Development 9,950,893 $ 9,950,893 9,950,893 $ 6,179,743

LFB License Agreement [Member]

Related Party Transaction [Line Items]

Sale of Stock, Number of Shares Issued in Transaction 114,855

Sale of Stock, Price Per Share $ 6.53

Sale of Stock, Consideration Received on Transaction $ 750,000

Minimum Value of Shares To Be Purchased 750,000

Shared Services Agreement [Member]

Related Party Transaction [Line Items]

Costs and Expenses, Related Party 40,000

Collaboration Agreement [Member]

Related Party Transaction [Line Items]

Option Fee Paid $ 25,000

Opus [Member]

Related Party Transaction [Line Items]

Accounts Payable 100,000 100,000 100,000

Costs and Expenses, Related Party 200,000

AOI Communications, L.P [Member]

Related Party Transaction [Line Items]

Related Party Transaction, Expenses from Transactions with Related Party 23,000

LFB Group [Member]

Related Party Transaction [Line Items]

Stock Issued During Period, Shares, New Issues 5,000,000

Other research and development 4,900,000 $ 1,800,000

Accounts Payable 400,000 400,000 400,000 100,000

Number Of Common Stock Shares Granted In Connection With License Agreement By Issue Of Warrants 2,500,000

Common Stock Purchase Price Per Share $ 0.001

Prepaid Research And Development 4,400,000 4,400,000 4,400,000 $ 1,900,000

Number Of Common Stock Shares Granted In Connection With License Agreement By Excercise Of Warrants 2,500,000

Common Stock Excercise Of Warrants Purchase Price Per Share $ 0.001

LFB Group [Member] | Maximum [Member]

Related Party Transaction [Line Items]

Equity Method Investment, Ownership Percentage 10.00%

Desk Agreement [Member]

Related Party Transaction [Line Items]

Costs and Expenses, Related Party 100,000

Average Annual Rental Payments $ 1,100,000

Operating Leases, Indemnification Agreements, Description This Desk Agreement requires us to pay our respective share of the average annual rent and other costs of the 15 year lease.

Security Deposit $ 600,000

Percentage of Occupancy 40.00%

Related Party Transaction, Expenses from Transactions with Related Party 100,000

Accounts Payable, Related Parties, Current $ 100,000 $ 100,000 $ 100,000

X

- Definition
The yearly payments due under the lease entered into in connection with the possession of the office space.
+ References
No definition available.
+ Details

Name: tgtx_AverageAnnualRentalPayments

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the purchase price of per share.
+ References
No definition available.
+ Details

Name: tgtx_CommonStockExcerciseOfWarrantsPurchasePricePerShare

Namespace Prefix: tgtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the purchase price of per share.
+ References
No definition available.
+ Details

Name: tgtx_CommonStockPurchasePricePerShare

Namespace Prefix: tgtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount represents the minimum value of additional shares of common stock to be purchased under licensing agreement.
+ References
No definition available.
+ Details

Name: tgtx_MinimumValueOfSharesToBePurchased

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of common shares granted in connection with license agreement by excercise of warrants during the reporting period.
+ References
No definition available.
+ Details

Name: tgtx_NumberOfCommonStockSharesGrantedInConnectionWithLicenseAgreementByExcerciseOfWarrants

Namespace Prefix: tgtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common shares granted in connection with license agreement by issue of warrants during the reporting period.
+ References
No definition available.
+ Details

Name: tgtx_NumberOfCommonStockSharesGrantedInConnectionWithLicenseAgreementByIssueOfWarrants

Namespace Prefix: tgtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the amount of option fee paid.
+ References
No definition available.
+ Details

Name: tgtx_OptionFeePaid

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Occupancy percentage of the office space.
+ References
No definition available.
+ Details

Name: tgtx_PercentageOfOccupancy

Namespace Prefix: tgtx_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Sum of the amounts paid in advance for capitalized costs that will be expensed with Research and development.
+ References
No definition available.
+ Details

Name: tgtx_PrepaidResearchAndDevelopment

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_AccountsPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Costs of sales and operating expenses for the period incurred from transactions with related parties.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpensesRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
This element represents the description of a lease related indemnification agreement including the nature of the indemnification, the maximum potential amount of future payments the indemnification agreement could be required to make under the agreement, the current carrying amount of the liability and the nature of any recourse provision that would enable the lessee guarantor) to recover from third parties any of the amounts paid under the agreement and any assets held either as collateral or by third parties that upon occurrence of any triggering event or condition under the indemnification agreement the guarantor can obtain and liquidate to recover all or a portion of the amounts paid under the indemnification agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12069-110248

+ Details

Name: us-gaap_OperatingLeasesIndemnificationAgreementsDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of other research and development expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_OtherResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8,17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_SecurityDeposit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: tgtx_AgreementTypeAxis=tgtx_LfbLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: tgtx_AgreementTypeAxis=tgtx_SharedServicesAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: tgtx_AgreementTypeAxis=tgtx_CollaborationAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=tgtx_OpusMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=tgtx_AoiCommunicationsLpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: tgtx_PlacementAgencyAgreementAxis=tgtx_LfbGroupMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: tgtx_PlacementAgencyAgreementAxis=tgtx_DeskAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

INVESTMENT SECURITIES (Details) - USD ($)
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Schedule of Held-to-maturity Securities [Line Items]

Amortized cost, as adjusted $ 49,789,401 $ 23,062,034

Gross unrealized holding gains 45,071 922

Gross unrealized holding losses 80 5,806

Estimated fair value 49,834,392 23,057,150

Obligations of domestic governmental agencies [Member] | Short-term Investments [Member]

Schedule of Held-to-maturity Securities [Line Items]

Amortized cost, as adjusted 28,701,209 23,062,034

Gross unrealized holding gains 8,061 922

Gross unrealized holding losses 80 5,806

Estimated fair value 28,709,190 $ 23,057,150

Obligations of domestic governmental agencies [Member] | Other Long-term Investments [Member]

Schedule of Held-to-maturity Securities [Line Items]

Amortized cost, as adjusted 21,088,192

Gross unrealized holding gains 37,010

Gross unrealized holding losses 0

Estimated fair value $ 21,125,202

X

- Definition
Amount after other than temporary impairment (OTTI) accretion, of investments in debt securities classified as held-to-maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.1)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.6)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_HeldToMaturitySecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investments in debt securities classified as held-to-maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

+ Details

Name: us-gaap_HeldToMaturitySecuritiesFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of unrecognized gain before loss on investments in held-to-maturity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

+ Details

Name: us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingGains

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of unrecognized loss before gain on investments in held-to-maturity securities. Excludes write-down for other than temporary impairment (OTTI).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

+ Details

Name: us-gaap_HeldToMaturitySecuritiesUnrecognizedHoldingLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis=us-gaap_ShortTermInvestmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentAxis=us-gaap_OtherLongTermInvestmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 30 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

CASH FLOWS FROM OPERATING ACTIVITIES:

Consolidated net loss $ (45,336,834) $ (36,984,848)

Adjustments to reconcile consolidated net loss to net cash used in operating activities:

Gain on settlement of notes payable 0 (95,427)

Noncash stock compensation expense 12,840,048 16,066,856

Noncash stock expense associated with in-licensing agreements 0 5,350,094

Depreciation 10,326 2,454

Amortization of premium on investment securities 377,770 127,260

Change in fair value of notes payable (93,522) 118,615

Changes in assets and liabilities:

Increase in restricted cash (3,114) 0

Increase in other current assets (4,055,116) (7,585,956)

Increase in accrued interest receivable (73,011) (26,652)

Decrease in other assets 0 13,870

Increase in accounts payable and accrued expenses 4,658,128 3,269,629

Decrease in interest payable 0 (94,590)

Decrease in deferred revenue (114,286) (114,286)

Net cash used in operating activities (31,789,611) (19,952,981)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property, plant and equipment (59,194) (4,498)

Investment in held-to-maturity securities (40,955,137) (9,218,008)

Proceeds from maturity of short-term securities 13,850,000 0

Net cash used in investing activities (27,164,331) (9,222,506)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from the exercise of warrants 1,009,985 2,890,305

Proceeds from the exercise of options 0 145,200

Payment of notes payable 0 (677,778)

Proceeds from sale of common stock, net 67,760,517 39,558,093

Financing costs (68,404) 0

Net cash provided by financing activities 68,702,098 41,915,820

NET INCREASE IN CASH AND CASH EQUIVALENTS 9,748,156 12,740,333

Cash and cash equivalents at beginning of period 55,713,784 40,485,466

CASH AND CASH EQUIVALENTS AT END OF PERIOD 65,461,940 53,225,799

NONCASH TRANSACTIONS

Reclassification of deferred financing costs to additional paid-in capital $ (63,788) $ 0

X

- Definition
The change in fair value of notes payable during the period.
+ References
No definition available.
+ Details

Name: tgtx_ChangeInFairValueOfNotesPayable

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the net proceeds from issuance of common stock over-allotments during the period.
+ References
No definition available.
+ Details

Name: tgtx_NetProceedsFromSharesNewIssuesOverallotments

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow (inflow) through acquisition (sale) of short-term held-to-maturity securities.
+ References
No definition available.
+ Details

Name: tgtx_PaymentsToAcquireHeldToMaturitySecuritiesShortTerm

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the maturities of held-to-maturity securities.
+ References
No definition available.
+ Details

Name: tgtx_ProceedsFromMaturities

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense included in APIC to obtain financing associated with the related debt instruments.
+ References
No definition available.
+ Details

Name: tgtx_ReclassificationOfDeferredFinancingCosts

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of common stock issued during the period in exchange for license agreement.
+ References
No definition available.
+ Details

Name: tgtx_SharesIssuedInConnectionWithInLicensingAgreement

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6401765&loc=d3e13305-112630

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

+ Details

Name: us-gaap_ExtinguishmentOfDebtGainLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of amortization of purchase premium on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeAmortizationOfPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonmonetaryTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow for loan and debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_PaymentsOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 31 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Balance Sheets [Parenthetical] - $ / shares

Sep. 30, 2015

Dec. 31, 2014

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 150,000,000 150,000,000

Common stock, shares issued 52,558,217 44,974,248

Common stock, shares outstanding 52,516,908 44,932,939

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 32 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

CASH AND CASH EQUIVALENTS (Tables)
9 Months Ended

Sep. 30, 2015

Cash and Cash Equivalents [Abstract]

Schedule of Cash and Cash Equivalents [Table Text Block]

The following tables summarize our cash and cash equivalents at September 30, 2015 and December 31, 2014:

September 30, 2015

December 31, 2014

Money market funds

$

5,626,816

$

12,364,537

Checking and bank deposits

59,835,124

43,349,247

Total

$

65,461,940

$

55,713,784

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of cash and cash equivalents.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document And Entity Information - shares
9 Months Ended

Sep. 30, 2015

Nov. 06, 2015

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

Entity Registrant Name TG THERAPEUTICS, INC.

Entity Central Index Key 0001001316

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Trading Symbol TGTX

Entity Common Stock, Shares Outstanding 52,519,686

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 34 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

INVESTMENT SECURITIES (Tables)
9 Months Ended

Sep. 30, 2015

Investments, Debt and Equity Securities [Abstract]

Held-to-maturity Securities [Table Text Block]

The following tables summarize our investment securities at September 30, 2015 and December 31, 2014:

September 30, 2015

Gross

Gross

Amortized cost,

unrealized

unrealized

Estimated fair

as adjusted

holding gains

holding losses

value

Short-term investments:

Obligations of domestic governmental agencies (maturing between October 2015 and August 2016) (held-to-maturity)

$

28,701,209

$

8,061

$

80

$

28,709,190

Long-term investments:

Obligations of domestic governmental agencies (maturing between October 2016 and September 2017) (held-to-maturity)

21,088,192

37,010

—

21,125,202

Total short-term and long-term investment securities

$

49,789,401

$

45,071

$

80

$

49,834,392

December 31, 2014

Gross

Gross

Amortized cost,

unrealized

unrealized

Estimated fair

as adjusted

holding gains

holding losses

value

Short-term investments:

Obligations of domestic governmental agencies (maturing between January 2015 and December 2015) (held-to-maturity)

$

23,062,034

$

922

$

5,806

$

23,057,150

Total short-term investment securities

$

23,062,034

$

922

$

5,806

$

23,057,150

X

- Definition
Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27337-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6435544&loc=d3e41834-113960

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5086-111524

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

+ Details

Name: us-gaap_HeldToMaturitySecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

License revenue $ 38,096 $ 38,096 $ 114,286 $ 114,286

Research and development:

Noncash stock expense associated with in-licensing agreements 0 4,138,844 0 5,350,094

Noncash compensation 35,756 1,200,575 2,733,110 6,402,296

Other research and development 11,538,246 8,352,154 29,719,891 13,197,183

Total research and development 11,574,002 13,691,573 32,453,001 24,949,573

General and administrative:

Noncash compensation 1,204,278 2,895,997 10,106,938 9,664,560

Other general and administrative 1,085,400 889,872 3,094,362 2,500,121

Total general and administrative 2,289,678 3,785,869 13,201,300 12,164,681

Total costs and expenses 13,863,680 17,477,442 45,654,301 37,114,254

Operating loss (13,825,584) (17,439,346) (45,540,015) (36,999,968)

Other (income) expense:

Interest income (55,977) (12,107) (109,660) (38,308)

Other income 0 0 0 (95,427)

Interest expense 246,527 234,787 730,710 695,914

Change in fair value of notes payable (360,218) (210,857) (824,231) (577,299)

Total other (income) expense (169,668) 11,823 (203,181) (15,120)

Net loss $ (13,655,916) $ (17,451,169) $ (45,336,834) $ (36,984,848)

Basic and diluted net loss per common share (in dollars per share) $ (0.28) $ (0.51) $ (1.01) $ (1.14)

Weighted average shares used in computing basic and diluted net loss per common share (in shares) 47,946,309 34,188,108 44,810,352 32,436,420

X

- Definition
The change in the fair value of non current notes payable recognized during the period.
+ References
No definition available.
+ Details

Name: tgtx_ChangeInFairValueOfNonCurrentNotePayable

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to general and administrative expenses during the reporting period.
+ References
No definition available.
+ Details

Name: tgtx_NonCashCompensationGeneralAndAdministrativeExpenses

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to research and development expenses during the reporting period.
+ References
No definition available.
+ Details

Name: tgtx_NonCashCompensationResearchAndDevelopmentExpenses

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense related to the issuance of stock in connection with in-licensing agreements during the reporting period.
+ References
No definition available.
+ Details

Name: tgtx_NonCashStockExpense

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GeneralAndAdministrativeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest income earned from interest bearing assets not separately disclosed.
+ References
No definition available.
+ Details

Name: us-gaap_InterestIncomeOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicensesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of expenses not otherwise specified in the taxonomy for managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Reflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.4)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of other research and development expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_OtherResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 36 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCKHOLDERS' EQUITY
9 Months Ended

Sep. 30, 2015

Stockholders' Equity Note [Abstract]

Shareholders Equity and Share-based Payments [Text Block]

NOTE 5 - STOCKHOLDERS' EQUITY

Preferred Stock

Our amended and restated certificate of incorporation authorizes the issuance of up to 10,000,000 shares of preferred stock, $0.001 par value, with rights senior to those of our common stock, issuable in one or more series. Upon issuance, we can determine the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock.

Common Stock

Our amended and restated certificate of incorporation authorizes the issuance of up to 150,000,000 shares of $0.001 par value common stock.

In December 2014, we filed a shelf registration statement on Form S-3 (the “2015 S-3”), which was declared effective in January 2015. Under the 2015 S-3, the Company may sell up to a total of $250 million of its securities. In connection with the 2015 S-3, we amended our 2013 At-the-Market Issuance Sales Agreement with MLV & Co. LLC (the “2015 ATM”) such that we may issue and sell additional shares of our common stock, having an aggregate offering price of up to $75.0 million, from time to time through MLV & Co. LLC (“MLV”), acting as the sales agent. Under the 2015 ATM we pay MLV a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock sold through MLV.

During the nine months ended September 30, 2015, we sold a total of 4,094,498 shares of common stock under the 2015 ATM for aggregate total gross proceeds of approximately $68.2 million at an average selling price of $16.66 per share, resulting in net proceeds of approximately $67.0 million after deducting commissions and other transaction costs.

We currently have two shelf registration statements on Form S-3 filed and declared effective by the SEC (File No. 333-189015 and File No. 333-201339). After deducting shares already sold, approximately $248 million of common stock remains available for sale under these shelf registration statements. We may offer the securities under our shelf registration statements from time to time in response to market conditions or other circumstances if we believe such a plan of financing is in the best interests of our stockholders. We believe that these shelf registration statements provide us with the flexibility to raise additional capital to finance our operations as needed.

Equity Incentive Plans

An amendment to the TG Therapeutics, Inc. Amended and Restated 2012 Incentive Plan (“2012 Incentive Plan”) was approved by stockholders in June 2015. Pursuant to this amendment, 6,000,000 shares were added to the 2012 Incentive Plan. Shares available for the issuance of stock options or other stock-based awards under our 2012 Incentive Plan were 5,676,574 shares at September 30, 2015.

Stock Options

The following table summarizes stock option activity for the nine months ended September 30, 2015:

Number
of shares

Weighted-
average
exercise price

Weighted-
average
Contractual
Term

Aggregate
Intrinsic
Value

(in years)

Outstanding at December 31, 2014

194

$

971.70

3.50

$

—

Granted

—

—

Exercised

—

—

Forfeited

(152)

463.32

Expired

(42)

2,811.53

Outstanding at September 30, 2015

—

$

—

—

$

—

Exercisable at September 30, 2015

—

$

—

—

$

—

As of September 30, 2015, there are no unvested option awards and no unrecognized compensation cost related to option awards.

Restricted Stock

Certain employees, directors and consultants have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the nine months ended September 30, 2015:

Number of Shares

Weighted
Average
Grant Date
Fair Value

Outstanding at December 31, 2014

6,400,001

$

5.86

Granted

480,592

16.00

Vested

(819,622)

5.02

Forfeited

(31,166)

16.76

Outstanding at September 30, 2015

6,029,805

$

6.72

Total expense associated with restricted stock grants was approximately $12.8 million during the nine months ended September 30, 2015. As of September 30, 2015, there was approximately $18.9 million of total unrecognized compensation cost related to unvested time-based restricted stock, which is expected to be recognized over a weighted-average period of 2.0 years. This amount does not include, as of September 30, 2015, 1,866,167 shares of restricted stock outstanding issued to non-employees, the expense for which is determined each reporting period at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date.

Warrants

The following table summarizes warrant activity for the nine months ended September 30, 2015:

Warrants

Weighted-
average
exercise price

Aggregate
Intrinsic
Value

Outstanding at December 31, 2014

4,148,228

$

0.94

$

61,792,184

Issued

—

—

Exercised

(2,925,687)

0.35

Expired

(11,364)

2.25

Outstanding at September 30, 2015

1,211,177

$

2.37

$

9,334,897

Stock-Based Compensation

We did not grant any stock options during the nine months ended September 30, 2015 and 2014.

The following table summarizes stock-based compensation expense information about restricted stock for the three and nine months ended September 30, 2015:

Three months ended

Nine months ended

September 30, 2015

September 30, 2015

Stock-based compensation expense associated with restricted stock

$

1,240,034

$

12,840,048

Stock-based compensation expense associated with option grants

—

—

$

1,240,034

$

12,840,048

X

- Definition
The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.
+ References
No definition available.
+ Details

Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

FAIR VALUE MEASUREMENTS
9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

NOTE 4 – FAIR VALUE MEASUREMENTS

We measure certain financial assets and liabilities at fair value on a recurring basis in the financial statements. The fair value hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:

⋅

Level 1 – quoted prices in active markets for identical assets and liabilities;

⋅

Level 2 – inputs other than Level 1 quoted prices that are directly or indirectly observable; and

⋅

Level 3 – unobservable inputs that are not corroborated by market data.

As of September 30, 2015 and December 31, 2014, the fair values of cash and cash equivalents, restricted cash, and notes and interest payable, current portion approximate their carrying value.

At the time of our merger (we were then known as Manhattan Pharmaceuticals, Inc. (“Manhattan”)) with Ariston Pharmaceuticals, Inc. (“Ariston”) in March 2010, Ariston issued $15.5 million of five-year 5% notes payable (the “5% Notes”) in satisfaction of several note payable issuances. The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share. Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915. We have no obligations under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above.

The cumulative liability including accrued and unpaid interest of the 5% Notes was approximately $19.5 million at December 31, 2014 and $20.3 million at September 30, 2015. No payments have been made on the 5% Notes as of September 30, 2015.

In December 2011 we elected the fair value option for valuing the 5% Notes. The fair value option was elected in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments.

As of December 31, 2013, as a result of expiring intellectual property rights and other factors, it was determined that net product cash flows from AST-726 were unlikely. As we have no other obligations under the 5% Notes aside from the net product cash flows and the conversion feature, the conversion feature was used to estimate the 5% Notes’ fair value as of September 30, 2015 and December 31, 2014. The assumptions, assessments and projections of future revenues are subject to uncertainties, difficult to predict, and require significant judgment. The use of different assumptions, applying different judgment to inherently subjective matters and changes in future market conditions could result in significantly different estimates of fair value and the differences could be material to our consolidated financial statements.

The following tables provide the fair value measurements of applicable financial liabilities as of September 30, 2015 and December 31, 2014:

Financial liabilities at fair value

as of September 30, 2015

Level 1

Level 2

Level 3

Total

5% Notes

$

—

$

—

$

181,668

$

181,668

Totals

$

—

$

—

$

181,668

$

181,668

Financial liabilities at fair value

as of December 31, 2014

Level 1

Level 2

Level 3

Total

5% Notes

$

—

$

—

$

275,190

$

275,190

Totals

$

—

$

—

$

275,190

$

275,190

The Level 3 amounts above represent the fair value of the 5% Notes and related accrued interest.

The following table summarizes the changes in Level 3 instruments during the nine months ended September 30, 2015:

Fair value at December 31, 2014

$

275,190

Interest accrued on face value of 5% Notes

730,710

Change in fair value of Level 3 liabilities

(824,232)

Fair value at September 30, 2015

$

181,668

The change in the fair value of the Level 3 liabilities is reported in other (income) expense in the accompanying condensed consolidated statements of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

CASH AND CASH EQUIVALENTS (Details) - USD ($)

Sep. 30, 2015

Dec. 31, 2014

Sep. 30, 2014

Dec. 31, 2013

Cash and Cash Equivalents [Line Items]

Money market funds $ 5,626,816 $ 12,364,537

Checking and bank deposits 59,835,124 43,349,247

Totals $ 65,461,940 $ 55,713,784 $ 53,225,799 $ 40,485,466

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_MoneyMarketFundsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 39 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

FAIR VALUE MEASUREMENTS (Tables)
9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]

The following tables provide the fair value measurements of applicable financial liabilities as of September 30, 2015 and December 31, 2014:

Financial liabilities at fair value

as of September 30, 2015

Level 1

Level 2

Level 3

Total

5% Notes

$

—

$

—

$

181,668

$

181,668

Totals

$

—

$

—

$

181,668

$

181,668

Financial liabilities at fair value

as of December 31, 2014

Level 1

Level 2

Level 3

Total

5% Notes

$

—

$

—

$

275,190

$

275,190

Totals

$

—

$

—

$

275,190

$

275,190

Change In Level Three Fair Value During Period [Table Text Block]

The following table summarizes the changes in Level 3 instruments during the nine months ended September 30, 2015:

Fair value at December 31, 2014

$

275,190

Interest accrued on face value of 5% Notes

730,710

Change in fair value of Level 3 liabilities

(824,232)

Fair value at September 30, 2015

$

181,668

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring and/or nonrecurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 40 0001144204-15-063716-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-063716-xbrl.zip M4$L#!!0````(`$F`:4=SF-9$#;,``+E1"@`1`!P`=&=T>"TR,#$U,#DS,"YX M;6Q55`D``]D)05;9"4%6=7@+``$$)0X```0Y`0``[%UKZ MSNDQ%SWOJT?O19>73W]]GTU';]@/',_]?`)/P6]C M!*`R^B^(SA7U7`;_/?K?NY__-_KV\#@:CW[__GUJDS>$T1M.+6\V&H^3=KZ: M`6F#O.?O7^]O1N@4KJZ]/_M3YYS^>T1@N\%Y.`G?/Y^\AN'\_.R,OI+\\$H@ MSO$B=*S`<2WZYC.*`Q@2D2U^;.JX?Z8>HZ\\]?P)N1-(9_3R,X&0W$ZOVL[Z M`?9F]2R^N+YUZ]6_I>A>:!C&671U?6O@Y-U(7@K/_O[SYL%ZQ3-S[+A!:+I6 M"HO#P9Z]WPD\&4&-]T1\1_*`C><^MF@G%SYCG)F^Y7M3?+:Y.7G<\A9NZ"_3 MR@JP=3KQWLY6%VE_2&,`QQ)3 M*SD/+(+QQ#3GZV=>S.`YZL_5A1S1WZ<V)#`1I(C81UNJB0TA\!^`3^4.Y\.@!XTD"T=]C2.LGL!LZ MX7+UV_I7QZ:_OSC8'T6P<4K,1.67U_]^\@60<4O^2%#]=)9].&GJ+--6"L$< M^XYG9Q&0T>R'Q-3B+PF9`4S>L[F6O(H1QV8>,L82V#1NKQYA(3&-)S^M=+AZ MMTBQ$#U)\*,I%B(R7-I4K,(P5NFC8I4ZBE7:8ZQV1*9`ZY(IT(Z(L=45VQYC M+X);MW<*C8/0,$0 MN`3R\O#;/Q=$0G+7W'/)_PTNWIU@SPK/.D`\H<#6[:TNV`3(^WSJ6$X8"S*R M$^U\/EGEC><"L9+;MI3RZ2RWB8W,9WG8CBX@S:?0A6T[E'SF],YT[&OWTIP[ MH3D=Z)3YQ:#HNMK^9ONNXDV#@5');OF8&,FV'E$]W/G[!OH_M MP#5]/#""+F&< M"_1SW.080ME^A+*'X,80BW8U%CT$&QY];`8+?SD$$RDJY*CE"'G`9*A#.3`D%WU++O9&CB&YZ%URL3=N#.%DI\/)O?%@2#)[D&2V MQX:"9;"?CNO,%C.6#/F_0HS(45'6H(OBY_FO_P_$ORT\3SE[-4TU&[WI"AO;N\W49O0Z8;CQ3U83/@ZJ$MW2_)`V5X_,IN;&6"W]$S6C>=.AD&VUT%V M`+H>WA;PR79D`ZT@N!D\VN#1.FLB/E*D63`^!X!-@RTCS/0.EUQ0%J-3T`"56DU/@%=?",^ M`Q>ZS84])'+9F@<#)[K(B2Y/NA7,"0Q4Z@&5.I:^9J*5]<3&M3M?A,$-?L-3 MR!)H?[\955:^K?NW%7:$L8R`*6A@2C6FH(_*%&E@ M2C6F2$?+%":`&;Q/S[W/WDX\#]ZGY][GH$P9O$^/O,_>9V0NPMEF\>!BXF.\ M6;SM&PFBA8&,#/%OX7"PI3ADC1?(KUV+RO>&[Z:FF]KJ0'_X9DOA#]'2.Q$?8Q4P@\&TVGWI+C*/CN[=SNGC*=G3\R[5KXW=L M/WJT(`#V@W@\Q/_N-P7*RI?<7ZBNCQ$$#&SI&UOZ%%X,Y.H9N?9[)BV]K#>P MI6]LZ?*"7V%Q\R#T'2O,J1UW\=OT[?ZO%6?$V)3RR!%\\%JYY6`&BAQUZ9]4 M?=FAKS]*U=!+SY][]`C+3V>*Z:YAO)G^W+[6SUY?%?S+%Z;@XE&.\^KN_QAG MP#HRVGOD_+-;Z5B&7)K!ZX5KT__0@/S-G.+>%X+CR914#\U1R)%9"\'^]8$$ MW2'!_I=)XR-&+`>^+@+'Q4%P81%M!4YR/ND#;DPNT$2R^,JJKI@M=1KNX8[H MCCF^-=T1,PN'GFX%VT8WD,.]?X(D6WI/70+U]"'FHO=Q^HTA6J,)XE MT^=-I^K$5!AU^OSII_E^1$7=FR9$G3@YKZ`\J^0#T0\2.V6T$=@@)K!!3TB/ M`QNBX3CNQQG?GMI;W=]\/[V_>B-'0J]\X0\7V*`Z@0T:([TM+S50I2M424\H MLWW>?OXS]'VWS$2G\A^%H8S"4F8(:KN2_Y#>5^I01FDQ_QFHTA6JI#V+TO[F MV;5GD8>^[Y*9J+D5=L_?&!@HTR'*="P8R>R*&:C2)<^RGTTP0Y]WIL];+B(! MGH`4]_D5#O[,R4P_9L?G*.-0O4^K^.YOEF)@05=8T/40@9B.Q%T,I.D*:;*F M8Y\;/&[GB^`C;.?8R#D8@[SON0XTZ'=$ORNN0:VP1]6\'[_WBX*GBY$W@R@MHYN:/^NY^(P/%L3:85VWDC M_,KV`GWTUV*&27;J^5ERE8;&*CS[QIP&K[#KS1R7WZ1(U=DVMU^:7&4D+Z'# M^6)+=6E(](92_?/I+^/QMVED4DFKZ_))X\*E,_6A'V M'K]LN;&3"/-W^JE4^PF>C&CCT7V49B,;6\[,G`:?3\#)%U6156C(9+Q4:CU1 MTXZ0-_L+4I`1%[*B:%#2='E'R'D?(B^M5(F+$.D:@(@>..$U5@]0@^QP&FWY@@?+RBWY#PYK,J&M.XP`Q#`;I!TB]QB[M@ M*U":SK'A-[@:O2&,""PXD1:L'[X?GV;^=Z;2\IOAF6S,, MR8`;+,G[R[=;I`*^52[;+C.P?GFN577X\"TPE*$&M=Q1O&FL)J(BM?#M+HF% M((`5$<77RRN%;V8ATF1`@C(].Y[+-EL4!_(MJJYJLJH;0-BJ97D+$M^LJCZ1 MX4)^\1?8OG',9V?JA`ZN;&41W\KJBBX!.D]:`T.C$LTR[?/DF%`E36'.\"_ MPB^87+`OO=DN9;=0T@`!K">T_B M*W=1.41'HA@=23K<1IANK2ZF(JWQ'4$CF&JX!B1R#8`$>'(AKF)K7`%:D<8$ M/B+26`[1A-"8\5U>3P)O`8F>),0D6$PCE=HO4(;$=QNJ*BL`E&N>I#&QHJ)" MN=4F7B2^BP!L-+?52BT@1?K@&_MJ0.@,L>?640??="M(49CX(=M,=1A%RN!; M9%DF2:P81E(&-73<"1DUTR7]/@?UC-$D:X5Y)+[U55?9='%+M0$5J8=O>LL# M6D<.MAW5`36G=Z9C7[N7YMP)S?+)B,0WNDC1R!.JP::2^2W6!E:D*8')U119 M4TF>6QG8HQ_-'R_KC#&^Y462+$E,\K+=4ATL13.2?"M<'9U=VVA':B;D(;G<=AOENU&0 M/FS/#(B:WAUJD>H%D_Y;LPE5D6X^JY"_(%4CY9#YWD_1R`A1V5%?%D&3V(OT MS7>0"LG4V>%='_N-YT[J+N3)`H$@:Y#@X&9TU@M/`5*4_A>$U0"0J-7)[Y$ M]9G$;%:59$[9CLYU:+5+#EL,3M4Z%;]\-55=T@')MY@Y@BC3#M^`*)"&; MD9_8%X*)*I`%JWF0-)+\W6%I1((I(2@C/04HU5P]-*E*/VDT@I2D')HHP2/6 MEMK?R.E]>Z>3D364P[>M8)5+YC15$TJQ9E2^654D!0!#;@R0)@;$ST!D$C+I MJNPJ26!KF/5.\-OG]`A@8-W<@N3W(Q-(::HW;!`H,$"6Y=V@4UWY:7&(]\ MSR+IP&C*L92P5GS'4@Y,(T.JA.+X7DY&@(NE(5O=J'4JH7;!Y2:*[E^1=0#>L9=%4FJ+)`*13[7:Q,SO>N!MTGH'(2B;("I=R$X*'*`T<7[?;5%9G=850&1(/`.=H7 M.%G=T+7L;NGV<8O'@3W3<2>TP1A4)U1!M_=C`FEZ,:Y/%B;5NL# MXZB+[T[&A%>2(:5R^R:`E>`6WV>,985&1%!I"1A'8WSO,":I+_F'76@L`2S9 MX!'?$?GLZAP3;#)0#"WGE";38GU0'&T)C3UH&E0);HF2()(T@)90%:L*`KZ) MEW0)Z)5013_&URNSB62"9;6C2.A2-X:'0!#$RVKN*?""(*T<')YB!#-EDJSI3<$IPQ2^\=4DH,$< MD[(3')YV!(>\#<5@=\46P(GWB+_2;X%>N]]-QX\V]-Z^T%F4>",&W;6RVK12 M@U&")1X5()C,1)5%T21TCGX%A\3I?C-%.P#T$DP5'"S7D8QH]="#0>=I75!1 M1-,0/4%0"_IF'Y;KI>.UVA93<%0=JD9F/UI!R[M"Y&E4%/Y#'4DM0BS#5X'? M`1)D)PM:@\C3HNB@(T2@!L([WWMQPEKY)A2B"X'.=!%BNSIILJ?AF7IC#$Q$8()3Q$`4`&D&-T^IJ#QN!>X)=PE2 M9H_!%^.&IV#?N'GZELOC9L/,BKC_AIW)*_G]XHU8RPG^M:#5"F]?HD=O%R$M M'TG/S^Q.>];#K$H$,G)<__I^\D76#%F5V%I@]="U*B.ORU2QC)(,=1VR M6XN*;T:A];=W[%M.0$+LOYF^;VX=E"G5>:(Y.6`8>K))KAJ8EN5X8DZ7LT6M M'T(SC`I$QL?,Z)X#SXV.T]!:K>F:5H)TTD"HDY(7'(6NJP71)@B@`55J31'Q MP??#<0")1S8E`M($HZ!(CMPCLP4:W)SBB^ZZ^&WZ]@^_5N0M*!C!6*E:@/8F M51-=+"A:P>:Q'5=&PR-?M-BW+\W$8^?@/"D1K,DZ4(SLL?K*`E4AS"_\.[I2 MQP8(9L<5`$#VL+P(16O0F^A`T0D^I3/"-CR0^5&<)ANZ;K0C>\ST??=TJCQ* MP5"%4-85<8]G!-@N=/./Q>J`^*-7T&M)5ITN/1>U=SN/O@5PCXE(@1/BU=?N MXJ;OL>5-W.B-U0>WH`H+25ED,KK9HI+[D:3#"FQXU`GJRAR\!VH$['27]@VN M$V\**M*`6OE#`F=/$C5AF/BQ9KTT:M]J:'B8"*+,]G52E)KMFQLEXDMDP)IY M9F62_#3]/W%XMWB>.M;MRPNFEVN,>WZ,J:J&K&JHS`Q2'I[6A6FB6_E1I[PI MC=`]Z1L>Z?PPE'(!J>M=#FUH(QX@?$H7=JZK)/YN MI:S=Z6&ISB:8Q(\F,_6E>ZRH@@+0==4FV'=\!"IKV)`+EKVWRT_W5G$-Q7N" M&G`Y191;TECD(9C=$^U;[E2UN0+WQLJ=1;B;"+L;5;7$$G=D61$[6=FP&*D* MY74%D4H(`J7TIR-%4K0_`AL17;!C/%L0OE_FBHE&FQFQ_"G'WL9:C4;M@C)^ MF4^*]%A1S<9:@M*"O8VU6DN:!>4/<[Y!TEO%-6+I!4Z=^:^$$KQ3#[?2>[H(1DYF1[&0P-XN9,VPO*28+=,.?ONJBA7<&1 M1!6HJJZH&19L-;P3/)X2184BLSM6RL&[PG.?O*>NS@3Q@:RDO@JY::H&#)YN M1"V]?B.&?.8M9=3T)*BY"I*%T^902*)J$ MSM&MH,ZBI)%_ZD(O/G:^^;)'#64+OAD&H:ZN=VH(6F\`*4^W_(4[0U+6IUA* MXMQT@T5=([["\7^OW:C0R>HP?][7J$MI5O!17T57#-9"ED'1('*>IODNB,29 M]$QUT\A7GXI.HLY[;&'GC787\64UM"^HWZ*J["&]:FA:D877'\+B+Q"V)TO\ MI?@27_:NT4F"#P8@U5"1(21:&7#MR\GK0+[+E55%ATC?DYP)#59OJ36Z!-4B MQX:L&(`GSS:(!H%S>D)04K)QS)DO:-?0M-`_I[_6)(30%&:>DD75*'?%3%1/ M=X'>^=Z;8V/[Z_*/@)JW=2'$"X+C+?Z@5S0INB"_K2YZ;@T[):QB:1@*,E)E M8G9"N!=Y>1THVLE,=W)+:5.PH=50%!T8R0F=*EB:%H*G<;Y;)I10 M@0*U'800&)KOCFNZ5O.6'PFJK1PJ6UG4-(,#&(\)!>DWWU_ M2;HSFL?D;+^2TM`%%61E(.N*K`JQ9]IO"'01=02U8Q6)Q'\:NX&B%NCM='.S M#Y^^J3KE!85CN;,*Z;8;PLKAM*!JK`33A9NKP;U;^_FU:;KT@CH.6U`Y%FSG M-]DV=\3&4Z'`#^LRR,F_1/@*)OWHGHR=IO.1H'PLEYVY$)I%SB.!L,JLKM6' M'T5);(CTTPP7?KTI7B0H1$N0TB(T276`_%;K`^/IL-SGU4L@BB/(^"S3M4L" M#1?_/WM/VMNXL>1?(687R7N`[8B'KO%N`/F,,&/+D36;3+X,**HE=4*1>CP\ MUOOU6]5-4B3%HTE1DF,\((17XO7':V=GXAYFQB!_S;/!,CX./STG:\ M"7&J'VDKZ>*WN[>^VVU9#1<=U2$Z#$)%["DY1P95;K5ZS>`S)H:INRZ=4R,X MU`]WMO?U0>D:N6G3V%&[O1`)42B:!+V(`:493O6AYK'V`-9`!EWK>+'2G\,` M%'@XL>]\:Q;M2&/X9@7$M!9W5]7!V*F+!,C/L.(K?2%; M?;E]Q414X"7X&TRY\KV`R>DBSH,5GGG6D#*!2K9]N=5*Q&J-P'I,`A19B'XY M`=H=%1C=/C`!DFL&$)M:0EM4Q!:%MI.2V*)9TQ`^V!;9\!H4J)055K!I($M\ M?T?I].*I,R43[PWG]G96"LZRDEYJ1VO'L^\K`KJ[-BVD6K%+;O=[:EM6M*0U M$ILREP`EM5)55>LK6K=XRKQ@H`+F):E6_6ZOK\5K\^=-V01HW[+,>2)1W%B2 MF6\26,IN,^N>R5H'%T;"[)0K$),_;><:OEK8SF8TWPZ&[O+;E^=[^X4X%OMB M0<"1$Q=3E[P7V\3[`YCC7B-B+BF:JK5;70$] MRX/G&/B\'_TLWI/HM3JGX03>G*BS^:,5[UO$BP54AN8HZ+P;R2HI%GL43D04 M$@\#2BJL:A``::J(68WF;A38]R,>Q8$F!@9]N2\@)`>B\WL*%4HJQ"JRK+25 MUB%D>B\?^ZY84+RZ4"$,KF<0C^=HWQ<_A$_B#N:<"@NXO!LS7[)*45L=I14O MV7GD58HVL=\CU8L76*S)U%NS->^4$\7KJW8OGD1]BCCX'=*\79+_K+;:7;E] MB-!2?-.SI);QV[*+*="+5TAOW[BDT"G9\7Y#&IH"O"2JWU_,688X3XB04X15 M`\*V($)4`_A:6/@*=-NC>","*AD4%U1LUF5N%!MY:ZY^D6WJ1TJ.O9 MUM-2=U:Z07R/&H#3`W$6Q.$CX7DNOCJ:3QS=IAZ0\OU'!]-5PQ3_M$%$)X<:A`Y8UGY9BF4BH*SV_NR/E9*[&A2F!3I MA``#'M<7`%600AWE.449TA.;75&(C8F3_1V%+Q[XKOTD165885RTMXD)=>E2 M+*/1+7/PQ?&*UW]':O8*J*D@-5NY\IE'AA(%#\Y4L\[\=\O]U2)5"L6"2!&M M%80#*6M5!/!^R"7K1C>`7%$I7V:*^VE37!\Y0;'/JTS?"+KRL<6U(M+)Q59# M2"N'1SI67B&*6FZH:YBV"Q.*[_)WBH,^N2=W.K%+/\73-@?DM^CYH;7V/?2&F'.=#],#5)OKX"P4GX1C+#7L\@S'""?PGQ5/9&T_A>FTGQ5/=&\^2BF][ M"6_<`.RG8B6%WU)0ELS;()@'4K+B+;?T(N-TF.ZO9J77&-X(IGLK6DF=USU% MN*I9R=L'Z)9L)77;B7/4P]J^6%1Q$#7K"M_O.RF>>RM9MSA`>2MX[J]B)9M8 M>PEO98.2JV+%D44:RD/;O8,KF?#AZ(DQW5_-BH.4MX/I_HI64O*VG@BS#:SH M]P=6U9I=CL-+^H2A]4WY*A@QVC+``5F>UICW('&M=Z5[E(W5.U-N!:, M:B7R&P]#*[SB4#TKL*30;E=M=>7PLM.QL4E+3L/S-U6`H:04\'E/T10U=O)S M%#2:HIV;,VO%W,&2FL/I>/$@T.X6;(H7_>=W7`>^M[0=/*NJ@)M`W7RYU4KM MXA7/OG-O9%O=_TEW1@ZKAL_[5X;7FBH`K(J<;:AL7RI^K4,`B`*X]R"P)D#@ M]@Z%"^8N%H4&*-RN1V$Q.)(EK+=8ANU,04$(MNB\\[&#*6NS8QE"ANW;P%MM M3Q^B^]R[/K.HJ`;ES+?%%IR;SM+;SK)OQZWZI9`?QD+6H4O%Y M!WO@[(B2.!@[S0)TS`KA[,2#/Q%9VK^7AY(N6IPM@`HV0;A(=(+-`3=9G:"H M76Q4O.MY2-17&><-?8&^ MY^U.M]-.]&\]$(Z'HJ60(_F6()\@]03Z^'32%J)QK!HCVVC-(J-8;QL^9>%" MZW:U-NT-(4R1^`AQXO%OAM:,O)+9Q&;J%'9OXO_-(*M(F-1O0B#S,&Z:I$R\ MW:%5X1#U$'05Z';4A*!F(IW9J2S/\,:0=L/BI*CK>N.`#N39/W]G5-@U*4)R=OIYR\6H/4S4#]!-[GP#3M'M5*'MSW M!&:&]7@X#4$%2M')4YH);*;P0Y\31K+.:KB&?FQE<1?J;(TOC'(G*R+]IIL@G8$HE MRC3.EXR8Z$UR1A'.;9CD@2(I,#DS+IYU69OR8K'1JL0*F MEN<`97S=Q#1W12AQ_A!2>A@LV9>65/ ME05.*[5>J]UO8A^^(MK'(_?_`>TP(_/PY!8XQ.S)_8YR%'(GT3X>N8,=B^-0 M7.#\$XQ+(CGH>(@?C^:/-JO"0V8"QR@U*2UP6MII*?U>_!+PT1`^E>U.19SL MQQO=VZ;4'U+VA8M['$7Z*Q+F5.;_I!SK"FY2MB]:)W`1;XAGL5WODS*L0@)J M]Y@^1H@P)W`_%9G5C&<2.EP&)@&/CJ)5XM1X0P%";&.B'AL4@73=#NMU)+_K M`&$?7=B?"4(GR,S#](YBK^KK0K3+0)P7:I!L$*/A&33NQ/9T,_X[MBU[M+VO MQ!M']?NXLP-#&GR%SPEMAZ9(K6#[L=A&YG$!/AJYA.\+J47M_E@1J%X_E6]^ M,*!/F_EW;3MK&XNF/E"38($TLKV.M/M;AA:+7!7K=3IRYS"Y4MDF,V61;E]Q MDKVCK]P;#&I1\T(F3DHOMP]9',+$K9_?="2(-W+&:(YX*G0-W1?(;0UO\63- M6`!2I93R%%0"V:%*7VEW>MU,V':2OC.?65.G%G`"F9:RK':T'-#8M#L7,[%M MY6B>?#8FR!5LET`+/UF19;D;;U16,GVIY.V;29/$(=VVK^C`OQ9((F+;,$JB M\4SK0FT7"W5MQ)CD-8R6:#J90,I1`23K^Z4+.-3\7JZ<,#O7XV]#ES-P%MS@5@M:2?84?N8G_E;'-:'=P& M$LM3X`OM7C+-[F#WZXEAJ_Y@P!5UQX@*$>@">UJL*7NR$&N/,VL0KZ3J7OF&W,V,MN`3(5M*# MK3)<\:I`U[[CD(J5D>.!?=`*.-W)>B?,+VG(5E2$+P"Q%A8%Y7%K85'2[JR@ M_%(.%F$CIOBCXKZLI"58O.1:QCS[PM(,2<7+O3:&0IZI%V\G=0A8FB&G<"DT M$11J2F6)$RK0];H`-$.[$O?4&-QY\E?6\J;`O-0%H!'"E;7!$8"[<@^%L"+; MR"KN,I%3.XBW-(@C>^6[U"*N.S``59=MO[)."(V455?;1675:S>2R"5"DVU/ M&BZKKZ9;]1RJ74GVBWOU%3B^V&@%8M-8"P)>QVM,7HA5925=VIFGL],-(C%3 M94!R[69)A2^Y6PV0H678*S+17X,`^HI89$[S+(L2NTRB?/L,(@A+;6L1521+ MF%1,F)U3@)5\IB^8E`$+P@4*RQ5-M%T0'B$2R M&MN>X)6(F,BZ8;(863`9^8,X]B@\XYD1^IDL=//6\C(SGM8< M`H6"R&0K;(&L94%8J6A05*TMWU+`!XX76(KY]-ZQ_?7VU!#6[`8O8H@M%3?Y M-0W5CD#*=SO-'#'8$TP+*W[MU*=D)_MHO\#/683U>\*BI]SZD0CRJPT;--H) M.P)E!+*SE03;&\@I!NY./P#)#'HBW MQ+*^88O0T7<+`K(E76]CV0P3"[SOUT'SVX/^2E?^*NY6QWC\G4&#=EG4'U[6A%6N*EI)_)6;QE&]*CUL\H$=:R#(JG69'C!V!0VM9UGKM M>`)W!03V*!K:$(*BZ;6=9`&`DFJA&<^!VKMT%JRX>.!!9J/C`I>*O(KA[DQ+'<,0GTL2Q(-M72> M874LPW;GR3,:>/71M@R!D[&]T"LXNV'HI>MZE\/:"'JQI>]>Z)5M#M5'CV^3 M.F2MTUDVNP_'M)*=)DV+&^1"&/?!IBD>E>PGR?UZV`0)&@/+\G5SC$&S&2RJ MLTK?M[ZU5([+#7'_R@@<*B!4LK&C<_-93;LTF%Y>..AQK3]#S]/[J7) M+[?CP=/ME\GP^OE,&CY>7W!(LB;9!>*:8#$DD]5G^42$3$D2BCYFB\#""?Y1 M\6IY[M#QN0/MVK*GMM3UPR=D)K'AXO@GQH]//W%TS.U\WJRFMEEC8A7Y/OF=SY48+(._Z35^<6XK M3-_)FE+@"E);:^C==RH1;9EMVS\5K6 MTUEWGPKAK%9[/G_*?8#+U9!J==SW`ZY6LGA?X()1"83"JB0`9@XAM9;`WF)] M,&LU`,RAJ"96+?OX#0!SX15I';17`\"=1RNJD9:HHIQO]=L]1>X60)BM2L+0 MY1)0P"=I6K^K*?&;`G6AJZ<^`E62T&UV^JTB$,54J+XUTEHBS5FTOJKTU7X] M.,/]DN#0*6R-R):.E2,@K567:)IWQ MC!)K!O;-Q3T4_',TOZ,6C$)U,VJQYVY;)L/3SW1AT3DU(/8.%I>82@'C&92X M$T#XR@1@:F`/RXT?3.]R1E\DU]N8Y'\_/`S&]\/'CU)K[<&_KY?2W>AQ\E&2 M\>\)71%7>B3?I;&]TJTS_L69]`QKD[GTX8>%=RFEAKO^?#L8?YS:WI*/='XW M>!A^_OHQ-=0E^^UY^,36TF6?M!7Z\O_`GM[*8W&]X/'X1^#R7#T*`T>;Z3G+P\PUU=I="<]#^\? MAW?#Z\'C1!I<7X^^/$Z&C_?2T^CS\'IX^\S0Q!G#V7^*X#@J]F5(!]AV6I>[ M$)^$2U2479G/!*!(/Z:`^?'L1Q>%_,<`Y(RQ(MQOB&LXE-V(DNRY%&;K[M*' M_H>W(9R3V]\GY\/'FUNT-:V+-K4NI;U@_XU(&//ITI3::W`I*]T@O@<6%%?) MJ[5N;:0Y[J5`F`!L\I;PZ#:;^@R
U(5^>PCC4",QW84TN3^7Y98L_<.? MFM3S7\&?3?^)H^HRTE+.8!S)=G33W$AZV#-5>AJJG^!IT],E:BWI%&9W M`%V8.OC2M8$'*V0.>Q10=CW'M@!=B;RNP>7HKAWPP/,@WX6]!.[Z!>^L,+U/XGL% M.A$Q!I\-,65D0)!,:C'YC,L>2M0:QF?B]9W"$`5VEX7CP29/^03&#WR0^_'PN2PXQR!IH?*Z[K@W2CYM3\`L( MKZ3]<\N"0,*!\>=/-^>?Y>V?]\/).)0H!/*T3N*]&SQD.D9VP%&0=Y!#GV^$ MKM8F"RIU9X,R,/,-#Z(VCQA+BTE28**X8<2_4.Q``,SP8L$9"*'C!5F)9W%3 MB2_^Q)X.LQXUZ@D$U%TN0,0#C3/I.0")?")@@CPD69H=)^AH`0HW!*5&I M7!WT'-0'I1C^9_N.-'-\6('@:@`'#-Q@<$'7N5-?;A!;1QQO^=A7;"_&[@D-$@^9;NS[#2,:YE9G@&R#X% M2R?X8QZNE<*D$DN6@-28@I-R\XYC.#!=FW&A^N7B^".2!.10#S1H*1K28 M@MT`(Y)%=Y@:!M9G?_IN$`"QD$%'+0Q<)#KU(%H"@=)YO;`SIM\` M(0!BHBF`*`A98/%`@3D/^+\%-L)UT68A)+HTUZF#7([6S2%.542%68K\TM"?#>911TJXWI+FW?G&&(`*$@#R]LZT_?XOFZD73$)+MD0%S' MZQ":L;'02O%\D0PI^A39S0W1'8D`T#/I!@C'2LFI\IF$6S0\-D@HVA:_G:>E MJ6XRU7&7!.PK1A&,8#-0`S39S'9R*L5E`:<`YOBFQP(K.[PWZD8@>DN'C3KN\OI:O!]:?[ M\>C+X\U'"<^>7;3QUIM9^$L)JGR&11$%)=\P(;^&!9O'M-8%'089?BL[``)4 M;4HL1'@1O7UD)6B`#+\%(2WE>3VST.J!@35M6&N";Z!H2=&&XX=UY'>YB<(@ M`8T]Q;O'\)F-LSM(:,8PP(6E&UL*S_W069YQ?X].#(P?7K_%8'<.L@?/@8]F MYGC7OFX#DP$#S`D+ M[F`DPFZ[22Y/3Z3!+E"T7ML0+['/%BS<'P\)Y'H'$7Z.\B4 M%"B#Q%0%=SEL0.E"NGW!P(\]EI@)0BJ"$<$*%"QG0J8N86"=H69(.WU*3<30 MPV4XNR@>/<)_F)$UA#LNWQ7#+4A8K=N.>Q8$HXQ.R7'L*4:"$.6P!0%F%R56 MS!F`7@(Q#(R8YCZN=:((GBV";=<[CP:(#6H#LQ8\7+L,=K*28\1IE<4-,Z`@ MP!K;*F`,1J+M&CG7G^()GX>A[X[!(UL^30GNR,%KX7(>P&87UD^YB&_Z**+` M9APA1&CE/=RI:M;+R.T++=/+L(49&+,S;M+(MKS067S[:FN> MSOA&<%#3)-BSXMJ.NVT@NP9=HT2RM0<*(AN86Z;D#,%(X20NMU+,<,W1V^+$ M(.-SMF6.%B`:/!Y3L%&#=?KVQ($9+0#!RN9-33HJ:2+RU1K3N5W.ABM,[(0I MZ;S00N@[&'5"PVP1OI_.D2)LA]Z?_AG$0CE&\4R:^AXSO"9=L36T9_,3$P_^ MQM]GQ*4+*]C%M-A&'TX?;GQ[#I@9-\]B1H<1W#PC+_PUR(N[/74/PZU@NQ"(Z7;'`GXEKR!('C>783XZIL]Z!+?NP5E:<;//]S$R#IGR7>!_ MHJ:W8>W0\QLL@06>PC0,D&F3NM[V:/%1=V?ZOZ(%X4.T<8W$`M&50.U)L/W- M,WDY/?Z_O7=M;AM'&H6_;]7^![X^S]8D5;1&DN_)S%0YCI/UKA/GL3V3L^=+ MBB(A"1.*U/!B1_OKW^X&0((2Y:LNH(RI9")1)`B@+^A['W:[[;<8G]LJOG>6 MY[=NWL[;X(,9N&':/3J4'1D#5X8+.5<84(6-+DRQ0Q@)Z(4CZ5D$!#\ARZHX MLXI@KUK@..]B^,=YI7&`#\=7[S0&@)Y\@BV<^+4C_#X.2"J)G>.K$V>_O>\Z MJKX9'=\GL>A:+3W*)SFP+3AXR(;+TW*O\^EQU(F'X0!]?L.V@<"G4-T@Z&I^FK5PIVHA!9Z6\+Z(?/) MJ*P9DWV]O(6("2CW2CDTRRLP+%-^&F'`B5,V.Q>QZ<[L7I.X1"Y=8>+&>;)H MB-L28`B)C`X$6/3B/%/;X$H8(484NTBO+ZMPI$HDDP;V,3S+XSQ%SU@0R"`) MU!L3-D3_+[J3I2P\HM&GQQ[!]!!\VRR4!H"R."MQ"B8+ZRWO)]PJ9Q(+U\J]WA@;L[!, MUGB<#X`0=>X(S$XQN+NX&SZQC2KEERF/8,E>RV!:%9/9>?LQQM&``_HL`0'\ M=LC]0J4JG$C*42GD;_(>907G*>(J@,61\XAB#QR982!*!Q*%(T&B;JGXAG#G MD2=0=4EP);_Q.#K3-(M($.>]3%*VIKJ1J+"N>,B9![%T\.$2 MB<6C%S&2+D*OGTE1,RA45[(MUSDB*31)P`+]944A0.`D++@U3 MT_0V=!D2&]#CZRQ%+T\7(HH`@$5`N+[$(HE!O4E)X*B(TZV>R#G)A$]7B\=( M"X(?8*T)@2=2"R\12UH?\1JG\1`7O/$X!.@CHL;BBJ[)H_%A`7Q_*=+[2\._ MIFA5OZ:*QUH834(%6(:"4'%0\3Q%R M(C@&@\YR\AZ)P!N?I**`HZ-/.051TRGVK.5*Y!#!V8B;882@=#6![(81F<*4-"Z*@H*.,]?-UF29K$"0P\P:3%$$SJ*@PD+>";,.C(N@8*(J.:I-_MBSQ&5`LR\X[5T7DR^8R1A.Q\JPN M^`@5O;JDB*@N8X-,S"G9JU/L\+2-;CBA.L;10'P;Q#0J$O/K;^X?V) M2NK0YI`2I]W.XFTIJ$U:SC^GKE0>H%"DN#H*[(>PLRO.2RJF-%^K$"NA;0_C M4*BM!;=#+`0#DQ0Y475%=12R?-7)FJI.6%R!NDP2!!^V/"E/5@ MG+`1ST<;:7#'9.$R;44$6T]O;[EP M9/J1EEV%VS/A>.YA00&AIY>&T")*;43-)*R)>WG!C5@AA@YHZ:@WU&5; M1FS-QA-B8E(8WTI,),,1I?G#@:T2S&/I3@*P`]F/X\1+)FYA9T$W-7P)1'ZA M>KGO)0DE="G_=2SRY&@VPGV"#A">T%S@C:!%)0,]!H_\*I1SYT1,S,_I>+B:LOTZ\2[J19+H=3KQ`5GRM6/4K3HW# M7BMSE`N3R5K.>X[Q!I1-KD5BBGL+[B/[5JE<(E[9/15\SY?>5NE`"@"SD MG7$"ZALEAJI@XSJKD(A=T00CS1Q5+9LQ\CAEW@*WS>XP,\E*''PPW):S^BOW M2)KI5Q;-LYRF#]IHAJ'*&%*>HBU(Q-8+]P'P:I\\"D9V^#4_F&"Q`L<[6 MI&7YVSTF+1'^=BD.0JH98.W?9ABN1("BJ*)2!BK6U*<0&H'X.2D!64;92:V! M8B=JHZ).XH`"'$3Y*A#<]`LR7\4+)S`=Y@$#4H%Z,K.@*/3B>(4-J1+.*9V" M20P<5\O!TBA(M5HM1^!]59X*]2TZ4$`IDDJ9R,0+7%6J)J&&H>1QB*IE86B? M9B-+R:F9BTZ=Y3L+M4[X14GWUL),X(R)0]$I5@OO5VI?L2,8^T]>#G+D,HIX MG8X<525[L,@5+"L1^F41S)I@S@I>E+&KLD2&4`_R$.!7)I/`4^0@9R0H`\#3 M(GR7ZC)@"E(B8GA80I5""/N*[$"8&$\S/6'!E\'$4WM7`R2RTNJQNL,".`H7 M2R".RG:_<8117'WG5>>UT+>FA\8]JZ*.Z[SJOBX#ZFY(4\;2&;2[!!A9)P9? MK[3I8F!X?.>U,A#(5*;JFRF2V4OCB!"5$C3#(BY8:N;X/M)F`@$P@C]*+UHQ M+:+^J4V8F@K"Y=7N]-(Y&8AH.$01Y'F4>$DVG;,B;:@L9B+C$E6\W(AE9`D/ ML,SRG&W%-Y<0Y9D.P0+[E9L_T.A`QYT:3&FP1+-9,3C-D7%$_R=I_2S+XU'9 M72ONK'ON'U5E+;)6E:`**@W%4FDEE18>\N2KPADMYW,<:4>_%]P0]R@.#V1R M-7D3Q;LD9T1I1$M[13LOYKVGZ@A`KHN=PH2-7&;15^+0*%8LSADR%V)$K=<*#@()T]U$*E("*M@E/#<2$HM0P"E2)-24VU"/"HI4+QGF6U*ZA.2Y)A/%[J;"#R+SL`J'(\*,&;V'6FGH`LRM*R[6V@QI5%GXF MDJ4]7YF;!B@`)IAB(5>B)J(2%;Y'\2TJ22B,P3R*RCRSM.!.!5SJZHZNZ,RL M/6*#..-EW;T;JFN'BH5">97((83IHGEA(3^EI025JD)G.5;]B5S)U5#41(#+ M!'II:DKK!&V?)5171.6H$'R+DA](DTG.,W6WJD#KJC1U#?P4'5JD9K!II$1N MS4&T]!)-"A6J8J&G*2UTC`7MR9KQ1C6=^0:L@H]):5\6IC7R6893D" M35'2.(T0T--"0J>($=PQM\`NHCO$3\5(ZG%BV@]1$![.3]&7VIZ`(8K,4A&) MTC>TWRIS2-.&))X7)9C+61#-4WH?]\*'BM@FRA!-EG]DF]+Y4@:OR36L5EF4 M1A$\A48(ONX^VZ-=\7]C$4J M(%ZSLD2%7(:ZNB*K\F@I9#1%:5/%2;V[8K)*Q_WRXK*.6IWZN"PL6W0?$+5] M%YQ5[D6Y<7=%G2VSY,V*S!OM0F,ZFFZ.9G MPA=_[?TP,6RL<2:9)027$7PRA(^TAY.Z(?7CTCQ7:D>EUB*#B9SW2BV&8>8F M)E6EH*)FI5#`\4$\_N!,$2E`7@8B2R_/"@VC""#1$X5Z++M%1C0GS6DZ_"45 M(B)/29NZ._.*)TK61Q$4YX>"&^K#T]7HZ`&;?H>'GXWHR8)_RZ M(GR+14+-Q:<24L#T%&;4OL@/#C]+$S.!40J"F,F=ZOH.ZFWU.Z@L+FKD'E/6 M!>5&R+)095J+>#*478,'K(J4/^FGP(D5*ZG4^2#AIXPTJJIL(@Y*RCXRTQWV MA6"+8A+9LH4KZ3L+^3`6!N:$88TLI6W7S1631PHTQH),PL>"1=+*PBI4.8U& MGHC?X/!SM4HKL#QI>4"M+0SCV[(H"2"ECRDN;`6Q=DT^QY;@6Q7Z;BR+2/*` M>PE5Z^OSDE`(&1FPGA+EJ`G`!Q%FX?P)0F\:<+]0R.$FT,FQ#(I@+UIQ4APK M8MD48ZCR`4>5OM>5?O;#*[QO(EH_RDDL!!06)-QCDUA:JZ@Z@V["F(@*+64; M"V*I,)=QGHQCZA]T1=6%/:6$EX:(>Z>K#`@9#Q61EMS:%87X'CX:F6`3AN$S M<]8_Y1ZL1`""MBT=LIJ(C>4#A-*C0902'Q0;T:Y+C;W!HNIF23%-$5ZIA^/V M.S+88`P8()%G(VA,F'N%6V#_$NHENBUL:WKD"`@]83QA3`4P1-OJ"HA!,`19 M0E]ATJ@&7V*ETH#QVB&M-Z(@O\I-4U;F^_MV%)8_88!68=@D*9')0$T<.#=A MGGB@]J6:`$41.\K&/?66(NJ5C>9(C\@RM\"HBM;2(XJU8_KJ?K$048%_)-(1DE MKM4-BP"3S.XBTS!-(7"5LULLO3)]L=E>Z,NV$I5E"/U)5D4NU^3B.HC=:0QB M:DT-CAYJ,C]IBD@'PISL4?J>ASDBWF?07LY19_G","R6"C53EW'S1&.;_J_/ M4H`2E4]2.8$]BP-(^8NGBV[KS`:-8+(,:C'`;$A#9019G^Z6\<$0QMCV,`)G MP#2=?>:E<=FFOC!X*GE)H5_]_*?G3NY=;T0E''MWK+ORG&@NI&?3!/A2M&=J M6;$D.\GYCF7,C_AZ2W5:,]7],\(V>!RW9YPHDYJ\D>HU%X2%;G[+G[.[MNNSWE\<-E M+_0]1VZGW79WVU-=(.8GI8L*KJ5%/9P`"90;_=C>?\6(]9CT%@=5'5^U]I9U M(!(6\!DP`8+D9=780%)K&1:OJ*[!1J5'6+X.G!G0&RXSWXJN8A"B#RR.,/@LIQZGL25:.+HD]%&(4LXMP_KVJ4R=%?5_I8JM4EA$U#&6(L`,'S(@X9UE+>'8%SJD MB$BJF]RMC)Q6S@38QGPT+GP(TX&[VN*%$%`X(*<++8C2X,)I+E)X1=)P:1:3 MGF^R:_3#^)8BK&?+(TQU13#O4'@XY3L5CJ&1?:/6H[BR`(Q&[SIR4$-FC&F# MZS)&78;]4IPQDKHH5Y"#>7MXG(@8`O6_C2LL-(:WV M>9+B@N`Z-7A.I"=]UE146E)R8"!EZBE^^RF=XDMZ*+^:%$QUR*(Y3*SF#1RK M=Z.37)8UT2T]ZL45[E2L7OHGQ2;(Y$U5C`0]IK1<%8^O>AR2_5KRD)KTO;JM M%31(%FJL#.^<1=-O<15C"#$2][Y-K5\-3Q5HM&[Q-1SESCV9RXJF=[E^ONX= M8"NW7>[H;8+U]X$_QK>438*<;79(PEQZ3N_O*!F^OLN(W:E&-$`)E2)6"%RD M(FK;*2D)N\]3;(DHV5PY4],?<'/(O:IAU&OR:]; M[2TUE5L>9,,WH'_]`]0+L%AUD8IF,/^]#1<_A][`6! M_%Z,GQ2?@F(R^L>D_(BOP6^__)RGVP//&[^YT+*$3@K7%WPYC@*]Y\9%OZCT M43;<>%]4M8:[M=2:,G?]"\HAH)Y=LQ_9NS#VO__V][_]_6^.\TLVR'Z\>8Y:"S$#G-3TP*6XGE(,OEZS_Z]:7=N<;_$'5\3IN'WW;:=/G+8<'`%G, M\0J^[;:/MGZ;.G.*,LIM-/I\7@,)]K(\UF>48:(+PUA_=C/-0>,Y_^5WD6\]$HCZC`/?,H6NE$=6IR M*R8Z4X*\F+/K#,*)'S-0I")&88^C.(J!/6%V)-HR>W$PD4<)O8ZJK:I4 M&TKSB_A?<*JP,<]`KU%;>/*^VZ;G!PP#"G*1?$6%_!AL3#@9C8>Q/]$;C%([ M+VVQUQ\OMSO==I:69!R?@D/?@[8D0^>3%-*:#%H!# MMU)?G"3&7`MT'LI&7GAXXGF!MXE-',<<]M271;B%HHFA:"'5R5#-?3"8-!.5 M+%36)Q8P3,H<-F#O-U@2B>B^NMYW6(]``0;O52N5M>#*#"8=]ZC8A@#5O%R-35J$W@DUA[+MLV2K?YIQ='O][%WV=(#2%+(>?MSN4 MM3*&/=[6"C3`+X"\SN[K$@02PP'PVU_>;Y]WRJ\?SZXO%4;QM?>AWG2&AT#W MI*VY[,HE=`%$)XR$5J53@.,P?Q@1)JGL64(>[<+E$Q8U(^"^E0PUF7Q#3$@JC!_JU["T9B.3U^Z/,R*DD.MVH M*C;5:E(4Z#Q0-1GP9W2P!)5$<]5Q4^3_8P,<5](!&NA&E4)V9+XKN'ZAOXJR M?JJC9.S\;PY4P["1VR6IQ'@:?L#SJ=/>_E]Z]!CT9#_4NF9VVHCUEVP@'6;E M+U?;_UJ%M(Q)D97$@HI2EHI>*JNE.8.FIY[/XXSN)4BC2FYD2R)U/X' M%Z_L"/6=9YQC-%@6]7C+D&]7'9%XJ$MIJ6PBY`K39(03HZFTHPQ`?C"K$'2B33Y5?;0'"HYMWR#`CPBT3RQ\\IFR# M2.JT%\AV2G_FD0BE+[!#P^Q[!D1%SJ/0+IDF>TQV@AHL^G?!-RE87G@/9ZIA MJU[T&J&5ZYNMG5W-PT4I@C8,=')BVBHD,^%(T+B,5 MFFZP>*#!H&)?.*>^-#R;E(:*SK,-#)VVJ0:&1Q]E*Q!4WSKOCD_^_?'RXO?/ M[]^(]L1XHD7/LD84<)6-H4!C(TZ2`E_QS4E0?<#:7T(HV`*V0>5H%3$B,]F; M(D@*SQ7\,"YD`<$V*^UST="-X\P.4F2SQG@B,^*#TK]'$CG)(&2]EB5E0`#O M\TQX8A_0BH:$N'PDH]<"UN<^)X_`8@L%[+;GE`HP1A-8(668J")<`/*-O#\Q MU%YPK**P=2G*D?,/WH^XY#SV>%%6^,]C`?!N@+CSBF1@-WK+3, M*),<(UGW0;?]265RCF(J*F-'TK="/C(>!0XD0DF)04"O:/$U$WVKE5("*:[0*D@QC]-LNQA`&[2LL9J^E=:U MZACZ7M5!(Y0[B*5,2O.%K!TWJ6%R>K_Q&8;'2CA1\VY\3)D8ROZAZS,LV.BE MNYN4W'WD++7(3J>SU]JM/65(601FYM:4Z)_MF$(YW96^'\*.)JB=:A)F<$R. MB^`*"L^>6[-?C*3WH11E(].\CZ>M+'G=SV5J>3FX+E/0J-)V4'I!B&F)X@(+ MW,?N]"8*#9)H;A:R2NNE##HM!PDG+,ID2L8<,:9U?Z'P(RUE>PY3=)U>GA'C MI:X$-(*KLO[H]X!A]6L524[&Q]GRD/,X9N$@$>R98EZP.J%>4%N*6]*$(,SY MR$9YP&0(`*RTM*)0^CD@4B;8I M4[@1!I,'6$"4Q41%A`!$M?B-)(YB3&(D-BB>?+X%I6,M**L1>"Z93ZYXYRQ- ML6AK75,)4ZPE+X.)G47`EB8RZP494=E`J;;CQ[L8\WY?:7P*NX-H;`IC(`BV M()?4CO#[F-*8X:0\OCIQ]MO[KJ.ZR9"0<1*KYU/ MCZ/.90RDZ/,;5@E:K386H=A9Y,/#^+;LD%*)B";!QH_)Z26]5D7HO<$'I%]D=4'\QIAF8*Z^N(Q"`YRU<(16_39$[TV^B$3988U M,SPUIPI4H`1%4Y1[I5S!Y14^U>U#5#F8F8O8=&=VKTFH(V>X<`Y0^Y!HB-LB M^E,*Y@ZPZ&&VG-P&5\*(HGO5+M+K<6<\Y=43@J-T38PQ&CK.4_0I!H$,+Z'H M?S9$SSDZXJ7$/J+1I\<>8#TJ=2MT!MIU*MX245KTN%57@\@(0.6^5C4K3T5?31=#EQC%/UL_)^PJUR)G%-[=9:_Z"-]E@B:SS. M!QB:K'%';(7$YQ]>BKOA$]NH^'Z9\J66[+4,6Y6;M-=Y^S'&T4ZP"UT"@H4H MRB45O\+]IER\,MX8_6Y9P7F*B!256T-1&P(5RWXL1;5GM^`;934N;S!(V(#" M202_\3AEQY9VFR#.>YFD;.7ZRR:5\''-E%78@*BA^""6KE%<(K%X]+]&TKGJ M]3,I$`>5Y*5:%RX%=0E8H*>QB&"3H63T2Y6^I?9-1KR2J$MJ_I<7Y:C&"2_M M@2N.()@8,1^1QXP.S!'&JU6O=*-IE^%$L@$],M%2 M]/(T-J*(<46'4!@D<[N(P-%<(!+347?1/BWX2CU?^NJ8J M?TU6]``JR`T+N)BGU%EK_;4JTIX4TDGM,2MBK3"D#0]TXG04NU;()9I(0K;< M2LL@%,S+SC9"71+%.\HT-A;HQ2_N+J"L*1>B,@DQ#A+KYSR7E?*$5.#JI8FB M?\_LE`K7D]9(IU)71&/J96:>JLER+,SC*HI*9&C>56+.N<)2)'H]95]%O^$- MU'2CJ"7S4@Z**J.?/@9.O'1X'`7XSVGI?GF^:7#'G@Z+YZ0GREU&'S1X;09C M;;*(C$GAF&P%+!0M]5.^RVPHTW>\4*0<%2791=RI=!9B&72FZE*,\\0?>K+S MWEQ'Z<:PJ0&6RPM^:;?VJSNL]6*:FFFQ M*C1%8<@+)O"&Z!1!:5KT&B%#G8R'H>`U+(`O,T3>L_2[;D3^,)T_S=^'YQW=<%5%&3^;>>Y9[KX9[GY7!8278-I>'F\B1 MS^KB\^ZH!SF;:$7^C303U>E!,=]&'[`P$F#Y,_HVP/HLT=1;*#K,#[TTY?V) MRL72YI#2H;"=Q=M2$IZTG'].79DN""D4?>TB5YU7U"%!Q@3I.U%1B,*N,HS# MHA:1&#RG(N$/?WO9ZS#3NDQC-U%79AAJZ5SR!FD:2J@M:=E^-6$CGH](TD=[ M#!E*6NCL$I>IU9^Z+FH0E%VMU5AZ,73,\2^SS40^PO3VE@O'\RG2DB)Q>R8< MCVA1LRH;ZE;X(I!3]A6S_I6EQ?^"K."3+"%=B3)]7"N/-*D)N<5\PC"^E9BH M&D4$*%NHNA"J9CS6F5(-Q]S"HH8Q$O`E$&G!1>>,J8)5&&>K%9&ZKA;>PV)9 M9:MG+;.24F6=B(GY49GD,C.G6`&G&GQPPO-TB)Y!B@/!K97ATL1XM5GK&8)2BU7J0%U%D`1PZ7) M:)KIL5IX!UN99-3.!`L$SL^]$+5\^&"X+6P/?YQ1.R&L M5$^MEJ4#"!.91+%5IR\:^863;7B2^FI29L(&F2_G\\IIMBJC-B_%,;.08GF= M`U.9ZZ;IMBKD5H.>=;ZL>^Z5]G.B,%0905Q3>$$ID/]D50$K4Q,*FI7E=WHJW'6TC6>Q'`$:"F< M^F0%:\<'4C5=M?)R4.3`JM".W@$L3T6-P&@[89A#1ZPU'V_W$]QI-4Z?(5,8 M\1".$XPT+$8`)B$K[J$N2B<<%3<7#:LID5?4`,;J6TD\D?U"XZA:Z6JJRVBB M1[/G8S&7XIV%REOV_=+CO^#0B\,;L>HR.TBIQ,6.8.J0;"Y,ZT/]8SJD6U4A MP[I]7.N\+*/,$TQYH_[%(JA<5OT1JE,>%BUDJ8Y0*L)$F-:I0L;5B_Z'3C]/ M1'"=5G>]3"Z6-:>U%?DRRG]J[VJ`1,9V/8A^6`!'X6()Q.)YA!*&5_:=5YW7 M0A>='IK*NU=0QW5>=5^7D:ZBSPQ6`Z+=)<#(TE?X>F5I*`:&QW=>UU2`+M\L M>K>E<22[:PO`RH!]:;7`]Y&F%PB`$?Q1G-+J`Q+U3VW"U%00+J]VIY?.R7A& MPR&*(,]3C=9D]7NM`:\6,*P"64=,5+>GYM=SME7T8"QZ[F8Z!`OL+PO6EW2@ MXTX-IFR*B'6OW#0K:*5`=CYZ&]Z7=2M/A37@R6Z$0U-%K6:+50)4TAA=%AD] MB5,;WK+^N7]4]0G)>%B"2J\'BV8^U;]I+.JW>6E1ZJ?E?(XC3=KP@AMB6,5Y MI=HI3.5T44Z33/X7)9&3\@C&9V3T^-QI4='1TI@?J%YI9)\LK>M3XD6102&F M))[4Q`%=NB@FBW=)9HP"D):H+^O;IZDZ=8KB]N2RD'4_*@&@%*299N4.3I][ MP+98@A%%1=I^L0>Q5@U>U(P\N;R0EH+B[I13`5;5TT()K+)Z\``SQFJ*`NA) M^"%NLVB\)NH`.RQ*XC`4A13QY)<2DRJH*LH-T+$D/2BIZL=12?+R`O97[OGJ M3%5R08E71F9F_*(RH1;JJJK!ZJ4\96SK5]6=2)LM`JF,DJW`BO8>"#0/)N4= M18_6VSCY7B*>%"1`BB.YKX)1PI$F*76FP2*(;P/5MQ"+X)1B++Z8JGG2HG&> M);5K:$XMI(7@DPI;D*PD42`4&;_4X"W,8%4/8*95Z4B8ZN:M^FDKMQ^)[YZO M3&X#E#E%+Y=8:7IXNZJPA@9^V:>\4#.GD!*Y-0=IUDLT MP5=HIX5JJ!1?U*?26]45K@\XEF&4!%4TWTSB-T`G2 M0BF@6"/<,;?`+J([Q$_%2.IQ8MHM5!`>SD_15]'4D"&*S%(12>\WM-]%UY12 M`9-X7A2R+V=!-$^IOMP+'RK5FRA#-%G^^2(/F+E2!J_).Z[6JI5V&#R%1S&B MNG3-HE7`+<@5;2XZ-DXW>X#5YDC](H5"3S=']G'WW1KOBOL9-0:G3!3-L!,5 MS=%PR$GD@&]#&2H7IX5*D\18*2G#/98=LMDV\0: MV7,Z/"H5,BM/2;V[.P>3)UK+;9H?2I*HH$\7]*0'J7^U\T5L[<*-,::=L+/A'4FRZI/5'R2 M1IZ(W^`T=K4R4+`\:0I!-3(,X]NR8A(V*Z;.D?).*:V<%=4H-U35H'2,G+O=)5%(^.A(M*26[NBENG#1R.;<,(PIFG. M^J=9X@/"TP7PT!X]ZA M`03#RF`+1%O1L>PU>D9A4'"\?0&%X\FY.EUC>W,T66Z^PFJKVP0[1P?>9DB= MS3Y@-$:%';%2I+)M86?4`W=`W@KC"6,J?B3:5E=``H,AR"K\RA,-K!5\B8M+ M8\YKARP`$05]5FZ:LKC?WPFJL((*8[S*$"`ACS]4V^IM,'63J":[7(\[9#$2F9AIDPSNFR*H;)Z01+EG_D0)WW&,U&*,='C M+J1?$`->\=6#Q"MB-VZP,"5U)R\J6U.W,9092`O)Y/@40B6-UWWM37<5-VD> M5C>9(C\@RR\+`BM;2Z,NF0)5E"-5-UK0OU^3B.HC=:0QB:DV;(EX^06R-F<^ST/1\QS),2WR]I3+;F6I['6'_5X[;,TZ4T5'>2+7MBHYT\+;B M1=*H*JNG]N!@RE/X2.^LL^?N[^RZ M[?:4DQ:7O=#W'+EPC+N[[:E60_/+.H@"W*7/(9P`"90;_=BFM\6(]9CT%@=5 MKH+.B+.E$3[,8X#M)(^7TXRMM3OILE)YUA:Y9PBV(Y+!Y@"I'FBD?5U M$\1"$7,H(9:HT%[I/X'#62M@0457%HO@J)B'JJO,(0QA#RLTK6W&6L>?8F>]3482XTH=`16I6(Y]5/0D)A\.":S6BW+7 M+<.&*:G,01<%Y:5M0J5>B=!U+"^"F6ED><,[R^+TL2^4;Q'65C>Y6QE^KQQ` ML(WY:%SX?::CO[7%"[&D4[%8ZAD7VCUJ.XL@",1N\Z)+>CZ(FA1,=KEIN2JI0[7V)<._Y"$U::=U6RMHD$S[V&K$.8NF MW^(JQA!B./=]FUJ_&IXJT`3EKM=PE#OW9"XKFM[E^OFZ=X"MW':YH[<)-G0! M_AC?4DH2'O['^42!".?9CO:[8=[P,K?75R^/[WY1:A9A=7M$R6[J$!C0OOGP%HN+M\X M_Z=-_\T@]5L'UG5]=G)\KEX%,,GBD;SQJYSC;AO60X?>KUM[^_^H<-\:#*@< MI^(X:\CB.@M8V^T0--UMQ`SV)HIO$V]<8-:[B^OKBT_%C)W.^(=#$3D2D9^] M(T_;@0-]!W;^L85X#_,'Y.W.;$?!L\I]`>95?D$N9I%@PY%`G5`:#G2J.+#[ M8G%`"NV6VYN_N$40^IK7)GG*]<676H8R?^GW4'C3]L'"V,)X+/Q9O2)\!_O>L>\2`(V0K)WG`P MURSW?YZPR@0CLNJ7^>7X_?NSSQ^W+^7+E;EN_4OOSJY]S]WO[KN'G?W&0=HB MMD7L.Q"[TW5W]G?=O9V#QH%ZB9AMR"G>I_]6=8J?#)G_G5R!$:8F1-]5<[JU MG>9/7O]*F-[CK"^&(\3J-V1Y''2)NU0G&ARYASM[;J?[%`N5)1-+)B^#3'9W MW)W=([>[NS9!PT0R6::@H=#C_/2#B($P10ZM$SZN,5O2BJ"/X!<[P"^".._A M^\W9D6>;&)^NGCURGPS6X)Z\>35\=W_/W=WON$>[;4M=EKHL=2V6NO;VW(/. MCGMPN#;AWT3JTJ6:,L[4F7W&^,C81X>QSE3"PEH8><@N^O5#7..[GA,$N]O( M(%CC8SQM)*:-Q+21F,_U!9FT.!N$9R,Q+1+82$P;B6FY?2/69J/T+(PMC(UT MK1CK1K&1F$U;K@U8>Z3%U49B-F.Y%K$?A]@V$M/@4]Q&8IH7.V-#S!:T(9L2 M8F8C,2V96#*QD9C&"1HV$K/)(JB-%;.Q8C82TU*7I2YC-L]&8CX_$G-1%0QI MZ`87/WU:I.9TG.<_61AW<,S6T<^T=%=81[LDC;(I' M)8CU%B6-"?5\7-W9NP(_EUM6=FEQH(+!V$#0A^B%&Q!:L519M=DQ@+L'>O1( MIV,C05]P%*`E=:/7]A@=J1+GV[$18L]BYRMFULN"\\/V7!>6J_3C-7`O61H,UCU0_:@M("T@+R/4# M\E0U1RU7C=T$7RQ4K8S4F,59"_1]Q.VEY89XP9]YFEE^O?%`'\8A.M;*71EX M/+*&C1<']C!.4V;AONEPI_;*+Q;*AB2V+3&VO&9OKH9QDFT#]$9:.$WZY@E( ML+$1>R8N=PG!KL_:C3M"6ANQ'>V-P@Y+#)88+#%88K#$8(G!$H,E!DL,FY2[ M_(BM46G=R]$=+WHA'W@9CZ/4B?M.$,-4,NX[@_B&)1$JDE[H>`,6^9B7\6I$ MJ3C1P.FQ[):QR+GPLQC3,8H$C>-\D*<9?M]_[;P:LC#8SN+MD4SA>;TN!#,Q M.=[$Y3:_OM02EU[#.KN'[D&[XW;;1XT#M<5LB]EW8/:AV][O-`[*%JDM4M^% MU&NK$F$QVF+TT@20([=S9#';/-UMM7[`]5.]B6J\B>*.(48K:Y6RZ&S1 MN7'PM>ALT7F#X&O1V:+S!L%W\]6H)?8)J-F;\S@:F!--::)V;>)R&\KE5FLL M:C!\+3I;=-X@^%ITMNB\0?"UZ&S1>8/@N_DJU6H]4PN,,MRG*,.R.C1<.C`I MT-!$-7ZMS:K,MEN9TJQJM=:N;L=M'QZZG:.N)1-+)I9,YI#)SH';[MB^0I9$ M+(G<(^3O=:S?Q)*))9,[!*Y.=\_MMJW`U8SNH*MU.5)W4"XOLVK8=.[1^[!X9&[V[:)3Y:Z+'4MFKKVW/:!I2Q+ M69:R%DQ9-JW14I6EJB5(@X<[N^[.^KPD)E+7'==VWG7R(+"MN_!/6MK M=DWL>SOOJJ[A6N/=3K7Q[NZ+10+;X:0QB]N`M=EVCB^C`97MRFI!;$'<9`YE M.;45N:S(M2&\^LG4:AOO;B18;;]6"T@+2),`:1OO6AGIQ0%Y4PS0MO&N!?K, M=MC&NQ;LMO'NBX&[;;S[/''-\-PGVWAW@=*K&;"V'>66%CK78.RPQ&")P1*# M)09+#)88+#%88K#$L$EE`1ZQ-:LM`?#<$GG_\J+<2R9E(UX5\TQ73*J09V)2 MRUH+MJRT#.DS4\)67J=EM35+NSMN>[_KMG>>D@]@J<-2QT93QU'79D):LK!D M,;4[>^YA>]\2AB4,2QBSTM3>@=O9L^4IFE'U;K7NTYFJ=T;5N3/1,K+>RB8F M61(;5]G$*+OC^M5<2UWF((BEKL52UQK59$M6YF"&):O%DM5:U6Q+6.;@AB6L MQ4N#ZU733:2NA]:YFZD\IY;\TU1EN)_IP8+TNW5(&KLR? MH$IEYGIQ$K"$2L"I8'WBQAS=LQUZDSC/WO3Y#Q:\O;>47#%^4GP*BMGH M'Y/RH]KD7W[.T^V!YXW?_).%P77\2;JLKPJCP#7[D;T+8__[;W__V]__YCB_ MJ`?.RCCLL^@]ZV7'4?#)2[XS&OSTK[PR#/QXPI+,X]%UXN',C].49>E[GOIA MG.8)*][C^+"!\.62]7_=^M+N?(,_Z%B_CMM'WW;:]'G+X0&`RO,S'GS;[>YO M_2:Q;J:*WSAS"M.,@)0S!5-77'"=*X2L4T%B@\HJ?KZX/G5V'-4%!DCV[/,? MIU?7GTX_7SM7IR>_7YY=GYU>S>#VDFLN;D[AR*).9&L/2S_>N;#[EO*5.0GS M@=*=.$_TC`7'2YWI\!#'RQQ/%7]PL.9#:W8#3%_Q7<`S?NX+/`*XK`%2].JP[:KU6'W7BP6V#(^%FL:K]2@L9Q M/LC3#+_OVUJP:Z,G(VN3;63EL4/WH-UQN^VCQH':8K;%[#LP^]!M[W<:!V6+ MU!:I[T)J6R#2\.5:C'Z"`'+D=HXL9INGNZW6#[A^JC=1C3=QN2M/W#'$:&6M M4A:=+3HW#KX6G2TZ;Q!\+3I;=-X@^&Z^&K7:!HGG<30P)YK21.W:Q.4VE,NM MUEC48/A:=+;HO$'PM>ALT7F#X&O1V:+S!L%W\U6JU7JF%AAEN$]1AF5U:+AT M8%*@H8EJ_%K;I)IMMS*E7^IJK5W=CML^/'0[1[9_F"432R;SR&3GP&UW;*\B M2R*61.X1\O[YW;;5N!J1H/ZU;H<9QK4HXX;UO@A#6A7 M;Z)19;T-2I^-*R^Y0>GZ-J^&3>\>N0>'1^YNVR8^6>JRU+5HZMISVP>6LBQE M6];6 M[)K8]W;>55W#M<:[G6KCW=T7BP2VPTEC%KW4BPVGZM%I`6D"8!TC;>M3+2BP/RIAB@;>-="_29 M[;"-=RW8;>/=%P-WVWCW>>*:X;E/MO'N`J57,V!M.\HM+72NP=AAB<$2@R4& M2PR6&"PQ6&*PQ&")89/*`CQB:U9;`N"Y)?+^Y46YETS*1KPJYIFNF%0AS\2D MEK46;%EI&=)GIH2MO$[+:FN6=G?<]G[7;>\\)1_`4H>ECHVFCJ.NS82T9&') M8FIW]MS#]KXE#$L8EC!FI:F]`[>S9\M3-*/JW6K=IS-5[XRJB962]E4U, MLB0VKK*)47;']:NYEKK,01!+78NEKC6JR9:LS,$,2U:+):NUJMF6L,S!#4M8 MBY<&UZNFFTA=#ZUSI[[0%E'-MEZFHJ\ATG\T84;*-[MD-O$N?9FS[_ MP8*W]]9E*\9/BD^!^O2S_C$I/ZH9__)SGFX//&_\YJR,43Z+WK->=AP%G[SD M.Z-[3__*>3:Y*O1N^/&$)9G'H^O$PXD>E M/+W&F10#.WX<9?#EDO5_W?K2[GR#/^C-OH[;1]]VVO1YR^'!KUL?/#_CP;?= M[L'6;Q+4,Z7SQIE3V$,$/CE3M?M<<<%UKEC"^TX%*A7JQ2&`EP\8L;@/6]F3?F:UL MW9BU61A;&%L86QA;&)N>9K_:G(.]?SB?X\QF%1B3KK4\\&]`NM82-V=^-9*] MCJU&8JG#4H>E#DL=ECH>2!V=PXZ[OW]H2<.2AB4-2QK-38%?;=4WI.:G@W]EYS4M+[-,U)!FV>>QF!)RQSLL*1E M2;16NS:&WPY-H#3$K$T[G!O"Q:5=]#RX_I5)-H MGU*WE+@,WSSR-P9*6.=AA2Q;V4 M)3,K+>!P]IU/TH>T4O<9.T4Z:CT9>PO\+,\%>T?[0BP;P M&8:FJ&YG!SZF69*+EM%!GM"C<&?$(^:,X(W#U&%1P(*:+M&V'_2]R?[F6S M3<_7;0LW0Y(U&*;/D#N?)E3N/=&%L]$N&U.DPC6R*24P+X=-G6$<)TLSQ_/] M)(?S.(Z,$'K[^9'&MQX%WT\I;'NA:XYAK6=0""Y$%G[0JN M95U+EK!.2.M`I:-?REK`L)0*HM>F><''F!%!.&9PMX5%WQ@CIKTZ[.ZZW9WN MZY>,X89PN^4*:E5]:PBM?E*OC41Z)::_' ME3]D01ZRB_[5T$L8C,6"DW@T9E%*#UYE\-#%&#^FQW[&;W@VJ?I1GN#C.+(^ M#D-\'"F"UXD)OHXGX0L/)`;Y-%Z4_V+Z.#MBO7V?(4VH(4*@:WZOJ^U[ M]%B?Q]3I-'<6\JRLG/]*->+#3%X_0IYIE58_-Z31%-`OA7ALH#"[9UF'LW+/$& M3+_$?K#$YRDKMVZ<<'^IU:&7P-DL+BP"%TY`X$A`L,I%!3AU^9HEHP8>#I97 M/!0_C@>#A`V\K((,9X`+/$JYKU_\8]F5XXTZ)U9FT7S\JN^U32QG\A@*4XN=%CO-A:G%3HN=YL+48J?%3G-A:J3B\'2%:8'! M$(;:CI>TPHU%<&P47S'B-6^+)`N/$+W$@)XH>'71:!TO,#K0&W]N7=E7ROJQV; MCKY/7[]%[^;I-\OU\9S*?+>U:3C6]&C>V6L-,@V%Z893I$79S8/IAE/D8D3$ ME:"GA=_:EV<21[7H:11Z&JRA+-<#\R%.^HQ;'\S:E]?0LW.YUL%7G;UEEKEM M*N@VG/":ZFK9W=]I[70M/%\8-3:!D5KXF;(\D[BI14^CT--@)639;I(Q3ZR3 M9(D=.\S7P)?=L6.=-I97N^O38LR"[8;3[B:X4[KN8:?3VMNQ$'UA]-@$3FKA M9\KR3.*G%CV-0D]#TO>7ZSB92M]?97.N)EDBUI'`]VA=?IV%]HQ)]%M(H.PS MB_8U(4MA8_->E\HX&I?W:K-R[#%A,,5;Q'^18#>?]"VCM_ANJD:X7"]6@Y3_ M%V(ZW;!4QD>#=\-2&4VP;9FPO`W-U+7H;;FWY=X6O2WWMNAMT;O!:M9R'6^R MI@*UAK>.MV8:EDPTK5D+TXL$N_FD;RVJ3<5WR^A-I'B+^"\2[.:3OF7T%M_O MU.E^SE#KT0=22S\Y/SV^?`/;/*PN<'I]4RNA2P^]C+PCD]V+\ MI/@4%#/3/R;E1[43O_R^>E+#B)1V,6I5[& MX^@JB_WO%V/\F![[&;_AV>0:A[EF/[)W(?SXV]__]O>_./ONVTZ?.6PX-? MMSYX,$#P;7>GO?7;%%P_'5]^/`,$`UC!7TF=`G;3N.N*"RYHQ`GO.UL+1).W M1%EGG]^?XLO;K3T.E%),C4?BKT2G611:QP3ZL/GJI75(?\*2S(.'V&@Q9\ MIKCC,N>I'1OG=&I4D0U1[>O9^^M_XNWZ,24!4W\F'['>OL^09E4\K+Q#).#6 M_*YM5_'"@[U_%`^>7)R?'W^Y@EG[@!O>.(7SY@(.H@_G%U_?.#<\Y;T9K\G< M6<@#?^:&>UFUXX5\$/VZA>>KMA4K;CO]-(%#;[^X9T[[10#LQ64AQBUB<:O/ MPC5J]1V])6QW9BL^Y\@(RPV)^^5GDAS2!H)_O4G8ZU[]8\#_E:$^)*H-])*? MZ>?C&Y9X`Z9?HM8TY;:]][+*SQ\\KJ'0'UZ8LY5BS3JQQ!`WT^+B)>H.`]N> MU>SEF9"[96BZ_R(3L_9=N,-MMSN-08@-Q?=G`W?C.L`N$LWW6H?[QJ-`0R-' MC*E_6W?,VPZ$1BS/I&(G1CM%=@_;[MZ1^45&FWD:FTN.3<77SGZKO;9>UB9@ MJ\$GZW(5Z#_(7V:\4-7,@]4$F=&H:/)',:57AYTC=[]KBS*N>WD;=(PN%V/W M6NVUR7PF(*O!I^AR]5/;G^49;JF-$2+76QQYN1K"JYV.V]G?MVU>7@+];HA* M>[`V8[$)V/H2_;_FI!F:)5RO(PB_43YB8X+UU^Q&;G>/W,.V^52SL:DK2^4; MC4M=6:ZZ#A*"5=>+SS9IY2%)*T](,5'Y*MD@^W%O^LOI#_S(GIVDTK%)*JM* M4KDG$81R3&3RB*]!VF$"U`Z/^L@_Z)K7`]R>S5!1*2/9,&$B(\6,Y)&%[V73 M$DKJTD&.VH],!S$SG2.C_8M@_Y)EA<#O[ZTKO6,%BUN$!'H[Y!G;1LQ@;Z+X M-O'&3XSHGUGOT];WF`C^:^15Y8H%KRJ_$].R(&XTB#_#(60AO"SSFTG[8#GU M$\AX2=E9:R#T0K8L]P6$S/++$RVM%@DL$FP($JS,VS*S"[5FI=6<`%?WJ;9> MFL8^]U"1O>79<$:Q79[U;4G;9*IW>P>-@Y1-B&\X^ZM49$NA@H<,142?R827N$MKJN-HR<04!#")3,S8$4L2!@@>U22/;GO58NOJ M[-\;*Y'FDX75S\.X2K: M4^X.+WJ_=;3L!\#EB4XNI_ZW0!/P$]RQ#,#T M=^Z9/LQ^9_>YLZ>;AW$(N)6>_I7S;'(<:2-\\28C%F7I<^*$=TV-$T[Y?]D; MYQ!C2IU.I]7FT4*'OS-*-SZ/T29E3#6ZN`OM9S[(_:?/Q007Q+69TF"L="%<[FR!FZ!L.3P M;7W&QL[R(D\<;R2BYC&6'J,2R&7@LR3C?8Z,&GM`\,B/DW&Y-.-^=C)XOI7*VGHIZE5_N3^E"+3_&E&Y!'KZ&`Y5_I;W5/J)4$= M*L8%ME,HA>O\SR(GT&ZI:K+%J\=>XMQ@"6U7!G.@K)PZ*8LXIB?$L"UQ2OL1 MPP;[\6@$NR;G1KN%DA+`"IMJP`.C.&$.3H&E+>?W,=RKMA3&AR/9B^!,S5@R MPDP'W''Q/E1-W%ZS!DD#)`=AX#M+C<9[],!V+J;%1G$ MTI9QKIR(G5CSH=+X7!M[T!AYT.S=>]*L[&!Y#,\Q$=Y-IJBSJ.R>@)T3Z!#N MP[D(J`NXP$(\TP8<>)S`4L)D5#_A/'<^Q,G(N=K><5XAQHIM..QV14PP_E!< MZKQ][5'N)1-*8@39`.A''')J-)>^H0*- M1QL>92F#PTU0AP?_R[QPX8C;W9LBD!$/0WG<,!!$A M+57G#WNK&`,*2_##CG.<;<--VY^\Y#O+G#-%]E=>"+,\AI-:;#>-]NG\#['- M^!=VHN6_ MM+V".ZI(BA827*#@PBE!P1L`!&8P$G88]W(,>XGO\6BG8%=)3I0L?@F<>V=J M'_Z![\%)#9(X30$&L<]8D,I=D6O`>TAZ+$"K@Q6-R8&^:98)KW3N[W,BGX=V M!R0^0B#3F-Y"<6S7;1_MNKM'A_-D@PKVY+-T@9GK)8,0DYS"3\3(,7S[P4=P M3SA9++O8/VQUZ_DV<$#D7J*I%/&^"NM:Z"PZ^ZW]_2FI![:*]M%%N3`/B=L` MPD3`_%>U-P=S6*GC]5$K!*S+?=D:4W$TH:+&J%L[(`M$J2<..3].L]2RBY7. M_2M(S'F2P)D$F$'M3[/;^$YA+:U(:U*\`WC6R&&]"5'RU2F22W\,*$><&$&):[3+3N[A[.E=0J_"IA M(X\C1M]X/"3S%+(K.B8+5I:RNS>TY7P58A0)/^*<+21!.0Q*3W=#959R`5R` M31O'Z)Z":R,A%8)4*:0S,OP(*O1YXNQT.AQT+.;I@0]CQG''JT M^CZ/X"YB-"F^`6?;`Z44/@/(F.Q]2]/%#9*N)UJB&I$DQP?L"_(P-)\Y>5H* MP/V0_>`]'F(;7%A4XG&,V2X%3M\;F+5'KJ4&>#6/:SF MB::>N[B!$=Z#)ZY+>`]!+\%L2Z3N+X`1J35FF3'W1ABSCB.ALI(22M9^YEQ_ M1-MZXHU9GG$_=1'!@/]K)J]+9?*"TZ$[A7\5_:OF]XK:BM8".C-N8#`XFW0& M13:#/&+28/`E3U!WEK,$3E?,VUVL=+Q_I^7LEB7$W&"^;WA51]FXKHG#L+&6\Z-FJIX^.+ZU$M"I MUR79773RN%%]T&T7^+L*C%$4!%Y0'=WC?KD]0L98*0(\;%0N>,*\ M)'U*+W0CEFU)I'%N=.A\*$E%M!;U:I-4;B- MZ^#[W+X`9O5C[AR9CZN-,0Z9UU5\$U#TZ*#3.FAO)!@;A*66HSX077=:>^8C M:X/KY3:`ZRZM`*Y9F+Z*6OWFX_OJ:O-W=AX)_L6I@W4ZT$=L\/.D;L,+@;T) MNJX)R]N@@WF!(#6279D+TPVG2(NRFP?3#:?()\=MK!X]+?S6OKR[&E;H:L>F MH^_3UV_1NWGZS7)]/*AIX;?VY9G$42UZ&H6>!FLHR_7`?(B3/N/6![/VY37T[%RN=?!59Z_[E'CM M#0?=AA->4UTMN_L[K9VNA><+H\8F,%(+/U.69Q(WM>AI%'H:K(0LVTTRYHEU MDCRE\MO&:.!/W8`FV%A>[:Y/BS$+MAM.NYO@3NFZAYU.:V_'0O2%T6,3.*F% MGRG+,XF?6O0T"CT-2=]?KN-D*GU_MOV'\9KL.K69I2;P/5J77V>A/6,2_182 M*/O,HGU-R%+8V+S7I3*.QN6]VJP<>TP83/$6\5\DV,TG?73#THP%3CS.>!PY MWJV7!*GC18'X-6%^/(CX?^$./QZ-691Z=)\?IYF3L-##9[.X^GBK>=NU0E#? M.<],HS=G_(9G$W@H00;D1!Q&'\%*AZG#(ISO+*MZ8T\''6N%('%.4DL5C1&) MOYZ]O_XGWJZ+21(P]3+A$>OM^PS67,1CRSM$`GC-[]IV%2\\V/M'\>#)Q?GY M\9DK@[LQ6?,:"OWAA3E;*=:L$TL,<7,N+EZG[C"P M[8'-7IX)N8.&EIM89&+@O@MWN.UVIS$(L:'X_FS@;EP'XD6B^5[K<-]X%&AH MY)(Q]9?KCGG;`=.(Y9E4;,=HI]SN8=O=.S*_R&TS3V-SR;&I^-K9;[77UDO= M!&PU^&1=K@+]![D^C1>JFGFPFB`S&I7-\"BF].JP<^3N=VU1T'4O;X..T>5B M[%ZKO3:9SP1D-?@47:Y^:OL#/<,MM3%"Y'J+O'9)DW-39+8[B!D[HR43[,DC@9J-L^)FZ^.U(CDCV(! MQL[R.LZ\T&$_,'N+.5Z:QCZGO*U;G@UG,T(&"664W'JIXXW'2?R#C^#N<.+\ MSR*1N--M'5:W;\3#$'/(@CRAI)('9HFTG/M2W9:]DL/64?U*8%89[?W#\^B* M?#PMZV8:0JYS.^3^T.$I`=67C_8PNZ=X2WP#.^$YMS*4>-L3\Z!TVVUJWLP85Z28J(0S-(;Q3F\)XAAQ"C.'![Y81XP%W!Q'N06.KF.>[B_ M[W;V#ZI3I-0DFL$,#<2::L73-!<[',71MI:-A1BJJ`KSF@JH!"QCR0AP-W"8 MYR.)C>.$LJSD[H.VA@\+3GC8[;;?CIB7Y@D;,=PG0(96\5OG+65;J1?Q=`;* M.)1*XRK!BU9O]#0EHY[<-1U.X1(!^G9!\1@ZL=8'>W.C>C8EVW:S@95O4V93EV7A[B[(-1=D-:YVVPO4; MV3K-!/0V6'Y5:"D]_C'EB386VD,>F%O+H=-R=_5U;R.,E MT.\F&!:[K:[YS:C0]D6PK?V/S(M$<*L#L6TRVFOP!,/W)W=G;=PZ,7C>ZVJM(3 M,^BKA8^X^G!?8KUS5V9],.,G MUB^86>_3UO>8>@77R*O*%0M>57XGIF5!W&@0?X9#R$)X62X3D_;!`Q9=-U# MI(O=)5;]:AY=&")PJ.A$0P4.X:21K3[6A3Y/WB,#LQ\,1QJCTD&>R827N$MK M*NUAR<04!#")3,S8$4L2!@@>U:31;GO58NOJ[-\;*YO%2<`2"@A3#D=<\AN,3WLK`@^W0V\2 MY]F;/O_!@K?W!I85XR?%IZ"8F?XQ*3^J??GEYSS='GC>^,T5]I<Q__^WO?_O[WQSG%_7\>];+WO/4#V/L MV5C&&5O9RA#F";8N MC>(,1AY[$Z1]&U6\ZK:,\]HQWM.&41P+3^_#.+?_HN%]%U<0)](]L.%P=ZZM MV9%0.WMZ)-2AC82R2#"+!*H'FX8#G2H./,5TL1DXL%G!SY;;F[VVQUA&'A/P MNLG[L(%I+,M"@\]QM&T18(.6OLD\P,)X\V%L^;SE\Y;/OVP>8)4VJ[1MSMHL MI3;W.'XR(/T\26!Z%HI&K:&%\H9#V?+OEPAU"^/-A_'+YM^&%+-<7OVH.KWK)(YN M&/!S3/S=^X?SF9*LOX@DZR=@PL:6Y5AK#;X-JGFS\@*69I6\.>RX^_NVWHTE M+$M8"R6LI^1,6)*R)&5)RIY5EK`L8:V2L+H'>V[GJ&T)RQ*6)2PK!%J2LB1E MQM[9LVK=9N)JZX'.8UL/+*\S19WI^*G>@HUM2K'>PNC/!KXY/'?UA='7MWGF M:=Z6M,S!#DM:&Z(B6*(R!R\L4=GSRI*6)2W3-L\\_=N2ECG884G+BH*6J"Q1 MF;-Y]KQZ9D.WRC-+Z>ZFYKO4WEX&=3YZ1`\RKC[<-_U[0Z0K"RJ&77)/LJ9` M9.%]M"XBYY.7^$/GT'6Z[4[;A:_1T,LR+W(H#X$%#H^RV('OQX.$,>S[!U\" MYTL(E^*^\XDE`Y8XK[(A<[;DE^+.K==.;T*W>R,`7SFXZQPG/,WBB'Y4G^7C M)W$R;KF.Y[QGH7?K))@I10_<#N,PG&S'MQ',+\U[*0^X[&Q6SK\R MI:N\M_6Z58+*^9(G:>[!8F!Q>".L=932X'X)X^-OTLEPGGMDW[3YX MES/"CS!1G@UI4-I$M4Y]9ENO77&7^K''L&$;WI'FR0V_P6_Z^BMSTE=TC#W> M$I;F85:]R=7&]KT1@]L>LH$M4UC-)A/@4@Z8A<\2FPDN\EC=JRQ;'0/$)WP_ MR0$G\7,>C3U.I`-\*,T0HQ.&'(`X0GF.>/23$X]U^A#=2P7=^?$(V`],''N0 MRKO%`"D^,4ZXS_"Y_UGD&CMNIUM=IS.&":78154GK>)3P1&1S03(ET;>=^;\ ME7L);$`XP7:-U'85N0\NH3@_&=P3X@.+G+^SUYZ"DMS9B&6P97&0^YGC>^G0 MZ8=O=I-_`J0]VY@DK$3]T(^$"_*(\2%RIYY MP/*8F*SW&M9Z]_)2<>=#9\O[,-&)JQIL(F@B>*OLJ/N65M%[/8V'?>9E><)< M)^"IGZP:!0!?`X\CG8T`%.B;A3X1X MT8.EPIP8O&92GEIT*!4M0)$J1OAVGL&@MT,.-]UZ:>60@PVWQ\`2&:R?C_(0 M\!6P-^1>CX<`"^!??IAC\\T[.:-`W93)OJX(.6\,B/F#`U`9L(Z%<6>'O(_`RY#G89]GCBW'AA7AS! M_5A<4(*LVMV6.'T>>1&>'S!;0&L!3QS? M2]-\-!8B>S8D5I9\1S8.)R='CH@WYD`>,!##-P.5B:G!M7)4'H&6F8MA7UTQ M1I-V=FDY_3Q!\<,)6.;Q,'U]#SXTM._[G+[MT^W=K_PA"_*07?3Q@6L9,69TNXV*[@%@EL5W!;2M5R M^T:LS7:*7'^S4`-J7]MNL;9;[(OG`1;&FP]CR^V=>_7Q+6,8@AR6LS2CQ;4G* M&+2P)&7/*DM8EK",VCOS*N=;PC(&.2QA62'0DI0E*4/VSIY5ZS83VZ[@3>[_ M8UMKV=9:&Z!Y6](R!SLL:6V(BF")RAR\L$1ESRM+6I:T3-L\\_1O2UKF8(<^BU)6M":NZ=[UA(Y< M!Z9VY$KY?]D;YQ![13F=3JO-HX4.?V?WJ9X"V'UMJ#Y?7)\Z!XY$WCT@CO.S MD]//5Z?.\$8V% M\>O'L^O+V77P-]K[$?I43E_I- MXFH"=L/">$S+$XWI:QHHSTZ/NA)[<["?/O7B8(*=XAGM^3B)!XDW2K$[)O7S MY"P,<.@A&WE9',8#[L/&CZC'&[;*Q$:>VOXEV!(S$ITX209+L7>GG/S,Q)EL MNRGG`8/A>TD0/L"L41!5.'72]R M\O%V/\%!91?>A?=:;\_I!PRS@`^BC_HT-:5>R-+MGH=MMN%VAHV]6=DG.!\C M%F,7[0'PF`'0Y^([Q._OSIDUSH]F#M,!_I!Q8H0IB)@@LP9\P('JXHD79A-L M8(P=RVDUHK^N^@6!(T;!3SRB)E_Q MU_!TY$R`50!3Z6<2\'V>I)E&U_1^?,"+)MAZ.@26@?)U*,33H.B2CK2>`].1 M+W:Q,?PKSE^KCO$\*3B;F$B:;6?Q-OV"T,D0?$-D4#![O..]%WG.!R_![L0G MP)W@G[,HS7B69]1<'7D3M<_&EL/`8_S0XR,!VLF]T]M@5F3VW#]Q?^BQT/G* M>`J',G9_/OW!_)RZHY\,/9Z0HG&&(@*`\^3T@FCF"QQJ/$`4P=:V81H3BI1/ M_@'P+AZO'-KX=/5>_3;MM"L;0Q_>UP3:RNY/E6^O/VYW.NW.9@BW3:;(LPAP M_:;H_=ZM$\7)VH/3$&;K:BLGP=>%N<"%0/6]IXNX)AI">QVPM#M%Y/JE MN_?O)";T*?KH%WA3"LZWP9\I"/QSS"=_[! M619Y(R%??)IXTY[X/(2#V+D%4DB8SP#1D>H= MU1)7L@24/Q_43@E>5((?J"T>`4U[/XB;#.,020\0G2/I9XA8:BQ#;PE'G3>)\,+Q# M>M5D3"&\"J8`8F]G[Q%B]7P!.H]"%&`J,\2IP=`AQW&5\!\(ND_8&%5_U'%H MUB`KCX3U`<`1!V+M$NY,Z`]##S@<2-8H2\.F#6*QM2FH"RGO`8/)4(W/"R9; MQU=;(,L1.)(`WC4#B3YJ#4G\@^823A:-3)UZ9$)+"_-@I1)@$:+`".X:POY% M.-&B!;BSTQ:V*=I$[/KL$(/ULGGW%%2RTZ&KNZ[8R(#UX6ADP8H6WVGMUR\> MY[C@-QW,82.(*\Q'L3H$C/72-`;L1IPC(0!$AM3Y'V!"Q=04HWNU5*3HSN,P M$OT+"0!TQC3E?2ZXG^R_`3CL%;C_""Q8@=;P$D18A\R1OV[]F0,#ZT^*`_V^ MI7Q%L]1$'6>:F2<(./)N8+H+1;.].6"/7W(''#W*X/ M=:4JUZMRTY[$:98>1\'ICS&)]9?"D/\%[?A3;M>#;YV]&;?KMZNA!R?!%4MN MX.5I\>I/Q#)P5L6EZ\F8'?_@Z92G]G`+SETN7O+[U?LM.%U\8)=ABIORVR[Z MYDNO\EW3K7B5+\:(0!\8^^*AR:RRD,-O.YK_6/J2OU6,OT]8Q]&=Z^CNT3IF MYS8-D"])[#,6I!^2>'25`<3$W>GI#R0-E,(>[0S?;=\Y-6U[[WWYHF:[J\UV M=VJVG3MGV]G=Z[:?,^4/'D_^\,*D//A=)606X!\1/U+Z&I%CY;-52:`4NGPUUX@[0!0+1(T.,+ MTH\7?1?JWU\YR`MP6`G-4+V<'-H\&N=92AX:F%\^$IP!I(U4R,'"4*?42RDY M:Z\30_Z5DV";U5F;>#<7]ZK./L!&0$9O'#EBX+WB/C ME5&1>EBDGBM>A#VJ@,]B)Q`>U=1ONB37*@$V%29:>4BL!TX!\B.BYI'%XV)* MNX=;4]+F:,NKOWG505)!.T?M MSCVH_KR=??Q6KG__IK;J'!T&3D<_ZO_*8[+=):@_(#_TR,P"ZE[R'=DL6KC( M(THQ//6\]Q';?D>D[7*$(DD)EF]:OFGYIN6;S^&;79UO"N'6@?F0S\*+',5< MJQP5?LH<+\&H*Q"]LW""XC"/RF\]F-R-1\DHP%8M)[6J-AJP36C&-W921*3:9A1U*8039W`R[S[O`CKY)"]B)\8/#QBR0#P^!5& MM`#*X>^1\SV*;R.,"_KD1<"P,A`"OPR]9.3YE`SDA77I0,6]>A*/3"HZ3CCZ M9Q\PBKRSDI?$51(44!I0H1J,IVG.%AVIL3&',,^F62.H#B*>(D/+FRL%!QP,1!;V+QU?7VP?=?4(0_'P$Y%.WFU^9"/"* M8E`+08BC%^EQ<27:89:"F*WW&A9[]_I2<>=#I\LI"\7&5MX-.\<`98W(STN/N*P.S=,N#8@KP6[4K(THE6*[Z,\1*O%[DMI:TZM46/8^]09DO(2%FI:CGJF$=?"EY0Z1U+1Y49#[Z<"%*UFBJZ MP!,Z8&(X!_MXE:Z!T%L7%""B#$MWOE#5I4J.^>?$"$B!LHK,%Q M`&(AG"DR6Q_9LC"$HV0=)RA#9(1D*KR#2`+PY$[Q1$I)I%_E4 MQW?Q:$@708J0LQ.>Y@R01*S+'WK10/BAY9HD9P%@B&#E%!-7PD#A**ITY61A MX/+-"D!I35@1A1[).]%+(\;LT62`R0J%!%D@O)>,_&1[K`V2NIOX-YF)+%1A MJRS_NAJ,A5H(J2HW2-=39ZL,BI-:9E\O'E#"JQ(4]RABW.#(KP7,W:E.7G/_ M3'FX=!>?MK@I5YWTL)U$S-9IU#=#HZA^C.[!:%T)1;UK'X8/%!PX>NQ0>+ M#QH^[%A\>-GX\-0>H)N!!%8R;,SB-F!M3^[3<0\--VT?+(PMC)N\-@MC"V,+ MXS4*70MI->7[C#VK[=:CY+`B!N3Q4%_O:M?9LVZ.NF4X^!??DV[./BRO)=T2 M-Z>FYYQ*]^L\A2=:ZK#48:G#4H>ECA=)'6MN76])PY*&$9MC26/=JF>U)$>G MO>HNT(]21\GMLS9EU,0NS[:!NFV@OH@&ZNL7URUUF8,@EKHL=5GJLM1EX.:9 MIS%8TC('.RQI6=):H3(^57/19M':+-H5QS/8X,E[UF:S:&T6K:5U\Q?W8E(B MGLX-YF71JOH>6GY,IYI$N_MBD<-R@,8L[L5P`)M$:_'!)M%:?+!)M!8?;!*M ME0RM9&@3L^8NW29F-69M%L86QA;&%L86QC:)5M\;FT3[A,`+F^UQYSYL2K;' M^B,C+758ZC!B[+F=H[8E#4L:EC0L:=@D6IM$NR2N:;,E MGK=/+R1;8OWBNJ4NE+DM=EKH,W#SS-`9+6N9@AR4M2UJ&)-$NJA4O M#:S27=5\7W)Z[L+GCNV-*<#8V7&\49Q35^]>?(,=O,<)2ZE==K7+<=R?:G%. MW;I#:DOM^7Z2P[_8HQV>SNYI26WBCC09FHND/:>R_)HVV$Z:CT9>PO\+@U*3 M^K)ANL(H'J59DHM^V$&>T*-P9\0CYHQ@Y&'JL"@`?)EM@6V;7=\[=\'OS^FP M>6;:?OE7[(-\>'_A.?R.%_)!].L6'I'/3>A?J,W[^49;3`2=/E<_E&S3RV8[ MNJ_;T&^&F&XP3)\A5#]-8MY[HG]JH_U1IHB\:V132AM8#ILZD^):(;_%$4A\ M/BLEOG4'0SYX_N&=%WR,&1%A9`9W6UAHD3%BVJO#[J[;W>F^?LD8;@BW6ZZ@5M4G M9ZTF+_FX,\/O\R+]/$L7_3:P.*HIO'+*C[,4UXTUWZ[`C>,7DG"]PZ9&(G9X MBGZ>.,G(9^/`0N`P><4C/QZQUP[[,6916@SI^7!Y[$43M./[<13@CP%^(C(D M!U":P3_"X`^OC<W$2L(3LQZH"#)+`&U%DEN[9#KU) MG&=O^OP'"]X^J):LD!2*3T$Q,_UC4GY4=/++SWFZ/?"\\1L\CO_`/7[/4S^, MTSQAZ37[D;T+8__[;W__V]__YCB_S-S\B7EX)^[25YX-?X_B'E#2#0Y_%HWS M++UDL*<^P$CL'7S-$W2>O/-2GIY+\$UH+-S]#-YXR?J_;GTY3B^B3O?;3N<; M6I>W'!X`NGA^QH-ON[L[6TX><7'G[U?OMYR`^1RX5XK[\5OW8*]SU*Y9VB)G M.[TE[UDO.RM\1-!*?S MB62A/,6AKX:`U#@@ON)Z,F;'/WCZ[9,7#;TL\Z+C*#A.>)K%T9>A!RS<9WG& M?=B+3RP9L$2,E`VR'_CH1?\Z\:(4]S&.<)RIC=W=^NW+WG_*K9M=U?2ZE;U- M3OP$-@SNA$E]AIT47V8!VS[ZMM/&#=A[\@9,37QO/D9L[P%*M'?HI"U7]H!Y M+V2I)0XO:JG[=R^U<[3W]*4BGKPYB4C$LV. M!PDC$JN9^H$V]3%0HC[WG:W?VBT`TR\_SYW$-$"^)#%H:T'Z`823LS3-O<@' M#,_=GEJUJJ4?W+/6@+9?ZX)E7EGKE#UF0AW#35R\!5@5S@!?? MP*RN$7>+$^DARZW.?`].ABF9IY!3QIE39,P(4<29DGM<<<$%114$16=KK2)4 M(V2X.T(L;@5H'4^"%NY-#(JF:)3H_=S(B6E%^HCU]GV&Y*`T4GF'R"RK^;VN M9<+AWB.C+:;TXKFSD%KZS`TKC=9X<"6<:0@^T916J=%]N*[R1C.+64RRX,%: M;>+K7OUCJC>I$[&!0%ZOXV/=JW],2=2O#$V5+-C&:[WD9_K=`[T!Y%_]$OL! M8C%/6;EUXX3[2VVT87%CS;AQ/`#=:@"RNHX(H-TE/$JYKU_\8]E-5Q9TLC7, M7S:SZF5%!]0<\A=YEF9>A/+,B@,P5[7J-84S+6AYRL>Q0&?8VJ*=%@SQ1;J\ M=MW.[J';[2[1Z;5@A-A0?%^C\_<%H'F[=60^1V]P!,3#=L!FOC:-;O8[[L%1 MU^T2S/&:VW,C^5124 M:2I,-YPB+:>1AF\<[:@Q5[GOLHQUI7["QWBQNK1.6U:TV+V.\?..*"$#]W\OGBYK MKGP)/5_47!FPR)_<48)EK[OUV_60IPZ.Y!0W.@G[*^<)H&2>.EGLC+V)$^<) M7$['#.'%G'3H)44!+IF0ZGA1E'NA0Z#!YBFBZI8?IZ)H%M[:V7,FS$N`\&$G M6N5&/F&+IG?Y79[RB*6`43#YE%/-IB]YX@]AP"^8#7L<`FK1>/^!*5STM1OG M[ORBE-455]G:V?@MI?.Q50WB%9H)F$GFR)<&`.^,L`!?YL2)`EKJ>/U, MOJ[/DQ3I;S3"$!D`>NJ%]'[/&2=QD/L9%E=+*HSQ*G! MT"''<5DRXA%66ROQ8D%`K525^7W<3P#&'QB[9#Y#`&%!FJN\=RYWO1X#ND![ MJGQ3=[D8L/L0+J2JZMRWG*GB06SL\>"3%^5]>)MH77,'&YV:V#V%M8XZ^L3J MWE4WF4N6`NC\X7$4O,=2?O$8MU/6IWK$Y.XKA;57,[D[WSW-82Y%,Z@O7@+G M55DY[514$Z2R1MKE%*O*Z8\\B+,\GZFWD->,B,UX$)QS''TEBP%,'?TO/Q`X68.ZIR84'$G67"?\YP M:5E(\AE5N_:-K=J5\O^R-\XA5LMR.IU6FT<+'?[.(E0])6[?5XWJ\\7UJ7/H MJ*#]]EOG\O3\^/KT/2B8E]?_<:XOCS]?'9]KA1BSN+M* M;:UYZORA:SC_\,YYQ^.,^<,H#N.!ZNU060Q?_K+65H+X(7T`S>^;>1$Y_P*A MQTLFRE74!4D5`*0GAGW@MYEO^``Z3GO,+?!3`/N]TV(:R2FHLCN?B] M\_9URSDCC2IB=`R(95'1YKHGW7):SJV'59PQ@;-^SY_:_7'/A>,/_U9QB11: MVAF?ZE'"N^"(2*^<")5ZPGO^9Y%3:K?: M[4YU-J"CBQD15-$PA#!U43O]#(HH^4:/-'R/8JG/.>^3EO,?+XJ<4W\(V)8$ MN)-H4G@7XQ>8^WN>`(K$J&2F)18H5.H7B+)R`-:@K]"JQ0**XRL M7@R[U*,7C,3D0,SCH=!*L99]Y54.T$GJ2`T5B'.AX.U4X?H/I7?'FHM9A[!M M+[O2N3^>1RG$`]RN8%Y!E$"B:./*%DN4!WLU3(*7M(B&F(>SC(*>D1#(7B&J MY7LE.2,M.RE6/A=U]>'($M7XBY.JY:`"E2`*AQ,7'__`>@D=?BC`B^U2+UXP M+^]T=MW#O;UY/!,93,TF+(5=[K?V=N9P2RIH&[$,+6-4_WCA+Z]#"^+1GSP= M"JI*(.$L3^RI-G6J-8]Q-9GI_AX%TIB,AM_"0S"'Z8(X`:)N"&JV=F0C8?DL M049JT4E*.T5RC]J(Q[8MIWFCU\G5W$#(\(6'8>B!%M-C M#-\*2DV@MUU)I(V5AM#!5,QN3A^6!W1?<8[IRISYSI1%)#P:>DN%?+NUNR+( MMUN=VC=-@P@D:W0&B[-=6CO1J4?V]408[)3R5TM^2HO[,X^F1*2'49T3\-3/ M4SQYO!Z(%FY!M848D0+V9+>(0'FASDHJE]Y(G+&XDP2>&^P>@+`O7@)8`6@^ MPBZ_B3.(XP"%FA#V`$A]2DKQ'H\UQ28NE6FL"G4Z<]C3-.K`5H^%IV0^&1>\ M10%%`J"NT'5X0KY5N"VLU;)[5D,1UI*^"Y53MA4)(#4I^-V4LO!@#Y_P2 MP\V$!1%+4A@P\@9*;3T_<5YIMCN\7S?5(:V+PQP9^U@@DG@)G0Y"E\'?BH@. MCV(]X&=@^=0,BWB#XNWB]"\DKQ*:S@4H9J<_0*ND6)*3H<<3V&)ZF-H3\1%< MY*ROW731[\,HB8L!`YY8%YXPPB.&<\'EM)SWCY-J:)L+<;"01W!IRQ00NG-X M+^@\D<_'7AB*+B@)`:YR0O.THGK/.<=6(^?42Q^/$#=@,7.1VAX>*YW[L2ZD M<33H9LPY4.(:,1BL-I\4@N()MF_IQ3*.B&XX&3+_^Q@YD$NVEZ>1.%%XF(JW ME+_^@>:`8AS`^@]QDB5HKL4QJ_?JMY63FK):?TI0&>0PP#`.059DU.X*F2WU M1R,Q\_JC6WV/-EJ3H3TSXTU&[8O(N?"SF/BC._=TI1#(J['G:WK/C+^K&B=9 M.3V)`A2NN.3?\/U\/)EBP0NUK^W.<2O@`/^)D^_."6)T3'3EI+0V8,XP*\`8 MCC2"2KGPC4Z<@`&GYUG1O7*&`T@[>2K,Y*4Y,74N0=Q,N(]`//'2X6.ISFI* MJ^;X_\K#2;F$@IM,29170K6]4JKM?+%R[IWS)7JFO5IF0;\&F\WF<>GK1SS[3;B;%9.M#@*)Q(VVCA3 M8+,,8-7Z9`FYCB9-D(2W4'SJ[LWB$Q!1:86@0PB$-Y&ZUF>L.'_*X-(B.(GX MD^).?L5^HWO2\=2!?;V]O6S]Z2=B*D\'/W79[YV?\^6>\<4O>GTW&<#^\G-!VZS<:_.>9T>'Z M+S_C4/P-_I]F\?\#4$L#!!0````(`$F`:4?)$LPAZ0D``%&1```5`!P`=&=T M>"TR,#$U,#DS,%]C86PN>&UL550)``/9"4%6V0E!5G5X"P`!!"4.```$.0$` M`.U=;7,BN1'^GJK\APGW&0/V[>7L6N>*]T@$4F# M(5?WWR,-8!A&TF@PF`;GDUE6K>FGGU:K);6&S[],AG$PQEP01B\KC9-Z)<`T M9!&ASY>5;]W;ZL^5X)>__?E/G_]2K09?,<4<21P%O6EPC23J?6!C:NG]<:GX%^-TXM//UW\6/]W\'OG_H_@YJD;5(.7EY>32/4@ MTQY.0C8,JE7]G)C0[STD<*`4H^*R,I!R=%&KZ?:3'H]/&'^NG=;K9[5%P\JL MY<5$D$SKE[-%VT;MG_=W3^$`#U&54"$1#9=2NAN37./\_+R6_J]J*LB%2.7O M6(AD:JI"O0)K"_VOZJ)957]5;9Q6SQHG$Q%5E`V"X#-G,7[$_2!5X$).1_BR M(LAP%&O%T^\&'/*DYO_)$1.*X'N[=MC M*Z.TDAPH,DCQ4#M6N]\>Z3E$ MQ=`M#3!;W^^!18^:VYB][`#*2M<[BQE;"A8K&H8H#I,XI>!.Z9/1%$\D5J"C MA:ZZQRV&UG3B5"K$+,P\-M93-N-9"\V?FL[+?21ZZ>2X/DIWU& MT17ZFSRK,^+AHD/U,<=]-D.:MZB)9#A,>ZL2-3`6\GW.AF6M.5>%.7`D0JG$ M1OIQ**X$C"MYE1*KC/@%D^>!5)\!L'*5<*X&G1\YKXUA<>1!QZOF@%EIAB%+ M5/R;SZ+*\]0W/,%1*;I*]0*+QS5PZW260@:8YVO8)MB?Q'6!@Z1M'829J#,(1*TN4XI9,K8^*(J, M",S\_`B!GS67>F`T+#N65F5@<>4YCE8!`(YY^;2X1<,XT5N]'<93.TO)22^1 MVOFZ3,-B5"KC*56>6U1BCH6+UVT]`)83E%I0;,L$@-VHP^?>GV+]!XH3[/`) M8VL`!&]W,*R[@1$UX`Q7Y7%#1KT(S3<]>C;SD'!I@+AQ@Z90XFC)*D0..,EM1A&9Z=5!)&K1*S0B4BMIWS2P21PMOX7( M`2?)78Z12/C4*\":&A\]JR;09D(_K1!:W1NCC_K$C.+H!G&JX(EF&"9#30N. MU.*`A,25)_L('SWC/D8P>\!/^2&MK%1;.WK:^8F4\]Q\#X=19H6:\@IQ/E46 M+DSL_.3W,][N&<73>\2_8WF;T*@$K$))`".M%'7K`ZD0(.1UAT)280^QS%&NLH=`UHS3SM7B66?N7Y#(GC/<3/1'UY#W[6!?J8-0LV8HYYL# MQ7!L`@#&13FJ\BF`&1C@@)4JVDY5Z\3(PQ=M`@=/G@T8Y#AGJGG;0X#+UK)Z M'6;]__CM+9YN,O@;#MY`1*([1I^[F`\]GE2](7%,?,"FOL.:IF-=06;8]+&(,`(JG@WUN%PNLK*'W$*Z5*\5L MI*9UCLN:#L9&!93E0?&-5[,@7+;WM3`&;W-@S["A\9Q&6R`:Q=F=\)C7=P?#0DE M0NKY8(R+22V4!,"H]_16".8]2X8,D:-`OS+!MK@K`,1YNF51P"W&"GE%H"/+ MYN/33_SPN"Z'#_"4JOR599=,Q:0Z9``P6;Q5XM`?,%.+8IB9QJGC.3@RM@;` M3J&_K9-E!`(]8,Z4+8J+BU:'2$L&P`&,FN*HEFMYB+3D0!1G_9OL:-G*S`>( M/N,6O46$I^4L[;[.AV8G8?K@Q7[&5%+^D+@I"3"^QK._I8L8;=WL*6W#4NNG^BB8-*/_&C)=D//N2#/W-IG:M>T")PM!S; M`.]DR]N2^\ZN".H+@QJ0TI[B4#_X5R('+3HK`M``GSE.DR5;#ER^GZ.C=4,[ M`+Z\=XU''(>D:.!FFQT=KV:8Q5?T]KAY,%9K:>U=LP5>G_-$2[8G?^XK>KK8HG-6O?F)'QZ$?;#-U?P61-ZVO]5IT>5FDX-)8 ML>C1\>T/WJY_ML32'2%VB7X-TD_H&X-\$W\W\.E/_YZR(7&^./ M.,1DK(.7,F$I3W!W](%\PFT(VT8*4/=('7SY\K5-(T2^AP_D$!8+6#RA`=D3 M?%XW6]X[_'K]:![C9Q6+%P$Y7%X'M@B* MZEF*_)SL!V(^A]U".XC=/(M1;@E%--S!X:MWQP`<9H>'K]YF`%R.I#"%&$?B M5AGN5\0YT@7ZF(?$?=?.+0:`]NT,"<,!K0,VX"/;5<577G(A%MI'GEQ;9#\$ MX1;L@`?W(QZAZ;P0RO.5"G:1H^78#OE=:Q45N(RWI<>-#_@E/7$4[;&NZ(]9 M>GAAO]A2JH^C8W0#&P`^H^V\>N6K.:Z8<&X&V46.CNMBR)!?M6JQQ>Q\<@<9 MNW?'`/QDAQF[MQD`WTU=.'R7-4-E'HX52*6YG.HWEDEE.&VTD:6B9Y-.`+C$ M=H:++73X&*$XM]]B*I!3[.\XCKKL'LF$$SE]PJ'^J]`^#1B7^B52MH1@DYZ. MCN^-+;&;(DP;Z2M)RUPK\]Z^L_61DF=!ZQVFH5Q-V?NONQ:>)QJ."]]=/8_? ME\RV`^#U6\19$][TAT.!XA$IE?5&1/O9Q"T"GPP0!X5VQ6J>&9 M)I@:0^?'I3O@JPG9HMS\E.GU(ZIE.@'#H_U\!VC:JW/5=;C'P++G5!SQG?64L>B&QZ[LT\EO;@ MR;#H_<8?F?M"TR,#$U,#DS,%]D968N>&UL550)``/9"4%6V0E!5G5X"P`!!"4. M```$.0$``.5]:V_CN-+F]P7V/_3V^[FGG,PE)U5,/K\5BU=_^\\<\>??, M\B+.TE_>'_YT\/X=2Z-L'*?37][_]G#U8?#^W7_^]__Z7_[VWSY\>/ MEFS\[G'Q[G-8A@]Y&/U1K.J_._SI\*>+=_##P<6';]GSAZ.#P]-W__OPZ.?3 MLY]/#O[/N_][^_7_O?MR__#NP[OOW[__-(86RKJ%GZ)L_N[#!_Z=)$[_>`P+ M]@X$2XM?WL_*\NGGCQ]Y^1^/>?)3ED\_'AT<'']<%7S?E/SY1Q&OE?Y^O"I[ M^/%_?KVYCV9L'GZ(TZ(,T^BU%F]&5._PXN+B8_U7*%K$/Q=U_9LL"LM:54JY MWJ$E^']]6!7[P'_UX?#HP_'A3S^*\8M<4&9@MR1#$K/K,RC)/B@?THJS`QAF;E MFS98"XL9?)__\^7/*GX.$^@CJP^9$R9OS8*\U^DS*TK>D>]95.5Q^:H68VFE M;5F0]2J,\W^$2<6^LK"H;N.2JTV+C:+20M[61.OPUST-&,@6`=]&W;X31G M5E8+97L69+YC"9\381HL%W":2XLPXEO&OJ+K-NMJ#;F'DV6CL]%D],0/K?SK M=M8/K&WG6$:39@*P#..UV9TA<+"JJ[ZQBY[&SR572?;=04=K-?V"),RC%9CE MC^TOOI@,XK3\.([G'Y=E/H9)\EZ)'C%>K&P/W&IQ6BNE;JVO2/`SH(=A]&', M)F&5E!8%%+1M4=QL'L:I&VF73?<6MF[GPYS-'UEN4]+U=ON*.0.)\JAZ9!]> M5&!16&'K?45.LW)H=2RM&GP1#'ILG,9\?;F!YM8^!"LH@SECO/H4E\B*K:ZV M*L*WDRQ:^V#"39]9+H16PRI8]-,T>_XX9C'`.SSA/_`)].3#P>'2NOD?\*M@ M]?761P$=NX:YKEBUGH2/+*F_&:BJ!">O"MNQV`]\(ZDOL&@8%/^P^O?DPR6.EAB\XKMAKP;-@V3IJ\/?\18-]LH%5P<'#DD M2S+C*P>QY_AC*KH M[VME`$A4-!A<'^T8'C@,Y MP!WLDHI+P)*'R74Z9C_^!UM(N=@H"R`.]Y,,(1"$C``#1^HY.T\O9,IO/L[3V@+B?A3DK1E7)W7>Y MK/+U0E(1X.W=R5L7%4+:$B]@_;A^H^#XGD'#O[;S;<,D+!YK`JKBPS0,GWAW M.OW(DK)8_::^O&WUJ^6O@Y=K5=FM`UXX..NY`EB0'+MX$!<,3EV>)(1W#@KU MK?=PB=1T;AHLL'8?L32$,Q%R`R$M'YRY/'YH745(:%+PN07$R75$#X:6\OV6 M%D\LBBZ'6/L*6%)"3:PTZC-&X!7%!G>/KD>X4#HL" M-@##1VZ;B$H);^L%@S./)YM.RYI`?B?W)GVI6)Z&M1G9*!^<>3SV2'0M(T4$ MPAN5EF.<+V/C7STDD7&G5#\X\'HG4E(@IU$?FY)*FQ^(UR_+R M@>7SUP=BTOV@H'APYO$FLRMA*!`G-S;=^;F&,P6W[&"`4X^QC^S9Y9D3W,Q!^I*P9G' M*TY3$C3AN+G#Z3YJ1MP,M(91,ERV"P=G'J\[NXX3!(:;"QU+^SO=?5UP[O'" MLRLAVPC;;6.Z,`!N+H^ZTW*;9T\L+Q>W2=B\>H`>5:^DWYALF,FJ M!><>K[N-B5(BD=\<[9ZQ7[-L_#U.1#>NFT6"O9KAUJ1&M.[-V-#:SVBM0\+R MP?D^&8)P"`@YWLP&C9#*[5MP3L:6HVV'JV5&].W-#'`3AX]Q4D?MX1&4MN(P M:!A*=9L(S@F8GY:85;?Z(U7@JVH?_:,"%%R*D*(7-IZ,S@L MXY>M`GH`:OA-7K'Q-@[9I*G?2G!.P$2A(`F990U!(E1[,V!\9A,&THTOL_D3 M2XNERU0C^D+-L4[U8$#`W-&)7&UT"*O>3"$KP>_8,TLK#2.[N$(P('!D[L6< M``_"E3?#1CMTDIHH0>G@G(`)OA-+&!B$(F]&#J-E3S#Q#P@"B!#IS>C2RBVWRD5-4#KP^?A94^G838L8#.)`[12(W`YZ/H7D-%!@BARYMQXB&OP^DOM&:S[<*!S\?2 MO4A"L"#\>+-,W/&HSRD;?PGS%&:!8AA%U;RJ(T3#^2^.8KFODZIRX//!=2_^ M-+$A?'JS9&QCO4ZCI!K7J63R6O%EF<>/5,G^IA`0!U@BC3E7.QT8:^ MRP<"GP^]>_4+B_B1OD/!A"(\#/6X30\NWIRQ!<>)\'KNZ:F_C7Q31K$`D+VV M]'LWD@?_!K4#^*BUPX'TD]@[?\V:P>&AR^VG\.6_L1X%IP5=9&\A.L"G"@82 M*V#IA[%=--S(XP,@-4`E+K>Q6B$"C-@33WY2=,3B!HADY3_FC"E?HROK`F*G MVUKM0`)21O1)%(`C%E3`.9VTH@RXXI5LQ($7!\=F&\7]9;*TOAG1#,@BJ@>( M7=X4[6K:U: M0/T%+EA!O4S"HH##'3^:ZDZ>FW6"PR.75QD[GSC%^(B%-F@+J1R`VX4!D]/[ M#//I4JQUY/8/P>,D+K57CHC.D/W)4DV-_L(?/,1EPD:3ZW0.OJZG0QDH>^$C=+2.#@>L:'!X[-2+5SF%R72GTG(;@KVP$<[T3&/2L:-P MY;1B+P[DUS#_@Y5+Q].E;\E#F$]9*9MCY+4`@DNGL)U,.#H([05K,"9'/D14 M]4!\IUY<>O.2CHJ-F&F#LQ==P0,WA.8RAR2I9KDN01,0LJ[G<]B]Y7&8?,GS M+)=-;8*B(.S>;Z!06/:"(.CI7CXZA(6#PQ,"VRA4@VIMMV'8BVC@5-^$IB`K MBE=.-OX<_:O'@OU9\F4]5\^5(&H+@\]^SL8F`=#[7` M!+5X7]>>\&"D-*4`AM-`(/J6_G7%2K3?%IQ:U(%.^J0 MKZ#$>3574K)6#B`1"*NRU=G%5`@DIQ9NP/7[Z,-3CT$C>CX(,X5)+3;!$*". MXZ0JXV=VSZ(JK]]U?OG!G_.R\16HB7L`5V5MAAI-5O!N65['QQC.N;(D]%MI M'U3G,4Z%I1YB41/V`BA@*:Z:^Q>0.(J?>!^^KR:\$_/=;795I>,1;-="K@*> M`.4JR;YC5A+SE@"BQW@7-MZ'=L5,+8X"EVXS?6$Z-DP/J-\(*,%CH`Q+H]P4 M+K7X!UL9CO18EE4+S@\]!KJPMKZK`,HC'MB8E&4Y]Y8!@-%I6*-N<'&PO_LP M0Y0(6?:\,I:B?`W3:A)&):SVZ51!SEI9$--CA$^+9`A0(2Z"":-8/#,V\'C?MHQL85=\P6"XG%$C&J#P!=7G<*(XH8Z1XQ M(.MCHQ-3I ]/L&<9JS'O!"?^!DW_2(A]^%=RP:9@T#O>(L5E0"L!Z?WW9 M@9UU>E%<3N*$Z/*A>#>R600D]ONF$M7BMK*WY782PL.AIFG8DGNHG&QTC:]9 MRA:-;Q4_@A?#\C+,\P5L2E01.14U`36!^(X]5A\M?,2B:W"]*GB5(:1V/GYZ%7R\:KF=KC:>AU^_5WEHP? MLJ\A/TN6BU?A=$Y&!JT$A^?^G&N48NJ?DZ0M0,=SZ9@K/2D9GTM8W!_84PFQ@WI?8*O?J?W[K7X( M=$GD,8>UCN&FXXG41BTFY_YV05I;HOWKBZI-E;\DG@)O+.4V"J\$6`D8FEW, M)4A/46B"6+S2$3=TWF3IU)1Q>47`2L`^O3O6=;1!+>@IMB.4D(Y5`8`$WI18 MLIS*05*+@8I)^UN:LRB;IO%?;/SW+.'9QWX%)79A%VL*%$(AT:];UN7@J45& M-4!QDQ5%I\&.MA4<#BCD%MYY?VBCIQ8A%8/QLB!VZ``O=0$RA83&;@G?0"L/ MAKKSZ^@7Z;[6R63K^SF?]]$O\GP*DS"-V/V,L?+7/*N>8*!AN&K[`N1]*IK:YWJT#U=VH6D=]9VJ!&/2WWL;^$6NX7V MY<>_QS#X\VBVN.'O-106;+T&0&'>(RF:$ZSL($K$Q.ZOA;/W-@BE><^H'="$ MWR"-78A34*^/F]A5MK<>0,M^ZZ$KD+W5?A'Z.GVJRJ)&?ZBTQTEJ`5J/K^5Z MC%4%TQA28E?6(GF/.O%Y](*2@+7-*9]K2(G=&XOD/>[$Y_$+2@)V-*=\KB&E M=@F[NK'A3C`Z43)%Y>$$0\8IM.^&6@*0ZEWE2E+U1;BX!J"CX=LIT;TF66U` MQ"X;K=)%:P-KDS>Z>1)OXO`Q3M;-HI_C@AM.8,60\"BO"*`)/!)T:<32P4_M M9O%;5K)B&1?$C&U%38!+P"7$)=U:"I#?'9*Z23@TNTI`HKZ(OG`YXX$@B^NT MV29>IT695W-51(\^S05'!_:2=9C)@)GYNS8%_(W,XF&_A'"Y)"(F=^MDT;L5&*5/?H6\]:+1`V&^/KM`EM?)VN8AF;;`Q=R@':]1UB>!?[2_KNA+QL:$YJQU=$#'9+"A+,V)NX7#[_$?(8L;\T>35D9X659086$` M1_AN*M1.W<[73.#O;U;^# M,S.:-SJ=A649IL-T/,SCHLS2VUF8S\.H7E?#I/C*\BG+44^5#JT`0M]!\:5] M7\!5%X"N3YKUZ]'7M"=940=V^?$$715S1M&J!]*[-"FX7$?TH%D[874@1C[- MJ6L"`J?';+V%1D_/A@2U`5IS]O)$$:%%R3%7]"-2]'+0.W*:9\?17*@!Z)U[GA\U=*])5AL0-9C0)H#V^@.QQ/]D;,T*T-UO+1C]=9N-1 M)K*750N.CCR&!;,Z;`6X$`*]V5_6)>:')VW:>&$`1=$+L0-9KVB0BV=O)I=U M.5?.9'>PA?MH#E3*$2+T'GIR6;HOL^B/69:`%$63 MG*%3.#9DW6Y:O$[YJA,_L]LD3(OZBZ-:`<,(?@L%;E2^2Z;M!(,S>YL/S8]+ M/9Q,VH!IP*7M'W=ZZJ9EP3[#'.U;>!G5@+N&D?B#C1^R^B2T&E3-_RM,97H- M@,)?\M0/?3GQ:O!:Y#1=UJI7O83YND!6CJBS*,.5!M+]5RA0C MEK\%P\NWT"KX%6?;\II]3O4`W1 M\P[M"[2>SKG!ROD&?^M;H%+?KA^T.IU0/]3\62V>8WYG\716LO'PF>7AE*WV M%K6CQ6Y.FC()0/T>P[*3ZYY&6B/GPZL"7QB=B%QU7'M2``V^?;%VVGEM:XZ< M6W-?!:PP>N_#1H(`&?]6-D`'RB/GZMU7!X)#H:^^;"A*<'3R;V5E=*(^:C[O M%L;TUF'3W]QL)`H0\J:,H%[41^W)@,5CK*?SG:8$H'[?_I>4SG=&6K/W_L%B MIWU4@W\T/MS>,4YC'98A+?,PXB'MN.ORD:H#[U8:H,5CS@8WG=F'!JF]]^BK M"'Q48XJ0/07S(`W0\N:L<#XT2.T=C$5SY#7@C=,BCE1QP9U]$U3\;V5MZZ[LD+@@BNSPJ"A\HJ12(.7)M MR_T6GAK9"<)S=.H]QIR,*`6EVU"(/0ZRG*WGU*EW2,_8.[7^$<+DD(@]\K%. M&JVG/';9(_M8YQ;:8GG.QO4V"[8(H[Q&/JZW.K:VTTQ!Z5B,1M&3,,:6O5!+0>S^3VN-N"1.P!R&4VGV=IUS50HS:@ M]OA`HQN1VK"(O:IHR6VP]$EJ`4J/KQQZDR>&0^U)PI;`RB4/J0'P*,0X[L=6 M&PHU3_XM8?66.EDU`.KQ&MH29UMXY-[L=")8'3H+877'BC*/HW*Y&>@5QDK5 M5G!T[C:4%2*`<3@K63O0<5P>L"IB7W,4],94! MF*#H1=S%>N!)=\0N,-RA=Q\FT5`$T#_%A_HT^ZY(==2N<=RA_T<];+WVW741 M@J,!Q6?Y-/NN2'74+K;D`!HH/OF@V8,1[>U=R*K^6Z>-%X3U MLO09#A4O:8'\[HJ5X@%Q%*-6TNSVIFK=NPA8EK9C-`>%H8Q`(<78%C1'1B?= M[EU8+4L[/IK#PU!&H)!BM`R:PZ.3;OZXN.(^&1,T?"WT.N^+*7`R'61G!TT6%WVEUX8X=!47T0VJ7QRPXH6L\/I-&=3.*PJPRWK5P8@^WYT,P4K=ZN@[&MD] M@KW&@^,N[B_(Z*HUOR6.]$Y!4@4ZE\NW`_((M984*QA82L1OX4JA6ZR!XP.7 M!Q+]*P0E16)3EP`,M=N"-_#P^_C0Z=&F8UB!FFW$NNU,"]2N-=Y&[Z)UF>*] MFY&]?]GPH(%#!D\R(.DPX@J`D4),-B<;#AWDY.((O.34X'U1S:JX`F"C$+7- M*:LRY,2B"0R3NG'H?T*-J%G6:P"P>[P>V@WK)IJ0WB31.9@_0*N5:>(7V1ET M[2.R@[2J2G`VL&=\VOZ.^FB\71R8]1.&3ZDF[+"+87@+!UV[86^.CV@$VY/2 MABU&4E#$#L)](Z<<']&(;:?0NI@J#`^QXZ0%CF@=Y2R21?90]JF"-9\5Q3"" M::-HM"R?#9$:@-+E5L[I7"B%1.R\)9*5_Y@SM05&61<0._43TIXGI8SHDR@` M1^R@Y9Q.6E.J*UY5\ZN_="Y+^YQB4FT7`SR$KE7,9M)M',2BN6E;JS<-J\'DDE@*B%?=D2]?>XG-VQI+[>*&;QTT/V!7I=N5`N M](8M@3IHG%8E9&FRJP.46CP3K[S3V@'NH@,H]XK>;!BUW/QF-(>)+8>5)8QJ M&)\6[;\H9G#]1D`9>WL^-D6)4.W-G-&64CFLMPL'QR49_D\C8`12`V#N[1V.%!+"F+\W M_MO"JJU36)W@^(S&]8V4`FW6VJ`0WOSETK'-&XTITA6!RBG3X_OXY2.B9G;A M3W_AU)N6V*%3JQY`=GG8VH#G-%&C^!A$G0,R< M!!;"F#<_!6N,$9LVK5.GG#B].2V`L/,LU?,^WRH+T`@$EI`,&#%-"`Z$&GO6 MA>$T9W6_DAD6U@J!8"Y]+]W9%`0HD">Y]LP)+]^4GVXWB@5G3E6L:400Z$NF MU;;HB%[MF0ZZZY7&M-Y/P"7O^+E#B4=<;>"`!E.]^_NNJ1S=1![8P+'T*6UD0FZ7"Q;*,?0M4 MZCM)ZZ[78[DJD-YE.?%2DQ[Q>)[1RUNC=LA'5OAL?;/(L8&Q=7H*"5J^!HTCK`2$_GBKK! M\6!O#^9:T!`VO9DQ6P(:F,PDM8+C,]_I@/N?P<6@$.[LO0-J25`?_>]8`?L4 MQG>X5U59Y6S5L;")5KN!X&S?SKI=\"&$>;-NMIX=U]E*-:Q>6!4`N*?#3(X( MH!\7^=B1ZI`>IVL=-,2+AU*G$K>V<9&YPLJ='8AD>A"Q[#EE\VQ`7_%(<%AL>:S2< M2K=0FV6#"^_)N+ONEL10$(W;\\Q2GH:^,=1:H%,78'C,R]>9$7UH"$,[LO5\ M#?,_6'E;/29Q-)I,&/][)^..J"$`N&>36!^<")'+^>3=KI/G?[V%Z39\;8*!L<#E[9&/"^>1"F"WHC(_19R MX5V&Q6R8COD_?&P^PW9/_2X-KP2*H1$6"Z$,,48I\!!+A/>ZO1,++OZM0?H& M\V9!3WX#S6[K/)7SMKP2=D3%`9?O$[8Q/3@.8NGW-'G9P.'[U-QKN#3R2]/N43@,V\PA;^%, M?-(ECXJ#,_&%GUSQ$J7HG8DOO.>'QYZNPB?&RJ?M[4+!R0&-K.Z(F@6$".2W M=FY5Z57Q]GJ]&,CF-Q$[IBZ94MNB6SOK654!&HV$(&8;?!R*O83LCEA2;Q7% M-0">WVPA&LK79*L-B%H:=ZM\T5J(;!*G7'R\V3TV[TF7#3A=]YM3]<1K`_U^XV'[(X]A8OKM&0Y*\I1VI*< MP\5V'58:!T7X?D1L=IUA$36UU.Q-R@5A"!*4`+(VL7A(JUHE#03AQ^]=5?B,,>E;> M+!*<'/M-RX5J<5O9VW([\9YWJ&D:9H@>*M^E$WH"RLR:`]3+8%2YHN-U0'J/ MP53$W5>P$*@A6'.<0!3_,!VE#/[WOUB>C53YQ86%82?ET4:CK6J)[,3\'*Y3 MV!"R%W>`&_XE]2VYI!;HQ"5##A9;;5#$G!L0>96V;&D]0.KT58;V#822#2,2 MV^"(.3XXHY'&CL`UGZIM@S+A[R,"W"B(M6?%JT_Z+*I*/= M".B"1JH=XWG7%*,]3PC[1"M'[79A`.4WGUI7'M1LM@%2\ZRPP!JM"=8E?RF+*%6@10KW9>)9K8G'' MGEE:20-9K9>$;N_;H]#(7TL*`V'%7HR/WYY`]K2\8NR.18SW,^YI?E\]+L7! M+NI5]8+S4X]#J*/7G!XHA!-O=J#/R^30ZI&R41*ZF&\?^4XC10@#8<6>'\MP M/(Z;UH?SK$K+IHOPG?HH'4:S&(3A"$:3VYS=K\(E?(T3QI^;"G-YV&@6P/O. M]F(^SJQ@1@CW[%3S$/Y8IKGXQ%*@0O[D05@C.#GUG0ZOT["4PD'8HA0DI+BM M\F@6%JQ^9#-,DJ7;P3]9F(\FK8*?61'E<8U%PJZE+X#Z?#]ZZ=0;K,)'>H_' MQS%K*Y`Z%*ZX`H!["POP&AJ$J@Y6)OF.=97_JUY`%+O4M;+!X,2CXVZ_G:D` M".*R[L\Q)EN$2;G02':U5A#`[-5Y088"H>30TYLOS$>DS],OI]YR-Y('8[I5 M@X''R"#1C(TKGO!2SST'>XG6J[W@Y,SEOD'X6,V,'.36N#M8.B_;+/@0U):] M9%>X%8M3$5FP7!DPTKJH46A=3A>$A MEJS&`D>T+HPLDD4W&G+U6,3C.,P7K1S3J@D3JP-(7;KN>)XPY:BI!5!^E9'? M;XTF+>3JR%W*RH#9:68-_0E5S@I"I28^8N\.=\`IL0G8';EDPR\_Q"67_SH= MQ\_Q&$Z6BLE86!X0>L_?Z&PBEB`F]DQQ2]+?XW)68^6P9_'30Z:(6M"Q)=`& MC3R.$JXTR=4!2NP5HU?::;Y,PJD\$PRE+H\6+K5.6D$A6)S@Y M]QYEV/H\K8G:WN-&0[+DZ7CDM4!TO\&&-95KP$@;F+V7BCOFA,:LYY(Z)K3`6E"ZB]=\B/+O6,$`X>PS>V9)]E0_2FR\';#G M>#K5@I.!]Z@,;F8D+>#VWN*9LR8?/\J*`(!`VE0M+9NQTX9G[S6<%WX(379. MB7+]'LUQA.*!]Z")UJ=`%*>;]V7.8NNZ/9]TBV(\V'K;)Y;;WJ.Q':F:QG35 M0^?*>P7OT5.$O6S=*@&A.(Y&8!LX=;(6M$`KL_BE7%E]F\WF5QLT#A.)& M82I"*P07;G.,6M*P0GY[3ZDPA;]$MEB@V0S%!0&2]QR\;LX)"%1[#Z5TN)`& M3Y`5#P8'!$X!B`Y5VMZ$8>]YD7.=TU@J[2E?N7+:.Q+?3!XWGW@H+PC$%4!P MWT^(I/U9?$D@PV+O%1&B_/M9F+/Q/% M5;O`8G4`HM.YT,B;&:5`F[4V*(0WK^\-K/)&8T?GBD#5_N[8VP,#LR#B@X.W M=PQ%4")$>7LU8![G>N`VIW>'...U8B7:;PN.Z-^;0W\G_=.:U;H0H9RYO'GE M?PU_Q/-JKJ1DK1Q`(A#3<*NSBZD02(Z0X,U'OOU*I^)BPG_PXUW!739XM,;6 MA"S;&A@T`YW7HXNBEPIO4LC?2MI,]-RB^L>_UG^2/]74:"$X& M'HT;5J@VP(F0["V8;*N;UJ&J0/1:;KUQO%8%>C&%:=?.F!4@0ZCS9REYE?82 M=L(QB%.;>58!/4?F\[*Z'5"%QWM6RR3KPD68]V90&?$`2"NOH6$ZWG8D)IEOQ?`5+)MW@POZ2LAL9?1FY>2GU:U!N# MT>3W,.4`D+XL1B%@>41GR.FL%\=15'U%*:1 M:(.!%P9!]WE[*,&$*-]>=(6OH*=Y-?]'F/#C0G/(>,@^L=4^=8P1H:P8#`Z< M!N5S3(HF/H0@;_:5)F7H5U;.,C@E/K.BY+/NZ'O*8U[39`>7NZ M3>D(%6&;DL7ERX\(A(Z+G5A=!!\+!J?[/.P=Z@3I/$ZL+P(ANAID=)L"D!Y3 M]=FTT9@A1FBU]\9G5+=]Q=@M''(QPM8*!1=.'8-=4R'`@BC9F]<.@FUE%>*9 M!ML^?"]A`]7FLYXM@[KV_&;+B@*0_N+-P6CC3JK!Q;YOQO11 M(J&P#SPEY8$MP9AWSC&_;L^2>,SE?HG77\"I[FEY!5_XR,SS(LF-1BZ>[<+! M:9=0U.'2KF/F MJ"\@2D'I-A1B>6Q6`OZ6%JO$K.KG+U@=0$C#45^B?X0P.21BB6VLDT;+N]\N M>V0SW6PDB)=PMYE*_O20@'NBV2(GA$`L1#JLJ@`^`B8P M,XKD6(BEGA'?]&LP)J\(6`E8L.1,8&=F-2YKF64PTW667H;%;&E!PWQTL:(@ M(XDW$FH]BHS&&!YK&6#D.K_,YORC2R=OB4\P?A5@VA#@(V%GZL.7*5IBB5U< M^\B?'I&P)YDR;(K07IH6EXN;1@IN!502OBE=R=0`9R^#BQT>?V4IR\,$)!Z. MYZ!K#K*,G]E2:(W=BF8+`)^`]TN7;8L10.?98`2K@D)`D^54U12`).`:;<2( MWLJJ!]Q>&AF+BZM"=-7RJJ@.P`GX?/9@W!RLO4PV.YFCN\_-`)>`E<8"MUHX M[:7+L>S.+9FGT;(`B8#UILMRBD"QESW',CO7:93-V4U6:/'S6AI@$;#3F-G7 M4!CV\NW880=6\&Q=5OT-J[(N0"9@Y3%C3A.4O=0]=GB\3DN6LZ)L1*Z7:`ES M@M(`BX"%1U/[8NI05/8R]EC<;392JC:53:G@])B`<:87.5MH[*7IL3N"U)O! MC9(`AX"QQ=!4`D8#;I-=84V-PD`.I.WVV>3>)2L6M_+00@ M"%@YS+9\F]+;RP-DZ9%7F*?068K50X1/81%'W#0>)U4I?+*G61/@$C!;F)&E M!%B([#/[.XND,I%N^E%^+GSBJRJ(,TS&`TB>V6X.@'`*V#C.^^R"5YT8B MYC<^FC2O$_?29;S+$V7/+N/'+H^[QB[CIV@\79'(+[=`LCQAF^6" MTQ,Z>2T$RA;MR(40K+E[:RA8GH1JNR1(2"#GEUAO"@6W`5ASSG:D8AK.U39T M3=:5^F6(-LLEESY+^;LKW2$51$SJH+E\ MB:UM":HLBM)J(#N!BVYM#O0A4?.6'H['<2,,#Q9RG5Z&3W$9)LI1(ZT'4`E< M?1N/(`U,U)RD'W(6%E6^T)OJ!*6#TU,"%^'&5*%(['DYVWJ-4`(4-EY9V=6I MPX05`!R!*W%CFF1@J'DLUUUIEB4@1M$`O4ZCI.*V\-LLKS5=EGG\6)5\8G_( M>#8!F/%!?TE]\=A<^$O/RS8^`,HC>A\HL[C:0T[-!;J);M>Z.)'U@,VR`(GH M?:&$3#$(>S[,6-)T<0ZMVG_CRP_=F(UFK0`T`NE.' M-0/@"!SC^G,GQV?/_=G*L../EVZ8T+6E1VO!V2F!TZ"S8;@.TYXCM)WAV)%2 M57,`EL`9T=WP7,=)S6%:UD'O8*^5QU&Y-/,-OX?Y^-=<[J_6J3U0]=X,:PM` MJ?EG2SNTQ4Z@:!"4LS<3@0VD]KS`_4P%5UD^87%9Y5TR^^JT&IP/"'B7NYT6 MMN!2D;`?&UQ^&X@L^<>W^$4_C7,_V#E;?68Q-%H,F&YV`C9J9W@ M['QOYMT>`.5^[:[/W!8(Q!L"@'MS7]`'(4*A-R^AX?A?59,-J7C(D)OEU7L; M_H#AU66T5D"3PP.V"7]6<0%[@GN6/S>I4T`7=RS*I@V'TBOZG4@`,^#>;==W MJAJD9WISCC)]@'AVOG=W5)O2(Q1G#^-'3.=HK"*1W&\J[\5E$A;%:-*H1POO5V1!,. ML1P8;2&5SNS;A0&3T]V#^=,#L=;%5&%XB*6\L,`1T=<&_V;RFR`YYZ30R*V MK[-.&M%=GA7VR&[TOK&2[PEN\^PYADW'I\5O!<^3_A+Q=AB5\7-*! MWQ2D49PP4,MK6.N'3%-%&B/?Q>=`KP3>1+CO2>YT1RR>P9N4YCY4A;QC_T>E[/KM$DCRP%-<\:6=H)-2CNU`^@( M^'#OBND>*J(6_N$S>\KAI*0:W^UBP>D%`0_-78_J;0U0"P5QG3ZS1B.-"H9S M_K3ZKUKBT>0V9_.XFDLXUJH/T`DX]3%XR+`HF=0_0J0Y*(^`R M[HID#"^U-'_;D@^C**]/&TT\')@)6?S,URJ8"HTHES4$RGC#(UR-G%H^0:0# M\Q!)_8;\9@L`GX!=U^FH%T.FEWE0*#QTW:R"+=!R?\HSRC:=^28.'^.DWMV8 M]P*=5D%-!*RW3GN&OAJH1?+8!K2:W)983!>'[>H`G(`=UQ7_&%YJX3JV)?^\ MC,9\QYY96LD3+"KJ`F0"!EQ7%`O!4HO#T>]&TYG[1W!V0,#01, MEU8VD)V0$XPP\C)K+N/AK@+D*KS5T6H`E(`-TB9IR"91J0-Y+!._9+>CXZS$ ME@6$5-8-SB@DV-XM[1)%(._/O-DD[]C3R_-LA1>2J@IHAX"1V3W3W,Y%",80H_.\P5TU-I[ MVICAC?H`G<`M@`UJA<`03OT9"[-TGJ6L#//%`QPRBS#2-MG(:P)<`F9A0UN, M#B2$07N9MNY8Q".4Q9,X6KXL6?DM*/=D1O6#`840^UHZ%^RUS5`BI`TDP<'^ M]I%_]!%FXUI#_Q]02P,$%`````@`28!I1V8MRRCW7@``IAL%`!4`'`!T9W1X M+3(P,34P.3,P7VQA8BYX;6Q55`D``]D)05;9"4%6=7@+``$$)0X```0Y`0`` M[;UK^W^^\&!>"/PB@>`5+79]!1%PA'N#G>'P^%P_[?_\7D?HR>< MY5&:_/M7;UZ]_@KA9).&4;+[]Z]^OG]_]J>OT/_X[__G__%O_]?9&?H))S@+ M"ARBAV=T$13!?19L?LLK>/3FU9M7/R#RP^L?SCZF3V??O'[S/?KUS3<_?O_' M'[][_9_H?]]\^/_0N[M[=(8^??KT*B0S%'2&5YMTC\[.X#MQE/SV$.08$<22 M_-^_>BR*PX]??PWC/S]D\:LTVWW]S>O7WWY=#?R*C?SQ81[X.S*,F+(-DT4##-$-R;'W[XX6OZ5S(TCW[,*?Q5N@D*RBHE7D@X M`OYU5@T[@U^=O?GF[-LWKS[GX5>$!PC]6Y;&^!9O$47@Q^+Y@/_]JSS:'V)` MG/[N,N$NAK@J4M/&]P%J7ANV0+BUS]\^YI2!+_YZT6Z.>YQ4JP38AR* MJ'B^3+9IMJ?&??V0P[945!-1].GT?S6`K:BOZ.^@FN$\/68;;$0[XVH7I^#! M!">RYQ%(V-IQF.QOD#Q318WZV"X(#K/GW7^.XR*O?T#VIM?CEK_]ZF3SAO``!S"_P`S5; M?S\2G.[PYIA%181SR?8T9A)KHC.*PKYDM8!7",!1`#L7G0`U,WBQ<8U?TDHN MIZZG$[&]3$H$[0_4U/R&?^I$N5F)M[$@5"4=*H4/.Y`6UZ`2/*;Z+RHXA]]25JODLV>_)E M1#_ME]XM(I,2+5U0(.WI]/L@ROX2Q$?W!-NO M_41G7?JRJ;\H;N5+Q_`KX+R0,)D)%HF8TGA.IN0)9P]I'3MR3Y!KK5&:=`-1 MLZHO4ES>3%;(H<(]!ACM8$>>%_O(\R'%X$SQ3IT?'=IM/95\HS:GEQ+0U126A MX$+3WY_!M5^(JGD\,Y-CUYJ3Y$D+;4^VP4]OC+N&$14!6)=3(>9<7!;.>.U3 MFD=F4L[^OE#I\'["I=!5M,%)CM>[#&-Z9Z"X"!*/MWOY(\&;B\RRH:@>JY2& MR:B'94"=AM*=D&#MEDHE0)V;*3WIF5&<]<)K^J!NA5POW,4+BU&X:ND3UPE3 M-DJM]4B[?\2(#(X((6%#TS;-$$$4$X5\7*$0/^$X/<"D*^I;\?P@NA0]T5C; M"D7))C[2L"718ZIF.84*LHQ\&3-/K$C1`T8'G,'-'W'1X(MI\0A.'(S]%!6/ M:(N)1Q/$:)>2I4T`[I5G1DZH:5#3UX`2!%$8U`;R8K,S7:>^'V>V2.[ESNQBRF@6;Z11SS1+!-.KC=4O M:GW028.+K-$";$]3UYM->B0N0K*[2>-HHY<6(0.RKH=2"OJ"V`Q&U6BO-@+U M3GHCP@%<^N#Q_Z.M8Y M>Y@JV*0HR-^/44A8U>Q>;S3-@!:H[2B(#C5\K*"$:KDM;SRS!/-1YILI&$=9 MBQZB\4'C`!P8<2P<!@AB>'"'\D>,"Q02Q_+EJVJQ\(_H1?`2 M)B-?AI`-^1YA%'6P(>*"GVA<9A<]`3)9E&-`%&8-\IR8#QKF(3B(J&WLY*SD MKM"+AY=T\D.:YQ$,P-LM-=P4F M[9)H&VTHX^CO"*\$S*%1K.09[^;%"$4!JCN9HV/.5NWP9;FTAXQP,SJ0#PPO9_$8%(1C$>!` MM"D+(K@L7@`Y]"D]QB$$//%G6$GX"HU_DK_G44@L2=CH*=@7L"XMD:%*`M_> M'+.,ZF$&Q)'_#_I/E+9^+)P?MUOP\$&_@_R1X466OH%\B*GH4D&LOO0IB.!= M,?H$-BU]@$1)",F"6=D0W"*0<)!')O*E6=BD^P-1AI(1(=X&Q[A`QX204W(_ M?8IRBCY9CY`FOU;Q3[8,IAI-_Q;D/]9XMXQP/5>"&7<9&2@(V4QD(4O=(12\ MH-@0]F%Z6_Z22GE*Y!@V#Q#039E_"Y?J!("&J]/M%A1C>RQ`Q"AWMW'Z"2BG M'-]0\:]7,3@0!I!%@ND.0<8L+N581TGI9E+^/0(V'N"A'OG'\4#^FF%B:N@C MZIPM!P@FV=^"#$ZE!*F)FV MT/9D^^<<7V_?Y<3?(M9JZ"&<:*!UN>0P[4L=&0#;2#W$;T$;9GQ?C&1!2KV0`5F7>BD%?9EN/35M1OLMJ>H5ZLNA[O)8M,]`*N2^P6G\ M-LI_>TO#*/"3S/S*H.Q;5RD-G/%LCT8P:(480/D/GT5.8[DXVZ>[5C8SJIYP M)/NDDCO"MX`UD'VE)H>_E:7PJ`6D+_NN#,"[>9(:4HEGQEE))(V]8PE M1A/7YJ+)C'[W^0`IODI?0@O:@:[IT,0+(X.B_G`+#I6`/JN>'_3:U41MN>5U MT5!H71^%-3(458">'&L[Y(&BZ8S2HK04&O1:^W M[ZL$IYLTCQ05@LW`'510A+L-3H(L2@6E@A7CW36-_ M=EXZ6(OA0AD1<]OFX8#A\',"Z;K1-L+A1;H/(BY9O>-K"F$A7-MX'*5*M!>^N:RV$`\-S%27XDORH975:@]V9G#;&DNT(AB$ZS@>!$;); M:',$O+;X,)=6L=5YC-L;:/\!;A]3[M$M';!\@23-\+`FON[%=E@$N`?`DO6W M+:YOV4,$;:GEQCL27A[O89E8H7*D9\*LQK_"FSX`RG_T1;@%`C,LXU)I<7XI M4;P-LNPY2G:TSJWYW40?WIO2._OWZ/;M[=7EY?N+?I1I91\U)09A9M M5FY.L^(>9_M6;PK9D6UPN(,*S(-8\U66R;"S@HQ#G;9`'IAJB#*ZTL0 M]ZHA$R"^Y+-*>FSV(R)<)4CRO@B^O:`5I*UZD:8*!Q]G;% M:RA.T0E*2+;#H<'6]\%!C/N22`>A7JC+[F$^)RO^>)A:2_V:DDQ%$8 M5S=\ZSILJP[7+GN6T8K3J#"F"'HGPUKBZX7DJEZF?B0$*\7:9!(7SSCT*1QX MW:#QR+F9POD+CEE(A=B@>R4R%\V!)QJCY-*>^EVER4X_/C8XVKI"#>/,5<8D MH_P,CIGB[VEH3"(Z?3U0RHT]@;_)H(1?\7Q#F%TU$J=GDH]8ML/(P:RK@((* M_MC-AJ\0!:A[QI?M8PB0%XHQFJI#315NJ$JP8#>TJ20ZXM;7%GU9LZV M!ON7)&M$285\J_"]!^FR:G&2*(@GB;-EN>3\)GB&"WVBMN0WV1&'/*JRJP>3 M65QU(].D4=">+$:GO@"(X07D&K-G/) MM:>B%WB+"0+AVW0/C*=Y#A5VSVK=U`.WKI2:5'&=@THPU(:KU?#9+R4<26-E M7#8M,/?*9B*&?2TSET'[ZE66O]-7J#Z`,Q7B,!7-Q(Q)WK**.2=9?1"Z.HA1?1"LTHA0>Y85JX M=Q/$6M$)]S*N?P3R[Z13;HI:%T$2&-<.F?1*A??)?+D4&D5%5E%!##SX9YNN MX7>O#TK94GAH7ET>Z1E^MQ9?9>I]LO!"T^ZK2=>PY>Y:<>SW$,!KX51SV:Y?"VQSLNJS")D(V:$*M/V=62Q7<-T10KFW7& M1MSZ>W7/;W3_W1Y<7>NOBR*+'HZL3=)]2H[G7EU-CJ:O>Y_OP0VE^16^?Y?V M-UGIB%'45(5\!D<[2.$=PGG@P6SI/=-AJZH'_%2Q5&TTW7-*,@9!?_E M]:O7K]]`?VWT!#!0Z`7ECT2_T8LWKU>O7]/_L=^0/>98/*89O)XEYX8T@<[B M0#G=>])C`1WAH1LX-'@G1XH[(O!X_T`F_/;U"H&TE&U!-N5OW]#??O?2O=Y) M9)9/"%8(K%W/+4VTU(P?ZL1'ZV$[Y,^DB8?:I8^[CEY]+U6L[[]9??_]GU9D M8Z+J\MUWJQ_^VW>K;[[[4S68*1T;^.:/JQ]>_ZD>^.TWY'\_5`,[*EEHZ^,* M*@(<\*:(GG#\[(%VBN1\R'D4"_F$,A>U'UK$SR".M),BY?&`RBDA[!:XD.(^ MT*2P'HRJT8@-=UC98CP-445#OB0-6B4MC(BX?\1M=:YXS'.3'[%G+H1P: M;%W\!S'F3&DYJ.-6SBWM/S"$$[P+"JRL8VF&=^E2$@\.2A:YEW*QG/0%7"4D M-BM;%$&4X/!=D$%)TWR](3OV,8;%NL#;:!/)*UJH@1U4LM"@B"_KP(!0!85> MM.!0"2AP^:??\NBDK8RBJTU$R$:YU?!EJ;!;>$-7<_B"&V9JXS*D?YELXB,< ME&_8_7<[XGV?PETR\5L)VP@JNZJLHE'X?]P'/+@J&,D9C6N%%:KG1N7DW9N& M(D7=^5'U`0]NHQ?C%+O(-GUV.)EH@W+CBY%^'L10JM%UF7$W]+F]9YIB`-5W M4M.MGS]OOO5R>02@WKWQEF?]M-YV>V!R1]#"906=_)MNC4PB#=FSIT[O@RBC M1[\6@A_HL1"'U\DMU-#*B-83G(D9R*I_G@=YI-\L?,9O6%?0.?G3EWZ8N[I& M:VMU-3^Z3E#]!:H9[6\@^A'M#L^V0H5.&9;.R#";5F5V+>R;GX54T#L[13'^ M.4D?$(%?;).A`H>@,TH\DR_)ROULN4:],,&?T:-%YMOH?H!U'W MBZ=JVJ9R\^TC^1>P!%U!&7AT3_0(HX;'Z.)(^7A##TRG;,]&:>M(TS9!56VV M8'[$X3'&UUMZZ4IP[C[RIG[C]0%^S->0`4(\1VTW;([)'31UGH$C?/=G-BE- M@X-ISQY@WDX1A!6[D$+EW"M4S>ZEPLTG.'QCZ7FEQH4R$9\&BNG"XZ.JR#1% M^^>$;5*DC/%H9.>BM9,D!"QPDP6CPDY<0T6OP19 M%B0&;U$%;"Z?D\G3RD:;0"89<(R##(51OHE3<(-H:MJG MBN*@G,AUGR13">WDJ8T3SUGT:7@;?,>J>)DJE]%DKC3-C&*9VM&9T#GG;*%R M,F^U_])O"O4X#TO+&ID,+)SX-$&J@4`562I/;W6H4795:D-6/X5%1 MN>&0[P=)5&Y(]%+VN-\'V3.H3][B1=#PXE!^RODNI2VKW2W)4%#M[3_GQSQ* M<$Y[+5PT5I MS@3CKO#$W8GYSA284S+;X M9C@UAA9`3C[;_<%>#-!;9A'`A+,](;"R/E/?<45LUXAU+S M2U0\WN*8!F/RQ^APG[Y+"K*=*LV.\4SN)4U)*_]HMAD,;]+8<(\,U\CE5(JH MR5K:?,I-GY#>!%GQ?)\%20[WS03!\^?V7Q1VT&02!T^[#2@F)VRT1GK.T27%O]!>:CA?-$%H'>6ZX(&1'T&3ICYXJPZ2O15:,EYBG<<`U!R7K;OCN^'C0X[_?H0TAR?R_^[)]U0WPR((^_?" M0MRYM,]Z)*)#$8SU)ARI6`/N:EAG`9Q*D#+>*('Q08J$QD<@1\XMD/9::,B2 MX_L4*`:ANBYIQM@/4K?PXWP26LC"%ZO"<9(+1`^ST?):?Z#M/E2K78URL]XU MCH(5]T;_!S@ZN.I#[+2W[A^B)-H?]\J5[XVSOO9]/+E``?L[^I6-\&#]!SG; MEP`)6Y=Z,G45)?BRP'OA@5D7VJ.G4VV:C)]/`3"BT/Z^H9(12/&/X(\HJT[B M:!LE0;*!DUDIKN1L3DNM8MKA(T"TPNHK=/](QC=CX%GP$5X%%VGU9!C>9T'O M9_ID,4JV:;8OGV;E>4J^`#?`GZ+B$874\J(]E>6@(1RTJ`F29Q1\ M)CPGL\-++X:#SV^V.&71?[EOS8N:B5$U,X*I46MN M>-]L(/[`%EB1 MUJS8`"NV9'+7[L%XH>^X"E,EWN+C$O)]^!\\FWH*XK+A^MTC<0'O<;:_I(7% M:!]VB6]@,HG]QR@F%'*/5`C@BFEJ"WY%"Q70*HT(*<]J577D+$314:C>43EZ/1 M7CM3PI[U$%@/W:8*? M6;X5N(_YNG@;9-DS<2!5#5J5D/:#^TI:N'`_0%3I\>:WJLW-0Y#\AD)\ M2/.H\$!>VRL\9,G=GTO^C./P/OT0%!#->VZB>OHG$\4,#L\F*MIDIQ.`/2O2 MLWT)W8X.>W@^T5I&\0G%8`TM^A3!W](,\HYR5M&3N#VL>$Z#GR(=2'L&^SZ& M-FW\&P0"2;/+\KJ":]/]L".FGJ0;&:XCMWF/642OI%29]&@PAX^2*GDOHRVK MSD_WH]=SA+RZC0_\?/=32ERN!"*CZQU.(#T`$&WP4^9?Z4]A75X-J.N+Z\]W MJ(%%%3`3V[:L2I.Z;'G#$^B\?HBC':N6`FH9IGMX-+M!NWK"($9!1;X_.6RF M@MO7S'%2Z\(KKUNY76_O\"'(@@*7*3WY^3,U,&_)KW9I]@QU<*IK#M7SC%FF M=^C/3^**S-EOM12$>F_EW%5^7HX>(+@#6UDU/ZOT57W!&T]K3@$2'Q;FDI[3 M4:SJ=^K7*S-_Z.24C>/4@FJW:G[OC_NXC*C-K8PR.;.HE@,W]4K74P9D7UUD M%'"B/YB/X9%_I5X/3@XU%\.>3%T7CSB[2I.=J5RI`*W+EI(2SJT'``00/@N9 MW@+U!RYRZZ(?4KG^[F1ZRK>6Q=L*CVI%>$ MF$14Q2#6Y5*"?5\()8+G-H9C0,-Z3W;:Z!^T0V).7-\@1T'XMR,TU76O+RI) MZBN'GABYUX2?DPQOTET"?/]S&H=1LON)^,MC-$0\E3>:(Z'60*-6J#T/*B=" M,).?RF9`]D]9FN?H2`"@GA2A[K&D;@<`_NJA2HYU]5-/B+W4VRNR]TU86I3D9UA70+=3>F$">EO%UAGJ"]0Y+L7GWKF-8(=6W!>J.>;7J, MU+$)D/JI?S+"WN5%M*RKM=PWGKHY91**GF:^A`8"^3P['(J0*]4=Y? M2:'<">,@#3+CR`!6B(*@-Q[=7&FLBU#>5(OB5KJ^&25=WW@E7=^,D*YO/)>N M;\RE:W!1W$K7MZ.DZUNOI.O;$=+UK>?2]:VY=`TNBH.$(./!*U9!*4&> M>.5#T9;W57W3ICE[<*`/+*XT$H"F3^TP#C*:&[*-=#APMT+US*B>&E5S>Y9# M-)>\B(,MNU3::5[!;JZQ]C@K__KX3*PH=+53VIZ^N8BDYC11S?9`2S0EJZ\F1F(UH=+O4-3V[2-T MJ\@O$W8NO4SR(J/59(652\9/9;?6[SAJ9=Y4:R)4SH0NDSI*T9I-?C4ZF6ZM MBK\STD^3#JK.`60J:$G`FL1#B=]F5\YS3&A_$=1M`E[2G;H9$3<;0G<84;`B MJ!H+0!,!3`L`_LL?OOWA7W/T4+JQ.?AHKUJ&*N\#1CFJ6AK0:MITKDVY5F1$ M7*Y5U%#NNA3Q!*WLU"*>K)+6+(OL+#=M.I\MC.Z9S<3**$]J/IH:&2.N_MGU MQ)XM$9Z1YU-"M^D)OY"E_#E)'W*ZXA1RTC!SZSX,\ MRJLCR[,J<7*A[WF1[C`'WW1-'%6W]L?*VQ_4_=P*U=]#](.K^LS_7$>[\"Y* M$C:".@P+V436]>"N"+)"=9:QREWFI@4%NL`;:KC0MV]6".I8+\J(=TGH)QO^ M[R.QU=^^IBSXWOWI<%$+I9.A,[-YFME?U,%.@-QE4F`BO]"N*SOB\+)T#BZ3 MJG6.B:.Y+![N/=2%^2Q)AVN;_5_TS'[?ZK>,?H4,*K%!%3K@+5<(N8ED^<+[ MFD5!R2+"T&U`#M)/5;$8>839W>G!,J-82RU@2%2QK/6`*SQ2`00OG^UX*W*V MB'+X'>UKUHYJ[!D-(>P_S8,-8'P`4Y:R_$!E^4BG.+:5(&)*\**,4[ST\4!A MPU`K3R+VK+3_1Q@!G:PY%2$O(]-AXA/2_RYPI#'\_LD<<4SY:O'(LT)E%[H* M#?2B0N2EV]L;5\QFH0F(T+3-[K:.F[6,].D>!49I^EQ'@PEJ/O-1P?AJRIL+ M*/4U4\=2.']AI[<$RMUZWML&2&*[WMYG09('&Y!,0?JJ;+!=41!AS%UD0Z;A M]1:U1CI/6U6SO+/\&OR><^F%&:CRX8Z77YA[.B@`SC-/=5@O%X*Q.:<",?@0 M)(]!403).@G7Y"A6I,G-8Y#MR=GV6$2;(,X_X&R',^&+B5&SV!4:8QKYK@'E M!/02OIP"]>9`;!(/GEA,6-B.[$U9U0DB22LK-NU^TYPV+/A\P$DN>EZA"6=7 M[#3H&"Z8V6IXG4)4#OI3,#`_MC#=!>H(D]GJ+"0^\CU.!](?$1+N?&HA\F,; MU%\H;4%R^R"#QG\O\_R(PS>JW-=ZF)M$UP;+X:Q6]GG(&H]8;6W]H/9 MJ8,+;T]&X>E2DVSR-DW(8A01.5.R'W/B8=YDT0;+!-A@#NO2;4)?7Z)H6YT& M>(5:X-4_8`)$9W"K'*[IM*E;QC+;5[R1`CO!";G!9-F3(MB5S=9OLG2#<9B_ M)\25>U>:W*>W^!`\M_`!1$7>R:0I[;HMTZCOBVLS&YSG:1/M:D($,Z)Z2G2? M(CII6Z+ITU.'M]>_&V9H75'/RXU;O(WQILC+;/1T"]?*%7_(OQ)ZN;Y]GL$<=)WPV8^3,\RG;;;-\!7UGIP?F MVK_I4\%E@=>]-]@#?%ISUBO/948*'/HD@]*D<$,DHN1**Z"X@;8NL,&.-:#$ M6.GBPCC?I*;-;;FL\*RV6*JD>KA_O;TKTLUO4*6:^,RL@^SZ@:`8;&0&5!/> M?AD33;JXHB9UG0?B@+4AJR;"OU;`'M1\,%H\KMZ)^A'K#?DM&2#-6#";P^ZAR)`^KGHU$ZX:'M$)F``B-@6JYO`DVV', MBG:\S/'+:;&]&T7E,@GQ9QS>IS2\5^E(J2GRDF"Z$]AO]Z9+&7C;+C`49/@]R'+Y-]W!#0L]EZRR###^P[.?/ MS9";X)FVQ?T49"$C*[\^%GD!Q]QD]_&H;(,Y^[<#K^P/$*C)8:HN=RPS1>,A MGWN6O"LYLR@_-(,"-KAQBXG'&FW@93IU(@3JH\,6NT4*%[+A?'G#10WXZ>QZ M/Y&!17Z9L'SL!;>\_H=.;K_C.+7D9L<^!N\2;LJW8Q\Q?6GV/LVV."J.U,(M M69O.DC%3GB?SI>"2M'W&Z)4O%.QV*]^WR(6!:(#8LU^+63LUC#/%O6_:F_^*58 M+#TF#GE(!.Y+L%<2S9O;7BG5[I3L%741X29Q\9N.@6^=H*WB^67AH,9*K;,O MNFQ`8(-]PE,<+702%.B.6).R.J$WI?D6T\/Y;9=4"4_'*`2D3JTPU[K?.G7OX;+4'/K M#`4EOW#%KP/CU^_EEGA9SGW!MZ8Z5G7!NU1]D^K1GI4;7<`LM6_-B85_>]>L M/!YS<9N/O[E5[&*>W]\NRGD-PWLZM[WSVP%C2[N4$3@A:UO?7THF:WN=S^W5C>J?S7,+X^7:4[,0RS6^`)5N&$C/#`Y9XK,VR,RND98G-N M+VJ*VZD!OQMC/'T--,SQ*64:+&0B9C?(D^S#"9GD@?M+=YZQ(2JG9Y+-N;VP M=]SD/OQN3/+T-=#RD$\EE6(A`[&`ASS!.GADD/7O9!U=96ICX)_YG8VWUM(X MW)A:V_D=BT4@?B=I("ZNWT:9`(MA@+*M*YR0LN['(,8B@]] MH[*YMK%Q8W^M\]Q=6DF-%6JA)2FC9=4%=KX.`U:ZSR;T@IPJGG&0Y8(^8M;M ML1N+,6B;79J+T['3XFU(1*JL;+<3;$[.3H_CN3N?V;J=UO>?G:^"AI76\*:_ M*$,^P:3,;<@GVY/3"6RT]JQ+0E&4Y-&FTW1^V:SL_C=/+G@AXY^U^EKUEUE[ MR2\JK5K)U?5NE]$'?'TV_'X2J.?BT1><*CULW!9,CI99MI/T\[L$67+GN8^> MLM?.D+EPEN&0%MZY M";+KC-8/#RE:-SBC]$CLF>X$UFV3-F5=@S9@_.T&:BVE?=,7+J2@TI*OGZ6#RF M6?0/:?TX%:!CM1N@1*EN#`8U0#ZIF!%!I6KEC*!`09`[71+)FUR'Y,+F5G=8 M>3E#O:F`O-"9F@)=?5FT]ZM6]'@D&5TMB3SI#*N6*AWM&!(IMYK1.H4;JD<' MT@L=Z=*BJR@M*-^T19>@KLJD*H);MTV3LV4@+VKHF MZ='4%SX&=0)'HDGDG&H>%KEK9.OIH;5"C M"#$[\CBP"4NMB2/EUSVZ:>N(0V57'MJ$$.Z57'C.&1*FU;*'M;%*H:+!SX.: M0HR4BN#VB,:AHW<^DX.Y5P?Y0698)Y8_EXU5#"UJ/#Z3Z0B94D\FG<8,FL7%@!_1S#`FW:O@ZSMVRP)7SU*.A6^&F[03T*0\8_!'E^DD%.K MRB>:_7/^I9J.XYK`BC(!_Y4-\T"ZEY29^5ZUZPJ,/5WK;0(?L*(%@&"\=6D7 MX:WJ?8I^94,]$%DIZ_LRI\%W.U[D593@RP+OAW;G"7-YZTVVZ9WN4<)LB$XG M$,#)=(?IY@CVAMJDA>FGU$3P1Y3A`\$6$D6W41(DFRB(4:D'4&5F$Q]#PHXH M00$JP,%\A>X?R?AF##&7Z`@)IT6*PBC?Q.28";.F&1U/0+=IMF?IJD&>I^0+ MP.!/4?&(0FI"T9XJ18Y"3'!@7TL)@FF&]D'RC(+/Y%1)9B\><8G#Z7CVG-:- M]>X%*N>1?T>=*7\#K)!K.^ MF'=*8TWF;.^6IMG++V%3&F[K;75/DO7\/O$M2=DPWMZ.5+9Z6*R9Y,SU$I=C M.6]>3Z=KP\QJ;L^.RG3\2S"C?Z&;A%,SVD?A"S*C''?=F5&&RLGWY)W.-ZBEU M49A?[^V95H72?PG6M8YE](IZ4=_\@BC'^R#*%BM^-2MZ7Y`]-EH5+P+:7*5# MBBH"7!$@6]47^9+Z'2^[C+H<_6?0W")W?X=1=NV-P4$`WG!7^!(V;&D#5$]V M;6,]8^*:Z6XO66%3?NH=`(D1.\$?)"[*[,G^/Q MHG?E[RL\`W*O_OGZ;F'5YY3)5/T%FF2Q.%),5NMZ6Z)UG=W"SJA9($D):K]( MDIH:KK00@$#"3V4%B#Q2,!O5D@QNSD>05HX5//;RZ>)Z3N)\NS;6U3"N.I21 M>DUP&KI?$%8(E(RUZP0(\!4("+HN]=EI0<`1B"]=PE#+`]%$^19O8[PA;@)L MWDF=0_FII*0L9(C"8P:J"8.8:7"]Q(JK<05K.^*R:F$1#<%^C"C>AZB3%\YR\%N5;/" M6$,QZ5"/U%*!.E7*17">HI(BI-4*22']5\>."DB5<4#^9U/%EC/'QT+_:EBCI@UM>EN%:/VRU@;&DF),1]E(6>.2TRW\SKSN(]G M3+7N;!9'AGUL+&19V^5G,,66?6(1&+],D[Y**V,Q#@Q2?="<;I,TI_(BOC/5 M,M43G8QQ&DVZF7WR.;ADRTK5'_3+4!FINDYLRHFYHD?Q.8R5QD0>Q+NF&RH6 MC#D=,S6*;%,CY6>PS9Z!HI_SS3QIJ[8Z5N?`-*UWNXR&AB^3(HN2/-J(DM=- M@%V:(#%%2K-3@Z(:=M$,['%1.'T"A?2<;+1M:=I]C:KIT]TQKT'-A*AFPE/% M!/_C9PKC)#&H6I9I@A&E9?NY5'EI.KD4Q*[!E&//O8VA;3(&ZNSXD26NL10= M0=%>AQ-XL'8E22B?<_+3>2AV)$W%B,]M+((',.&N911QK M@KWL+:8(P'73K`9S9=YX'CR/4BB("L+\WB#`?=EPJ[6`0]-F1'YIB M1H>)IJ2,U!UU[]VKB5S4N+U'0\XL]KR-Z>1$9P>W1+7:Z$Y@OTNN+F7(0H3CTC/Z9QB+.QAV9<,ZF/` MW[WI+S[$UKYY$//4_O(K^X([[^BM[,7=$@)O&G'KM=">VOQ:L!]T'F,+>UF+ MA]K=!X:Q[2]RMYR!HG_U=,>'V&CYM?0HK,E2?>/RJD,/Z;J,`BV:P`!R=``" MTJV$!FN[KD2^.SNN4KAG+D(B5S49A/L"(T)I$)03<=]`7G,9E,4JQ@K&3-&A MXT,>A5&0/=\%,;[>LC;5U.N!A=# MT5L*B_+4H`&>Q?7V/B,R'FQ@6U#Z>CK`]B5,AR).U-KBM6+>(?EG"]0C9U%_ MS3CQ,URP"1O>VS0[I%E0X`]1C/,B340G1^EHNQN=$&>N/DXU$-4CG=LD#:YW M]C8=EL^Z_D)SHACO6@:$1F-0"IQ;"2WN*R1A<5L@=WW%XUW+@M#M'90%/WQ> M%?<5LC#S0>ACFKS;'^+T&>/6A5(NVQRD('8E0HX]US@1;ES*X55*``/P8[?0 M6(N.<&@OQ/SR(=\\%$!>R(AP&Y%)B1^[B=::Z$C*W('+/#]".C`K>R\S(4,C M+8+9UEEN"H;'NEQKH>)SJ^V'MLNX+5GQ ML;H]4\G6=+]/$VIKA+ZE9*S]HJP#^/(^)8RI0E[+WF!HID;IH-U*@S2@P&KU M49&P<.5&Y9(RP:2M=QFF";NR7:LWR*X1ZV/(O^,I_^['+C7(T(ZYDG#S!%X4 ML";LUUO6@GW]%$0QI(.\3S/:J4$6I5WLDZ?S^D#-O06:6+./HNLM&Y2C^KO0 M^H1U13G1%C)C^3FID<_'NC@@Q\^MG)\G\?A#4\-G>Q)BI-[V+&1];L394[3! MP^35#9@I)?D]))ZV__XVS8N/:?$?N+C%FW271/\@M%,WE9!7_@K&O9'83=N( M6+>FUCG-Y0K440^&@3!OF>A^A08S!OFJ:T0`"S*F0,^X0`TBJ^IH!?:AA8Q; MJWO:?*>8+,!]FS;:C8WI6VZ7!N8+L.79*7=&&2*VA=L`:PK^[S/0ECE MP`M::YN9$>8>?L2?Z)_RNT<<;V_Q+LJ+C.)T5P0%]3-%48SI\SIX:#*-#\-/ ME\KZHVS2:F\LCS)D7O9WHDAT:I2UYD9Y-;G#REI+\(41'S3G.**H)?WM.=#= MPO1KI4,OP(#;)G4@3]YF"CG<2VR0LM?BA6>0 M/ZZ3$/X#KQ2>@AAV$<5+`!F0_2M0&07<72@9A8*$G$+@A]9XY[=/^@O"W2YJ MKH:+(CW#N`W_5GGA/FU:AP5_1G'!0'2=)WS,N?#BLCI35WU2ZC$Y46=%1"PU M-=VJQ./AT;;3C@4X\PDB]4#$ME3W.18:7.\E'*M9/I/?=*7J\BX8[,Y_NI(4 MS>OY4%=^=&?7Q?[JGVW8YW)6.;$6.JP"F;;G7URER>X>9_LV4A*_87BX=7]` M@+54(6F`?'/,,B+7TJ#W9.REM0=&D7"H2(AQGJ.2"`3J1"/_`5'4(,I8O6*W M-ZGCR"(K<\91E6`/^B.JM3*$V!KB<7:3JB M.DU$11FTQ!<)E1FTW4&6,VA[&'(9M-7?I3$,.WZ;"M<`_LZ2]-(M>CCFQ)7( M'9:P%(M`-^=7O/YSB)[\*0HWS)'X"1^@M`10&HFP+()"?(,:7^:V^R)^DC&,WB#+XM?#D!,^]G=?0A:##.TNI9B;-M\Y=<,EY:ZJ\>9) M"N?@_9.<#G6HJXY\.)S@>C+(']L7E]<'S.[, M[]-;3`Y)EPDY4N*\N$Y:N%W@!V&"STR3VS5/-P7:``>W@&K-I,3\DN+N.A,YJV3K[_0)FS9Z?4"%4;B=O M6;AKG81-6%+B+6A!6_<9]&CB:ZJ6EJ,$DB_^8?"EE5KK^ MANKZ7P9C.PE`BC]_/FH-;PO%LF4CM'PD0U)JUR>@0\'3V72H(QX+N#;0"21( MGIVG.JCEK)?PH"MD-KT%PDQ)AD+>`(MLYS7.3GSQ^"OZ79VSC(51G2QC,YD$136GG9K&8XBVFTH)D# ML4D\,H*C%I87V@FK:C$]BGG$^2U^PLE1EDG!C;2?%,7A*CBAY*@J4;0U'IJ&NS3(Z&NB1:G&=&6K?I/*Y](:I&^&'3Y\+7IE$7R$/?J$N%84K> M2!C24@+`@F/7?9UQX@#*\]'KUT?<+-!'P_P=*7%+K@/SO!97K.KGL/UYCV3@>EF M7LUI76S'ONZ#SV4#YW.?(;LMZ/08YO,G*< M*/NUD]__!PZRZVUKX`7.-UET&-I36OR9[0O6[<)\O.E+=#4S:D^]0M7DB,Z. MFNE7"#X`.V$+8(5:'W'YX,XNGQHN-3>_97TQ)3]LVH69-:MO1Q91*XNUX3>/ M.#Q"A\9;',,3Y9L@*YY;+1KS\^?.7Q3/[4;.9[^J^TBZN6IRY3Q@$\KQB`*T M^W@2D_+PW/NS\\R9622`*PP^??FG9)S'P89U6]CA9/.LU>]"#F,Y/UR./Y?3 M7`U';#S2:X]AYQ1K2$LK4BPFRW7:KX9X=;-YM65K`:&7OQ-40?DA^,)4!YGH M>_"LT)@>+?%W'6;1DS0M#9CY9>+5]N&G+#T>Y*F6_5&6DVS[.')WP=L'1$W[4R6IB,E1NNRC-C(]VX-0&]$1[+C287'><*BV1+I M"M#,^][UX:BH+M@>85@&HU8VP&.FK( MV,)4W)01!OEA]X4<'N[..,Q>BU&X`$(FM'IWMT,:*T)_F;0B*++@F]$T]F-N M9E1RH;:`A=GH!`.=^'");";$G)J.D&`GFPR]F"+(4B,O-HX^]8J-@ ME[AD/-,Y#X1,L1`2ZR]9!2>"]#9-\B@LZU)42=#7YNZ*SCPN14Z+3H4<=N9H M4OQ3#7_%VB8PD>)W21$5$>TGUMKZ5N@O4+9W5>V$L`]`<1.O-%%?DB7J:2K& M]G3VNGC$61686"SJUWFP@,S@?5^]("]JZ5NG1Q(6`2B@_ZATM28--G3&0 MK[[2&`O7E'8G942BU8*.G7A^(MM>`=$)LBTFF&Y_OT3%8[\&S_DS]0NNM[\$ M&4"(6Z7,_R'+;586X!1749Z%Q7K]#JL86?DA=$DK&I:?0O`MQ!=W.G]F'AM, M5GW1:9\7>^QKQ3(8XW8EXU@UPHIQM)U+^8*U+!T$C'MX9BU589I/Y;?:W559 MGQCX%^NSZCJQ8S$-[G:%659])]7MJC'JI.Y*(B2:<+;K=RGIX&MXM8Q$+^]= M$3*QH_0C:&HE4]%>QA55!TH5*VO*]-JUXND*7J^8EXG4.2N[M'Z`OL@;]=.S M`0C7I99:N"N++/U:#?8@EUNQ!(JZ2L/\MUEG/B]RXJ/6V39J"1*#.*@N+\2> M-[HY5,0@9_16MI1Z(F>G`VTU]46LDD-5!.X'Z`NCC@Z+1YJNWGJ M$+9\I[>$M1U@KK;32+,9VO3*GEWIEX:>ZV@:)6?L%`QGVOH<[#98H$7>_2.< MVPG".T),35Z5ME!V7XU:&0Z,#P-1``$+O#[VB]6LU\Y5H6/359V<:6#>\MY, M$NN7]%$VGLB)F3"B5&A$VK,HK[-<5OB9B6IJ@S:M23PP+9-HZAJ>-F4B*[1C M8<3:!J7TW3ASP+.Z[7V5>_48%,1NH:`@OW\XLI[4-"%KV".I7?@3L%?FMF+( MFHTU%*Z/`NK;>M\NZDVOLE7FS(,VN:8D480]OIT?=3'OY9W\3SC!61`3G-;A M/DHB.)D4T1,NT=(X2&O/8%V1]&GKRU\)206O"UM79>SZ.P,"7/LFX)OXQ&>"1;/.2(I1ND9C8DV]R&$J[V.C',S5@K!"VUQ:ZO.H8R9S-'F?6!9TA1QDM4 M9W"T@]SD(9SYO&0VJE2-%:(#YU:&'QC*"8V)A2IE,,2<*8![L9<("9]!K9`0 MRU$HAH/HBK0/K/AC8&5IT^X97':_A1CHS MN.+`16VR[$1?=)I_&""-91%8%X96$4V12L249W^/A#WX,GD?1!FM4'*]A5L' M]CP:RE.5KZ=%-YOZ\):?`>K3Q;WIH*#P/!B`6=T6>/Y+[S;9!*QPUT(/_?7, M]$Q41@G:`I5/E,ITBQ("E4-#O`5K&.@]>AQ/&]Q:;FKZX(:P3V."R@H`77JA M\U^Z2Z)_X+!]O^C'K:*IJG8?3([24P].]V-.]3Z=YDU/\0MMHUVC!=D"5&7O*J$PKE9%@VM.T7W"T>R3?7Q,C%^QPIRCY];'("[)8!&U]!1P[H76] M'$UY7ZBKB5`Y$VHJ=Y7%NEK3#6BRVUUK?C8$)1O*@EO'O*JVM3\%-4?)JR]"W"')HRK596G9`K:UW"C[->"ZN/YT#MJR:EVXNV)2+F]NL_23@[ MT]+*.U`-C72WO,(>4]T%]J.EE)C)PD4>VS1JKN,WWN(LPR%]_R_L-B4?[N!( M/H@UUT>T&E:6Y7#?DDJ'[?S)2\7S258A@>T7)T5,"S!"B()N-O+&8THPV_9" M1<5`J*"&0!4(<\U\:-`Y*T'>]&+3%+:>J320-(O5P<,P`NL=Q#=!!,5-@T-$ M3MY*`ZJ`LU\17$$'5T>['H\`X"R"5Y$4Q`,A,UHR&G8 M*0.:IQHJ"W[,%*-EP(F>U4KJ_DCE/>V7:L!49D#'@NG9`&MN%M13NL*#:923 M9O/"H*EI-G6_!JT:J_`&,_IGW\Q98&+FH,);3*8Y<<=,PHW:U`U:M-*:,;=M MT.;3&GBQ4#1<6S1-JS#!-1LV"?9GFG:+!TS434URY\29OIKBVQ$#?UB5'Z:@U6;?PITS^CF;D?/;C MXR/IUK>0JRH(UTQ7WD32"5>(3NGV8FDN+K2-9+]0K0?Q["DRSL6\IPNX<^UF MQFA&]59.Z(M^JRDW4?`J?'5Z&F[.!YF*>W9]-4GH-?7=2.*=*[S0.KU/LRV. MBF,FK>4Y:59?5%^3!S-N\*V)7;Z7FYS-=; M.&&\C]-/.NV0Y6`.-%E*!:^J54_MZRV+05`(KSILZRP,+W^ZJV(S._EOQ[R@ M+2KOTUL,U$%&==4H/YS/>EU==BD8C/ M@,\QRA^92;[`#\5/090`$82BZ^U]\%EBR?3`[9>+T*.*JQG1`0./$`#)R9>` MUN5JP.J0OY`9W%;E'$DCI07"_K@H8ES1J5'KS6IY"`.IY&I$&(NDY;SK\X`8 M@_:+5ID+*P!PDX$]A/E@&O;9`XSLM'Y;MM2*;OQ(EXINH_>A;F?NE40N3(/9 MS0I)FG(W32-([%AYF;RMKQ)_B8K'R^2JZ@6_KEK!"R^EC>>Q?!MM3N?P0X4J M"'.9H&86!-/`K^J)4#V3RPR;Z41W%:KJ&!CD>;J)J--)KYRCY"RN*0^JZ=SF MTTRG_2]5;G/WQEV4(1B!C2F+EF[3##&.X(8?SG,$1^IZ]V9YDJ+;V[(O("T` M9%2^47>'6=^>>UCV);#]9R\V8@-\W6^T0R+0WU[%ZV^SJOP39N=2=A!=[Z&> MYC\H3M?;FPSOH^->(L.:\`XJT.O1Q9=XK^#J-B!M4+#();!;91A+7Y^8`QL) MI[NH(3W'&[+%0*S!O28922A?^-Y8/.7DM0M:R\AZT1JU_-ZI2Y9+U(JF_OM!@I:X`O,_GN9-/>G$/Z5 M;K4J4`>[K)(:?H-E0]&+"N@ER&,K@P``77?=&D\6H:65$K`1TF)W"]43.G[W M-)$XETI$^S.5_2C6>8X''YN:@7N@3(-4Z2@4V8E9BZVJXPR#]DVKS.B#.PA* M5-5\)9`0Y5:]Q.*H5C&5++I4L_5FD]'8"VNF<(LW.'J"[?0CEN4NF$[D@>HI M*-7UW$IW*B:'^>=W\^(O4#,W:B;WH/7B(MQ1IKJ[U_MY](/KD,QG0SQY>K,8I]ZN[_Z,WE]=_W*'WM]>?T#7-^]N MU_>7'W]"Z[?WEW^YO+]\=^?!RYEY=6A>N^+Z=0SQALIG/NO-WX]1A@D=!+GB M^8:L=$&.)N_(;P^"?.8QD]CO#&5"(=P!02BNN@-VKMKGX[ZKT]GN'M.LN,?94$KCZ)GLIF>-HE6HA?>-%L(\\.]J)M1,A>A<""9; M5@WOE77M9B&_E>5)?/9',L-9D9[M*\)5Z8^3%U@KQ6L62M=["(S1AP3@@*7' M8ANGGZ!<#?SW)2H>L_2X>R2G%?*)G#9G0B_R(,8O685B,O,9<8GV,B:Y3@\; MK_V=C+&IJN_\",.D>L$CC/$'?#G"F'/&\`A3?\"'(XQFA',Q7O4/,9O[.KY-'$L+R+VP^HE*# M..BX*<1^H(AX=1I/O7@S-8*&\NSD85D8E1CQ33=U9&A"K(HXAAV=HV_:/^)/ M]%E[?DW<@2".4U8J2A2E,IO#;GS*D+ZA@U;7$2MK7Y`I6/V+',$D9^MZ%H=5 M+B82V]U<(.S2+_FP@FIJ+J-0$RGL-[\BJWOH$!V)NDNDL,C-W/Z]2ARCR)V` MTW@M=AYJ>A\E9-$6##49?\"74),Y9PQ#3?4'3C_4-)U7_5#3^\N/ZX]O3R74 M-%*+-$--DU3(GH4!U-<)?4\*%X-/9!.$3%YJXOLYAQ([8C:-=6MA2"4GYV`/ MX*:8_M":855UHQK(K/4@X6XBV1_?W:/+CV]OWZWOWI$?$%7W]<<+]L.[__7S MY5_65^\^WM^Y5_$Q8MQ7Y/$R;$]=K[-=D)055-[6%8#)/PCB-\S5*ZNKE/8G MB.OJW?E%E&_B-#]FD*)_%^V2:!MM("F`Y>]#87DRWX98JGO\N3@G9/PF47G[ MJ%@W&PZXW=?!-@K4SVB0H!:IC084?:D100TFJ$&%PK2000TVJ$('_0H((8J1 M8\_%@P68SBR;=M"5?>C;4K?&P;7[U!"@8T@-YO#$<1JF3]MK:MLCO]3'>#GU M?`CE6MK/CZT5+]F]37/I@W0QB+/C_JI(>D3)J'+1<=Z>3-Q,K6RE)+U`GC*I+\W)]#@P9V_">EZWVC@K/^2]R4Z\ M2R&G"I,[%0KTP+DYH`4+ZYL`<\WOP_NBY!Q=(WH--O>`OK84E!$H;*9.6RO% MM*S](9LO[C#F*8%H#_YJ[7#$FO21U`@KE/Z2TB^]B'(?L/%S?&! M'..NMUL,?Q;=MIO/8[F_A#F=^GI75O-E\R`V$:IF*5GSMF(7LKA5<>5G#J_1CSZ>`2MU/1T_?1*U2JO MXY;JZKNCCNOK,*2OU8/X)HB@&UQPB(H@'FY9V7[89=$BHYMUC!PVY=]4=XJ6K4WWT;P<=KKDGV^C.B?G0_TB>T\-H.0?XD'*A&I M;'L+%6]:MUOE=GNNLE?)`;-C/G=;L(.7E>1?18KP_A"GSQBN4$H(P!IEM.; M=6@"?XP+/QZ36C80TA[OMJS#E'9EU`6@WZ8QB%NXEH*:DZV4AKQ9D!L5\&+T M%;I_)..;,<3RLSJQ9$,-64(6AEG3C(XGH$3-]F5F;:_+=4BC.VA/8P8Y"C'! MH:PX2Q`DVKD/DF<4?,:TL!YH-,/!AQ.*7.CYLXB.Q#OM[5`5HBSW=(U7;B:3 M>%#+74*A;J.&NJ9K.84W;]$F4H$QTV7`0\>FYD+K$:7!2UI M=:F4%WB+LPP31_D))T?92S$-6`]4D*='4_,J0%1"^J9M:L+:/13"BII,1HU; M]1*(GEJKI')W*F^$9HV=>(3>],]%$V>[2VW!X\Y%^$.37$[M+BSK7ER`AT4 M#'5DWI?;#C??=(_O@\_T$=2SS@LC,8B+K5:$_<`.2X8B,G;%GMN14VSY7V\> M*%HBQ_(.*Y6O@8U50[@L)G4/QGA9>'>=P$MN3)3Y"4,]])SA+%&=4;/93_@> M13,7-Q)>\+"9Z&FKGHMV"\B]U^"+"&; M-Q1SH%CK;YU*2.NZKJ:%2RDN(>`:EMWB^KNANJ'.I@9JRF)?VXP$T6:=T.K: MNGSZW#1WD)U-Y6`.ZH5*J>!O[^J[^OJ1>PO"O8SIK`I?>E-W25S[6376Y9&M3X6CVD6_4/^C'?^;WGB!T[CEZY+A%J?@4A" M>UQ5H+9\^]MD^979GLT'W>O.8C*GYS_-)G`6,P,[S>,'5&NH/;R=O+H*,R[M MC?[!@ZB>$$.*67G-Y5XINDO,I5X-K.^$7(T+G/]6/ZR0/X,8'&HW-V,86_Y6 M)?\-M9ZX^/%*0L+I3F*`DLT6*RY!!CRTL?L,)A,*"]!GVS?P:EMB@N1@]NLJ MR:G@L^+R\K*[`H`L6_9>G<*XMQ`ZZ\)52])>E`G6Y')_"*(,!/=Z>T^8&CW$ MF'JW1?4/L%[LT2PY8/V4IN&G*([5(8)99[=KLV;C"1?DKB>&8H35U.4!J9H< MT=E1/3VJYO9XHGQ/0#\&>ZSY5+D_W-&390YK\=-E&$K. MMV2P=Z^8AWD__)I9QO@)U'X1&3@9B MV=!)L>>,'1N-V'#$QE<1/J?'T4S M5T"^?@K`IEFAWD2-=2=_:\WE/J0P8=&Y>N135]SBG1?K=/Y\@8E5B63/6KB1 M]N^;.%RYVZ)R!"J'N)X"C;S?$0)(,):++! M=MT#$<9<#:]Z'&R"]4B7'H$NZO7?H+1(BPC?=G*I\'3V<`W)F2#$'Z(DVA_W M].UN=0]YGY[C&[**C\%POV5=0+O"K4-)7UI*F/)Y>G.+?9^B"/X:L M]1ZZ:S0/;=G3]'U);/U$/6A*A)0%)@>*Z3X0G[CZ5.E1Q_0(1E\65-NM:W72 M%N..:AG*L,U MI;=0?(J6R2K9$[P/P6?0"&$L3S#.NDCU\>0,._N[!U$N*6?[8B%AZY1@;2]D M)C,C*@#+P5H)YGR%"2[$J305=K9P,RK^62=C2CA9)>K=<+*>G-M\$4@93=;_ M*GK"_5N^_$/PMS1[&Y.UDEZ]39K-P3O",33S;_*J6Z)/U.O!'KDGRJ7HBYGF M.M@3I@O\4)BU:Q1"6!Y\]NE#X6_71<4:]&5(:P$LUN](DSWQ;HH@:Y_) MN+;Q`Y*DA+1?@4-)"U=$HH%H'[AS;PI.C2#I^B-M<'Y_N_YXMWY[?WG]T8,. MYYIBQM6X,)$QBT]&GH(H!M?_?9K=!3$N;ULB7-:=:_XMT1^32>P_/3&AD,^Q M*('/R%GK+"?@J!F_JFHZ-K]R+Y[F"\H](AFYFA-"'#\?""%)4;VMHO%O471C M>*S=P(8`W[[TE,.:5W=TH,M8AB;BG:JX48YPS$(RQY*@,D\'!70"UU$#F?1T M`@9JT9D@P_>[ZP23__M_<9:2_\CS*06#[4JQ"&,N0>LG1/Y,_P=#Z0_.4RCU MD3][\^;U&P_.:FHIZ0BKAHA8O-%*GX.X>"[?!\GNKWH#[=]6]3'E;!L;4#W@ MV,P6<.C$;[IZ$[;4]T&4L;:0.(`0@];MEP+([A:KHH!K M7$[&5ZUF&PAOKL),R?GG==@D9T%+_CM.@X'P6RSZ18^-'W#QF+9JV5Q_2LA: M/$:')D-.LF\8S&&_$)@!?8(NPPRX5;MHA6IXU$S@?O\P7DNN?-:XA9RPBU15 M6EJ]3EBNV$^LL=-E\K9^2?(+L1;]:^5SXG1M"%I1CJ^WOP10%D;\FFBAC]G= MM9;BF*#)X/46=;H-E5F M,F3I!N,P?T_8\R$HQ`%[Z6C+CQE$.'.O&#7T&]%>E937]# ML6L+(M><[D,.#;5QWJR">50+-*O0GMB79A7ZG#!L5E%/?,K-*J9QAZK_D3&$ M_%_%CQ-H5&&H'YJ-*D8IQX3]_A9O(`.P?C9[O:U:Z-0M,VA%+Y$'H`]OUR
R"PKY3MX!J^LM0<(>>P\P4UFVAFFXQK#%]D;:?AQV"*#R#4P#K6N;2 MS9C`@/)9'+2D)S8`3!!FER&=\.'ZYO(MD)\^%!#R:[71&?!3JFI6(<3PHSJP M[=PM,57PCJ,R3KLGF",6TNFV&6BU] M`?Q&8?W*72@KMO@0CTTY<,9 MW0D<%)+1I(RO'4.EN80$T62P__*';W_XUZJU](H6O?/H58S90O*58LQ7T>*= MUOX0I\\8MQ1(^?9%`F/_SDJ"/[=IE6.[VY3[A"KMM>#NH/068H)+U(H3#P1^ MJP(%-UFTP54?&9%7-&HJNX[1.&KYVMJM.Z#!RYRZI`>BQ[4O,D&T.^[(9+DV-?8YWKS:I4]?AS@"._\=_`"J M^UW+O)-?_?6B7'789`:4DA]B3=D&L..RTK.\C+]O)*&+FTYK(TQ'=)>$%.?@H5 M[HUUHLM]?(5*S08B,A+!4#_T>Y#;0XHN8?72$O$^RC=!_!\XR-Z3WPQ%H*2C MG4@%C[-0+MA0!&,1'>R'9`BX/B0;4I;;D0XFGOKRT1GO4$*Z>*MDI#0AWDG) M`/?%*Z;%%!\0R`DPT.MRH<`6^Y<3X>A9APMJ^)6 M*&2,;LN#FLO+BL);(HM9$-/PU/_$0W5C)6,="`./KT`:RH$LUHC(4!_D0LZRSA-\L!:#3.9MA83#2PG!?19`FZ>[Y_U# MRC&_I*$WQNK"]_'C@YP2D0O1"N2OJM<<+4@?;(3.&@VX%]H+-.'NB,XY*E0[5W1!74Z8LIHV!(:(-/2]07=H%!TA%,B$9->(6$@_Y;PB*#[ MN";>-7["<7J@L=_@&1*I1#*J!VO[A9(6/?R;'PJ&*CBTAI-2`XE*4+>/?4:1 M)M2`0TES5M$,G5_#%LT'-J=KU3`1T=[C'U/Y7#IF?=ED.5Y)$FO5($XBUP+L MA<'KUGA/6DCHKL50$%N]$!-3CR+:`E%:6$$RUG[RT`"^0]E!;)BR'H(=&ZJ) M=\MFMDAHNENY-HDR<>'R=>2R,M,+9LCT#`CBG=?6'[&P(*0>K+O7S1)ZY.^% M*T#88;MG:@+MRUMA`^K@Y7!2/1\L7P]30JDST3Q7*I\I0<9_D44/1VKURW1\ M3,_AKI7&1%R%CXCU9'6Z0_XA2([;8%/0.@X*![PWUHG#W<=7Y&!WQGG@3:OP M5GK/^_8$[D5<+#Q#KK%$W_4E MZ@Y>H:M7-[Y$OY2+T&U:K;<"SKOQE94TJ2EN5V2'\BUMD`%)FVUF7WKY&?!" MN]7?JJJP6GHSG:8$]#%>!]3],Y*9Y$2S5^`X(;'8&&"S@?TI+X,;+92@N@&[ M2I>HAAZX_68`>E1Q!KH$JV)WJX[LL@(@#-B]&)LL'%?Z7WO5"&6,TBLR#_DW M^1?YX2'(,27]_P=02P,$%`````@`28!I1T>D3DR40```C$<$`!4`'`!T9W1X M+3(P,34P.3,P7W!R92YX;6Q55`D``]D)05;9"4%6=7@+``$$)0X```0Y`0`` M[7UK<^,XLN7WC=C_4-OW)"@D&1WQ(W;-54`A),G`0*)?/SU/W],HP]O+,W")/[; M3X<_'_ST@<5!,@KCR=]^^O9\^W'PTX?__.__];_\];]]_/CA%Q:SU,_9Z,/+ MXL.UG_O/J1_\EJWZ?SC\^?#GBP_PAX.+CU^3MX]'!X>G'_[WX=%?3L_^?!A1O\.+BXM/Q;]"TRS\2U;TOT\"/R]$I9S7![0% M_U\?5\T^\K_Z>'CT\?CPYQ_9Z">0P8_S^NDV`^97%^&8]NXCS,%W?Q.$FGQ:Q_ M^L#'_?9XMS%]&.,5:)VQ>1X&61@'G(U/O.4G^6"?8*X-9WL7O[$LYS_QQ()Y M&N8ARXQG*1[$PNQN_3#]AQ_-V1?F9_.4\9\PGQXRBH7Y/>5)\-MK$HU@_=W\ M/@=^C"_(7_PML:SFFSLX79W(F6LAK+K#-G2WE]3RK*AVOH.U)RJ M=*Q6O@DU)XH/9/G[4'-^HB%<[7;7+/?#*'MF/_*Y'^UGS]O^S=9VON4/6=KZ MUJ.UM(/4G:UTK+;VD+J3E0_6\FP/K4[W<$]?03@;P:^^,IA9,C^S-]*C=F1[;F^EQNS.MN[S4`UH^.]5= M5<(QVIE;75G*AFKKB_&4P_\O]L3A>#CCMLY:UW&CL=NP;S04O7*\%FT?#:>N M.VSK&C028KW'/CU*`DV?C#B+TE)JA(. M_QM/]@.7+QE_0\M7`T7^"XN*X3WMOE[EX*<[U:5HBI>MC`4_3Y*W3R,6?H+9 MG_`_$<^;>? MX/X`$,8(41NM?(N#HY<,JBB89$V2H17"=3/XP1JJI-`*;3E89*?I>@W6F+V3DFS(Y`)>$SQ>[@6($M M+%D7[\0U=V9K3(5%3.A)!PA]AF$5!/(FWF!P2I"R#1)PVMX1B(DZ)4S4)0`8 M<1"WD3]!F-IH`T#/ND>5`(*8JS/"7*U@/[`T3.#P-;J&>Y=B=6VT!>#GW>-. M`D7,X7D'.+P-,[CN_Y/YZ2W\C>HCM]4:P`^ZRZ,0C)C)06>8+)53G\M*>Q#` M1=?9W($CYO.",)_E.?J134)^AXWSK_X4VUQ%3;W!Q4'W6,21(!?R`_(,7H$` M4C^ZBT?LQ_]@"RF%6VT!^6%7.11"04BD;%:YFJ?IQD="?L[!F@-^BH86!95R M-`B;],TNMV'$TBO`,4E2^8+<:`FHG1MAZBY'`1"$/LIVF>?4Y^$P3XOI2Q(A MQ&VT`:04;2\*R@00$+(HVUR6WX%D.DWBPAOCZ15DE0WG.8_[X0#EWT))1Y!) M!^TSNK@0KIN8;4!$G[8?W5I_C!,&`QD]PE75;NQG+P7`>?9QXOLSKGNGGUB4 M9ZN_*9[K*DJX_&OO?1[9-7LI'HJ*E^[W64E>[LP'\6?^RCA/HG<1^,S3/ MA;5%+EZ.:FB6EM0;2U^2C-T[7EF"V%('RVIW%MRS5&-AR3MZ1Z>NEE9Q@MN8 M&'?8XG_YV<^X[^.B#"K36&VF0WE'3M^]#*@1+\%:>'ORH=L(JW:P$/D!Y'WG MTUB`X@[>T<#5PMN^_XT%S]->>DI]NZ7;UCI\9GM10W5=P(5K\.:FCZ"`=?"6PN&M\+55?O^,35 MEP,-2S'ZFAB,XM'XP&A1(O[4F(+MUY)LE@;%P;K=G8W&BL4[>2D5.:Q/#'H#R\E\C5:E%W*.^$ MA$G22$T:8:436%%?7[YE;#B^R?)P"D<,D:^BN*%W?N#4=;@1V2(H=&(JZG,I MCOO47_!:_;T3IQX=C8C7!V@I MP^RW*YAVF/,_R38)O)=W?M'A/4"%BT[\2A-+W1N+Y^R1!(C]6'P-KC.:=.(UP;:0E=>':BN^AH$`W?AJ#U+('EA;BT-\W M%#V]D^Z>(G6@V8H2:N79X6XZ\\.TS%[W[,>3$*Y`A4;GJ__!_:9!P:,Y]Z+^ M)4E&W\,HTGR9L#.Z=]J]BZ5M^+:BEXB\"$LK23AX\!7/1^/15][1.W7FLLY+ M1(WF$2L3."*RUO*J-1K(.R7Q@J1!"_*E-T?;$T]!C4(I3AS>U\E5;\,8YA+Z ML#]FQ95=R^U=W=T[=>:#NYX>ECE2W-`[)7%BTA8NLM1V,=')&6F!TR>X%/AI MF""Y)*7MO3,21QX!10HN=T#022S9Y%M:@OH69S,6A..0C="\D\H^WAD))RN< M,>S#*,/3!S^*M43N)8DJ\<;>&0D7*_,ENXF@#UX49:ROCLOF1D/OC,39%2%& MS*(`08\<'TITRQPZVGQNM??.:+B[[#(EHU0$PI+7`05FD0M:?N6GZ2*,)T5H ML?F]>[._=T;CA1(EU,0]183-DEL"!85X>DW2_)FETTJ>!^D#Q&YS[XS&$Z0A MW2@42QX(%-B]BW,&;.2/+&"@T'`R6R=D3!1F:Y1!$B? M'`%T.=V4PCD)>Y0IG;L8;+W(YTGN1ZX]NJ3NRE^3.%"2K#^(=WY.XG:L?8TR MA4;CF=Z.;MPG\43_+"UH[9V3,%)JDXU!:._9?/^D/J3)C*7Y@CL9K9+H%6>/ MKTRVQ&7=O',2-DMMFI58;"7^I,#WRAU$PNVJB=>QO7ECW@AGG31K5$K0'<([)V%T-'HT,L*&:$4GHV`JP/4?E?!.<'&@P+T1G4J-$&%$G#@Z M:=A:NO&NDD>"Q.!OTCD@V)&!;+/7'\4[)V$*4U",?!T,82**TDE#V?5RPM60 MCQ7LA5I#=+I[`Q)FM5JJH8T/T8E.!L&L0"_C1_6U8+.#1R,Q?R/>!8@0ICMI M0JLF&%;3+&CMG9-XXJK%,08'(;B3YC2CS[W@BD+UDMY-`KJG)BCJ%X#\]ML>Y:S.E`0@CLI`7L`793LQFS"\RLX]B#E]5'9:)7$Z#((YM-Y4:CDFHW#()1[CJHZ M>VX+AS=B7Q,=H@WF%C.8&[5+U3HMT4.2%I3E>1J^S(LDN<\)MQW!1P]F#U.9 MK$);C"Y@=7[`!AXYWT4.3'HX4T8G&=CXG MR8A$A>_=90?3+V`N45>#*NBGSJKQ_IU%H^?DBY_S*56FII,H3-G7.R6Q(`V) M$"])/;`]20TFK"KO;CFV45O^PED.L/6T*KO\4LZC8?S(-2N%[S^H*1P(TM7_ M_.QGH7X./VN_X='(^*^D4KQH[8J!1#6YO>I@(8EOSPXG M5>A5:(%%=33Z.>_P@(39MUW5K"&2UBKC.?D4[1Y^W7V'=N?"_:9J/496.P)M M!++&BE.>%S,O\YYGET$>OJT(,,LD6W=P$`U1B^(N@8@1P)(,>I$I"^!:'>1,]JS$NB)>HV=)&COVR83'58&0+,G3)2$3XU*E*(OEB:X/MQ[/L]AE;$,SF7P15^6 M2Y#7"$!Z@$B<7H>-F!/OJ%)D?:@=(`+(_Y@RIJPAH.P+8B)Q696RJ$^\`%NO M"@N4)WA^$$_B(E1#LS*(J!^(QVGPBH6UKX&O#]4(MM`I5[VP/8B#1)B*!F=B MLB6H+!4LH+'&KR(_R^"$S"_NNNM[NX]W>.34$=[FVA9CLU3)P"GE563*1;W; M&`1!XK"N8$I,+P;'4D$"I[P^ASF_X=_%H_`M',$55K&,A>U!'%T_FDMP6:I, M0(OF7\/\]9%%!4/9:SA[3FY`8/E"N;8-1P(1DCBT2_C55`@=G);J&CA5E0(C M&SWX:;YX3OTX\X,"\N=%]5\4VX3^(""XKA_M3<':JIQ`1DV4F\9N8Y`$B2.^ M*7=J#:CBLU5*P>Z+XS]85N@W2\-DA"QD<4-`Y?0QH\%BE0&R52>A19K0)88U M]0Z/G;H(RN2M8J:*P%:E`KO)VZ8C1= M7#KH;)4HV!>;\F6GZ@>8G3I6:--BQ&85FZT2!';YO)M.X7.)*5-F^DJ)ENE!=S> M^OUXHEK+ZS:`V_WQIZ%I9Q.+K=(`[CG\PJ8O+%6Q6+8"["121VZ1(6&L.F]; M6?J=AV_L M/7?&S0^>#HF-;D'$W%%H7E(Y'*]$\\#2(I[E^7`!IJSXTCW=Y3=)DM;BRE@6Z4( M')]JMNJ*ZRF'K)MW?DC\F4OS)*.":*L,@=W+RT/*9G[(@^09R(M/_)J]L2@I M*DLO8TC1;X5&7^_BH,L'54.C_V`9VV+)PI.-]H"-N(^6=H< M"G#9JAS@.NI[N>]L?9.6`:DN(E'%$]*(1I5W!(HOG+UMK&.@Q7/$8EB-^GN' M9R2R>>G0@#Q]Z,.D$].:L>#G2?+V:<1"KA`G_`]<#TXJ>@!_Y=VSB1^5OK[( MRX>@%8"E4=Y!GYE-:E%,=.)4=0E4>+9O-P&83DTAJ.1W"=J==A]"2,6:*C.L M:_8$$='(J%9W41KA[$,XZ9RW006@HWI9"WE?[UUX5?V)A M>)`Y,>M2[4^7/7'T(MU50VFL_DX=%6/UAX``$B8N>\K4CK**I-:'E%TBUR3E M5Q7O!((A85MK@VY$L12RZ$/^KR$WRMPG\<144>0=04`D;''[4Q8=>?0ADYCZ M=*'S4&321S^FXW^GD2\.O@OL,_6T0UL*!`F"<-SRSHCAV\K#UG'=.D^R;): M&PTZEG2S0E2'2B.GI!>(AH19J@:? M"L7`L/;!GUP$\JB6&ARM14/")-6J&FQ@[<.+K@CD<2TU.%Z+AH25J54UV,#: MJQ?2HL"M1I9247OO\(*$2:CI.5("K@\/G3OPU-X8XAX@$AHV'9PO38*K>/KP M-/F^`@3Z?QO&\'>A'[V7`/,+N%KOE4V'!B&3\`VS=]EL(H<^/&O>A_Y+&&V: M/]_-.A)5DG<$`=$R534B6JQ$.A*P]?J9L]3Q`\/7)&?9,FF,F:8H>H*@B!FP M[*N*E@C:>]TD]]YPV)L'AXMS\P6)I#L2">SJE2<=SN[B\N9R%\/OSJ>RE"UU MAP(HM"P`J+@WEU@SO'UX:%AO24\!B_TT3'1+&%?;@SC<5XNI32-R4\"!]N$% M887J6YS-6!".0X:75U/V\0`4A>4OX0PA68[(K='?RDXON]@U&0X$Y#[%H:4E MWUP.O7H6J`B`U_O]%BVF^:X+'4%^%\-UF&4\ MGV8Z9Z.[N$R+?A>O\J";;)1MS@/8<9]BW*(J.Q1BC[((619@F0,>Y);"<.R: ME?]M8=`WA67JNZK+*4SN8N,_X3DBE-81EZ3FN/)C\YD;57IP]%!2^,N@*B!U8.=<7Z.%X;;1^2+*P4%*U MM5.GNW=TZLS->CT_94*OC88P91+O4?KB59BT*JC^M&&NS$1'IR1>DD0DF5@H M"QA_6BAW['FG)'R7)9P96RA/>^*6O):)CA/*;F,0!`DGY!H+=PM#'ZR(#ZNI M/N5)\!L<:(9I`7=4'.Q6->8D!.L-``(C\>"(42DFW@1;CY)6;\(N,&:7\_PU M27ELK;8N;'<$.9'P-VZB`V),/;)7B>#>9=GRDW=$HTQ,<\ZK>&SEL7;N MYR4".H2[?^['(W']+("<:#L>->=\!9*ZWWV-WB`O$EE, MS91`&Y@ECV`*NWX%L\'G7M(+)$3"=[PV]6)`_?'PW8&J_,@C/4`PM(QM]9BN M@NE3YJ$=H'J?=UDW$!(MRUL]QG<0M9V!97H=8BJ(B'IO?S%CU_]'+Z3E_'H,@VS/(D? MX/,Y]8/BD^-'V1>63EB*)B*H,0J(P[VOLI0J`;5U(+I]0$`8+Y)"#V=PJN#% MRZ^2K*CZ\6/&72%D&ZJJ'T"FZ>HKWUOU8+E-,%*#2?F.J^X)L-U[N^IQ8TAJ M%=^?"4-6.1J.#FFZPZ&+5P/.GRE"JBDUSMTN:`V^-`FNXNE#BI"K)'YC:1Z" MHE=#RY6IGZ3]0#PTS'8R]C!+CA)7'Y)UV/&2.^_:H4L#CBTK?(_9@O'!96 MJL28[L[++`08[P^K^L3:,:P<^B[F1XCPC3U$?IP5/STL5.,R@+^%!E*?&Y,Q M8/*TW-74DA:#D1E&]`4!@[N]HY@R+ MMV03R'V(.Y;AU7H0TQO`&YR1\.8SH==<0;;Q]B%>^68ZBY(%8Y7%I'P[0_N` M6$@$,9J0*%8#!422ODF:>Z32&&\Z#HC$:/U_]HM\/E/N MZ;,D+^7YE/BY[//BOE9*KQ`E_GBNW#^F\!G^ZMA?5T!_/: M:$5"EARVFB?'I*&SOT##/+N+E;8*NS_D'1V[-V!2TE:1>'J4\:\0:_E<6#7[ ME'%6%9EG-S]8&H29-,[0?#"0IWM_<:OJ5E,$3;W=+DJ5BMF$ASQW>N>[3=(Q M"W,>Z[2'[4_P:\"(>\L^I3T0E5%39[T>:>W-CUE8/I_N0VL%OP:,N'?KIZ2U MJ(P:.R'V2&T=7XV.W3^@45)91$*V?"E%^7F[I[++DQ.WE;2NLCN_!82X=PZD MI+*(A&PYC[I/MV)Q3?_*PLDK?#$NX>;G3]CJ"E"XX>UGWY7-`(CKC*5TW[NQ M6FZVO&P[8[_*C`PG;:F^O5D`C9UY2;:C_K9E1\.%F(CZK^3C?`48302(_(,] M5K0@OC[Y2#>6G\!VY&HE&$[%.SKY@SV%M"+`/KF,6]A-=FQ2[KX+1E,!,GOV M4N-$@+;\ZSNQ&OIS,S[Y\T&HMMQL!0_TSGKI2.DU9P#D_6F""QDB,0O& MV5_(''X:"!'?33`ARG(:.)@-4-K#YP(7,D26A?'S+I%OA9USY1U(*HRS,%#5 M$&[M-X&PCBGS'\RPWTQ2B#+7?,XE<6FU\VG;%-:> MSB1;/^H=G?;0%MFBJ!!MMO`R2RN-PV&/\SALQ3#;CL5\9/!#89`O*^C5SN4@ M&P=`D(C`-9#XYGIM@+H/.1V*+4'9`SUW\/> M!1*/N&2_^E.=7.;V?P[((%&Z5*`AMM\@54+H0_:'K06JS/P@;`_BH%')M#6J MQ:HE$8;;_!"6#UU7D9]ER^^X;IKU[3X@%IJA4W4_40JD?<@)446F_-CL-@9! MT"BB(&=*3"\&QVW-F^:7C?LZR5]48X%H:+Y3F"[NAA+H1\FD<@#::[P]Z^F;9;%M/>I:*"'7^24(IO?;3 MS1A.`?BC^6!!4_M%PK-42HF,MT4K@OM'L6M^75S"[R7,[T%Q9)A,$ MXFEFZ:.YK,Q%^X=*ZO'G_0I([]0;>I?N5WCN0..W>9&]@I:#_E&/'?0'%ZWZ MS/SJ<\W,:SOFB_I[1Q=.WYIJ2%C3)P9'VP='_+6\G@"S#XM>U_.QVA[$0?.A M!>=.X>VXBZX7COE+5-_B;,:"],+)D>/XH!-6P+:.'`5\6QYU>SF87DXF:7$S4N:)U.\,8NB^T<\4 MKBU7KST=-%OBO9>602E<6^Y(]!THCOOK0'%\<&YMG14_L^/;(_69D'2!J3FU MZ]20HV`]*0'VP3.B7HK"XP/W1AHE/6(SG0!(+YP>>I"-\/B0A'.50$/$JM2> M$/J0C;"VN^B]Q,7#WN`@:/>WOII[F"WT??`#V?)HOOG!Y2'S#Q=W`('0R&]G MB5JQXLBP6W(!(1&A\)Y6GN^N:IT0=P"Y.+T:[D"@^4)I MJG5$;P"0FU,7E?WHC(DL+.51S)/.87=GU$;&G:; MPY0Z5!RAD!]F9,#`]<'`8#?Q]/&1^_=_*678-U8*J`\&B*;YI8^/2)0B4#`E MIA>#TX=K_.^?=&FM7"JLCBPI>LM=P]IS<@&[G"^49QW`D MD"&)*XJ$8$V-T,%I*TC`\7DIXJ\/#WX*"R>%KP.^H.`Y#IY MUS%%:"M0@(QN*+>*W<;>\0F)*Y$I=VH-J.*SY>[O]FEA_I*%H]!/%T\^WPBU MGA:P/B`7]_[_=9X6Y(!L>?B[)?H=&3\*#\>5!:%V551V!DG1\/.04XGPKPG/ MELN_W1OU59+.DA2VJ"]AQ+(\B3$3I*0UX'.?1, M[@]3,O%KL57%@O#EV%BU.V>Y*01K[QV?NG]SEQ.@Q5@5#<*8L0W++F-?D_AF M.HN2!6,5I[Q,MB-*N@!2]P'QIMNB$@_B*K$O.Y89<_(-4MH)T+H/6E>RH<]@ M%17"X;[,59AQ/\OF?ARPLE:";-'MM@1<[H-(3=<:!@.A9U\6(BUZY"M+U!:P MN3?[8B)7LE/%@/#3+2L-O^NPW^<@L)LW^'\:$8A(#Y")^^-DS7L["@>AN'OF MF2V$ZLLZUL<[/B-AEI/2ILUT%1/"=<3``'+GC'#N\:O4#^;@_ M`S7Q]L5!(:1WR^EH"YYR<0O;@SRGY).VU! M#B3"H20DB5E%D"",.C;U7$Y25NBN[-:RT0C0N$_":WIA$2!`^'!LR%E/5'Y- MV6KFG1'@1"!C&1/5F2/1#HY-,Y?Y5&[W7#<`%.[?$822%3&P.6M$]MWR`'KD ML:DJIXU5&\#M_CY?QR=C$P!"7,?<<3@FM=/R>ROOS&W]<80,"6/5>2.<.2Z> MLZN+]ZI:.9(N@+13=R\]/`ASW;*K/*RF6L`M(O"SRWG^FJ3AOX6U&/0ZPL?> M_>=/R:!XB>H@0[CO9(*33;P/?CI,B_OKJ,CQ^,#20@3:JH`-X!V?NW_ZM:(2 MEGP1R*)Y*M'2O79D@"FMLF**@L&O_`9:^A0$3"VY= M,[J04?;,TP-5__TJR?*O2?Y/EC^R()G$_"!0OJ6"X)9_Q=L=2M1XOQ,!(HED M)#17;A>20E3>V/;7:Y5WH=U`#T57>K>*7`H%R1?2K3#,VE^RI2]8I3!%^6UK MXR2!_1;P0-%NV.X10BX,1"EI5)4J1%76Q[J>IS#S\HM0'H:^LN_%/V5/KRP: M/[))R-.M<2#KYURI[:O!N"`Z]Z\UAGID$3BB,WNN-67+FI($C(VR6Q#NRNUN M.*[<%:6&%$5?[WC081N*%CA$%[KED%A!96!2E?3RCL\H.B::VDG$L!#*C0WI MK7PR*K,O3#N/(/?TC?%;Q.T\GZ=LI_:(.@@1NCOFH_@>*5D4 M/M,PAV)=0"J=7=MR3`C3W7),M&5JT_D"6/\M[[R[WXV6A($H9;?\**N&6[X& MGU@`Q^\\9$L!O_]OB;;I#^(-3CK[3&.*$M&/?7EEMI(#L'8AD\%)9^T;,D0( MQXX]/?DY*LPRF!1\1GGN-7\B/55NM_4N"%0=K7N`%(-!\N$Z=@-57F6_,M14 MI-,7L%.,`%43J0\.(=9QV*[4G/7%3W]C^RR`H&@BDTKF= MM@E2A/\FKJI.BKA\37*6P>&3'S"6Y5MA774'J(G=;]`6] MI\1O+,U#6#+%&E*E@A*U]HXO2.27;TZ1\#Z#0W9;Y$7C4WVO"O00-@9P[OW- MM'9T%88^E&"IPKN:IZG8=4'2&D3AWI0@(4F\WZ)`+%5E:5)EP`ZQ]TD\>6;I MM(I4PJRH.4C$O7'!F%H[M!HX5:(K!4HH5$85>!3T5;FY@&+DA<"&1"TC,-7#BOR8HE.9B"YBL3@%0;>2<'[MW2$!$+ MR!#,W>WU746$(O/'9C,`Y/ZM5B!B&1'5F?>ASNG:O_4I8+&?AHENYK)J>Q`' MK3,XNJHT8/2AMND*U;?L'22>0L:@_B<'\$-CLYX3`L54BEQ:KZ MW"3N`2(A4?96PIA^&8^^)G&@=#S0Z.V='-$Z MRFMIA#8P6Q55*>C"YC)8B>#1SUG5,5Q[F\`&\`8G'?JTU,'60G55)^_@L/V- M>,S5"/Z0)5$X\HM@K*6].1N.UY]5)S[S=S',E*WGH_$RCO3P3K>,22Y>FK!G M='%#F#()]TNI1!6/3!4@?7"QM_-F>$K$/B(@R>3-\!0WBW3+I][NF^$I$6L( MSIGIF^$I;@?IZ)._S&2"-P9!.'WL;[!PMS#TX:7_'FYK<'#)'MD;B^=2#]O- MEB`"6J_Z6^2(J12"L/203^%FPE-H9G#[6N8`R#2.>E@7D`V)&F1F!,O16'K6 MI\`T3ST%@N0A.]>@S%$RTSS:RSN"G$@$I,IY%'.O@XR$#SWZ'!%SK.WNG1R3@.0B-AO&N@+^9P^^3&4%\] MU*(B80^TH!E:2&WY,[@_<"S?IN.)Y/N"M@5AD+`2UCE$(&!L.2408K9\?+Y/ M,BUNWUN#0$A8`\ULP"@0A%ECZY][9N&\DVRBU+\>*/N"L$A8$LU8UX2%Z$`G M*SZNG*M*N,6!1L,'L=(:1$+"BJC)G9AX%!="M;ZY\**D.F83[L_E_FQ?(E0= MX:@FB(&'0L[)J-S`A])I;\1JD M+\-20;[R8AQW\:T?ID7MG^&8&QU*%V?N)(MGLS+J#X(@896K16X-I`CE^L8Y M0BL:E5F=TQB(AX1IKM$J5Z!#R->WOFV2_^S\7/Z0)N,P5URTWAN!%$B8T\Q. MVMOS1U@TMH^YOU;=^&D,FIJMBGM]]K,PX*].833/Y56AY3U!4"2L8V9$:X%" MV#OO#PUW.W\"=LHKE6I`:RO%/4&!+&2,*F9Z4H3K(@*6?#+ M^=;%GX;$Y*FO!2V!BFXSXL5BXK MP8E7`H5.O$[&@I\GR=NG$0OYEGC"_\`Y/*GLA/!7WCV+7G3-5X(@60#B>3*,&?S?_V)I`O^1$R5L[`U.G%[,M1F2 MS-Y2R(O[,_M66.T]_R5U$DM)+Y"F^_(>VE\R;4!]2&B)@%1&F4K[@7A(F&"4 M#!H17\7F-I&E+C)>D!B3'B3,M/7QMPE-^287M01ZT'KEPTI#W+AR5K3@1QQ>H$1N'<9BS M^_"-C>Z`FGC"TS=>9AG+X;#QQ?]7DEY%?J9:ZH8C@0P[>)ZN!=)6L`AE17G' M_=6?JC."K4@3`GF&PGCR_BJJ/!6B?4`N1&PV-2D5 M:X@";PO),EMX\[U7Y5%'.P!*IR\?9A\)'2RVXDT(K-PZ&<)."*2O53`D6XA; M0&@$CB"K\-L,<,?Y+6./+&!\,^+)W)_F+TLHV&)4]?/.3^G=VJ0<&L!J'!]" M87E>+V>J7IY;+4&KZ;G::"U/(9#&D2%M+L_+T2@L9W8Y3>9Q7FHE_[0,XTN0 M#P#AZ(?CAY0]K?*&?@DCQ@M?X0D?&@X+@J/GM*->W%90VXHTH1$&R-\`G_T? M2]_ZSRR&8ZDZO?=.#^_DE)[97&M+D`)J'&)"B&M!&;WL89X&KW[&BM(;EU&T M?`/^)_/3X;C2\)IE01H6L"J!QA`L93YNMK^Z5LN:) MN`.(I1_'C@T\MD)@[-[-E\?@!W]1N#$77TO%36"CK3Q(ICC1Y.0D79=KK123,N[>B=G M[LK(!*]L-(>[PEC/YT99;:;.>"``&DX.6D0A3^/U@=,)BK'@)%$8^(?C(G&U MKH/$=A\0"XF@_P:<*OPGQ(CIQ-LT*+E00:9\"MUM#((@\=*I8$I,+P:G%V5N MYB]9.`K]=/'D\Q6AM<"Q/B`6&JXQUA>X''$?2N14@/%WW.&X(BYUA2ME9Q`4 MC7!O.9,(_9KP+,4;.=6#YS#G8._B4?@6CN!4KM@,A.U!'#1RZ]G>""1H^Q![ MM`/OUS!_+03$9?4:SIX312ANS9%`A"12]$GXU50('9QN8Y6P(O21'Y2)`"8L M#A;O>0'$ZU_9QSLY)W'[L[8':")V&V]D2"ZZCC5Z`5SW=E,U'P8D5G&YC2;" MW-#&+[^DR7PFC^?>;`5PW(?ZZDA<0)0("8U*.`A!URS[33,]@J"I=SYP;[RN M214*QW&P$$+479;-_3A@99UVV3=NMR7(@,9=QNJ7#2<#$NF>[:X\+=".(V[,:9:O265' M0.W>LT:+&3-&J^@(Q;RTG#=M0,/Z;VO9HA@=1Z_L);>:VS,J*OI=AG:G[3A4 M!=E$A[,Y'B:VU0)P.'UB$T4+6E M2#\^>F+I&\P_TR1/VLD;7+CW7SG;=P87[D#=3]M2`'(4?0`0?;+%J:%MQ>Q#0*$:AT7%PT*_+"H(08;9;*4/,DSX.#DF80;?(D#!6G3?"6;<2Z7[Q?X33^53) MVD8[P$\B$=,.)6+F!'-'N.M6#A!D*[J7I&+2[0I2ZF=DBAYP))"A6SEXJT[: MU;)<&7\ZYVG+*OAEYRR#86#_I+&A:[&,G,&,\2+:TK7`-@!<0KR>IV$\*1TK M2NA?V??BG^11;CH#>"<#$H?S1AIB@!31C6[%NE661)$)8U484F_7V.@"*X;& MT<'.#B'`AC#>L2BX=XA7\)$-1ZPT0ZWRJ@W-/Q[J<4!^)*+E+.F&+F!$8;IE MQ1OR5`Z'/'T4>B)>K.L)F2"(=IHAJZ*!%],+;H4`^"_)G&@3"6DT=L[N2!A]&VB&-HP$5&TC9S`]'XK,1MIZEG0!M9Z^9NNB0)!NN?=O@<.%/V&4< MS_WHD8L\6F;DPUT4\2[>>7>/=WK8$!:[93P]U+?12T=88S1NX=<*WO",`CF,S\.1&?P"\M?D]%=_,:R MO"B8\#UF*4_,\Z[6DLU7>PR0>&=/;C7!(DKBN%)7<^/0S8\`D(;97FQS@A_S M!J?=WF1:E`JB&&=$&QS&EPV)"MXP]^"%Z MU-AHY%W0<.6OS:``#<)-+UP.5P9'7FZMZIRWSOVGMLTV'!EDW/D'8BLB0%*N M=LMU<>M%M((R9)FZ!(U.=^^B^^=3?9R(5C2Q,CJIFP'GI!%?#"/N7)-$X8@# M7N#1K<":S@`I1]:&VP\-JJL610!D$*6H.PB!AG)0P):86 M!].'P@T5$YJ2UIVV(`82!D1C3A$D),LKP`V..SL`KJAP/^7?G<*4J4KS(NT& M@$G$EVE3IP_*4AT%$F$!ZUKNW#YZ%U_YLS#W(^5*E?8#*9&X:1JO6@U4;HLO MV"'].65^-D\7>INRH+5WZK9.?6V"42RV2C`L!COOV$$O8N# M:#[BX>Q)6G"2YVGX,L^YF)X3'HL&IQ28.$QE+X,YWF6^S&7B$R'MMN"2&@95/3400S#5@6+ MYLQB:53%B2X*9\F;'[H^86:C@&A(V%/T&*X-T%:EBU9">:4)3AH3CPT#@B%A M=6G.O!RAK9(8^Z0>T>4K/WN]9YFEI;\:S3L[)6'#:6T+V`1JJP8'A:V@ID*H MA@-!D3#MM+(R^]^.OHE383:TV@\ M(*E#&XH%J+9JEM`P.T@6DD454@P(@NW0%F0#JZW:*825"%U+MTDZ9F$^3^ND M/-09U3L?D`B";'=+V@%LJ\X+V0\;OK*6LA`&6S8?%,1+R[K:SO:TA;=Q"9J+ M4IUB-N&.Q!05JEA;#?*O;O;W3L](/*'9VW:VH-FJ9T-\@[&8D/?TC,2SF\6- M8PN;K2HY>[>W?/'3WUC^,'^)PF`XAIF*C>6UQO'.SCOTO6@`T59]G/U;5RS0 MCP\$PNG0NUH3C+:*YKC_(ER._C4O4Q!DSPGB-%1(X[-?1$B]N^(7HBMC4N%8 M]?L\S.`,M:P+5TKQD07))`X5F9GV-`/8MSMX.=JK<&P5#'*OU0]I,@[S>[G- MYKT1+.H.O@!OS]]6[2`RMI4N>)*<=>AAN0WLMHH>E?X&-['C^W(S/Y*S#KTU M*V#8JE8DXI5PE/=#(>%7!MT!=G]#OL\NW.WL-4.^SVD9F=3RQ3;?75AN0[XM M\WH5^5FVE(YN%.MV'Q`++0-2A2P%K6(H;D/(+86_59`I0U=W&X,@:%W`Q$R) MZ<7@]"H&_;ZF#_XYK3.P_EK=PM"'$/-5(O"EKA:!?W'`BBS^LKNPI)MW1M=R MPFE#;L=*1/:#S0D>;`$_=P.[C9+OF>/S['H>9L?8G6[`>O=.KP-JIU=$K'J' MUD'?#JU/`8M]N*GJ'EBK[4$<)`^K`_4'[7^PMW"T(>3ZU>6\V_20YJ\A7`4^KSXEO$L MUNL*)I=!'KZ%11;*(K/%'/YN^8]P\-$X4]CY`6]P3-;O>X!:>6UBMW1N[MXK MX>F`Q"NA32Z5+XL%9DO)F]PSOO&@=(/58[@P5K5C4(]1PW%`,B3BW_:E)PV$9"NK%P7GKFL&:=TJC9NN\=95<&?W;?J&`C'5O*Q5CY.5Z]^/&%W\:T?ILN2BE^3G*T*E&#?(D4W`$["K+O7 M3X^63!KG!B-TG@4A\C29[)J5_ZV(;>D\KW&+UQ\$!$C"H+S_K<9,0K:2E-'X MAFUC?X\QYB(V4JS-KM[Y`0F#HRF]NDHB0MLXAQGMW8=[<2R+:%UF&9/ZY.AT M!X&3"+EK2T4PQ(WSG9%6D\L@2(O;81EI`3LX"]_X%QJV<".%D0T$@NSU[J+& MWCA)&FDE*I8.#]UIMMULCP"B(_'^T.J.(P;=.(,:?7W9JOYX&8^6R^@^]%_" MJ#@1FNN0SJ@@8A+O#*WJE;X@^I1M;5<8JTUY*0?3S]IN=Q`:B1>'MK0'0]RG M?&J[J*^7$![9&XOG,G=;95\0%XFGAK841`C75F8T"MK1S-^@-;RVDK=1V`-7,4W/ MR67P^SQ,&4@(8.>+A\B'JTH\XF'(,^2%WGP0$"")-Q*;ZH`X/!K*I''Z-RLW M0>3!;`?,WUDT>DZ^^/D\#?/%$POX?T%:3Z])FC^S5/3$6G,D;T`CHW%[*M-( M,(T3QVWJS7,#!T1,>=(D8&R4W8)(EW#$5WY):Q`;":-TVTH@`6\K01R%KTXS M,;9VQ`%!D[!?M_]ULB$G:[G=J)Z\;\/8CX,63]Z&/P!B)V$GMW+RKH6]3_GH MJGO]LKS*JMZ*(G@([09"(F'PMDDY1S=8I2Q0.CJHN(%<2KR'M:XE<`HARZ-N_V[RF@W`V M='PSS?P0MC(_BI+2BP^[?YF,`2*A?#6WH!0U18)HR9Z]GVVG?UK+4S_UTV87 M[YS&`78/GQJI!!#UZ*0_=#-9MG9G\LX.*3^B650U&W)"%-+8>]K]59Z+XC(N MO'^Y@?W-C_@R++/3;S]Q2Y3/9!@080W&J+\WH%'!4(LQP9W7#"="N05CJY/\M\-TXL?+N&;8]I[FTRG(;SA^ M"B=Q(9$X7[I=%_5-HC#@#]H.4N'NSD(GA13:";3AS-5.6Y7Y>]KADH"'"M'K M&[4?O6?`88OTD$M.^I@-A)/-NH%$/\37`C+4NI M@HEL..+SE8L=!3GIJ7<5>4<@S5F";?',WC5/9TO0'L,[.R+QW=>AP^2LCT*U MG[,;68%__<2G^^)GK!#N_P=02P,$%`````@`28!I1^0U57=($```,[L``!$` M'`!T9W1X+3(P,34P.3,P+GAS9%54"0`#V0E!5MD)059U>`L``00E#@``!#D! M``#M76UOVS@2_G[`_@==#CCL?7`<)VUWDVMWX29.UKC$]ME.=[N+Q8*6:)NH M3+FDE,9WN/]^0TKRJTA1LI,R=P**QA8YY#-\^#(D1^.W/S[.?.G?SN_+MW]Q^G-1@Z->?+ MER_''I00RA*.W6#FU&JB'NY.\0PY(6(3'';0#/,Y[VX%$GI;O$_II(_?CB/EI_K.Z2!XACM/L M(M4+EP+KF5_7X\1E5E]3[B^W4/!ZH423F5`>(NJN0.R`3E1LG)^?UV5JFC7B MM0E"\V7F,>(CF35)D`U7.VG4SAJIB!M$-&2+31TY=H\GP4,]211B9UMB$6/0 M)55R2:H0?+4IZ&&2+0,)&=GQHSO-SB]2,O0A]`'S,%LD3LO0AB+H7-DR,DF( M-#9%.'&S!2`A(SL0$"[FF&=2(U,R=.'AG"DJ@92,6CP\9]@5!&8M9I M4J]%0Q(NVE`VF\D:CQP"S:3-L421XO#PF%`B\39.&C!CIN+K'Z$H)R[+62OL M;7V[A&_^M%U\Q+'7I3_(S\`DA]*DK)@^$ODDBUYV54E121?Y;N0K*TW$ZAND MK!6Y'UN7`?4PA;K@`P]\XHF>_![Y8C8<3#$.>%6V$XR=5>D5N7N2VQVW/D>PNIGPNLRKI_1U04H% MHW'!%9L'8M-T9LX1U//\IC3/U11]^"GZ$O'IM1]\,9VA5_GU+']79H(6A3NR M](K:7&J[;((H^9>L';8;@V@V0VS1'0_(A)(Q#!#8T+AR]T[HI`RTY2F3F-<&V(T8*)`.O(L`_(C_`=1J(I9ZLADYVDYZ6QS/%B)E!&+B?IH'O8<;7-Q89S_6=-O5?.3(1E] M[(OM"FP_P\60(2''I:OS/>-3G?Q@56 ME)7;/JT3IDG7T[5S2)&YE:JHVG-/MK)T3"<7^JJ)KGXW6.E?*5"U1 MISL'%*I-5\54N=W7.D<9S_7L[!Q3;.S$*DJ>V,2\PB$B/A_BQS!*+]4.49"> M])USD+W,S:1J)ZF[ZBMEKV[0I89-0SN'.>DLM@99/LL?G;F"S5R7K.=@Y5U-N_:JKH).RMPO)(2=EH1M@=A9SF$G>40MG/BDD_86478'H1M&"&Y MN?3D&7N05";(GJ>:&\9'5H*>*+V'265K[,?*QI#2I.LYVCGTR.:H&D%[^`5E M$9:72<_:SM''KL]01=T!O8BR,JR=RYSQ$[6'T?TVH^$_$?.CCL2.#*5R( M]]3?'7$RFPO?Q_C9E.'QNR,1GJ*6!I_X`Y0^?ISY:191@R:L@^P%V^V45)P6 MD;R:KP_V`(4$<\S$Z7,]!7_DU`^H&#!25+%-$NU4RT>CHFJ!"/;MU0@&0%&- MML;,8?6*Q]MZ"`?XMA[B03X"M0(6.C0SC(PJ%DH<@>8V<&51&A'QK9;*U<2C M6N.T=M8X?N3>JO6+@%CI6`Q$*E<"1':D&O8 M#WGZI+8JJI#^FK`M.D`98LGGVJJ(4D"RPN&8(%F72[_LC24KQ(X1F'7!Y;?: MJIA2<':B\9A`60K)3_MVD]U(/2885E+QQ]JJ@%(HML/_F&!(9<2'O>O?C@QD M!"`5DI]*0-B-,B07&XHGPI`UF[E\QC:DQ/1U+J;-QIN]81A.GFL0PH-4KX^U M9`IIO936JI`2"+41MTQZ2BHC/I28,_0QH8P:9%MJ7YZRPUD50Q+03FDP^D!@ MY5=>699Z3DW"\4E`^BA8S1$7\0"AO\9FJ8Q?=P'/")VT0SP3NZHC!R6YP$1E MD3!:92XP$TG@#:6<%[$D[A8EOB^.D]*\/`)A$D8B]88%T3RMA$#Q\998V+U_ MF*%4J+A]+&*/6FIDAJJLMOEB__[>#]Q/J59Q(+>+,'V>I=D8^?R95,M$JM#R M?<0)Q9Q?8>XR,A=527?(A6U*F@!5,ODY(IZXIE@V3,-.)8V0*K3L,3Q'Q.MC MCF$I$WZ/5_@!^\%F6`,U'C M*I@A0K?ZI2(GF)$1^\N[$4,:BMHV5/*2%%;2&KWR( M"MW:,[#0`0KR6XP%S#;&,N&9J6(--PI<9>;O6S!E!?CGYVAWU3+$J;(ZXYD1 MI%PREZ'LHO%8R-)P&%Q'U$M"@M))&M=N4^54@6=>J\O`5K1`EDOVY12!G@+O&)U*`O7GD2ZH/Q2*`>-((4<0(#\PZLY#!`02VO35T_\L3?%F(41'#43_H!(;N>,V#Q;:U7P'05!UKUG\E,J6Y2:'9"#,+%"P*6*%W5[AGK=;/@,NCY'CS M:UO?S,=:0DEK>JP)2+5=YPH?J@F.(Q+W6.!B[/%K%LR64=Z'01_/T>(RH`_" M4T7ZKHZ69XU"ZWED0?<@]602T?XKCR+WCCGLFE! M*8:[@/)]+!1S9?1J*.Y%-8`>^_Z-8)%I6PYU@29(3GI?%/_9F,LK;3G?:K0* ME1.!+NN3R304=Q7"OV1#-7EO\C8L(QU:C]`Y"+=0C35DAIK,";-2CP27 MD19=V.^!I2E^;/%G+!Y@KPGK,"S9:7OT8(;"6[:$O%@YS%U>.26-81<86$^J M_],,N@/HONSV+TI]0]1%!O(+T]\`LY'VSN//:P^/K>$+_J M/D!86CMWPM992UJ8.M5V@QI:IU861-4=U+K]9,T!32:J`E:K-8KHP"D]?M@\ M$+_`?$=\+(ZFK#M+4B$T5LB:.V:JX4K'4PE=GH09:$S4L0:5K)A*718^5=;QL,6,)TI$^]Q MKB*V])R*O30[^(M,XH,I]L=]/"%"`0%A^2-[-E_$[J^;!$@ABY:P;&`&=%AT,*F`I9I'X+-GY3RR"2P/OC6S^`XB%?+XXM>:SK^% MYP#7E:D'29>^Z(M+C1J&;S19-U_E+&FX^KA*72ZGX]90,-K MC/O8Q;`U]@3U@VB4-(W-]D4^=M64XWDRJ`GRFS/A@!J+"V1=VG2G!#\D/X7= M8W@PQRX9$^PMMW//ZOQ6\.6FO35337<^IT!1I6OVCRR9S.S#B;O M#$'4:5L7RP"GVH=%0DLPY(+93&RC8?<=[[5OQ#62<%D&PXUBZ4HJ'**WK9_W M\B71M7!-T>)=>+O>0:].M[!N0C5!_#"N->2B9#V&(; M)A.M7K/UJ\/L%[O3FC-#DL.T!O\QVR==&-/):Y*M87841'Z0KB%G^%O/_H2ZQ MTN@P72.[A5Y"%\EOB5@)6>"V4=^FL5D/M2P->XL-EN*J%+%65I=:-H^37.BJ MLSBTB-_[#IKNYX@P_!/VO6%PAT+QTXR+U4\T#J8!"X>8S6QNA3+:J&QZ'*Y? MSFQ=HG>%7ZSO!_)W+*TVY@NI46)9B0.:]**13]SN>(Q%LLU=I+@N>8=8UEC# MIN?4S7!FC=&[AJ7,DIW?^^Q;K`OULK4S*-E%Q0D%$S=O`;N.8%;#J?.6S6.N M@!+&'N@6.;YHP:E"Q6+^R;XK[4Q4RBA.<[`UXMO-(1@?PCNA2<$`"],OG.,P M#M\!E-P$@?<%8-D9E_-0RIA<>'3@D7UKQC8R]1WG]I&_-;U7@TW%2_QZ4Q,@ M([\O''/\U(2T-Z"J%K2!^U37=:,YU+S8UQUJ[PL6!2I5N!5"R2R:);N;>"T= M!N]Q>C?CV;P$&H`W=.JR:.'30-.[/R7]-?:9L9FV;+RJR$:3+L7P[U?,@JY% M;\@H$`H`DQI+-&INKL%\8)(MFA.*(\_?:&:/"?B<5<]"Z M.P%O`'MSR,WM,_!S\"F]XT2YUQCW$'E6&['@T-W"6>97(`YW4?%4,1;,X&L& M*.'"BV&U<_CJFYAL4`8K:'KHM;%Z=[#--VUF\/4]]P[12/P$5W2@FX*G_=F2 M+;2J``"F&P4`%0`8```````!````I($2^```=&=T>"TR,#$U,#DS,%]L M86(N>&UL550%``/9"4%6=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`28!I M1T>D3DR40```C$<$`!4`&````````0```*2!6%`Q0````(`$F` M:4?D-55W2!```#.[```1`!@```````$```"D@3N8`0!T9W1X+3(P,34P.3,P M+GAS9%54!0`#V0E!5G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``#. %J`$````` ` end XML 41 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

RELATED PARTY TRANSACTIONS
9 Months Ended

Sep. 30, 2015

Related Party Transactions [Abstract]

Related Party Transactions Disclosure [Text Block]

NOTE 8 – RELATED PARTY TRANSACTIONS

LFB Biotechnologies

On January 30, 2012, we entered into an exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the “LFB License Agreement”). In connection with the LFB License Agreement, LFB Group was issued 5,000,000 shares of common stock, and a warrant to purchase 2,500,000 shares of common stock at a purchase price of $0.001 per share. In addition, on November 9, 2012, we nominated Dr. Yann Echelard to our Board of Directors as LFB Group’s nominee. LFB Group maintains the right to nominate a board member until such time as LFB Group owns less than 10% of the outstanding common stock.

In connection with the LFB License Agreement, LFB maintained the right to purchase at least $750,000 in additional shares of common stock at a purchase price per share as defined in a November 2012 securities exchange agreement. Accordingly, in February 2015, LFB purchased 114,855 shares of our common stock at a price of $6.53 per share for net proceeds of $750,000. In May 2015, LFB exercised their warrant to purchase 2,500,000 shares of common stock at a purchase price of $0.001 per share.

Under the terms of the LFB License Agreement, we utilize LFB Group for certain development and manufacturing services. We incurred approximately $4.9 million and $1.8 million in expenses for such services during the nine months ended September 30, 2015 and 2014, respectively, which have been included in other research and development expenses in the accompanying consolidated statements of operations. As of September 30, 2015 and December 31, 2014, we had approximately $0.4 million and $0.1 million, respectively, recorded in accounts payable related to the LFB License Agreement. In conjunction with the development and manufacturing services discussed above, certain agreements between us and LFB Group require payments in advance of services performed or goods delivered. Accordingly, as of September 30, 2015 and December 31, 2014, we recorded approximately $4.4 million and $1.9 million, respectively, in prepaid research and development for such advance payments.

Other Parties

In March 2014, we entered into a shared services agreement with Opus Point Partners Management, LLC (“Opus”) in which the parties agreed to share the costs of a rented facility and certain other services. Our Executive Chairman and Interim Chief Executive Officer, is a Managing Member of Opus. During the nine months ended September 30, 2015, we incurred expenses of approximately $0.2 million, principally for rent, related to this agreement. As of September 30, 2015, we had approximately $0.1 million recorded in accounts payable related to this shared services agreement.

As discussed in Note 7 above, with regard to the Collaboration with Checkpoint, our Executive Chairman and Interim Chief Executive Officer is also the Executive Vice Chairman of Fortress and the Executive Chairman of Checkpoint. In addition, Mr. Weiss holds equity interests in TG, Fortress and Checkpoint.

On October 3, 2014, we entered into a Desk Space Agreement (the “Desk Agreement”) with Fortress, to occupy approximately 40% of the New York City office space recently leased by Fortress. This Desk Agreement requires us to pay our respective share of the average annual rent and other costs of the 15 year lease. We approximate an average annual rental obligation of $1.1 million under the Desk Agreement. Fortress does not expect to take possession of the space until late 2015 or early 2016.

In connection with the Desk Agreement, we paid approximately $0.1 million in advance rent, which is recorded in other current assets in the accompanying consolidated balance sheets as of September 30, 2015 and December 31, 2014. During the nine months ended September 30, 2015, we incurred expenses of approximately $0.1 million, principally for our share of project management services, related to this agreement, of which $0.1 million was recorded in accounts payable. Also in connection with this lease, in October 2014 we pledged $0.6 million to secure a line of credit as a security deposit for the Desk Agreement, which has been recorded as Restricted Cash in the accompanying consolidated balance sheets.

In July 2015, we entered into a Shared Services Agreement (the “Shared Services Agreement”) with Fortress to share the cost of certain services such as facilities use, shared personnel costs and other shared overhead and administrative costs. This Shared Services Agreement requires us to pay our respective share of services utilized. In connection with the Shared Services Agreement, we incurred expenses of approximately $40,000 for shared services as of September 30, 2015, which included only costs for shared personnel costs.

On September 1, 2015, we paid $25,000 to Checkpoint as an option fee for the exclusive right to enter into a collaboration for certain compounds licensed by Checkpoint. The option has not been exercised as of September 30, 2015.

For the nine months ended September 30, 2015, we incurred expenses of approximately $23,000 to AOI Communications, L.P. for manuscript services related to TG-1101. Our Executive Chairman and Interim Chief Executive Officer is the owner of AOI Communications, L.P.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

NOTES PAYABLE
9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

NOTE 6 – NOTES PAYABLE

The following is a summary of notes payable:

September 30, 2015

December 31, 2014

Non-

Non-

current

current

Current

portion,

Current

portion,

portion, net

net

Total

portion, net

net

Total

Convertible 5% Notes Payable

$

181,668

$

-

$

181,668

$

275,190

$

-

$

275,190

Total

$

181,668

$

-

$

181,668

$

275,190

$

-

$

275,190

Convertible 5% Notes Payable

On March 8, 2010, Manhattan entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among Manhattan, Ariston and Ariston Merger Corp., a Delaware corporation and wholly-owned subsidiary of Manhattan (the "Merger Sub"). Pursuant to the terms and conditions of the Merger Agreement, on March 8, 2010, the Merger Sub merged with and into Ariston (the "Merger"), with Ariston being the surviving corporation of the Merger. As a result of the Merger, Ariston became a wholly-owned subsidiary of Manhattan.

The 5% Notes and accrued and unpaid interest thereon are convertible at the option of the holder into common stock at the conversion price of $1,125 per share. Ariston agreed to make quarterly payments on the 5% Notes equal to 50% of the net product cash flow received from the exploitation or commercialization of Ariston’s product candidates, AST-726 and AST-915. We have no obligation under the 5% Notes aside from a) 50% of the net product cash flows from Ariston’s product candidates, if any, payable to noteholders; and b) the conversion feature, discussed above. Interest accrues monthly, is added to principal on an annual basis, every March 8, and is payable at maturity, which was March 8, 2015.

The cumulative liability including accrued and unpaid interest of these notes was approximately $20.3 million at September 30, 2015 and $19.5 million at December 31, 2014. No payments have been made on the 5% Notes as of September 30, 2015.

In December 2011 we elected the fair value option for valuing the 5% Notes. The fair value option was elected in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments (See Note 4 for further details).

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

LICENSE AGREEMENTS
9 Months Ended

Sep. 30, 2015

License Agreement [Abstract]

License Agreement Disclosure [Text Block]

NOTE 7 – LICENSE AGREEMENTS

Anti-PD-L1 and anti-GITR

On March 3, 2015, we entered into a Global Collaboration Agreement (the “Collaboration”) with Checkpoint Therapeutics, Inc. (“Checkpoint”), a subsidiary of Fortress Biotech, Inc. (“Fortress”), a related party, for the development and commercialization of Checkpoint’s anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. Checkpoint retains the rights to develop and commercialize these antibodies in solid tumors.

Under the terms of the Collaboration, we made an up-front payment of $0.5 million, will make development and sales-based milestone payments up to an aggregate of $164 million, and will pay a tiered single digit royalty on net sales. The royalty term will terminate on a country by country basis upon the later of (i) ten years after the first commercial sale of any applicable licensed product in such country, or (ii) the expiration of the last-to-expire patent held by the Dana Farber Cancer Institute containing a valid claim to any licensed product in such country.

Michael Weiss, our Executive Chairman, Interim CEO and President is also the Executive Vice Chairman of Fortress and the Executive Chairman of Checkpoint (See Note 8).

TG-1101

In November 2012, we entered into an exclusive (within the territory) sublicense agreement with Ildong relating to the development and commercialization of TG-1101 in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize TG-1101 in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.

An upfront payment of $2.0 million, which was received in December 2012, net of $0.3 million of income tax withholdings, is being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which we will have certain ongoing responsibilities under the sublicense agreement. We recorded license revenue of approximately $0.1 million for each of the nine months ended September 30, 2015 and 2014 and, at September 30, 2015 and December 31, 2014, have deferred revenue of approximately $1.6 million and $1.7 million, respectively, associated with this $2.0 million payment (approximately $0.2 million of which has been classified in current liabilities at September 30, 2015 and December 31, 2014).

We may receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will make royalty payments to us on net sales of TG-1101 in the sublicense territory.

X

- Definition
License Agreement [Abstract]
+ References
No definition available.
+ Details

Name: tgtx_LicenseAgreementAbstract

Namespace Prefix: tgtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for research, development, and License Agreement activities, including contracts and arrangements to be performed for others and with federal government.
+ References
No definition available.
+ Details

Name: tgtx_LicenseAgreementDisclosureTextBlock

Namespace Prefix: tgtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Business Description [Policy Text Block]

Description of Business

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. We are also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs seeking to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors and anti-PD-L1 and anti-GITR antibodies.

We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. To date, we have not received approval for the sale of any of our drug candidates in any market and, therefore, have not generated any product sales from our drug candidates.

The accompanying unaudited condensed consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X of the Exchange Act. Accordingly, they may not include all of the information and footnotes required by GAAP for complete financial statements. All adjustments that are, in the opinion of management, of a normal recurring nature and are necessary for a fair presentation of the condensed consolidated financial statements have been included. Nevertheless, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying condensed December 31, 2014 balance sheet has been derived from these statements. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Liquidity Disclosure [Policy Text Block]

Liquidity and Capital Resources

We have incurred operating losses since our inception and expect to continue to incur operating losses for the foreseeable future and, may never become profitable. As of September 30, 2015, we have an accumulated deficit of $140.5 million.

Our major sources of cash have been proceeds from the private placement and public offering of equity securities. We have not yet commercialized any of our drug candidates and cannot be sure if we will ever be able to do so. Even if we commercialize one or more of our drug candidates, we may not become profitable. Our ability to achieve profitability depends on many factors, including our ability to obtain regulatory approval for our drug candidates; successfully complete any post-approval regulatory obligations; and successfully commercialize our drug candidates alone or in partnership. We may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates.

As of September 30, 2015, we had approximately $115.4 million in cash, cash equivalents, investment securities, and interest receivable. We anticipate that our cash and cash equivalents and investments will be sufficient to fund our anticipated operating cash requirements for more than 24 months from September 30, 2015. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for our drug candidates. We are dependent upon significant future financing to provide the cash necessary to execute our current strategic plan, including the commercialization of any of our drug candidates.

Our common stock is listed on the Nasdaq Capital Market and trades under the symbol “TGTX.”

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update to ASC 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods or services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 is effective for us beginning in fiscal 2018. We are currently evaluating the impact of this update on our consolidated financial statements.

In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements—Going Concern, which requires that management of an entity should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued. This update will become effective beginning January 1, 2017, with early adoption permitted. The provisions of this standard are not expected to significantly impact the Company.

Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. Actual results could differ from those estimates. Such differences could be material to the consolidated financial statements.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

We treat liquid investments with original maturities of three months or less when purchased as cash and cash equivalents.

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Restricted Cash

We record cash pledged or held in trust as restricted cash. As of September 30, 2015, we have approximately $0.6 million of restricted cash pledged to secure a line of credit as a security deposit for a Desk Space Agreement (see Note 8)

Marketable Securities, Policy [Policy Text Block]

Investment Securities

Investment securities at September 30, 2015 and December 31, 2014 consist of short-term and long-term government securities. We classify these securities as held-to-maturity. Held-to-maturity securities are those securities in which we have the ability and intent to hold the security until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method.

A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in interest and other (income) expense, net. Dividend and interest income are recognized when earned.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and short-term investments. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

We recognize license revenue in accordance with the revenue recognition guidance of the FASB Accounting Standards Codification, or Codification. We analyze each element of our licensing agreement to determine the appropriate revenue recognition. The terms of the license agreement may include payments to us of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. We recognize revenue from upfront payments over the period of significant involvement under the related agreements unless the fee is in exchange for products delivered or services rendered that represent the culmination of a separate earnings process and no further performance obligation exists under the contract. We recognize milestone payments as revenue upon the achievement of specified milestones only if (1) the milestone payment is non-refundable, (2) substantive effort is involved in achieving the milestone, (3) the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone, and (4) the milestone is at risk for both parties. If any of these conditions are not met, we defer the milestone payment and recognize it as revenue over the estimated period of performance under the contract.

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

Generally, research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. We make estimates of costs incurred in relation to external clinical research organizations, or CROs, and clinical site costs. We analyze the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued liability balance and expense in any accounting period. We review and accrue CRO expenses and clinical trial study expenses based on work performed and rely upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven, and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.

Prepaid research and development in our consolidated balance sheet includes, among other things, certain fees related to development and manufacturing services. These development and manufacturing agreements often require payments in advance of services performed or goods received. Accordingly, as of September 30, 2015, we recorded approximately $9.1 million in prepaid research and development related to such advance agreements. As of September 30, 2015, approximately $1.5 million of the prepaid research and development balance has not yet been paid.

Income Tax, Policy [Policy Text Block]

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. If the likelihood of realizing the deferred tax assets or liability is less than “more likely than not,” a valuation allowance is then created.

We, and our subsidiaries, file income tax returns in the U.S. Federal jurisdiction and in various states. We have tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination. We recognize interest and penalties related to uncertain income tax positions in income tax expense.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-Based Compensation

We recognize all share-based payments to employees and non-employee directors (as compensation for service) as noncash compensation expense in the consolidated financial statements based on the fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

For share-based payments to consultants and other third-parties (including related parties), noncash compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties (including related parties) are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.

Earnings Per Share, Policy [Policy Text Block]

Basic and Diluted Net Loss Per Common Share

Basic net loss per share of our common stock is calculated by dividing net loss applicable to the common stock by the weighted-average number of our common stock outstanding for the period. Diluted net loss per share of common stock is the same as basic net loss per share of common stock since potentially dilutive securities from stock options, stock warrants and convertible preferred stock would have an antidilutive effect either because we incurred a net loss during the period presented or because such potentially dilutive securities were out of the money and the Company realized net income during the period presented. The amounts of potentially dilutive securities excluded from the calculation were 5,634,005 and 9,100,404 at September 30, 2015 and 2014, respectively. During the three and nine months ended September 30, 2015 and 2014, we incurred a net loss; therefore, all of the dilutive securities are excluded from the computation of diluted earnings per share.

Impairment Of Tangible and Intangible Asset Including Goodwill [Policy Text Block]

Long-Lived Assets and Goodwill

Long-lived assets are reviewed for an impairment loss when circumstances indicate that the carrying value of long-lived tangible and intangible assets with finite lives may not be recoverable. Management’s policy in determining whether an impairment indicator exists, a triggering event, comprises measurable operating performance criteria as well as qualitative measures. If an analysis is necessitated by the occurrence of a triggering event, we make certain assumptions in determining the impairment amount. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized.

Goodwill is reviewed for impairment annually, or when events arise that could indicate that an impairment exists. We test for goodwill impairment using a two-step process. The first step compares the fair value of the reporting unit with the unit's carrying value, including goodwill. When the carrying value of the reporting unit is greater than fair value, the unit’s goodwill may be impaired, and the second step must be completed to measure the amount of the goodwill impairment charge, if any. In the second step, the implied fair value of the reporting unit’s goodwill is compared with the carrying amount of the unit’s goodwill. If the carrying amount is greater than the implied fair value, the carrying value of the goodwill must be written down to its implied fair value. We will continue to perform impairment tests annually, at December 31, and whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable.

X

- Definition
Reflects the description of business of the entity.
+ References
No definition available.
+ Details

Name: tgtx_BusinessDescriptionPolicyTextBlock

Namespace Prefix: tgtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure related to policy for impairment of tangible and intangible asset including goodwill.
+ References
No definition available.
+ Details

Name: tgtx_ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock

Namespace Prefix: tgtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.
+ References
No definition available.
+ Details

Name: tgtx_LiquidityDisclosure1PolicyTextBlock

Namespace Prefix: tgtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61082-112788

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61044-112788

+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investments in debt and equity securities that have readily determinable fair values (marketable securities). At a minimum, the disclosure might address accounting policies for investments classified as trading, available for sale, or held to maturity and may include how the entity determines whether impairments of available for sale or held to maturity investments are other than temporary, how the fair values of the entity's securities are determined, and the entity's accounting treatment for transfers between investment categories.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section S50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6381980&loc=d3e87707-122711

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62652-112803

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section M

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 2, 12

-Article 5

+ Details

Name: us-gaap_MarketableSecuritiesPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814

NOTES PAYABLE (Details Textual) - Convertible Notes Payable [Member] - USD ($)
$ / shares in Units, $ in Millions
9 Months Ended 12 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Notes Payable [Line Items]

Debt Instrument, Convertible, Conversion Price $ 1,125

Interest Payable $ 20.3 $ 19.5

Debt Instrument, Interest Rate During Period 5.00% 5.00%

Ariston [Member]

Notes Payable [Line Items]

Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt 50.00%

Debt Instrument, Interest Rate During Period 5.00%

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: tgtx_NotesPayableLineItems

Namespace Prefix: tgtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt.
+ References
No definition available.
+ Details

Name: tgtx_PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt

Namespace Prefix: tgtx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The average effective interest rate during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateDuringPeriod

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of interest payable on debt, including, but not limited to, trade payables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_InterestPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=tgtx_AristonMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

NOTES PAYABLE (Tables)
9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

The following is a summary of notes payable:

September 30, 2015

December 31, 2014

Non-

Non-

current

current

Current

portion,

Current

portion,

portion, net

net

Total

portion, net

net

Total

Convertible 5% Notes Payable

$

181,668

$

-

$

181,668

$

275,190

$

-

$

275,190

Total

$

181,668

$

-

$

181,668

$

275,190

$

-

$

275,190

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

FAIR VALUE MEASUREMENTS (Details 1)
9 Months Ended

Sep. 30, 2015

USD ($)

Fair Value, Measurement Changes In Level 3 Instruments [Line Items]

Fair value at December 31, 2014 $ 275,190

Interest accrued on face value of 5% Notes 730,710

Change in fair value of Level 3 liabilities (824,232)

Fair value at June 30, 2015 $ 181,668

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: tgtx_FairValueMeasurementChangesInLevel3InstrumentsLineItems

Namespace Prefix: tgtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of interest recognized during the period, arising from liabilities measured at fair value on a recurring basis using unobservable inputs (level 3).
+ References
No definition available.
+ Details

Name: tgtx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 48 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Consolidated Statement of Equity - 9 months ended Sep. 30, 2015 - USD ($)

Total

Preferred Stock [Member]

Common Stock [Member]

Contingently Issuable Shares [Member]

Additional Paid-in Capital [Member]

Treasury Stock [Member]

Accumulated Deficit [Member]

Balance at Dec. 31, 2014 $ 80,101,884 $ 0 $ 44,974 $ 6 $ 175,476,521 $ (234,337) $ (95,185,280)

Balance (in shares) at Dec. 31, 2014 0 44,974,248 41,309

Issuance of common stock in connection with exercise of warrants 1,009,985 $ 2,922 1,007,063

Issuance of common stock in connection with exercise of warrants (in shares) 2,922,275

Issuance of common stock in connection with cashless exercise of warrants 0 $ 3 (3)

Issuance of common stock in connection with cashless exercise of warrants (in shares) 2,915

Issuance of restricted stock 0 $ 481 (481)

Issuance of restricted stock (in shares) 480,592

Forfeiture of restricted stock 0 $ (31) 31

Forfeiture of restricted stock (in shares) (31,166)

Issuance of common stock to related party for cash (See Note 8) 750,004 $ 115 749,889

Issuance of common stock to related party for cash (See Note 8) (in shares) 114,855

Issuance of common stock in At the Market offering (net of offering costs of $1,262,569) 66,946,725 $ 4,094 66,942,631

Issuance of common stock in At the Market offering (net of offering costs of $1,262,569) (in shares) 4,094,498

Compensation in respect of restricted stock granted to employees, directors and consultants 12,840,048 12,840,048

Net loss (45,336,834) (45,336,834)

Balance at Sep. 30, 2015 $ 116,311,812 $ 0 $ 52,558 $ 6 $ 257,015,699 $ (234,337) $ (140,522,114)

Balance (in shares) at Sep. 30, 2015 0 52,558,217 41,309

X

- Definition
Represents the number of shares of stock issued during the period due to the exercise of warrants.
+ References
No definition available.
+ Details

Name: tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrants

Namespace Prefix: tgtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represent stock issued during period shares exercise of warrants cash less
+ References
No definition available.
+ Details

Name: tgtx_StockIssuedDuringPeriodSharesExerciseOfWarrantsCashLess

Namespace Prefix: tgtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
No definition available.
+ Details

Name: tgtx_StockIssuedDuringPeriodSharesMarketPublicOffering

Namespace Prefix: tgtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the value of stock issued during the period due to the exercise of warrants.
+ References
No definition available.
+ Details

Name: tgtx_StockIssuedDuringPeriodValueExerciseOfWarrants

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represent stock issued during period value exercise of warrants cash less
+ References
No definition available.
+ Details

Name: tgtx_StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an market public offering or a secondary public offering.
+ References
No definition available.
+ Details

Name: tgtx_StockIssuedDuringPeriodValueMarketPublicOffering

Namespace Prefix: tgtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares related to Restricted Stock Award forfeited during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock related to Restricted Stock Awards forfeited during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate value of stock related to Restricted Stock Awards issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568447-111683

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=tgtx_ContingentlyIssuableShareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

INVESTMENT SECURITIES
9 Months Ended

Sep. 30, 2015

Investments, Debt and Equity Securities [Abstract]

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

NOTE 3 – INVESTMENT SECURITIES

We record our investments as held-to-maturity at amortized cost.

The following tables summarize our investment securities at September 30, 2015 and December 31, 2014:

September 30, 2015

Gross

Gross

Amortized cost,

unrealized

unrealized

Estimated fair

as adjusted

holding gains

holding losses

value

Short-term investments:

Obligations of domestic governmental agencies (maturing between October 2015 and August 2016) (held-to-maturity)

$

28,701,209

$

8,061

$

80

$

28,709,190

Long-term investments:

Obligations of domestic governmental agencies (maturing between October 2016 and September 2017) (held-to-maturity)

21,088,192

37,010

—

21,125,202

Total short-term and long-term investment securities

$

49,789,401

$

45,071

$

80

$

49,834,392

December 31, 2014

Gross

Gross

Amortized cost,

unrealized

unrealized

Estimated fair

as adjusted

holding gains

holding losses

value

Short-term investments:

Obligations of domestic governmental agencies (maturing between January 2015 and December 2015) (held-to-maturity)

$

23,062,034

$

922

$

5,806

$

23,057,150

Total short-term investment securities

$

23,062,034

$

922

$

5,806

$

23,057,150

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Debt Security

-URI http://asc.fasb.org/extlink&oid=6509901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Equity Security

-URI http://asc.fasb.org/extlink&oid=6511694

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

FAIR VALUE MEASUREMENTS (Details Textual) - Convertible Notes Payable [Member] - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2010

Sep. 30, 2015

Dec. 31, 2014

Fair Value Measurement [Line Items]

Debt Instrument, Convertible, Conversion Price $ 1,125

Long-term Debt, Gross $ 20.3 $ 19.5

Debt Instrument, Interest Rate During Period 5.00% 5.00%

Manhattan and Ariston Pharmaceuticals Merger [Member]

Fair Value Measurement [Line Items]

Notes Issued $ 15.5

Debt Instrument, Convertible, Conversion Price $ 1,125

Percentage Of Cash Proceeds From Operation To Repay Convertible Debt 50.00%

Debt Instrument, Term 5 years

Debt Instrument, Interest Rate During Period 5.00%

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: tgtx_FairValueMeasurementLineItems

Namespace Prefix: tgtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt.
+ References
No definition available.
+ Details

Name: tgtx_PercentageOfCashProceedsFromOperationToRepayConvertibleDebt

Namespace Prefix: tgtx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The average effective interest rate during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateDuringPeriod

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The fair value of notes issued in noncash investing and financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

+ Details

Name: us-gaap_NotesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: tgtx_TypeOfTransactionAxis=tgtx_ManhattanAndAristonPharmaceuticalsMergerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 87 235 1 false 35 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.tgtherapeuticsinc.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] Sheet http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets [Parenthetical] Statements 3 false false R4.htm 104 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 105 - Statement - Condensed Consolidated Statement of Equity Sheet http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquity Condensed Consolidated Statement of Equity Statements 5 false false R6.htm 106 - Statement - Condensed Consolidated Statement of Equity [Parenthetical] Sheet http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementOfEquityParenthetical Condensed Consolidated Statement of Equity [Parenthetical] Statements 6 false false R7.htm 107 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.tgtherapeuticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 108 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 109 - Disclosure - CASH AND CASH EQUIVALENTS Sheet http://www.tgtherapeuticsinc.com/role/CashAndCashEquivalents CASH AND CASH EQUIVALENTS Notes 9 false false R10.htm 110 - Disclosure - INVESTMENT SECURITIES Sheet http://www.tgtherapeuticsinc.com/role/InvestmentSecurities INVESTMENT SECURITIES Notes 10 false false R11.htm 111 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.tgtherapeuticsinc.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 11 false false R12.htm 112 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.tgtherapeuticsinc.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 12 false false R13.htm 113 - Disclosure - NOTES PAYABLE Notes http://www.tgtherapeuticsinc.com/role/NotesPayable NOTES PAYABLE Notes 13 false false R14.htm 114 - Disclosure - LICENSE AGREEMENTS Sheet http://www.tgtherapeuticsinc.com/role/LicenseAgreements LICENSE AGREEMENTS Notes 14 false false R15.htm 115 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.tgtherapeuticsinc.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 15 false false R16.htm 116 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 117 - Disclosure - CASH AND CASH EQUIVALENTS (Tables) Sheet http://www.tgtherapeuticsinc.com/role/CashAndCashEquivalentsTables CASH AND CASH EQUIVALENTS (Tables) Tables http://www.tgtherapeuticsinc.com/role/CashAndCashEquivalents 17 false false R18.htm 118 - Disclosure - INVESTMENT SECURITIES (Tables) Sheet http://www.tgtherapeuticsinc.com/role/InvestmentSecuritiesTables INVESTMENT SECURITIES (Tables) Tables http://www.tgtherapeuticsinc.com/role/InvestmentSecurities 18 false false R19.htm 119 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.tgtherapeuticsinc.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.tgtherapeuticsinc.com/role/FairValueMeasurements 19 false false R20.htm 120 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.tgtherapeuticsinc.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.tgtherapeuticsinc.com/role/StockholdersEquity 20 false false R21.htm 121 - Disclosure - NOTES PAYABLE (Tables) Notes http://www.tgtherapeuticsinc.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://www.tgtherapeuticsinc.com/role/NotesPayable 21 false false R22.htm 122 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Sheet http://www.tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTextual ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Details http://www.tgtherapeuticsinc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies 22 false false R23.htm 123 - Disclosure - CASH AND CASH EQUIVALENTS (Details) Sheet http://www.tgtherapeuticsinc.com/role/CashAndCashEquivalentsDetails CASH AND CASH EQUIVALENTS (Details) Details http://www.tgtherapeuticsinc.com/role/CashAndCashEquivalentsTables 23 false false R24.htm 124 - Disclosure - INVESTMENT SECURITIES (Details) Sheet http://www.tgtherapeuticsinc.com/role/InvestmentSecuritiesDetails INVESTMENT SECURITIES (Details) Details http://www.tgtherapeuticsinc.com/role/InvestmentSecuritiesTables 24 false false R25.htm 125 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.tgtherapeuticsinc.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) Details http://www.tgtherapeuticsinc.com/role/FairValueMeasurementsTables 25 false false R26.htm 126 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1) Sheet http://www.tgtherapeuticsinc.com/role/FairValueMeasurementsDetails1 FAIR VALUE MEASUREMENTS (Details 1) Details http://www.tgtherapeuticsinc.com/role/FairValueMeasurementsTables 26 false false R27.htm 127 - Disclosure - FAIR VALUE MEASUREMENTS (Details Textual) Sheet http://www.tgtherapeuticsinc.com/role/FairValueMeasurementsDetailsTextual FAIR VALUE MEASUREMENTS (Details Textual) Details http://www.tgtherapeuticsinc.com/role/FairValueMeasurementsTables 27 false false R28.htm 128 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.tgtherapeuticsinc.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://www.tgtherapeuticsinc.com/role/StockholdersEquityTables 28 false false R29.htm 129 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) Sheet http://www.tgtherapeuticsinc.com/role/StockholdersEquityDetails1 STOCKHOLDERS' EQUITY (Details 1) Details http://www.tgtherapeuticsinc.com/role/StockholdersEquityTables 29 false false R30.htm 130 - Disclosure - STOCKHOLDERS' EQUITY (Details 2) Sheet http://www.tgtherapeuticsinc.com/role/StockholdersEquityDetails2 STOCKHOLDERS' EQUITY (Details 2) Details http://www.tgtherapeuticsinc.com/role/StockholdersEquityTables 30 false false R31.htm 131 - Disclosure - STOCKHOLDERS' EQUITY (Details 3) Sheet http://www.tgtherapeuticsinc.com/role/StockholdersEquityDetails3 STOCKHOLDERS' EQUITY (Details 3) Details http://www.tgtherapeuticsinc.com/role/StockholdersEquityTables 31 false false R32.htm 132 - Disclosure - STOCKHOLDERS' EQUITY (Details Textual) Sheet http://www.tgtherapeuticsinc.com/role/StockholdersEquityDetailsTextual STOCKHOLDERS' EQUITY (Details Textual) Details http://www.tgtherapeuticsinc.com/role/StockholdersEquityTables 32 false false R33.htm 133 - Disclosure - NOTES PAYABLE (Details) Notes http://www.tgtherapeuticsinc.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://www.tgtherapeuticsinc.com/role/NotesPayableTables 33 false false R34.htm 134 - Disclosure - NOTES PAYABLE (Details Textual) Notes http://www.tgtherapeuticsinc.com/role/NotesPayableDetailsTextual NOTES PAYABLE (Details Textual) Details http://www.tgtherapeuticsinc.com/role/NotesPayableTables 34 false false R35.htm 135 - Disclosure - LICENSE AGREEMENTS (Details Textual) Sheet http://www.tgtherapeuticsinc.com/role/LicenseAgreementsDetailsTextual LICENSE AGREEMENTS (Details Textual) Details http://www.tgtherapeuticsinc.com/role/LicenseAgreements 35 false false R36.htm 136 - Disclosure - RELATED PARTY TRANSACTIONS (Details Textual) Sheet http://www.tgtherapeuticsinc.com/role/RelatedPartyTransactionsDetailsTextual RELATED PARTY TRANSACTIONS (Details Textual) Details http://www.tgtherapeuticsinc.com/role/RelatedPartyTransactions 36 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. tgtx-20150930.xml tgtx-20150930_cal.xml tgtx-20150930_def.xml tgtx-20150930_lab.xml tgtx-20150930_pre.xml tgtx-20150930.xsd true true XML 52 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

STOCKHOLDERS' EQUITY (Tables)
9 Months Ended

Sep. 30, 2015

Stockholders' Equity Note [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes stock option activity for the nine months ended September 30, 2015:

Number
of shares

Weighted-
average
exercise price

Weighted-
average
Contractual
Term

Aggregate
Intrinsic
Value

(in years)

Outstanding at December 31, 2014

194

$

971.70

3.50

$

—

Granted

—

—

Exercised

—

—

Forfeited

(152)

463.32

Expired

(42)

2,811.53

Outstanding at September 30, 2015

—

$

—

—

$

—

Exercisable at September 30, 2015

—

$

—

—

$

—

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

Certain employees, directors and consultants have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted share activity for the nine months ended September 30, 2015:

Number of Shares

Weighted
Average
Grant Date
Fair Value

Outstanding at December 31, 2014

6,400,001

$

5.86

Granted

480,592

16.00

Vested

(819,622)

5.02

Forfeited

(31,166)

16.76

Outstanding at September 30, 2015

6,029,805

$

6.72

Schedule Of Warrants Activity [Table Text Block]

The following table summarizes warrant activity for the nine months ended September 30, 2015:

Warrants

Weighted-
average
exercise price

Aggregate
Intrinsic
Value

Outstanding at December 31, 2014

4,148,228

$

0.94

$

61,792,184

Issued

—

—

Exercised

(2,925,687)

0.35

Expired

(11,364)

2.25

Outstanding at September 30, 2015

1,211,177

$

2.37

$

9,334,897

Schedule Of Share Based Compensation Expense [Table Text Block]

The following table summarizes stock-based compensation expense information about restricted stock for the three and nine months ended September 30, 2015:

Three months ended

Nine months ended

September 30, 2015

September 30, 2015

Stock-based compensation expense associated with restricted stock

$

1,240,034

$

12,840,048

Stock-based compensation expense associated with option grants

—

—

$

1,240,034

$

12,840,048

X

- Definition
Tabular disclosure of Share based compensation expense during the period.
+ References
No definition available.
+ Details

Name: tgtx_ScheduleOfShareBasedCompensationExpenseTableTextBlock

Namespace Prefix: tgtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for warrants activity.
+ References
No definition available.
+ Details

Name: tgtx_ScheduleOfWarrantsActivityTableTextBlock

Namespace Prefix: tgtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested restricted stock units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Notes Payable [Line Items]
Notes payable, Current portion, net	$ 181,668	$ 275,190
Notes payable, Non-current portion, net	0	0
Total	181,668	275,190
Convertible Notes [Member]
Notes Payable [Line Items]
Notes payable, Current portion, net	181,668	275,190
Notes payable, Non-current portion, net	0	0
Total	$ 181,668	$ 275,190

FAIR VALUE MEASUREMENTS (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
5% Notes	$ 181,668	$ 275,190
Totals	181,668	275,190
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
5% Notes	0	0
Totals	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
5% Notes	0	0
Totals	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
5% Notes	181,668	275,190
Totals	$ 181,668	$ 275,190

STOCKHOLDERS' EQUITY (Details 1) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2015 $ / shares shares
Equity Incentive Plans Restricted Stock Activity [Line Items]
Number of Shares, Outstanding at Begining Balance	6,400,001
Number of Shares, Granted	480,592
Number of Shares, Vested	(819,622)
Number of Shares, Forfeited	(31,166)
Number of Shares, Outstanding at Ending Balance	6,029,805
Weighted Average Grant Date Fair Value, Outstanding at Begining Balance \| $ / shares	$ 5.86
Weighted Average Grant Date Fair Value, Granted \| $ / shares	16
Weighted Average Grant Date Fair Value, Vested \| $ / shares	5.02
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	16.76
Weighted Average Grant Date Fair Value, Outstanding at Ending Balance \| $ / shares	$ 6.72

STOCKHOLDERS' EQUITY (Details) - Employee Stock Option [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Equity Incentive Plans Stock Option Activity [Line Items]
Number of shares, Outstanding Beginning Balance	194
Number of shares, Granted	0
Number of shares, Exercised	0
Number of shares, Forfeited	(152)
Number of shares, Expired	(42)
Number of shares, Outstanding Ending Balance	0	194
Number of shares, Exercisable at September 30, 2015	0
Weighted - average exercise price, Outstanding Beginning Balance	$ 971.7
Weighted - average exercise price, Granted	0
Weighted - average exercise price, Exercised	0
Weighted - average exercise price, Forfeited	463.32
Weighted - average exercise price, Expired	2,811.53
Weighted - average exercise price, Outstanding Ending Balance	0	$ 971.7
Weighted - average exercise price, Exercisable at September 30, 2015	$ 0
Weighted - average Contractual Term (in years)	0 years	3 years 6 months
Weighted - average Contractual Term, Exercisable at September 30, 2015 (in years)	0 years
Aggregate Intrinsic Value, Outstanding Beginning Balance	$ 0
Aggregate Intrinsic Value, Outstanding Ending Balance	0	$ 0
Aggregate Intrinsic Value, Exercisable at September 30, 2015	$ 0

STOCKHOLDERS' EQUITY (Details 2)	9 Months Ended
STOCKHOLDERS' EQUITY (Details 2)	Sep. 30, 2015 USD ($) $ / shares shares
Equity Incentive Plans Warrant Activity [Line Items]
Warrants, Outstanding at Beginning Balance	4,148,228
Warrants, Issued	0
Warrants, Exercised	(2,925,687)
Warrants, Expired	(11,364)
Warrants, Outstanding at Ending Balance	1,211,177
Weighted - average exercise price of Warrants, Outstanding at Beginning Balance \| $ / shares	$ 0.94
Weighted - average exercise price of Warrants, Issued \| $ / shares	0
Weighted - average exercise price of Warrants, Exercised \| $ / shares	0.35
Weighted - average exercise price of Warrants, Expired \| $ / shares	2.25
Weighted - average exercise price of Warrants, Outstanding at Ending Balance \| $ / shares	$ 2.37
Aggregate Intrinsic Value of Warrants, Outstanding at Beginning Balance \| $	$ 61,792,184
Aggregate Intrinsic Value of Warrants, Outstanding at Ending Balance \| $	$ 9,334,897

STOCKHOLDERS' EQUITY (Details 3) - USD ($)	3 Months Ended	9 Months Ended
STOCKHOLDERS' EQUITY (Details 3) - USD ($)	Sep. 30, 2015	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense associated with restricted stock	$ 1,240,034	$ 12,840,048
Stock-based compensation expense associated with option grants	0	0
Stock compensation expense	$ 1,240,034	$ 12,840,048

STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2014
Stockholders Equity [Line Items]
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition		2 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 18,900,000	$ 18,900,000
Shares available from Shelf Registration Statement		$ 248,000,000
Common Stock, Shares Authorized	150,000,000	150,000,000	150,000,000
Available-for-sale Securities, Equity Securities			$ 250,000,000
Restricted Stock Or Unit Expense	$ 1,240,034	$ 12,840,048
ATM [Member]
Stockholders Equity [Line Items]
Common Stock Value Reserved for Future Issuance		$ 75,000,000
Commission Percentage	3.00%	3.00%
Common Stock [Member]
Stockholders Equity [Line Items]
Proceeds From Issuance Of Common Stock		$ 68,200,000
Sale of Stock, Price Per Share	$ 16.66	$ 16.66
Proceeds from Issuance of Common Stock, Net		$ 67,000,000
Stock Issued During Period Shares Market Public Offering		4,094,498
Corporate Milestone [Member]
Stockholders Equity [Line Items]
Restricted Stock, Outstanding, Number, Ending Balance	1,866,167	1,866,167
Restricted Stock [Member]
Stockholders Equity [Line Items]
Restricted Stock Or Unit Expense		$ 12,800,000
Incentive Plan 2012
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,000,000	6,000,000
Equity Incentive Plans [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	5,676,574	5,676,574

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 65,461,940	$ 55,713,784
Short-term investment securities	28,701,209	23,062,034
Interest receivable	158,527	85,516
Prepaid research and development	9,950,893	6,179,743
Other current assets	457,918	173,952
Total current assets	104,730,487	85,215,029
Restricted cash	578,126	575,012
Long-term investment securities	21,088,192	0
Property, plant and equipment, net	69,225	20,357
Goodwill	799,391	799,391
Other assets	141,717	137,101
Total assets	127,407,138	86,746,890
Current liabilities:
Accounts payable and accrued expenses	8,583,003	3,991,625
Accrued compensation	768,750	702,000
Current portion of deferred revenue	152,381	152,381
Notes payable	181,668	275,190
Total current liabilities	9,685,802	5,121,196
Deferred revenue, net of current portion	1,409,524	1,523,810
Total liabilities	$ 11,095,326	$ 6,645,006
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value per share (10,000,000 shares authorized, none issued and outstanding as of September 30, 2015 and December 31, 2014)	$ 0	$ 0
Common stock, $0.001 par value per share (150,000,000 shares authorized, 52,558,217 and 44,974,248 shares issued, 52,516,908 and 44,932,939 shares outstanding at September 30, 2015 and December 31, 2014, respectively)	52,558	44,974
Contingently issuable shares	6	6
Additional paid-in capital	257,015,699	175,476,521
Treasury stock, at cost	(234,337)	(234,337)
Accumulated deficit	(140,522,114)	(95,185,280)
Total stockholders’ equity	116,311,812	80,101,884
Total liabilities and stockholders’ equity	$ 127,407,138	$ 86,746,890

Condensed Consolidated Statement of Equity [Parenthetical]	9 Months Ended
	Sep. 30, 2015 USD ($)
Payments of Stock Issuance Costs	$ 1,262,569

LICENSE AGREEMENTS (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
LICENSE AGREEMENTS (Details Textual) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2012	Dec. 31, 2014
License Agreement [Line Items]
License revenue	$ 38,096	$ 38,096	$ 114,286	$ 114,286
Deferred Revenue	1,600,000		1,600,000			$ 1,700,000
Additional Amount Receivable On Achievement Of Pre Specified Milestones			5,000,000
Deferred Revenue, Current	152,381		$ 152,381			152,381
Licensing Agreements [Member]
License Agreement [Line Items]
Upfront Fee Received From Sub License					$ 2,000,000
Income taxes					$ 300,000
Business Acquisition Purchase Agreement Period Description			license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated
Collaboration Agreement [Member]
License Agreement [Line Items]
Upfront Payment Amount			$ 500,000
Royalty Expense			164,000,000
TG-1101 [Member]
License Agreement [Line Items]
Deferred Revenue, Current	$ 200,000		$ 200,000			$ 200,000

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)			1 Months Ended			3 Months Ended			9 Months Ended
RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)	Sep. 01, 2015	Oct. 03, 2014	May. 30, 2015	Feb. 28, 2015	Jan. 30, 2012	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Oct. 31, 2014	Nov. 09, 2012
Related Party Transaction [Line Items]
Other research and development						$ 11,538,246		$ 8,352,154	$ 29,719,891	$ 13,197,183
Prepaid Research And Development						9,950,893	$ 9,950,893		9,950,893		$ 6,179,743
LFB License Agreement [Member]
Related Party Transaction [Line Items]
Sale of Stock, Number of Shares Issued in Transaction				114,855
Sale of Stock, Price Per Share				$ 6.53
Sale of Stock, Consideration Received on Transaction				$ 750,000
Minimum Value of Shares To Be Purchased									750,000
Shared Services Agreement [Member]
Related Party Transaction [Line Items]
Costs and Expenses, Related Party							40,000
Collaboration Agreement [Member]
Related Party Transaction [Line Items]
Option Fee Paid	$ 25,000
Opus [Member]
Related Party Transaction [Line Items]
Accounts Payable						100,000	100,000		100,000
Costs and Expenses, Related Party									200,000
AOI Communications, L.P [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party									23,000
LFB Group [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues					5,000,000
Other research and development									4,900,000	$ 1,800,000
Accounts Payable						400,000	400,000		400,000		100,000
Number Of Common Stock Shares Granted In Connection With License Agreement By Issue Of Warrants					2,500,000
Common Stock Purchase Price Per Share					$ 0.001
Prepaid Research And Development						4,400,000	4,400,000		4,400,000		$ 1,900,000
Number Of Common Stock Shares Granted In Connection With License Agreement By Excercise Of Warrants			2,500,000
Common Stock Excercise Of Warrants Purchase Price Per Share			$ 0.001
LFB Group [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage													10.00%
Desk Agreement [Member]
Related Party Transaction [Line Items]
Costs and Expenses, Related Party									100,000
Average Annual Rental Payments		$ 1,100,000
Operating Leases, Indemnification Agreements, Description		This Desk Agreement requires us to pay our respective share of the average annual rent and other costs of the 15 year lease.
Security Deposit												$ 600,000
Percentage of Occupancy		40.00%
Related Party Transaction, Expenses from Transactions with Related Party									100,000
Accounts Payable, Related Parties, Current						$ 100,000	$ 100,000		$ 100,000

INVESTMENT SECURITIES (Details) - USD ($)	9 Months Ended	12 Months Ended
INVESTMENT SECURITIES (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Schedule of Held-to-maturity Securities [Line Items]
Amortized cost, as adjusted	$ 49,789,401	$ 23,062,034
Gross unrealized holding gains	45,071	922
Gross unrealized holding losses	80	5,806
Estimated fair value	49,834,392	23,057,150
Obligations of domestic governmental agencies [Member] \| Short-term Investments [Member]
Schedule of Held-to-maturity Securities [Line Items]
Amortized cost, as adjusted	28,701,209	23,062,034
Gross unrealized holding gains	8,061	922
Gross unrealized holding losses	80	5,806
Estimated fair value	28,709,190	$ 23,057,150
Obligations of domestic governmental agencies [Member] \| Other Long-term Investments [Member]
Schedule of Held-to-maturity Securities [Line Items]
Amortized cost, as adjusted	21,088,192
Gross unrealized holding gains	37,010
Gross unrealized holding losses	0
Estimated fair value	$ 21,125,202

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Consolidated net loss	$ (45,336,834)	$ (36,984,848)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:
Gain on settlement of notes payable	0	(95,427)
Noncash stock compensation expense	12,840,048	16,066,856
Noncash stock expense associated with in-licensing agreements	0	5,350,094
Depreciation	10,326	2,454
Amortization of premium on investment securities	377,770	127,260
Change in fair value of notes payable	(93,522)	118,615
Changes in assets and liabilities:
Increase in restricted cash	(3,114)	0
Increase in other current assets	(4,055,116)	(7,585,956)
Increase in accrued interest receivable	(73,011)	(26,652)
Decrease in other assets	0	13,870
Increase in accounts payable and accrued expenses	4,658,128	3,269,629
Decrease in interest payable	0	(94,590)
Decrease in deferred revenue	(114,286)	(114,286)
Net cash used in operating activities	(31,789,611)	(19,952,981)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(59,194)	(4,498)
Investment in held-to-maturity securities	(40,955,137)	(9,218,008)
Proceeds from maturity of short-term securities	13,850,000	0
Net cash used in investing activities	(27,164,331)	(9,222,506)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the exercise of warrants	1,009,985	2,890,305
Proceeds from the exercise of options	0	145,200
Payment of notes payable	0	(677,778)
Proceeds from sale of common stock, net	67,760,517	39,558,093
Financing costs	(68,404)	0
Net cash provided by financing activities	68,702,098	41,915,820
NET INCREASE IN CASH AND CASH EQUIVALENTS	9,748,156	12,740,333
Cash and cash equivalents at beginning of period	55,713,784	40,485,466
CASH AND CASH EQUIVALENTS AT END OF PERIOD	65,461,940	53,225,799
NONCASH TRANSACTIONS
Reclassification of deferred financing costs to additional paid-in capital	$ (63,788)	$ 0

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2015	Nov. 06, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Entity Registrant Name	TG THERAPEUTICS, INC.
Entity Central Index Key	0001001316
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	TGTX
Entity Common Stock, Shares Outstanding		52,519,686

CASH AND CASH EQUIVALENTS (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Cash and Cash Equivalents [Line Items]
Money market funds	$ 5,626,816	$ 12,364,537
Checking and bank deposits	59,835,124	43,349,247
Totals	$ 65,461,940	$ 55,713,784	$ 53,225,799	$ 40,485,466

FAIR VALUE MEASUREMENTS (Details 1)	9 Months Ended
FAIR VALUE MEASUREMENTS (Details 1)	Sep. 30, 2015 USD ($)
Fair Value, Measurement Changes In Level 3 Instruments [Line Items]
Fair value at December 31, 2014	$ 275,190
Interest accrued on face value of 5% Notes	730,710
Change in fair value of Level 3 liabilities	(824,232)
Fair value at June 30, 2015	$ 181,668

Condensed Consolidated Statement of Equity - 9 months ended Sep. 30, 2015 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Contingently Issuable Shares [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	$ 80,101,884	$ 0	$ 44,974	$ 6	$ 175,476,521	$ (234,337)	$ (95,185,280)
Balance (in shares) at Dec. 31, 2014		0	44,974,248			41,309
Issuance of common stock in connection with exercise of warrants	1,009,985		$ 2,922		1,007,063
Issuance of common stock in connection with exercise of warrants (in shares)			2,922,275
Issuance of common stock in connection with cashless exercise of warrants	0		$ 3		(3)
Issuance of common stock in connection with cashless exercise of warrants (in shares)			2,915
Issuance of restricted stock	0		$ 481		(481)
Issuance of restricted stock (in shares)			480,592
Forfeiture of restricted stock	0		$ (31)		31
Forfeiture of restricted stock (in shares)			(31,166)
Issuance of common stock to related party for cash (See Note 8)	750,004		$ 115		749,889
Issuance of common stock to related party for cash (See Note 8) (in shares)			114,855
Issuance of common stock in At the Market offering (net of offering costs of $1,262,569)	66,946,725		$ 4,094		66,942,631
Issuance of common stock in At the Market offering (net of offering costs of $1,262,569) (in shares)			4,094,498
Compensation in respect of restricted stock granted to employees, directors and consultants	12,840,048				12,840,048
Net loss	(45,336,834)						(45,336,834)
Balance at Sep. 30, 2015	$ 116,311,812	$ 0	$ 52,558	$ 6	$ 257,015,699	$ (234,337)	$ (140,522,114)
Balance (in shares) at Sep. 30, 2015		0	52,558,217			41,309

FAIR VALUE MEASUREMENTS (Details Textual) - Convertible Notes Payable [Member] - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2010	Sep. 30, 2015	Dec. 31, 2014
Fair Value Measurement [Line Items]
Debt Instrument, Convertible, Conversion Price		$ 1,125
Long-term Debt, Gross		$ 20.3	$ 19.5
Debt Instrument, Interest Rate During Period		5.00%	5.00%
Manhattan and Ariston Pharmaceuticals Merger [Member]
Fair Value Measurement [Line Items]
Notes Issued	$ 15.5
Debt Instrument, Convertible, Conversion Price	$ 1,125
Percentage Of Cash Proceeds From Operation To Repay Convertible Debt	50.00%
Debt Instrument, Term	5 years
Debt Instrument, Interest Rate During Period	5.00%